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Foreword
The year 2020 has been challenging like no other in recent history. The coronavirus disease (COVID-19) 
pandemic has had a devastating societal and economic impact, claiming many human lives, dis-
rupting the social fabric and family lives, and causing further suffering, as patients with other health 
conditions could not access health services, including for mental health conditions. It has also shown 
that international collaboration and solidarity are essential for safeguarding health and well-being 
across our interconnected world. The international drug control system is an example of multi-
lateralism in action: Member States, which have committed to ensuring the availability of controlled 
medicines for patients in need, exchange information with each other, through import and export 
authorizations for controlled substances, and with the International Narcotics Control Board (INCB), 
through reporting on licit requirements for and statistics on narcotic drugs, psychotropic substances 
and precursor chemicals. This practical international cooperation is key to ensuring that important 
medicines reach health professionals and patients and that precursor chemicals can be traded inter-
nationally for licit purposes while preventing diversion to illicit channels. 
During the pandemic, Member States discussed with the Board how best to address the challenges 
in exporting or importing controlled substances. Member States took action so that licit trade could 
continue unimpeded despite the international transport restrictions put in place to prevent COVID-19 
transmission. With the officials of many competent national authorities required to work from home 
during lockdown periods, the ability to exchange electronic import and export authorizations 
through the Board’s International Import and Export Authorization System (I2ES) proved invalu-
able. Based on the learning of the past year, INCB has started, in cooperation with Member States 
and international organizations, to review and update the Model Guidelines for the International 
Provision of Controlled Medicines for Emergency Medical Care1 and to facilitate their implemen-
tation so that the international community can ensure the availability of medicines containing con-
trolled substances during emergency and other crisis situations.
The effects of the pandemic are likely to reverberate for years to come. Chapter III of the present 
report contains an analysis of how the pandemic has affected the global supply chain of medicines, 
increased demand for controlled medicines needed for the treatment of patients with COVID-19 
and disrupted the provision of treatment and related health services for people with mental health 
and substance use disorders. At a time when precious resources are already stretched, people affected 
by drug use disorders must not be left behind. Governments must ensure that services for preven-
tion, treatment and rehabilitation continue to be provided. The Board is also gathering data and 
information on the impact of the pandemic on drug use and drug trafficking patterns.
The pandemic has had a disproportionate impact on the well-being of older persons. However, 
there is also a hidden epidemic of drug use affecting this population group. This issue is addressed 
in chapter I of the present report, following previous thematic chapters of INCB annual reports 
that focused on women (2016) and young people (2019). People are living longer; one of the chal-
lenges associated with a longer life is increasing vulnerability to drug use and drug dependence. 
Drug use and drug-related deaths among older persons have been increasing, as has the number 
of older persons in treatment for drug use problems. The chapter includes recommendations to 
improve knowledge of this hidden epidemic and ensure that this often-overlooked population group 
has access to the services necessary for their health and well-being.
1 World Health Organization, Model Guidelines for the International Provision of Controlled Medicines for Emergency 
Medical Care, document WHO/PSA/96.17.
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The launch of the INCB annual report for 2020 coincides with the sixtieth anniversary of the Single 
Convention on Narcotic Drugs of 1961 and the fiftieth anniversary of the Convention on 
Psychotropic Substances of 1971. In a special publication to mark these anniversaries, published 
together with the present annual report, we review the achievements of the two conventions and 
examine new and existing challenges that the international community faces in this area. During 
the Board’s 129th session, in November 2020, we met with Member States to commemorate the 
thirtieth anniversary of the entry into force of the United Nations Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances of 1988 and explored possible ways of addressing 
the rapid emergence of designer precursors and pre-precursors. That challenge, together with 
achievements in the implementation of article 12 of the 1988 Convention, are covered in detail in 
the Board’s report on precursors for 2020.2 
INCB continues to have serious concerns about the deteriorating drug control situation in 
Afghanistan and we are continuing to work with the Government of Afghanistan to support its 
efforts to address the drug situation. Pursuant to article 14 bis of the Single Convention on Narcotic 
Drugs of 1961 as amended by the 1972 Protocol, which we invoked in May 2018 with the agree-
ment of the Government of Afghanistan, we have recommended to the competent United Nations 
organs and specialized agencies that technical and/or financial assistance be provided to the 
Government in support of its efforts in that regard. Chapter II, part D, of the present report out-
lines several areas that require urgent support by the international community, which have been 
identified in consultation with the Government of Afghanistan, and chapter III sets out the most 
recent drug control developments in the country and surrounding region. Afghanistan faces extraor-
dinary challenges and we reiterate the importance of drug control as a cross-cutting issue that 
should be put at the top of the development agenda for the country. If illicit drug cultivation and 
production, drug trafficking, drug use and drug use disorders are not systematically and compre-
hensively addressed by the Government of Afghanistan with the support of the international com-
munity, the broader development efforts focusing on promoting sustainable development, prosperity 
and peace in Afghanistan are unlikely to be effective. This is a broader issue that affects other coun-
tries as well and, in chapter III, we reiterate that effective drug control contributes to fostering peace 
and security. INCB calls upon regional and international agencies and all partners of Afghanistan 
to accelerate the provision of further support to the country in the areas set out in the present 
report, on the basis of the principle of shared responsibility. 
INCB is continuing to work with Governments to ensure the availability of controlled substances 
for medical use while preventing diversion and abuse. From December 2019 to November 2020, 
INCB Learning training activities were provided for a total of 114 officials from the competent 
national authorities of 19 countries. In addition, 812 officials of the competent national authorities 
from 101 countries and territories completed online training modules to adequately estimate and 
assess their needs for internationally controlled substances. Moreover, in 2020, more than 
1,000 law and regulatory enforcement officers from 104 Governments and international organiza-
tions participated in training on new psychoactive substances and non-medical synthetic opioids 
under the Global Rapid Interdiction of Dangerous Substances (GRIDS) Programme. Details of these 
and other activities are included in chapter II of the present report.
Recent regional developments are highlighted in chapter III of the present report. INCB remains 
concerned about legislative developments in a number of countries with regard to the non-medical 
use of cannabis and is engaged in a close dialogue with Member States with a view to supporting 
them in implementing the provisions of the three international drug control conventions and 
safeguarding public health and well-being. We see a continuing problem with the use of 
2 Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2020 on the Implementation of Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2020/4).
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methamphetamine and synthetic opioids and related overdose deaths, and make specific recom-
mendations to Governments to address the situation.
We continue to call upon Governments to implement the international drug control conventions 
with full respect for human rights standards and norms. Drug trafficking and drug-related violence 
should be addressed through comprehensive and balanced measures, and responses to drug-related 
criminal conduct must be proportionate and respect human rights and the rule of law. The need 
to better safeguard human rights protections and place people at the heart of drug control policies 
has played a role in the evolution of the terminology surrounding drug control, and we call upon 
Governments to examine any drug control terminology that has potentially stigmatizing effects. 
INCB is committed to supporting Governments in the implementation of the international drug 
control conventions through close cooperation and capacity-building. I urge Governments to care-
fully study the recommendations contained in chapter IV of the present report and to implement 
them fully for the benefit of their communities. While the recommendations are directed at 
Governments and international and regional organizations, we also recognize the valuable role 
played by civil society, particularly in terms of improving the availability of controlled medicines, 
promoting a human rights-based approach and providing prevention, treatment, rehabilitation and 
other related services. We therefore encourage civil society organizations to take these recommen-
dations into account in the planning of their activities. 
Building back better from the unprecedented challenges of 2020 and ensuring progress towards 
achieving the Sustainable Development Goals will require the international community to work 
harder and smarter. The mental health impact of the COVID-19 pandemic is yet to be fully seen, 
and evidence-based prevention and treatment services must be stepped up to stem an increase in 
drug use disorders and in mental health conditions. The ultimate objective of the international drug 
control conventions, to safeguard the health and well-being of humankind, is the shared responsibility 
of us all. 
Cornelis P. de Joncheere
President
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Chapter I. 
A hidden epidemic: the use of drugs among 
older persons
Introduction 
1. People throughout the world are living longer; with a 
longer life come a number of opportunities and challenges. 
Among those challenges is the increasing vulnerability of 
older persons to drug use and drug dependence.
2. In 2016, INCB devoted chapter I of its annual report 
to the issue of women and drugs and, in 2019, to improv-
ing substance use prevention and treatment services for 
young people. Patterns of increasing drug use and drug 
dependence among older persons led the Board to devote 
the present thematic chapter to this development.
3. According to the United Nations, there were 703 mil-
lion persons aged 65 or over in the world in 2019. That 
number is projected to double, to 1.5 billion, by 2050. 
Globally, the share of the population aged 65 years or 
over increased from 6 per cent in 1990 to 9 per cent in 
2019. That proportion is projected to rise further and, by 
2050, it is expected that 16 per cent of the global popula-
tion, or one in six people, will be aged 65 or over.1 
In 2018, it was projected that, in 2020, the number of 
people over the age of 60 would be greater than the number 
of children under the age of 5, for the first time ever.2 
4. The trend towards an ageing population originally 
started in high-income countries and occurred over a 
relatively long period of time. This trend is now also 
visible in low- and middle-income countries and is 
occurring over a considerably shorter period of time. For 
1 World Population Ageing 2019: Highlights (United Nations publica-
tion, 2020). 
2 WHO, Fact sheets, “Ageing and health”, 5 February 2018. 
example, it took France 150 years to transition from 
10 per cent to 20 per cent of its population being over 
the age of 60. Brazil, China and India are expected to 
make the same transition in 20 years. In Japan, 30 per cent 
of the population are aged over 60; by 2050, it is expected 
that Chile, China, Iran (Islamic Republic of) and the 
Russian Federation will have a proportion of older persons 
similar to that of Japan. Furthermore, by 2050, it is also 
expected that 80 per cent of all older persons will live in 
low- and middle-income countries.3 Planning for the 
impact of these global changes and the possible problems 
and challenges of substance use among older persons is, 
however, needed now. 
5. In line with the global trend in population ageing, 
evidence from the United States of America and many 
parts of Europe suggests that drug use and drug-related 
deaths among older persons and the number of older 
persons in treatment for drug use problems has also 
increased in recent years.4 This increase, mostly in high-
income countries, may be the result of the ageing of the 
“baby-boomer” generation (those born between 1946 and 
1964, which was a period of increased birth rates, and 
who came of age during a period with relatively high 
levels of illicit drug use and medication misuse). This 
upward trend in the number of older persons who use 
drugs is likely to continue as the remainder of this 
generation make the transition into old age.5
3 Ibid.
4 World Drug Report 2018, booklet 4, Drugs and Age: Drugs and 
Associated Issues Among Young People and Older People (United Nations 
publication, 2018).
5 Sarah Wadd and Sarah Galvani, “The forgotten people: drug prob-
lems in later life – a report for the Big Lottery Fund—July 2014”, 
(Luton, University of Bedfordshire, 2014).
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6. Limited epidemiological data exist on the extent of 
substance use among older persons. In general, 
comprehensive and long-term data on substance use are 
available mostly for high-income countries, with the age 
range normally considered being 15–65. Information on 
substance use among people above the age of 65 is limited 
even in countries in which regular drug use surveys are 
undertaken. Data collection on substance use has focused 
on the general population (15–65 years of age), young 
people, young adults and marginalized and at-risk groups; 
some groups such as women and, in particular, older 
persons have been neglected in such data collection. 
Scientifically, epidemiologically and culturally there has 
been a tendency to ignore older persons and this is 
evident from the gaps identified in the literature and in 
the prevailing attitudes to older persons within society. 
The problem of substance use among older persons has 
only recently been recognized as such and specific studies 
have only recently started to be conducted. One of the 
consequences of limited information and data is that, 
while the challenges of ageing well are recognized worldwide, 
the challenges of those who use drugs ageing well are not. 
Defining older persons
7. Most industrialized countries consider a person aged 
over 65 as an older person. This definition is associated 
with the age at which a person is entitled to receive pension 
benefits, although the age for retirement is increasing 
towards 70 in several countries as life expectancy 
increases. However, the definition of older persons is not 
common across all cultures and societies. In many low- 
and middle-income countries and in non-Western cul-
tures, the age of retirement is not institutionalized and 
pensions (where they exist) are not always sufficient, 
forcing older persons to continue working later in their 
life. Beyond the chronological milestone (65 years) and 
the economic status (retiree), other factors, such as cultural 
role in the community and health status may be more 
relevant in some societies for defining older persons. 
Defining older persons who use drugs
8. Some studies across Europe have chosen 40 as the 
threshold for considering persons who use drugs as 
older.6,7 In Wales, United Kingdom of Great Britain and 
Northern Ireland, people who use substances (alcohol 
6 Catherine Comiskey and others, Addiction Debates: Hot Topics from 
Policy to Practice (London, SAGE Publications, 2020).
7 Lauren Johnston and others, “Responding to the needs of ageing 
drug users” (EMCDDA, Lisbon, 2017). 
and drugs) have been defined as older if they are aged 50 
or more.8 The Advisory Council on the Misuse of Drugs 
of the United Kingdom has found that, in recent years, 
statistics showed a demonstrable shift in the age profile 
of individuals accessing treatment for drug use in the 
United Kingdom and the ageing cohort is considered to 
be those aged over 35.9 A literature review of alcohol use 
and alcohol use disorders among older persons in India 
was focused on those aged over 50.10 For a review of 
health and social issues among older persons receiving 
opiate maintenance treatment in Norway, older persons 
were categorized as those aged 45 or over.11
9. The lack of consensus on what constitutes “older” in 
substance use statistics can have a huge impact on people 
who use drugs and on how practitioners and services 
work with their clients and patients.12 It was estimated in 
one study that the ageing process among people with sub-
stance use problems is accelerated by at least 15 years; a 
range of physical health problems typical of older persons 
is evident among this prematurely ageing group.13 
Global estimates of the scale and 
nature of the challenge
10. As mentioned above, substance use among older 
persons is underresearched because national epidemio-
logical studies on drug use tend to limit the population 
surveyed to those aged under 65. However, some infor-
mation is available, and it points to a general increase in 
drug use among older persons. 
11. In booklet 4 of the UNODC World Drug Report 
2018, entitled Drugs and Age: Drugs and Associated Issues 
Among Young People and Older People, it was stressed that 
there was evidence in some countries that the use of 
drugs among older persons had been increasing over the 
previous decade at a faster rate than among younger age 
groups. While there is no universal evidence, there are 
some statistics available that show that these changes are 
being observed in high-, middle- and low-income nations. 
8 Wales, United Kingdom, Advisory Panel on Substance Misuse, 
A Report on Substance Misuse in an Ageing Population (February 2017). 
9 United Kingdom, Advisory Council on the Misuse of Drugs, Ageing 
Cohort of Drug Users (June 2019).
10 Abhijit Nadkarni and others, “Alcohol use and alcohol-use disor-
ders among older adults in India: a literature review”, Aging and Mental 
Health, vol. 17, No. 8 (May 2013). 
11 Zhanna Gaulen and others, “Health and social issues among older 
patients in opioid maintenance treatment in Norway”, Nordic Studies on 
Alcohol and Drugs, vol. 34, No. 1 (March 2017), pp. 80–90.
12 Comiskey and others, Addiction Debates. 
13 I. Vogt, “Life situations and health of older drug addicts: a litera-
ture report”, Suchttherapie, vol. 10, No. 1 (2009), pp. 17–24. 
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12. In Germany during the period 2006–2015, past-year 
use of any drug increased more among those aged 40 and 
over than among younger age groups. In Sweden, past-
year prevalence rates of the illicit use of any drug among 
those aged 55–64 was 5.8 per cent in 2017. In terms of 
specific drugs, the use of cannabis has been on the rise 
among those aged 55–64 in some of the most populated 
countries in Western Europe. Annual prevalence data 
from France, Germany, Italy, Spain and the United 
Kingdom show that cannabis use among those in that age 
group has been increasing at a higher rate than any other 
age group. 
13. In Australia during the period 2007–2016, preva-
lence rates of drug use among those in the 50–59 and 60 
and older age groups increased by 60–70 per cent. In 
Chile, the past-year use of cannabis among those aged 
45–64 showed a fourfold increase over the decade to 
2016, and an almost thirtyfold increase between 1996 and 
2016. Similar patterns were also revealed for cocaine use, 
for which the annual prevalence increased fourteenfold 
among those aged 35–44, while it declined for those in 
the 12–18 and 19–25 age groups during the same period. 
14. In the United States, the number of people aged 50 
or older who had used drugs in the past year rose from 
just under 1 million in 1996 to almost 11 million in 
2016.14 In 2018 and 2019, among persons aged 65 or older 
14 Comiskey and others, Addiction Debates.
in the United States there was a past-year illicit drug use 
prevalence of between half and one third of that among 
the population as a whole for most drugs (see table 1).
15. If the rates for some selected drugs (those for which 
a comparison is possible) from 2012 are compared with 
those from 2019, the increase in the prevalence of use 
among those aged 65 or older is evident. Between 2012 
and 2019, past-year use among persons older than 65 
increased three times or more for most drugs; for the 
population as a whole, the increase was more limited. 
16. For instance, past-year prevalence of cannabis use 
for those aged 65 or older increased from 1.2 per cent in 
2012 to 5.1 per cent in 2019 – representing a rate of 
increase of 325 per cent. For the total population, the 
increase was relatively contained, from 12.1 per cent in 
2012 to 17.5 per cent in 2019 – representing a rate of 
increase of under 50 per cent. A similar pattern can be 
seen for the illicit use of other drugs. The past-year non-
medical use, or misuse, of pain relievers doubled (from 
0.8 per cent in 2012 to 1.7 per cent in 2019) among people 
aged 65 or older, while among the total population there 
was a slight decrease (from 4.8 per cent in 2012 to 3.5 
per cent in 2019) (see table 2).
Table 1 Past-year illicit drug use among those aged 65 or older and among the total population, 
United States of America, 2018–2019
Drug type
Past-year use (percentage) 2018 Past-year use (percentage) 2019
65 or older Total population 65 or older Total population
Any illicit drug 5.7 19.4 7.1 20.8
Any illicit drug other than cannabis 2.1 8.5 2.7 8.6
Cannabis 4.1 15.9 5.1 17.5
Opioids 0.4 1.1 0.5 1.1
Pain relievers (misuse) 1.3 3.6 1.7 3.5
Cocaine 0.1 2.0 0.2 2.0
Stimulants 2.4 6.6 2.5 6.6
Hallucinogens 0.1 2.0 0.2 2.2
Methamphetamine 0.1 0.7 0.1 0.7
Source: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, National Survey on Drug 
Use and Health, 2018 and 2019.
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Table 2 Past-year illicit drug use among those aged 65 or older and among the total population 
for selected drugs, United States of America, 2012–2019
Past-year use (percentage) 2012 Past-year use (percentage) 2019
Drug type 65 or older Total population 65 or older Total population
Any illicit drug 2.3 16.0 7.1 20.8
Cannabis 1.2 12.1 5.1 17.5
Pain relievers (non-medical use/misuse) 0.8 4.8 1.7 3.5
Cocaine 0.0 1.8 0.2 2.0
Hallucinogens 0.1 1.7 0.2 2.2
17. New prevalence estimates on substance use in 
India15 and Nigeria16 show, within the 45–64 age group, 
a considerable prevalence of non-medical use of pharma-
ceutical opioids and cough syrup. In Nigeria, those aged 
60–64 had the highest annual prevalence rates for the 
non-medical use of both cough syrups (3.7 per cent) and 
tranquillizers (1 per cent).
18. In the Islamic Republic of Iran, a study found that 
environmental factors were the most common reason for 
drug use among older persons. Such factors included easy 
access to drugs, a lack of sports and recreational facilities, 
and friends also using drugs.17 
19. A study on the consequences of the long-term 
misuse of anxiolytics and hypnotics by older persons has 
highlighted the risk of drug dependence that results from 
the long-term use of benzodiazepines by older persons.18 
In Japan, for example, an evaluation of prescription 
patterns for hypnotic and anxiolytic agents showed that 
the proportion of prescriptions for those drugs is dispro-
portionately high among older patients.19 The study also 
showed that high doses of anxiolytics and hypnotics were 
15 Atul Ambekar and others, Magnitude of Substance Use in India 
2019 (New Delhi, Ministry of Social Justice and Empowerment, 2019). 
16 UNODC and Nigeria, “Drug use in Nigeria 2018: executive sum-
mary” (Vienna, 2019). 
17 Fatemeh Kazemi and others, “Predisposing factors for substance 
abuse among elderly people referring to Qazvin addiction treatment 
centers, Iran 2017”, Journal of Qazvin University of Medical Sciences, vol. 
22, No. 5 (2018). 
18 N. N. Ivanets and others, “The efficacy of psychopharmacotherapy 
of late onset depression: the optimization of treatment duration”, Zhurnal 
Nevrologii i Psikhiatrii imeni S.S. Korsakova (Korsakov Journal of Neurol-
ogy and Psychiatry), vol. 116, No. 4 (January 2016). 
19 Takaaki Hirooka, “Excessive prescribing of hypnotic and anxiolytic 
drugs in Japan”, Nihon Rinsho (Japanese Journal of Clinical Medicine), 
vol. 73, No. 6 (June 2015), pp. 1049–1056. 
commonly prescribed to patients, mostly older persons, 
suffering from sleep and/or anxiety disorders. It was also 
common for such patients to be prescribed more than 
one medicine containing hypnotic and anxiolytic agents.
20. In the United States, people aged 65 and over make 
up more than 10 per cent of the total population; 
however, they account for 30 per cent of medical 
prescriptions. There is a higher prevalence of past-year 
use of pain relievers, tranquillizers, benzodiazepines and 
sedatives among that older group than among the 
population as a whole (see table 3). Moreover, there have 
been reports of widespread overuse of psychoactive drugs 
in the treatment of older persons suffering from dementia 
who are living in nursing homes, assisted living facilities 
or in their own homes.
Source: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, National Survey on Drug 
Use and Health, 2012 and 2019.
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Table 3 Past-year prescription drug use among those aged 65 or older and among the total 
population for selected drugs, United States of America, 2018–2019
21. In the UNODC World Drug Report 2018, a threefold 
increase in deaths from drug use disorders was noted 
among those aged 50 or over in the western Pacific20 and 
the Americas over the period 2000–2015. In the United 
States, although the rates of drug overdose deaths 
increased over the period 1999–2017 for all age groups, 
in 2017, rates were significantly higher for those aged 
25–64 (31.4 per 100,000) than for those aged 65 and over 
(6.9 per 100,000). However, from 1999 to 2017, the greatest 
percentage change in drug overdose death rates occurred 
among adults aged 55–64, increasing from 4.2 per 100,000 
deaths in 1999 to 28.0 per 100,000 deaths in 2017.21
Challenges experienced in prevention, 
treatment and recovery across the 
policy domains
22. The general lack of data on substance use among 
older persons22 translates into a lack of attention to the 
issue in the development of policies and programmes. 
Given the limited number of dedicated programmes and 
the limited collection of scientific evidence, it is difficult 
to identify the interventions and policies that have 
resulted in positive outcomes in terms of prevention, 
20 Australia, Cambodia, China, Japan, Malaysia, Mongolia, New Zea-
land, the Philippines, the Republic of Korea and Viet Nam, as well as the 
Pacific island countries.
21 Holly Hedegaard, Arialdi M. Miniño and Margaret Warner, “Drug 
overdose deaths in the United States, 1999–2017”, NCHS Data Brief, No. 
329 (Hyattsville, Maryland, United States, National Center for Health Sta-
tistics, November 2018). 
22 For the purposes of the present chapter, “older persons” are consid-
ered as those aged over 65.
Drug type
Past-year use (percentage) 2018 Past-year use (percentage) 2019
65 or older Total population 65 or older Total population
Pain relievers 35.0 31.6 35.0 30.0
Tranquillizers 21.4 16.9 20.1 16.0
Benzodiazepines 13.0 11.2 12.6 10.7
Sedatives 9.1 6.1 8.3 5.7
treatment and rehabilitation in relation to the use of 
drugs among older persons.
23. In the outcome document of the thirtieth special 
session of the General Assembly, entitled “Our joint com-
mitment to effectively addressing and countering the 
world drug problem”,23 age- and gender-appropriate ser-
vices and policies are briefly mentioned, but no emphasis 
is placed on the specific needs of older persons.
24. Older persons misusing drugs have different char-
acteristics. In some studies, they are considered as falling 
into one of three groups: (a) maintainers (unchanged 
lifetime patterns); (b) survivors (long-term problem 
users); and (c) reactors (later uptake or increased pat-
terns). In other studies, two distinct categories are identi-
fied: (a) early-onset use; and (b) late-onset use. 
“Early-onset” refers to drug use by those who have a long 
history of substance use and who continue to use as they 
age, while “late-onset” refers to the use by individuals 
who develop a new habit as older persons.24,25,26 The 
development of late-onset use may be associated with the 
prescription of pain relief medications: such medications 
have the potential for misuse if prescribed inappropri-
ately. Managing chronic illness among older persons is 
complex and adequate pain management is also an issue: 
many older persons report that they do not receive 
23  General Assembly resolution S-30/1, annex.
24 Colin Atkinson, “Service responses for older high-risk drug users: 
a literature review”, SCCJR Research Report No. 06/2016 (Glasgow, Scot-
tish Centre for Crime and Justice Research, 2016).
25 Anne Marie Carew and Catherine Comiskey, “Treatment for opi-
oid use and outcomes in older adults: a systematic literature review”, Drug 
and Alcohol Dependence, vol. 182 (2018), pp. 48–57.
26 Brenda Roe and others, “Experiences of drug use and ageing: 
health, quality of life, relationship and service implications”, Journal of 
Advanced Nursing, vol. 66, No. 9 (September 2010), pp. 1968–1979.
Source: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, National Survey on Drug 
Use and Health, 2018 and 2019.
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adequate pain relief from their health-care providers 
because their use of other substances has increased their 
tolerance to opioid analgesics.27 In addition, as global 
populations age, the proportion of older patients under-
going surgery and receiving additional medications is 
increasing. The use of pain relief medications is an essen-
tial part of health care; further challenges include a lack 
of health insurance among older persons, which may 
force them to procure their medications or pain relief 
from illicit sources. The widespread prescription of 
benzodiazepines among older persons and the risk of 
their overuse has been identified previously by the Board, 
when it called upon all Governments to remain vigilant 
to the consequences of misuse and overuse of benzo-
diazepines and urged the close monitoring of the con-
sumption levels of those substances.28
25. The classifications of early-onset and late-onset use 
are important to keep in mind in the development of 
interventions and programmes.29 However, regardless of 
classification, the ageing process can trigger psycho-
logical, social or health problems that enhance the 
probability of, and susceptibility to, substance use, which, 
in turn, aggravates pre-existing problems. 
26. Service providers and health-care professionals need 
to consider the possibility of co-existing or pre-existing 
mental health disorders, such as cognitive impairment 
and depression, as well as complex physical presentations, 
such as the presence of pain, insomnia or the non-medical 
use of prescription and over-the-counter drugs, among 
older persons who use drugs.30 For example, a review of 
substance use disorders in India in 2015 highlighted the 
overlap of substance use and medical comorbidities.31 In 
a study examining adverse drug events, it was highlighted 
that clinicians also need to be aware of herbal or dietary 
supplements used by patients, who may not volunteer that 
information but may be prone to drug interactions. This 
is more pertinent for older persons, as drug sensitivity 
can increase with age.32
27. Polypharmacy, that is, the use of five or more medi-
cines per day, be they prescription, over-the-counter or 
27 Johnston and others, “Responding to the needs of ageing drug users”. 
28 E/INCB/2015/1, para. 769. 
29 Rahul Rao and Ann Roche, “Substance misuse in older people: 
baby boomers are the population at highest risk”, British Medical Journal, 
vol. 358 (2017). 
30 Ibid. 
31 Siddharth Sarkar, Arpit Parmar and Biswadip Chatterjee, “Sub-
stance use disorders in the elderly: a review”, Journal of Geriatric Mental 
Health, vol. 2, No. 2 (December 2015), pp. 74–82.
32 Paula A. Rochon, “Drug prescribing for older adults”, UpToDate, 
8 June 2020. Available at www.uptodate.com. 
illicit drugs, is a growing problem among older persons 
around the world. The negative medical, nursing, social 
and economic consequences of inappropriate medication 
use and polypharmacy have been highlighted in a study 
reviewing the extent of them globally.33 In that study, it 
was found that attempts in different countries to improve 
the clinical and economic outcomes of inappropriate 
medication use and polypharmacy included a variety of 
clinical, pharmacological, computer-assisted and educa-
tional programmes. The conclusion reached in the study 
was that new approaches to research, education and clinical 
practice guidelines were required that were completely 
different from the “single disease model” and based on 
palliative, geriatric and ethical principles. Such new 
approaches might provide fresh tools for treating and 
reducing inappropriate medication use and polypharmacy 
and may also be relevant when considering polydrug use.
28. A series of studies and reviews provide some 
evidence of the challenges experienced by older persons 
who use drugs in relation to health and community and 
social activities.
29. With regard to health, the main issues in relation to 
older persons who use drugs are:
 (a) A higher risk of death from disease, overdose and 
suicide;34,35,36
 (b) A younger median age at death;37
 (c) Premature development of degenerative disorders, 
cardiovascular conditions, liver disease, physical pain, 
curtailed physical functioning, respiratory problems and 
diabetes;
 (d) A higher risk of HIV and hepatitis C infection;38,39
 (e) The exacerbation of other age-associated diseases 
33 Doron Garfinkel, Birkan Ilhan and Gulistan Bahat, “Routine 
deprescribing of chronic medications to combat polypharmacy”, 
Therapeutic Advances in Drug Safety, vol. 6, No. 6 (December 2015), pp. 
212–233. 
34 Johnston and others, “Responding to the needs of ageing drug users”. 
35 Atkinson, “Service responses for older high-risk drug users”. 
36 Sarah Larney and others, “Defining populations and injecting pa-
rameters among people who inject drugs: implications for the assessment 
of hepatitis C treatment programs”, International Journal of Drug Policy, 
vol. 26, No. 10 (October 2015), pp. 950–957.
37 Stephanie Yarnell and others, “Substance use disorders in later life: 
a review and synthesis of the literature of an emerging public health con-
cern”, American Journal of Geriatric Psychiatry, vol. 28, No. 2 (February 
2020), pp. 226–236. 
38 Johnston and others, “Responding to the needs of ageing drug users”. 
39 Atkinson, “Service responses for older high-risk drug users”. 
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(this is particularly associated with problem opioid use);40
 (f) A higher risk of falls, fractures, injuries and road 
accidents as a result of impaired driving;41,42
 (g) Increased difficulty in conducting activities of 
daily living such as personal tasks concerning self-care, 
increased physical pain, an increase in the incidence of 
depression and difficulties with day-to-day life;43
 (h) A higher risk of over-sedation, overdose, confu-
sion and collapse;44
 (i) A higher incidence of chronic mental health 
challenges.45,46
30. In relation to community and social activities, the 
main issues faced by older persons who use drugs are:
 (a) The stigma associated with substance use 
problems may lead to a sense of shame that prevents them 
from seeking care, thus preventing families and health-
care providers from identifying their need for care;47
 (b) A higher incidence of financial problems, 
un employment and homelessness;
 (c) Limited contact with family and the community, 
which leads to social isolation, loneliness and exclusion;48,49
 (d) A higher likelihood of receiving treatment as a 
result of contact with the criminal justice system than 
through self-referral or general health-care providers;
 (e) Fear of being faced with a judgmental attitude 
from drug treatment service professionals. 
40 Ageing Cohort of Drug Users. 
41 Marie-Claire van Hout and others, A Scoping Review of Codeine 
Use, Misuse and Dependence (Brussels, 2014). 
42 Ana Diniz and others, “Elderly substance abuse: an integrative re-
view”, Psicologia: Teoria e Prática, vol. 19, No. (2017), pp. 42–59. 
43 Van Hout and others, A Scoping Review of Codeine Use, Misuse 
and Dependence. 
44 Diniz and others, “Elderly substance abuse”. 
45 Johnston and others, “Responding to the needs of ageing drug users”. 
46 Atkinson, “Service responses for older high-risk drug users”. 
47 Carol S. D’Agostino and others, “Community interventions for 
older adults with comorbid substance abuse: the Geriatric Addictions 
Program (GAP)”, Journal of Dual Diagnosis, vol. 2, No. 3 (2006), pp. 31–45.
48 Atkinson, “Service responses for older high-risk drug users”. 
49 April Shaw and Austin Smith, “Senior drug dependents and care 
structures: Scotland – qualitative report” (Glasgow, Scottish Drugs 
Forum, 2010). 
31. A review of the epidemiological data and the evi-
dence presented above points to three areas that need to 
be addressed in relation to drug use among older persons: 
(a) research and data collection; (b) combating stigma; 
and (c) the need for integrated, holistic and age -
appropriate care.
Research and data collection
32. When discussing the challenges of drug use among 
older persons, the lack of data is one of the main prob-
lems that countries face. Because of the lack of monitor-
ing and information, drug use among older persons is 
often not diagnosed; this is why it has been referred to 
as a hidden epidemic. Improving the measuring and 
monitoring of the health and well-being of older persons 
is a necessity in general, but an imperative in relation to 
those who use drugs. While recognizing that there is 
always a need for improvements in monitoring, it is also 
true that existing monitoring systems are not being ade-
quately used. For example, data on treatment demand 
from existing monitoring systems could be used to 
improve information on older persons who use drugs.
33. It is recommended that the age range of the popu-
lation surveyed in epidemiological studies be expanded. 
There is also a need for innovation and the harnessing of 
big data when addressing new global challenges in 
substance use. It is therefore also recommended that 
policymakers and service providers look at using 
innovative assistive health technologies or drawing on 
existing technologies or innovative ways for coordinating 
the treatment of, supporting and monitoring the out-
comes for older persons who use drugs.
34. For example, remote communications systems can 
be used to provide access to telemedicine and can facilitate 
consultations with and monitoring by online health-care 
providers providing substance use services to older 
persons in rural communities. A further example of the 
use of remote communications systems for this purpose 
might be the adaptation of existing telephone or mobile 
telephone technologies currently used in the care and 
monitoring of older persons in their own homes or in 
the homes of family members. The development of remote 
communications technologies is essential to support 
those who are caring for an older family member.
35. The need for improvements in the assessment and 
monitoring of prescription drug use has also been 
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highlighted.50 The development and use of a prescription-
monitoring system has the potential to reduce, in general, 
but among older persons in particular, multiple prescrip-
tions, prescription-shopping behaviour and emergency-
department visits. In addition, it is important to improve 
diagnostic and assessment tools relevant for use in an 
older population who use drugs.51,52
36. A clear priority is the development of monitoring 
systems to measure the nature and extent of drug use, 
including the misuse of prescription and over-the-counter 
medications, among older persons. The Board therefore 
recommends that Governments establish or extend and 
improve existing prescription-monitoring systems. Where 
monitoring systems already exist for illicit drug use, it 
is recommended that the common artificial upper age 
limit of 65 years be removed, and that the monitoring 
be extended to prescription and over-the-counter 
medications. 
37. Harnessing the power of and adding value to existing 
resources, including data sets, assessments and monitor-
ing, and opportunities from novel, smart and emerging 
innovations and technologies are also recommended. 
In terms of adding value to existing data, it is recom-
mended that analysis and research are undertaken in 
relation to relevant existing national health record 
systems for older persons in order to provide prelimi-
nary estimates of the scale of the hidden prevalence of 
undiagnosed drug use, including the misuse of pre-
scription medications, and related comorbidities among 
older persons. This process should be repeated on a 
regular basis. Appropriate record systems might include 
hospital emergency department systems, out- or inpatient 
record systems, medication or pharmacy systems, general 
practitioner systems, health insurance systems and road 
traffic accident record systems. Where multiple data 
systems exist, it may be possible to use more advanced 
data analysis methods such as capture-recapture techniques 
to provide estimates of the hidden prevalence at the sub-
national level. 
Combating stigma
38. The global nature and challenges of substance use 
have been addressed at the highest international policy 
level. The thirtieth special session of the General Assembly, 
50 Rachel D. Maree and others, “A systematic review of opioid and 
benzodiazepine misuse in older adults”, American Journal of Geriatric 
Psychiatry, vol. 24, No. 11 (November 2016), pp. 949–963.
51 Ilana Crome, “Substance misuse in the older person: setting higher 
standards”, Clinical Medicine, vol. 13, No. 6 (December 2013), pp. s46–s49. 
52 Diniz and others, “Elderly substance abuse”. 
in 2016, was devoted to addressing and countering the 
world drug problem. In the outcome document of that 
session, Member States recognized drug dependence as a 
complex, multifactorial health disorder characterized by 
a chronic and relapsing nature with social causes and 
consequences that could be prevented and treated 
through, inter alia, effective scientific evidence-based 
drug treatment, care and rehabilitation programmes. That 
recognition of substance use as a global health challenge 
is significant in relation to addressing stigma.
39. Older persons who use drugs are more likely to 
suffer from stigma, social exclusion and isolation from 
family and friends. Such increased stigma was identified 
in a study of older persons in Austria, Germany, Poland 
and Scotland, United Kingdom.53 In that study, it was 
found that the impact of stigma on older persons who 
use drugs can be profound and can be a significant barrier 
to treatment and recovery. Advocacy and practical 
responses to address stigma include challenging media 
language and stereotypes, encouraging public figures to 
speak out about their personal experiences, providing 
improved training for non-specialist staff and facilitating 
greater contact between people who use drugs and people 
who do not.54
40. The Canadian Coalition for Seniors’ Mental Health 
has developed guidelines for the treatment of cannabis, 
opiate and benzodiazepine use within older populations.55 
A common finding was the recognition that social stigma 
and cognitive impairment among individuals may play a 
role in the underidentification of substance use among 
older persons. Taking into account the quality of the 
evidence, cost and feasibility, a set of recommendations 
was developed, a key one of which was ensuring that 
screening was non-judgmental and non-stigmatizing. In 
a review of substance use among older persons, the lack 
of recognition of the problem and the role of cognitive 
impairment and stigma in underdiagnoses were also 
identified.56 The issue of stigma in relation to drug use in 
general was also recognized by the Commission on 
Narcotic Drugs in its resolution 61/11, entitled “Promoting 
non-stigmatizing attitudes to ensure the availability of, 
access to and delivery of health, care and social services 
for drug users”. 
53 Shaw and Smith, “Senior drug dependents and care structures”. 
54 Charlie Lloyd, “The stigmatization of problem drug users: a narra-
tive literature review”, Drugs: Education, Prevention, and Policy, vol. 
20, No. 2 (2013), pp. 85–95.
55 Canadian Coalition for Seniors’ Mental Health, “Guidelines on 
opiate use disorder among older adults” (Toronto, 2019); and Canadian 
Coalition for Seniors’ Mental Health, “Canadian guidelines on cannabis 
use disorder among older adults” (Toronto, 2019).
56 Alexis Kuerbis and others, “Substance abuse among older adults”, 
Clinics in Geriatric Medicine, vol. 30, No. 3 (June 2014), pp. 629–654.
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41. It is recommended that existing evidence-based 
prevention strategies are used to prevent the stigma-
tization of older persons who use drugs. It is also 
recommended that older persons are involved in the 
development of messaging to combat stigma at the 
community level and in professional development 
training for those delivering both universal and targeted 
prevention services. It is further recommended that 
anti-stigma training programmes are monitored and 
evaluated on an ongoing basis to ensure that they remain 
up to date and fit for purpose.
42. In particular, it is recommended that older persons 
who use drugs are consulted and supported in the crea-
tion of messages to combat stigma that are to be used at 
the community level and in the creation of training for 
use as part of the continuing professional development of 
staff working in relevant services. 
Need for integrated, holistic and age-
appropriate care
43. Beyond the problem of stigma as a barrier to the 
recognition of the problem of drug use, it is recom-
mended that Governments develop effective service 
responses for older persons who use drugs. These should 
include the co-treatment of multiple issues, such as those 
relating to physical health, mental health and drug 
dependence. Ongoing personal support should also be 
offered. A seamless continuum of care is needed to ensure 
that older persons who are struggling with a substance 
use disorder are adequately supported, from screening 
through to recovery. The Global Strategy and Action Plan 
on Ageing and Health57 also addresses integrated care. 
Within the plans for integrated care it is highlighted that 
long-term care services need to be oriented around the 
functional ability and well-being of older persons. It is 
specified in the strategy that this can be achieved through 
care that is integrated across many professions and 
settings, as well as condition- and care-specific services. 
Dementia and palliative care services are given as exam-
ples, but the recommendations are relevant for drug 
dependence and mental health services. The International 
Association for Hospice and Palliative Care has also 
re iterated the need for training and access to inter-
nationally controlled essential medicines with regard to 
the treatment of severe pain, mental health conditions, 
substance use disorders and palliative, end-of-life care. It 
has highlighted the need to address ageism, the right to 
pain relief as part of palliative care, the importance of 
57 WHO (Geneva, 2017).
global access to essential medicines, and the lack of train-
ing among health professionals in those areas.
44. A study58 comparing the effects of substance use and 
mental health services when integrated into primary care 
with the effects of such services when using enhanced 
referral to outside providers found that, although no 
differences in clinical outcome between the two models 
of care were noted, access to and participation in mental 
health and substance use services were found to be 
significantly better in the integrated care model. These 
findings could potentially be used to address benzo-
diazepine and opioid misuse among older adults in 
primary care settings.
45. The Royal College of Psychiatrists of the United 
Kingdom, in its information guide on substance use in 
older persons, recognizes that it is usual for people to be 
assessed and treated within a range of services, both in 
parallel and sequentially. To ensure appropriate referral 
and to improve the quality of care and of outcomes, it is 
important to work within a model of coordinated care 
where there is a lead service with a defined coordinator.59 
46. The Geriatric Addiction Program was developed in 
the United States to meet the needs of older adults expe-
riencing a range of problems related to drug dependence 
and general health. While the majority of clients were 
referred to the programme for alcohol problems, approxi-
mately 15 per cent had comorbid drug problems. The 
programme was a community-based intervention pro-
gramme and focused on providing substance use inter-
vention, assessment and linkage services for older adults 
from their own homes. The evidence from the programme 
demonstrated positive outcomes but, in spite of that, the 
programme has not been widely replicated.60 
47. In general, research has shown that older persons 
who need assistance not only prefer to be cared for in 
their own homes rather than within formal institutions 
or nursing homes, but also prefer to be cared for by infor-
mal caregivers or family members instead of professionals 
and formal carers. Indeed, in many cultures and societies, 
58 Maree and others, “A systematic review of opioid and benzodiaze-
pine misuse in older adults”.
59 Rahul Rao and Amit Arora, Substance Misuse in Older People: An 
Information Guide, Faculty Report No. OA/AP/01 (London, Royal Col-
lege of Psychiatrists, 2015).
60 D’Agostino and others, “Community interventions for older adults 
with comorbid substance abuse”. 
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it is the norm for older persons to live with and be cared 
for by their adult children or younger siblings.61 
48. Domiciliary outreach, according to the UNODC 
and WHO International Standards for the Treatment of 
Drug Use Disorders, is work undertaken in the homes of 
target populations.62 This is important in areas where 
people who use drugs are isolated from their communi-
ties because of stigma and discrimination. Domiciliary 
outreach involves regular visits to the homes of people 
who use drugs or of their family carers. Drug treatment 
programmes that include domiciliary outreach and inte-
grated care and are specifically targeted at older persons 
living in their own homes or in the homes of family 
members who are caring for them have the potential to 
create substantial cost savings and to reduce unnecessary 
suffering and the burden of care on family members and 
relatives.
49. Peripatetic outreach is work undertaken in settings 
where people are either already accessing some services 
or where target populations are highly likely to be encoun-
tered (for example shelters for homeless older persons, or 
housing projects). Instead of focusing on individuals, 
peripatetic outreach focuses on organizations and settings 
where target populations can be found. Peripatetic out-
reach places emphasis on broadening the range of people 
who receive health education messages, and on training 
more workers and staff to provide education and outreach 
to their clients.
50. The need for a wider holistic view of treatment and 
recovery for substance use reflects the changing concepts 
of recovery in mental health services and also reflects the 
principles of the Convention on the Rights of Persons 
with Disabilities, which adopts a broad categorization of 
persons with disabilities. Pursuant to article 4 of that 
Convention, States parties are to undertake to ensure and 
promote the full realization of all human rights and 
fundamental freedoms for all persons with disabilities 
without discrimination of any kind on the basis of disabil-
ity. Moreover, the International Covenant on Economic, 
Social and Cultural Rights recognizes the right of every-
one to the enjoyment of the highest attainable standard 
of physical and mental health. Regardless of the age of a 
person or the balance of economic costs and benefits to 
society, it is a basic and equal human right for both older 
61 Catherine M. Comiskey and others, “The BREATHE Project, a 
mobile application, video-monitoring system in family homes as an aid 
to the caring role: needs, acceptability and concerns of informal carers”, 
Digital Health, vol. 4 (2018), pp. 1–8. 
62 UNODC and WHO, International Standards for the Treatment of 
Drug Use Disorders: Revised Edition Incorporating Results of 
Field-Testing (Geneva and Vienna, 2020). 
and younger people to receive appropriate treatment for 
substance use dependence. As the needs of older persons 
who use drugs have been demonstrated, in studies across 
the globe, to be both unique and complex, it is imperative 
that a flexible and adaptable model for a coordinated con-
tinuum of integrated care be developed. It is important 
that policies and practices are used to work towards 
developing a comprehensive integrated care system for 
older persons who use drugs. 
51. Implicit in the definition of integrated care is the 
notion that care should be centred on the needs of indi-
viduals, their families and communities. There is a need 
for cross-cutting clear leadership, expert guidance and 
direction that transcends the priorities of a single policy 
domain and places the older person at the centre of the 
solution. In terms of participation, be it in health or 
wider social and security policy, it is recommended that 
older persons who use or have used drugs be included 
as part of the integrated care policy development 
process. 
52. In terms of ensuring access to a continuum of care 
for older persons who use drugs, it is recommended that 
existing outreach services for people who use drugs be 
expanded or developed to include domiciliary and peri-
patetic services and that those outreach services be used 
as a gateway or entry point to a continuum of inte-
grated care for the most marginalized of older persons 
who use drugs.
53. Historically, older adults are less likely, in compari-
son with other age groups, to be screened for substance 
use and there are several factors that inhibit screening 
and subsequent identification of drug use. These factors 
include possible clinician discomfort in assessing for drug 
dependence, the similarities of the symptoms of substance 
use with other illnesses common in later life and the 
common perception among older adults that symptoms 
resulting from the use of drugs are part of normal ageing 
rather than resulting from the substance use itself. 
Furthermore, in some cultural and social settings, drug 
use may be seen as being one last pleasure or indulgence 
afforded to older persons.
54. The screening and assessment of older adults for 
drug use are recommended, and improvements to such 
screening and assessment are also recommended. It is 
further recommended that existing screening and 
assessment instruments and evidence-based programmes 
currently in use for older persons who use drugs be 
culturally adapted for older persons from varying 
societies and backgrounds. 
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55. In line with best practice and the WHO priorities 
for ageing it is recommended that a system of integrated 
care be established for older persons who use drugs. In 
services that support older persons, other than drug use 
treatment ones, there needs to be an awareness of and 
information about the potential for substance use by cli-
ents, the impact this may have, and how it can be allevi-
ated. Moreover, there needs to be more awareness of 
referral pathways to services for the treatment of sub-
stance use disorders. Work towards an integrated care 
system will ensure that older persons who use drugs 
receive seamless care when and where they need it, be it 
from their primary care provider performing a medi-
cation review to their potential treatment for existing or 
future drug use- or age-related comorbidities. At the 
individual level, this may involve the development of 
guidance documents and care pathways for primary care 
providers and general practitioners, as well as guidance 
documents and shared care protocols for systems of care. 
Such protocols would outline the roles and responsibili-
ties of staff within organizations and provide a means of 
inter-agency partnership and referrals between special-
ized and recovery services on the one hand and health- 
and social-care services on the other.
56. It is recommended that countries involve older 
persons who use drugs in the development of services. 
Listening to and acting on the views of service users are 
vital parts of the planning and delivery of health-care 
services for all citizens.
57. Given the commitment by Member States in the 
outcome document of the thirtieth special session of the 
General Assembly to age- and gender-appropriate 
services, it is recommended that any policies developed 
for older persons who use drugs be underpinned by the 
principles of independence, participation, care, self- 
fulfilment and dignity, as set out in the United Nations 
Principles for Older Persons,63 and should be developed 
using Active Ageing: A Policy Framework64 and the 
Global Strategy and Action Plan on Ageing and Health.
Moving forward
58. In 2020, an unprecedented and unexpected 
pandemic raged across the globe, ignoring borders and 
other boundaries. The COVID-19 pandemic is having an 
impact on the global population in drastic ways, with 
older persons facing the most severe threats and 
challenges at this time. Although people of all age groups 
63 General Assembly resolution 46/91.
64 WHO (Geneva, 2002).
are at risk of contracting COVID-19, older persons face 
a significant risk of developing severe illnesses owing to 
physiological changes that come with ageing and poten-
tial underlying health conditions. A group that is particu-
larly vulnerable is older persons who use drugs and, as 
the pandemic continues, countries should ensure that 
older persons who use drugs are provided with focused 
and appropriate health and social support to enable them 
to survive the pandemic while preventing drug use and 
its associated consequences.
59. The needs of older persons who use drugs range 
from individual needs to family, community and system 
and service needs. Health needs can be complex for all 
older persons and even more so for those who use drugs, 
particularly if those drugs have originally been prescribed 
by health professionals or if the substance use is a chronic 
relapsing condition, ranging from the inappropriate use 
of alcohol to the misuse of opiate pain medications and 
others. Other needs may be related to the fear of elder 
abuse; isolation from family and loss of friends; fear of 
stigmatization; fear of entering into contact with the judi-
cial system; and fear of poverty and homelessness.
60. However, guiding principles, policies and good 
practices exist to address these very issues. Countries, 
communities and policymakers need to move away from 
a deficits-based model when addressing the needs of 
older persons who use drugs and need to embrace models 
based on citizen engagement, integrated holistic care and 
the co-creation of ongoing professional and community 
development to address stigma at the individual, family 
and service levels. 
61. Older persons across the globe who use drugs are 
faced with health, security and participation challenges 
never before experienced on a global scale. The Board 
would like to urge Member States to take action on the 
combined challenge of substance use and ageing in a 
comprehensive manner and to make use of the available 
scientific evidence and the recommendations in the 
present report (see chap. IV) to address the deficits of 
the past and move towards a more positive future for 
one of the most marginalized groups of society: older 




Functioning of the international drug  
control system
A.  Promoting the consistent 
application of the international 
drug control treaties
62. The fundamental goal of the international drug con-
trol system is assuring the health and welfare of human-
kind. That goal is to be achieved through two, twin 
actions: (a) ensuring the availability of internationally 
controlled substances for medical and scientific purposes 
and, in the case of precursor chemicals, ensuring their 
legitimate industrial use; and (b) preventing the diversion 
of controlled substances into illicit channels.
63. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at achieving the overall goals of the conventions. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance their effectiveness. In the present sec-
tion, the Board highlights action that needs to be taken 
to implement the provisions of the international drug 
control treaties, describes problems encountered in that 
regard and provides specific recommendations on how to 
deal with those problems.
1.  Status of adherence to the 
international drug control treaties
64. Although there were no new accessions to the 
three international drug control conventions in the 
period under review, they remain among the most 
widely ratified international instruments, with near-
universal ratification by States.
65. The 1961 Convention as amended has been ratified 
or acceded to by 186 States, with the following States 
having yet to become parties: Cook Islands, Equatorial 
Guinea, Kiribati, Nauru, Niue, Samoa, South Sudan, 
Timor-Leste, Tuvalu and Vanuatu. Chad has ratified the 
1961 Convention in its unamended form.
66. The number of States parties to the 1971 Convention 
is 184. The States not yet having acceded to it are the 
Cook Islands, Equatorial Guinea, Haiti, Kiribati, Liberia, 
Nauru, Niue, Samoa, Solomon Islands, South Sudan, 
Timor-Leste, Tuvalu and Vanuatu.
67. With 191 parties (190 States and the European 
Union), the 1988 Convention is the most widely ratified 
of the three international drug control conventions. The 
States that have not yet acceded to it are Equatorial 
Guinea, Kiribati, Papua New Guinea, Solomon Islands, 
Somalia, South Sudan and Tuvalu.
68. The Board continues to engage with States having 
yet to become party to one or more of the international 
drug control conventions with the aim of supporting 
them to accede to these important instruments without 
delay and to ensure the comprehensive incorporation of 
the conventions into national law. 
69. As the Board has repeatedly pointed out, the three 
international drug control conventions provide a common 
normative framework for effective international drug 
control, in particular in their capacity as the legal basis 
for international cooperation, extradition and mutual 
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legal assistance. The Board encourages countries not yet 
having done so to take positive steps towards accession 
to the three international drug control conventions and 
stands prepared to assist them in whatever manner 
possible. 
2.  Changes to the scheduling of 
substances under international 
control
Narcotic drugs
70. At its sixty-third session, in March 2020, the 
Commission on Narcotic Drugs, by its decisions 63/2 and 
63/3, included two new substances, namely crotonylfen-
tanyl and valerylfentanyl, in Schedule I of the 1961 
Convention as amended. In accordance with article 3, 
paragraph 7, of that Convention, that decision was com-
municated by the Secretary-General to all Governments, 
WHO and the Board on 7 May 2020 and became effective 
with respect to each party upon receipt of that 
notification. 
Psychotropic substances
71. Also at its sixty-third session, the Commission on 
Narcotic Drugs decided, in its decisions 63/4, 63/5, 63/6, 
63/7, 63/8, 63/9, 63/10, 63/11, 63/12 and 63/13, to include 
10 new substances in the schedules of the 1971 Convention. 
DOC was included in Schedule I; seven substances, 
namely, AB-FUBINACA, 5F-AMB-PINACA (5F-AMB, 
5F-MMB-PINACA), 5F-MDMB-PICA (5F-MDMB-2201), 
4-F-MDMB-BINACA, 4-CMC (4-chloromethcathinone, 
clephedrone), N-ethylhexedrone and alpha-PHP were 
included in Schedule II; and two substances, namely, 
flualprazolam and etizolam, were included in Schedule IV. 
With those additions, the total number of substances 
controlled under the 1971 Convention was brought to 159.
72. The scheduling decisions became fully effective on 
3 November 2020, namely, 180 days after the date of com-
munication by the Secretary-General. 
Precursor chemicals
73. At the same session of the Commission on Narcotic 
Drugs, the President of INCB announced the Board’s 
decision to recommend that MAPA, a pre-precursor used 
in the illicit manufacture of amphetamine and metham-
phetamine, be placed under international control.
74. The Board had conducted an assessment of MAPA 
on the basis of information received from 50 Governments 
and concluded that it was a substitute chemical for several 
amphetamine and methamphetamine precursors listed in 
Table I of the 1988 Convention, namely P-2-P, APAAN 
and the recently controlled APAA. MAPA started to 
emerge in late 2017 and, since November 2018, an 
increase in the number of seizures and amounts seized 
has been reported.
75. The emergence of MAPA is closely linked to an 
increase in scrutiny of APAA. MAPA is therefore another 
illustration of the concept of designer precursors, namely, 
close chemical relatives of controlled precursors that are 
purpose-made and can be easily converted into a 
controlled precursor. Similar to APAAN, APAA and other 
designer precursors, MAPA does not have any legitimate 
use and is therefore not traded widely and regularly, 
although it is advertised by a number of online suppliers.
76. At its sixty-third session, the Commission on 
Narcotic Drugs, in its decision 63/1, decided to include 
MAPA, including its optical isomers, in Table I of the 
1988 Convention.
77. The number of seizures and the amounts seized have 
been a concern since the emergence of MAPA in 2017. 
With the scheduling of MAPA, INCB hopes to see an 
impact on the availability of the substance for illicit drug 
manufacturing purposes, and a first step towards an 
encompassing solution to address designer precursors. 
78. The Board welcomes the efforts made by the 
Governments that have already put the recently 
scheduled substances under control and urges all other 
Governments to amend the lists of substances controlled 
at the national level accordingly and to apply to those 
substances all control measures required under the 
three international drug control treaties.
3.  Submission of information by 
Governments to the Board
(a)  Statistical reports for narcotic drugs, 
psychotropic substances and precursor 
chemicals
79. In accordance with its mandate, the Board publishes 
its annual report and the report on the implementation 
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of article 12 of the 1988 Convention.65 The Board also 
publishes technical reports that provide Governments 
with an analysis of statistical information on the manu-
facture, consumption, utilization and stocks of and trade 
in internationally controlled substances, together with an 
analysis of estimates and assessments of requirements for 
those substances.
80. The Board’s reports and technical publications are 
produced on the basis of information that parties to the 
international drug control treaties are obligated to submit. 
In addition, pursuant to resolutions of the Economic and 
Social Council and the Commission on Narcotic Drugs, 
Governments voluntarily provide information in order to 
facilitate an accurate and comprehensive evaluation of the 
functioning of the international drug and precursor 
control system.
81. The data and other information received from 
Governments enable the Board to monitor licit activities 
involving narcotic drugs, psychotropic substances and 
precursor chemicals and to evaluate treaty compliance 
and the overall functioning of the international drug and 
precursor control system. On the basis of its analysis, the 
Board makes recommendations to improve the workings 
of the system with a view to ensuring the availability of 
narcotic drugs and psychotropic substances for medical, 
scientific and industrial needs, while at the same time 
preventing their diversion from licit into illicit channels.
Narcotic drugs
82. As at 1 November 2020, the Board had received 
annual statistical reports from 158 States (both parties 
and non-parties) and territories on the production, 
manufacture, consumption, stocks and seizures of 
narcotic drugs covering the calendar year 2019 (form C), 
or about 74 per cent of those requested. That number 
represents a decline compared with previous years (173 
reports covering the calendar year 2018 were received in 
2019 and 172 reports covering the calendar year 2017 
were received in 2018). The decrease is probably due to 
difficulties experienced in the collection of data by the 
competent national authorities as a result of the onset of 
the COVID-19 pandemic, which affected countries in all 
regions of the world. Most large manufacturing, consuming 
and exporting countries, however, submitted statistics.
83. A total of 109 Governments, or 51 per cent of all 
Governments, submitted their data on time, that is, by 
the deadline of 30 June 2020, which was more than in 
65 E/INCB/2020/4.
2019 (102 Governments) but less than in 2018 (113 
Governments). As at 1 November 2020, 56 Governments 
(26 per cent) – that is, 49 countries and seven territories 
– had not submitted their annual statistics for 2019. It is 
expected that several additional countries and territories 
will be submitting the data over the coming months. Most 
countries and territories that have not submitted their 
reports are in Africa, the Caribbean, Asia and Oceania 
and some are in conflict and post-conflict situations, 
which, in addition to a general lack of human and finan-
cial resources arising from such situations, presents addi-
tional obstacles to drug control efforts.
84. Most countries that produce, manufacture, import, 
export or consume large amounts of narcotic drugs 
submitted annual statistics, although of differing quality. 
Accurate and timely reporting is an important indicator 
of the effectiveness and efficiency of drug control systems 
and the availability of good data is vital for the Board to 
accurately carry out the monitoring function accorded to 
it under the international drug control treaties. The quality 
of some data is a concern for the Board, particularly if 
they are data from major producing and manufacturing 
countries, as they indicate deficiencies in national mecha-
nisms for regulating and monitoring internationally 
controlled substances. The Board urges Governments to 
continue to strengthen their national mechanisms to 
monitor the cultivation, production and manufacture of 
and trade in controlled substances. This may be achieved, 
in part, by improving and developing national data-
collection systems, training staff of the competent 
national authorities and ensuring close cooperation with 
companies licensed to deal with internationally con-
trolled substances.
85. As at 1 November 2020, the complete set of four 
quarterly statistics of imports and exports of narcotic 
drugs for 2019 (form A) had been received from 175 
Governments (162 countries and 13 territories), or about 
75 per cent of the 213 Governments requested. In addi-
tion, 13 Governments (about 6 per cent) had submitted 
at least one quarterly report. A total of 26 countries 
(about 12 per cent) had failed to submit any quarterly 
statistics for 2019.
Psychotropic substances
86. As at 1 November 2020, annual statistical reports 
for 2019 on psychotropic substances (form P) had been 
submitted to the Board in accordance with article 16 of 
the 1971 Convention by 170 countries and territories. Of 
the 197 countries and territories subject to the reporting 
requirements of the Convention, 154 (78 per cent) 
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submitted their annual statistical report for 2019. 
Furthermore, of the 13 territories not subject to the 
reporting requirements of the Convention, 5 (38 per cent) 
submitted their annual statistical report for 2019. In addi-
tion, 114 Governments voluntarily submitted all four 
quarterly statistical reports on imports and exports of 
substances listed in Schedule II of the 1971 Convention 
for 2019, as requested by the Economic and Social Council 
in its resolution 1981/7, and a further 33 Governments 
submitted at least one quarterly report for 2019. The 
Board notes with satisfaction the significantly improved 
rate of submission of the annual statistical reports for 
2019 on psychotropic substances and the number of 
non-party countries and territories that have submitted 
an annual report.
87. While the majority of Governments regularly submit 
their mandatory and voluntary statistical reports, the 
cooperation of some has not been satisfactory. In 2020, 
about 64 per cent of the countries that submitted form P 
for 2019 did so by the deadline of 30 June 2020. A number 
of countries informed the Board that, owing to operational 
constraints stemming from the COVID-19 pandemic, 
they would be delayed in providing the required statistical 
reports for 2019. However, ultimately, most countries were 
able to submit their reports in time for inclusion in the 
annual and technical reports of the Board.
88. The Board notes with concern the high percentage 
of countries and territories that did not furnish form P. 
A total of 19 countries and territories in Africa failed to 
furnish form P for 2019. Likewise, seven countries and 
territories in Oceania, nine countries and territories in 
Central America and the Caribbean, four countries in 
South America, four countries in Asia and one country 
in Europe failed to furnish form P for 2019. Form P for 
2019 was furnished by all countries in North America.
89. The Board takes note of the countries that have pro-
vided data regarding their use of psychotropic substances 
for the manufacture of preparations exempted from some 
measures of control pursuant to article 3 of the 1971 
Convention: 10 countries reported using 29 substances 
for such purposes in 2019. The Board recalls recommen-
dation 13 from its annual report for 2019, in which it 
called upon Governments to ensure that all aspects of 
article 3 of the 1971 Convention were correctly imple-
mented if they wished to exempt a preparation from 
certain measures of control.
90. The Economic and Social Council, in its resolutions 
1985/15 and 1987/30, requested Governments to provide 
the Board with details on trade (data broken down by 
countries of origin and destination) in substances listed 
in Schedules III and IV of the 1971 Convention in their 
annual statistical reports on psychotropic substances. As 
at 1 November 2020, complete details on such trade had 
been submitted by 149 Governments (88 per cent of all 
submissions of form P for 2019). A further 21 Governments 
submitted blank forms or forms containing incomplete 
trade data for 2019.
91. The Board notes with appreciation that a number of 
countries have already submitted consumption data for 
psychotropic substances on a voluntary basis, in accor-
dance with Commission on Narcotic Drugs resolution 54/6.
92. For 2019, a total of 88 countries and territories 
submitted data on the consumption of some or all psycho-
tropic substances. The Board appreciates the cooperation 
of the Governments concerned and calls upon all 
Governments to report on the consumption of psycho-
tropic substances on an annual basis, pursuant to 
Commission resolution 54/6, as such data are essential 
for an improved evaluation of the availability of psycho-
tropic substances for medical and scientific purposes.
93. The Board notes with appreciation that reports on 
seizures of psychotropic substances were furnished by the 
Governments of India and Romania. The Board acknow-
ledges the interdiction efforts of the Governments 
concerned and calls upon all Governments to furnish 
regularly to the Board, pursuant to Commission on 
Narcotic Drugs resolution 50/11, information on seizures 
of psychotropic substances ordered over the Internet and 
delivered through the mail.
Precursor chemicals
94. In accordance with article 12 of the 1988 Convention, 
parties are obliged to furnish information on substances 
frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances. That information, 
provided on form D, assists the Board in monitoring and 
identifying trends in trafficking in precursors and the 
illicit manufacture of drugs. It also enables the Board to 
provide Governments with recommendations concerning 
remedial action and policies, as necessary.
95. As at 1 November 2020, a total of 120 Governments, 
corresponding to nearly 63 per cent of the States parties 
to the 1988 Convention, had submitted form D for 2019. 
However, the Board’s analysis of the global precursor situ-
ation continued to be affected by late submission, the 
submission of incomplete or entirely blank forms, and the 
inability of some Governments to gather information at 
the national level and consolidate it into a single 
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submission. For example, of the States parties that pro-
vided data on form D for 2019, 78 reported the manda-
tory information on seizures of substances listed in Table I 
 or Table II of the 1988 Convention, and only 50 reported 
seizures of non-scheduled substances. As in previous 
years, most Governments did not provide details on the 
methods of diversion and illicit manufacture.
96. Pursuant to Economic and Social Council resolution 
1995/20, Governments are requested to provide informa-
tion regarding their licit trade in substances listed in 
Tables I and II of the 1988 Convention on a voluntary 
and confidential basis. As at 1 November 2020, 115 States 
parties had provided such information for 2019 to the 
Board, and 104 had furnished data on licit uses of and/
or requirements for one or more of the substances listed 
in Tables I and II of the 1988 Convention (see figure I).
Figure I Data submitted on form D by States 
parties to the 1988 Convention, 2015–2019
97. Complementing the aggregated seizure data received 
annually from Governments through form D, since early 
2012, PICS has provided a secure online platform for 
sharing information in real time on chemical-related inci-
dents such as seizures, shipments stopped in transit, 
diversions, the dismantling of illicit laboratories and sei-
zures of associated equipment. PICS has provided leads 
for national authorities to initiate backtracking investiga-
tions and, on several occasions, the timely communica-
tion of details of precursor incidents has led to further 
seizures or has prevented diversions. The usefulness of 
PICS, however, depends largely on the timeliness of the 
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follow-up and cooperation to identify those responsible 
for the diversion of and trafficking in precursors.
98. As at 1 November 2020, PICS had registered users 
from more than 285 agencies in 123 countries, who had 
shared information about more than 3,100 incidents. 
During the reporting period, information on more than 
300 new incidents were shared through PICS.
99. The seizure data reported and a detailed analysis of 
the latest trends and developments in trafficking in pre-
cursor chemicals under international control, as well as 
their non-scheduled substitutes and alternatives, can be 
found in the report of the Board for 2020 on the imple-
mentation of article 12 of the 1988 Convention. 
(b)  Estimates for narcotic drugs, 
assessments for psychotropic 
substances and annual legitimate 
requirements for precursor chemicals
Narcotic drugs
100. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables both exporting and importing 
countries to ensure that trade in those substances stays 
within the limits determined by the Governments of 
importing countries and that diversion of controlled sub-
stances from international trade is effectively prevented. 
For narcotic drugs, such a system is mandatory under the 
1961 Convention as amended, and the estimates fur-
nished by Governments need to be confirmed by the 
Board before becoming the basis for calculating the limits 
on manufacture and import. As at 1 November 2020, the 
Governments of 161 countries and territories had submit-
ted annual estimates of narcotic drugs requirements for 
2021. To ensure that Governments may import narcotic 
drugs for medical and scientific purposes, estimates are 
established by the Board for countries that are unable to 
supply them and, for 2020, 28 countries in all regions of 
the world operated on the basis of estimates established 
for them by the Board.
101. Governments are obliged to comply with the limits 
on imports and exports of narcotic drugs provided for 
under articles 21 and 31 of the 1961 Convention as 
amended. Article 21 stipulates, inter alia, that the total of 
the quantities of each drug manufactured and imported 
by any country or territory in a given year is not to exceed 
the sum of the following: the quantity consumed for 
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medical and scientific purposes; the quantity used, within 
the limits of the relevant estimates, for the manufacture 
of other drugs, preparations or substances; the quantity 
exported; the quantity added to the stock for the purpose 
of bringing that stock up to the level specified in the rel-
evant estimate; and the quantity acquired within the limit 
of the relevant estimate for special purposes. Article 31 
requires all exporting countries to limit the export of nar-
cotic drugs to any country or territory to quantities that 
fall within the limits of the total of the estimates of the 
importing country or territory, with the addition of the 
amounts intended for re-export.
102. The system of import and exports continues to be 
implemented by Governments, as trade increases, and it 
works well. In 2020, a total of 19 countries were contacted 
regarding possible excess imports or excess exports iden-
tified with regard to international trade in narcotic drugs 
that had been effected during the year. As at 1 November 
2020, nine of those countries had responded. The Board 
continues to pursue the matter with those countries that 
have not responded.
103. The Board recommends that Governments 
continue to strengthen the capacity of competent 
national authorities to adequately estimate the medical 
and scientific need for narcotic drugs, including through 
the use of globally available e-learning modules, and 
also recommends that Governments enhance domestic 
data-collection mechanisms so that they can present 
estimates that accurately reflect the national needs of 
narcotic drugs for medical purposes.
Psychotropic substances
104. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of annual domestic 
medical and scientific requirements for psychotropic 
substances listed in Schedules II, III and IV of the 1971 
Convention. The assessments received are communicated 
to all States and territories to assist the competent authorities 
of exporting countries when approving exports of psycho-
tropic substances. As at 1 November 2020, the Governments 
of all countries and territories, except for South Sudan, for 
which assessments were established by the Board in 2011, 
had submitted at least one assessment of their annual 
medical requirements for psychotropic substances.
105. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 36 Governments have 
not submitted a revision of their legitimate requirements 
for psychotropic substances for three years or more. The 
assessments valid for those countries and territories may 
therefore no longer reflect their actual medical and 
scientific requirements for such substances.
106. When assessments are lower than the actual legiti-
mate requirements, the importation of psychotropic 
substances needed for medical or scientific purposes may 
be delayed. When assessments are significantly higher 
than legitimate needs, the risk of psychotropic substances 
being diverted into illicit channels may be increased.
107. As in previous years, the system of assessments of 
annual requirements for psychotropic substances continues 
to function well and is respected by most countries and 
territories. In 2019, the authorities of 18 countries issued 
import authorizations for substances for which they had 
not established any such assessments or for quantities that 
significantly exceeded their assessments. Only one country 
was identified as having exported psychotropic substances 
in quantities exceeding the relevant assessment.
Precursor chemicals
108. In its resolution 49/3, entitled “Strengthening 
systems for the control of precursor chemicals used in the 
illicit manufacture of synthetic drugs”, the Commission on 
Narcotics Drugs requested Member States to provide the 
Board with annual legitimate requirements for imports of 
four precursors of amphetamine-type stimulants (3,4-MDP-
2-P, pseudoephedrine, ephedrine and P-2-P) and, to the 
extent possible, preparations containing those substances 
that could be easily used or recovered by readily applicable 
means. The estimates help Governments to assess the 
legitimacy of shipments and to identify any excesses in 
pre-export notifications for the substances.
109. Although these estimates are provided to the Board 
on a voluntary basis, as at 1 November 2020, 172 
Governments had provided an estimate of their annual 
legitimate requirements for at least one of the above-
mentioned substances. During the reporting period, more 
than 114 Governments reconfirmed or updated their 
annual legitimate requirements for at least one of the sub-
stances. During the reporting period, the Governments 
of the Marshall Islands, Timor-Leste and Viet Nam sub-
mitted an estimate for at least one of the four substances 
for the first time.
110. Governments provide estimates of annual legiti-
mate requirements for precursors on form D and can 
update them at any time throughout the year. The latest 
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annual legitimate requirements, as submitted by countries 
and territories, are regularly updated and published on 
the Board’s website. They are also accessible to registered 
users through PEN Online.
111. The Board notes that accurate estimates of national 
needs and related import requirements remain key 
factors in preventing diversion. The Board therefore 
re commends that Governments regularly review their 
annual legitimate requirements for individual precursors 
and inform the Board of any necessary changes or recon-
firm the published estimates. The Board encourages the 
competent authorities of exporting countries to use the 
published estimates of importing countries and suspend 
exports until any doubts about the legitimacy thereof 
have been dispelled or discrepancies have been removed.
4.  Efforts to prevent diversion from 
international trade
112. The system of control measures laid down in the 
1961 Convention as amended provides for the monitoring 
of international trade in narcotic drugs to prevent the 
diversion of such drugs into illicit channels. As a result of 
the almost-universal implementation of the control 
measures stipulated in the 1971 Convention and the 
relevant Economic and Social Council resolutions, there 
has been only one identified case involving the diversion 
of psychotropic substances from international trade into 
illicit channels in recent years. In addition, the 1988 
Convention requires parties to prevent the diversion of 
precursor chemicals from international trade to the illicit 
manufacture of narcotic drugs and psychotropic substances. 
The Board has developed various systems to monitor 
compliance with that aspect of the 1988 Convention and 
to facilitate cooperation between Governments to that end.
Requirement for import and export 
authorizations
113. The universal application of the requirement for 
import and export authorizations laid down in the 1961 
Convention as amended and the 1971 Convention is key 
to preventing the diversion of drugs into the illicit market. 
Such authorizations are required for transactions involving 
any of the substances controlled under the 1961 
Convention as amended or listed in Schedules I and II 
of the 1971 Convention.
114. Competent national authorities are required by 
those conventions to issue import authorizations for 
transactions involving the importation of such substances 
into their country. The competent national authorities of 
exporting countries must verify the authenticity of such 
import authorizations before issuing the export authori-
zations required to allow shipments containing the sub-
stances to leave their countries.
115. The 1971 Convention does not require import and 
export authorizations for trade in the psychotropic 
substances listed in its Schedules III and IV. However, in 
view of the widespread diversion of those substances from 
licit international trade during the 1970s and 1980s, the 
Economic and Social Council, in its resolutions 1985/15, 
1987/30 and 1993/38, requested Governments to extend 
the system of import and export authorizations to cover 
those psychotropic substances as well.
116. Most countries and territories have already intro-
duced an import and export authorization requirement 
for psychotropic substances listed in Schedules III and IV 
of the 1971 Convention, in accordance with the above-
mentioned Economic and Social Council resolutions. As 
at 1 November 2020, specific information had been made 
available to the Board by 205 countries and territories, 
showing that all major importing and exporting countries 
and territories now require import and export authoriza-
tions for all psychotropic substances listed in Schedules 
III and IV of the 1971 Convention. Upon request, the 
Board will make available, to all Governments, a table 
showing the import authorization requirements for sub-
stances listed in Schedules III and IV pursuant to the 
relevant Economic and Social Council resolutions. That 
table is also published in the secure area of the Board’s 
website, which is accessible only to specifically authorized 
government officials, so that the competent national 
authorities of exporting countries may be informed as 
soon as possible of changes in import authorization 
requirements in importing countries. The Board urges 
the Governments of the few remaining States in which 
national legislation and/or regulations do not yet require 
import and export authorizations for all psychotropic 
substances, regardless of whether they are States parties 
to the 1971 Convention, to extend such controls to all 
substances listed in Schedules III and IV of the 1971 
Convention as soon as possible, and to inform the Board 
in that regard.
117. I2ES, a web-based electronic system developed by 
the Board together with UNODC, is provided to 
Governments at no cost to allow countries to securely 
exchange import and export authorizations for the trade 
in internationally controlled narcotic drugs and psycho-
tropic substances. Greater use of the platform by 
Governments will help prevent the diversion of inter-
nationally controlled substances from international trade, 
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in addition to facilitating more rapid trade. The Board 
continues to encourage all Governments that are not 
yet doing so to utilize I2ES and seek the assistance of 
the Board’s secretariat in using and implementing the 
platform.
118. The 1988 Convention does not impose a require-
ment for import and export authorizations for trade in 
substances listed in Tables I and II of that Convention. 
However, Governments that do not apply some system of 
control over exports and imports of precursors are not 
fully complying with their treaty obligations to effectively 
contribute to the prevention of diversion. In addition, 
pursuant to article 12, paragraph 10 (a), of the 1988 
Convention, Governments of exporting countries and ter-
ritories are to provide advance notification to the authori-
ties of the importing Government of planned shipments 
with a view to preventing the diversion of those sub-
stances (see below for more information on pre-export 
notifications for precursor chemicals).
Discrepancies in international trade in 
narcotic drugs and psychotropic substances
119. Discrepancies in government reports on inter-
national trade in narcotic drugs and psychotropic 
substances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. Those investiga-
tions may reveal shortcomings in the implementation of 
control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
120. Since May 2020, investigations regarding discrep-
ancies for 2019 related to the trade in narcotic drugs have 
been initiated with 73 countries. As at 1 November 2020, 
replies had been received from 43 countries. The responses 
indicated that the discrepancies had been caused by 
clerical and technical errors in preparing the reports, 
reporting on exports or imports of preparations in 
Schedule III of the 1961 Convention as amended without 
indicating it on the form, or inadvertent reporting of 
transit countries as trading partners. In some cases, coun-
tries confirmed the quantities reported by them, resulting 
in the initiation of follow-up investigations with their 
trading partners. Reminder letters will be sent to the 
countries that did not reply. 
121. Similarly, with regard to international trade in 
psycho tropic substances, investigations into 598 dis-
crepancies related to 2019 data were initiated with 92 
countries. Owing to delays in the reporting of statistical 
data for 2019 by some countries, investigations into trade-
related discrepancies for that year are still ongoing.
Precursor chemicals
122. With regard to precursors, the 1988 Convention 
requires parties to prevent the diversion of precursors 
from international trade to the illicit manufacture of nar-
cotic drugs and psychotropic substances. In line with the 
provisions of article 12 of the 1988 Convention, which 
have been complemented by a number of General 
Assembly, Economic and Social Council and Commission 
on Narcotic Drugs resolutions, many Governments have 
adopted and implemented measures that have contrib-
uted to the effective monitoring of the movement of sub-
stances listed in Tables I and II of that Convention and 
to limiting cases of diversion from licit international 
trade. Details of the systems of controls applied by 
Governments over exports and imports of substances 
listed in Tables I and II of the 1988 Convention are 
compiled by the Board and made available to competent 
national authorities on its secure web page, as part of the 
Board’s work on the control of precursors.
Prevention of diversion of precursors from 
domestic distribution channels
123. The diversion of precursors from domestic distri-
bution channels remains a major source of the substances 
listed in Tables I and II of the 1988 Convention that are 
used for illicit drug manufacture. The control measures 
applied by Governments to domestic trade in and distribu-
tion of chemical substances vary from country to country 
and often fall short of those used in international trade. 
INCB calls upon Governments to review their domestic 
control mechanisms, in particular the procedures for 
granting or refusing registration of chemical operators, 
and the requirements for end-user declarations, as well 
as any related thresholds that may be exploited by 
traffickers.
124. Public-private partnerships and voluntary coopera-
tion with relevant industries play an important role in 
addressing chemical diversion, especially from domestic 
channels. INCB promotes such partnerships through 
general awareness-raising and hands-on advocacy in 
specific cases. In addition, INCB, in its efforts to support 
Governments in the prevention and investigation of cases 
of diversion of precursors, has developed several 
platforms, tools and projects to facilitate the real-time 
exchange of information and cooperation between 
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Governments. The two initiatives of the Board focusing 
on precursors used in the illicit manufacture of synthetic 
drugs and on chemicals related to illicit cocaine and 
heroin manufacture, namely, Project Prism and Project 
Cohesion, respectively, contribute to preventing the diver-
sion of controlled substances from both international 
trade and domestic distribution channels and to closing 
knowledge gaps, including with regard to modi operandi, 
during time-bound operations.
125. Detailed analysis of the latest trends and develop-
ments in legitimate international trade and in trafficking 
in precursor chemicals under international control, as 
well as their non-scheduled substitutes and alternatives, 
can be found in the report of the Board for 2020 on the 
implementation of article 12 of the 1988 Convention.
Pre-export notification for precursor 
chemicals
126. To prevent the diversion of precursors, article 12, 
paragraph 10 (a), of the 1988 Convention allows the 
Governments of importing countries to make it manda-
tory for exporting countries to inform them of any 
planned export of precursors to their territory. Since the 
report of the Board for 2019, the Governments of 
two countries, Honduras and Tunisia, have officially 
requested to be pre-notified, thus increasing the number 
of Governments that have invoked that provision to 115. 
The Board encourages those Governments that have not 
formally requested pre-export notifications to take the 
necessary steps to invoke article 12, paragraph 10 (a), 
of the 1988 Convention.
127. Real-time communication between importing and 
exporting Governments as regards international trade in 
precursors and preventing diversion into illicit channels 
is facilitated by the Board’s secure web-based tool, PEN 
Online. As at 1 November 2020, the Government of one 
additional country, Guyana, had registered with PEN 
Online, bringing the total number of registered countries 
and territories to 165. INCB urges the remaining 
32 Governments that have not yet registered with the 
PEN Online system to do so as soon as possible and 
calls upon Governments to use PEN Online actively and 
systematically. The Board stands ready to assist 
Governments in that regard.
Article 13 of the 1988 Convention: 
materials and equipment used in illicit 
drug manufacture
128. Illicit drug manufacture requires not only precursor 
chemicals, but also equipment such as specialized glass-
ware, tableting machines and other hardware employed 
in the process. Under article 13 of the 1988 Convention, 
Governments are required to take appropriate measures 
to prevent trade in and the diversion of materials and 
equipment for illicit drug manufacture, and to cooperate 
to that end.
129. The Board believes that article 13 is a valuable 
complementary tool in addressing illicit drug manufac-
ture. However, it is currently underutilized. In order to 
assist Governments in increasing the use of article 13 and 
preventing specialized equipment from reaching illicit 
laboratories, in March 2020, INCB launched a set of 
guidelines on the control and monitoring of equipment 
essential for illicit drug manufacture, as well as a 
dedicated page on the INCB website on the matter.
130. The guidelines are intended to facilitate the work 
of regulatory and law enforcement authorities by provid-
ing a range of approaches to prevent and investigate the 
diversion of such equipment. The approaches range from 
raising awareness within the industry about the misuse 
of equipment for illicit drug manufacture and conducting 
voluntary initiatives in cooperation with the industry to 
establishing more comprehensive regulatory systems.
131. The guidelines were launched at an event entitled 
“Equipment used in illicit drug manufacture: approaches 
to preventing and investigating diversion as complemen-
tary tools in addressing illicit drug supply”, organized by 
the Governments of Canada, the Netherlands and the 
United States, in cooperation with INCB, on the margins 
of the sixty-third session of the Commission on Narcotic 
Drugs. The Board encourages Governments to make use 
of the guidelines and increase the operational use of 
article 13 of the 1988 Convention to prevent and inves-
tigate the diversion of equipment essential for the illicit 
manufacture of drugs and precursors.
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B.  Ensuring the availability of 
internationally controlled 
substances for medical and 
scientific purposes
132. In line with its mandate to ensure the availability 
of internationally controlled substances for medical and 
scientific purposes, the Board carries out various activities 
related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
medical and scientific purposes and provides, through its 
secretariat, technical support and guidance to Governments 
in their implementation of the provisions of the interna-
tional drug control treaties. 
133. An analysis of the main trends in the manufactur-
ing, export, import and consumption of the main opioid 
analgesics (codeine, fentanyl, hydrocodone, hydromor-
phone, morphine and oxycodone), expressed in S-DDD 
per million inhabitants per day, shows that the highest 
consumption of these drugs is in developed countries in 
Europe and North America. Countries reporting the 
highest average consumption of opioids for pain manage-
ment in the period 2017–2019 were the United States 
(25,368 S-DDD), Germany (22,517 S-DDD), Austria 
(18,489 S-DDD),66 Belgium (15,487 S-DDD) and Canada 
(14,073 S-DDD).
134. The Board evaluates these data in terms of S-DDD, 
which is the international unit of measurement estab-
lished by WHO and used by INCB for the purpose of 
statistical analysis. It is not a recommended prescription 
dose. The availability levels of narcotic drugs expressed 
in S-DDD are calculated using the following formula: 
annual availability, excluding the manufacture of the 
preparations in Schedule III of the 1961 Convention as 
amended, divided by 365 days. The result obtained is 
divided by the population, in millions, of the country or 
territory during the year in question and then by the 
defined daily dose. Regional S-DDD is calculated on the 
basis of the total population of the countries reporting 
consumption, and the overall amounts of opioid analgesics 
reported as consumed. For the analysis, the Board uses 
the following most commonly used opioid analgesics: 
66 The Government of Austria also reported data to the Board con-
taining a breakdown of the country’s morphine consumption for opioid 
substitution treatment, which corresponded to 93 per cent of consump-
tion in 2019. When taking this information into consideration, the con-
sumption of opioids for pain management in Austria during the period 
2017–2019 decreases to 14,532 S-DDD. According to the information 
available to the Board, this is a unique situation and the S-DDD of other 
high-consuming countries should not be affected in a similar way.
codeine, dextropropoxyphene, dihydrocodeine, fentanyl, 
hydrocodone, hydromorphone, ketobemidone, morphine, 
oxycodone, pethidine, tilidine and trimeperidine. 
135. The regional analysis confirms the persistence of a 
global disparity in the consumption of opioid analgesics. 
The reported consumption of some countries in North 
America, Oceania and Western Europe resulted in 
regional averages in 2019 of over 9,000 S-DDD (19,003 
S-DDD for North America, 9,984 S-DDD for Oceania 
and 9,200 S-DDD for Western Europe). In North America, 
a sharp decrease in 2017 and 2018 was followed by a 
slight increase in 2019 and, overall, it remains the region 
with the highest consumption of opioids for pain man-
agement in the world. Declining consumption had been 
reported in Oceania since 2012 but, in 2019, it increased 
to 9,984 S-DDD. A general upward trend in consumption 
was evident in South-Eastern Europe until 2018, when it 
reached 1,415 S-DDD, but it decreased to 1,192 S-DDD 
in 2019. In Western and Central Europe, consumption 
has been relatively stable, but in 2019 it decreased to 9,200 
S-DDD, from 11,021 S-DDD in 2018 (see figure II).
Figure II Consumption of opioids for pain 
management, by region, S-DDD, 2000–2019
136. Consumption well below those values was reported 
for other regions. Of those regions, South-Eastern Europe 
reported the highest consumption in 2019 (1,192 S-DDD), 
as part of an overall increasing trend with significant 
fluctuations since the early 2000s, followed by South 
America (603 S-DDD and Eastern Europe (601 S-DDD), 
where there was a significant increase in consumption, 
from 269 S-DDD in 2018. This increase can be largely 
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which almost doubled between 2018 (321 S-DDD) and 
2019 (608 S-DDD). An overall increasing trend in con-
sumption was also observed in West Asia in the 20-year 
period 2000–2019, albeit with a decrease from 564 S-DDD 
in 2018 to 479 S-DDD in 2019 (see figure III). The rela-
tively high average consumption in the region is driven 
mainly by Israel (13,066 S-DDD in 2019) and Turkey 
(606 S-DDD).
Figure III Consumption of opioids for pain 
management, regions with the lowest 
consumption, S-DDD, 2000–2019
137. A comparison of the consumption of individual 
substances shows the prominence of fentanyl over the 
past two decades (see figure IV). However, after peaking 
in 2018 at 285,959 S-DDD, the global consumption of 
fentanyl decreased to 224,805 S-DDD in 2019. The con-
sumption of oxycodone has also been increasing, at a 
lower level, and, since 2009, has replaced morphine as 
the second most-consumed opioid, reaching an all-time 
high of 45,726 S-DDD in 2018 and decreasing to 42,592 
S-DDD in 2019. The trend in the consumption of mor-
phine, on the other hand, remained relatively stable 
between 2004 (25,644 S-DDD) and 2019 (27,746 
S-DDD). After decreasing steadily since 2014, hydroco-
done consumption increased from 14,161 S-DDD in 2018 
to 20,415 S-DDD in 2019, levels last seen in 2015. 
Hydromorphone consumption decreased from 11,834 
S-DDD in 2018 to 7,713 S-DDD in 2019, the lowest level 
since 2008. The United States accounted for almost all 
global hydrocodone use (99.3 per cent), whereas the con-
sumption of the other drugs shown in figure IV was 
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consumption of fentanyl decreased globally in 2019, espe-
cially in North America, there were significant increases 
in various countries in all other regions.
Figure IV Consumption of codeine, fentanyl, 
hydrocodone, hydromorphone, morphine and 
oxycodone, in total S-DDD,a 2000–2019
a Total S-DDD of a drug is the sum of the S-DDD of all individual 
countries reporting consumption.
138. Figures V and VI show consumption in total 
S-DDD by substance and region. This analysis highlights 
once again the prominence of fentanyl in most regions of 
the world. Oxycodone consumption is highest in North 
America, Oceania, Western and Central Europe and West 
Asia, although it is also consumed in other regions. The 
share of morphine is less pronounced in most regions, 
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Figure V Consumption of codeine, fentanyl, 
hydrocodone, oxycodone, pethidine and other 
opioids, by region, S-DDD, 2019 
Figure VI Consumption of codeine, fentanyl, 
hydrocodone, morphine, oxycodone, pethidine 
and other opioids, regions with the lower 
consumption, S-DDD, 2019
139. The Board considers levels of consumption of 
opioid analgesics in quantities between 100 and 200 
S-DDD to be inadequate, and less than 100 to be very 
inadequate. In this context, the levels of consumption 
reported in 2019 in East and South-East Asia 
(207 S-DDD), Central America and the Caribbean 
(160 S-DDD), Africa (90 S-DDD) and South Asia 
(20 S-DDD) are of particular concern. The Board 
reiterates that there is an urgent need to increase levels 
of consumption of opioid analgesics in all countries 
reporting inadequate and very inadequate consumption 
levels and calls for targeted public policies and support 
from Governments, civil society, the pharmaceutical 
industry and the international community to that end.
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1.  Patterns and trends in the 
production, manufacture, 
consumption, utilization and stocks 
of narcotic drugs and psychotropic 
substances
Narcotic drugs
140. Global production and stocks of opium increased 
significantly in 2019. Opium imports, on the other hand, 
showed a marked decrease, from 53.5 tons (5.8 tons in 
morphine equivalent) in 2018 to only 11.3 tons (1.2 tons 
in morphine equivalent) in 2019, with one traditional 
importer ceasing imports altogether. The continuing low 
demand for the drug could signal a move towards the 
eventual elimination of the drug from the international 
market for opiate raw materials.
141. Overall utilization of poppy straw and concentrate 
of poppy straw derived from the morphine-rich variety 
of poppy straw decreased in 2019 compared with 2018. 
Global manufacture of morphine in 2019 continued to be 
below 400 tons, a development that began in 2017, 
contrary to the situation in the previous decade, when 
the global manufacture of morphine was always above 
400 tons. In 2019, global manufacture of morphine 
amounted to 379.2 tons, 87 per cent of which was 
converted into other narcotic drugs or into substances 
not covered by the 1961 Convention as amended. The 
remaining amount was used mainly for palliative care 
purposes, for direct consumption and in the manufacture 
of preparations listed in Schedule III of the 1961 
Convention as amended.
142. The differences in consumption levels among 
countries continued to be very significant. In 2019, 
80.4 per cent of the world’s population, mainly in low- 
and middle-income countries, consumed only 12.8 per 
cent of the total amount of morphine used for the man-
agement of pain and suffering, or 1 per cent of the total 
379.2 tons manufactured (see figure VII). Although that 
is a slight improvement from 2014, when 80 per cent 
consumed only 9.5 per cent, the disparity in the con-
sumption of narcotic drugs for palliative care continues 
to be a matter of concern.
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Figure VII Morphine: distribution of 
consumption for medical purposes, 2019
Note: Percentages in parentheses refer to share of the world population 
(i.e., total population of all reporting countries).
143. In 2019, after some fluctuations in the preceding 
years, global manufacture of thebaine remained high, at 
127.7 tons, almost the same amount as in 2018 but 
considerably below the record level of 156 tons in 2016. 
The demand for medicines derived from thebaine may 
have been affected by the restrictions on prescription 
drugs imposed in the main market, the United States, in 
response to the abuse of such drugs and the high number 
of overdose deaths that have been associated with them. 
Nonetheless, the data continued to indicate a high level 
of demand. 
144. In terms of the semi-synthetic opioids, global 
manufacture of oxycodone and hydrocodone decreased 
again in 2019, after showing decreases in 2018. Global 
manufacture of hydromorphone decreased to the lowest 
level since 2004, and the manufacture of ethylmorphine 
and heroin increased.
145. In the case of synthetic opioids, global manufacture 
of fentanyl increased in 2019, after a marked decrease in 
2018. Consumption of fentanyl, on the other hand, 
decreased, while reported consumption of fentanyl 
analogues (alfentanil, remifentanil and sufentanil) 
increased. The manufacture of diphenoxylate showed 
growth, after declines had been recorded for some time. 
Reported manufacture of tilidine rose in 2019, after his-
torically low levels in 2018. The manufacture of pethidine 
has trended downwards for 20 years but increased slightly 















second consecutive year. There was no report of manu-
facturing of ketobemidone and less than 1 kg of dextro-
propoxyphene was reported as having been manufactured 
in 2019. The manufacture of methadone declined in 2019, 
after increasing in 2018.
146. The cultivation and production of cannabis for 
medical and scientific purposes has been on the rise over 
the past five years. Prior to 2010, only the United States 
reported production, which was related to scientific 
research. Since 2000, and particularly since 2015, an 
increasing number of countries have started to use can-
nabis and cannabis extracts for medical purposes as well 
as for scientific research and have also authorized the 
cultivation of cannabis. For 2019, the licit production of 
468.3 tons was reported. However, as manufacturing pro-
cesses and yields are not standardized, some data are 
being clarified with the relevant Governments in order to 
ensure consistency.
147. The United States continued to import coca leaf 
for the extraction of a flavouring agent. The global licit 
consumption of cocaine, which had been stable during 
the previous two decades, ranging between 100 kg and 
300 kg, amounted to 466 kg in 2019, a further increase, 
after 394.1 kg were recorded in 2018.
Psychotropic substances
148. As at the end of 2019, 149 substances had been 
placed under international control, up from 144 at the 
end of 2018. Of those, five new substances were included 
in Schedule II of the 1971 Convention: ADB-FUBINACA; 
FUB-AMB (MMB-FUBINACA, AMB-FUBINACA); 
CUMYL-4CN-BINACA; ADB-CHMINACA (MAB-
CHMINACA); and N-ethylnorpentylone (ephylone). As 
these substances came under international control in late 
2019 and countries are not required to collect data on the 
manufacture and consumption of and trade in substances 
prior to their placement under international control, 
information on the licit market activity is limited.
149. In 2019, similar to previous years, benzodiazepines 
accounted for most of the manufacture and consumption 
of and trade in internationally controlled psychotropic 
substances. Of the 36 controlled benzodiazepines, 21 were 
identified as having a significant presence on the licit 
market that year. The main manufacturers of this group 
of substances overall continued to be Italy, China, India, 
Brazil and Germany (in descending order of the amount 
manu factured), together accounting for 90 per cent of 
total global manufacture (see figure VIII). In 2019, the 
most-traded benzo diazepines were diazepam, midazolam, 
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clonazepam and alprazolam, in terms of the number of 
importing countries. The total reported manufacture of 
those benzodiazepines amounted to more than 185 tons, 
with manufacture having been reported in all regions of 
the world.
Figure VIII Benzodiazepines with significant 
presence on the licit market: share of global 
manufacture, by country, 2019
150. In 2019, the Board received data from nearly 
85 countries reporting consumption of at least one 
benzodiazepine, which represented a decrease from the 
previous year, when 100 countries submitted national 
consumption data. The highest rates of consumption of 
all benzodiazepines with significant presence on the licit 
market combined, measured in S-DDD per 1,000 
in habitants per day, were reported by Spain, Serbia, 
Uruguay, Israel, the United States and Hungary, in 
descending order. The most widely consumed benzo-
diazepines in 2019 were alprazolam, lorazepam, diazepam, 
clonazepam, bromazepam, lormetazepam and estazolam, 
each of which were reported to have been consumed in 
quantities greater than 50 S-DDD per 1,000 inhabitants 
per day globally. In 2019, Cameroon, Saint Vincent and 
the Grenadines, Spain, Thailand, Venezuela (Bolivarian 
Republic of) and Yemen provided consumption data for 
the first time in over three years.
151. As in previous years, phenobarbital was one of the 
most manufactured psychotropic substances under inter-
national control, at 382 tons in 2019, an increase of 
almost 80 tons compared with 2018. China (181 tons) 














quarters of all global manufacture, a trend largely 
unchanged from previous years. Hungary (44 tons) and 
the Russian Federation (25 tons) were other major manu-
facturers of the substance.
152. Eighty countries provided data on their consump-
tion of phenobarbital in 2019, down from 99 for 2018. 
Average consumption, among the 80 countries that 
provided data for 2019, stood at 0.59 S-DDD, down from 
the 2018 average of 0.79 S-DDD among countries and 
territories that reported consumption for that year. The 
decrease in global consumption is probably a result of 
fewer countries reporting consumption for 2019.
153. Regional differences in the consumption of pheno-
barbital remain difficult to ascertain as consumption data 
were only provided by approximately half of the countries 
and territories that submitted a statistical report on psy-
chotropic substances for 2019. Countries and territories 
in the Americas and Europe provided the most data on 
consumption in 2019: 20 and 25 countries and territories, 
respectively. In contrast, the number of countries in 
Africa and Asia providing consumption data for 2019 was 
low (12 and 17 countries and territories, respectively), 
continuing the general trend of low consumption data 
reporting from previous years. 
154. Global manufacture of methylphenidate decreased 
further in 2019, following the downward trend that began 
in 2017. Total imports of the substance, however, regis-
tered a further increase in 2019 and reached 53 tons, its 
highest record for the past six years. Global stocks of 
methylphenidate registered a considerable increase and 
reached 132 tons in 2019, up from 79.5 tons in 2018 (see 
figure IX). Unlike the year before, the United States 
accounted for only half of those stocks, with the rest being 
held by Germany, Switzerland and the United Kingdom. 
155. A total of 58 countries provided consumption data 
on methylphenidate in 2019, with the majority of those 
with the highest consumption rates reporting further 
increases in their consumption of the substance. The 
countries with the highest rates of reported consumption 
of methylphenidate in 2019 were Iceland, Israel, Canada, 
the Netherlands, the United States, Spain, Denmark and 
Sweden, in descending order of the amounts consumed. 
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Figure IX Methylphenidate: global 
manufacture, imports and stocks, 2010–2019
156. A detailed analysis of the patterns and trends in 
the manufacture, trade, stocks and consumption of psycho-
tropic substances is contained in the technical report of 
the Board for 2020 on psychotropic substances.67 
2.  Supply of and demand for opiate 
raw materials
157. The Board, in fulfilment of the functions assigned 
to it under the 1961 Convention as amended and the 
relevant resolutions of the Economic and Social Council 
and the Commission on Narcotic Drugs, regularly examines 
issues affecting the supply of and the demand for opiates 
for licit requirements and endeavours to ensure a stand-
ing balance between that supply and demand. 
158. The Board analyses the data provided by 
Governments on opiate raw materials and opiates manu-
factured from those raw materials to establish the status 
of the supply of and the demand for opiate raw materials 
globally. In addition, the Board analyses information on 
the use of those raw materials, estimated consumption 
for licit use and stocks at the global level. A detailed 
analysis of the current situation as it pertains to the 
supply of and the demand for opiate raw materials is 
contained in the technical report of the Board for 2020 
on narcotic drugs.
159. The combined total harvested area of opium poppy 
rich in morphine and opium poppy rich in thebaine 















this significant growth has continued since 2017. However, 
in this total it should be noted that the harvested area of 
opium poppy rich in morphine increased by 40 per cent 
and the harvested area of opium poppy rich in thebaine 
more than halved. The production of opiate raw materials 
rich in morphine increased, while the production of 
opium raw materials rich in thebaine decreased. 
Morphine
160. The total actual harvested area of opium rich in 
morphine increased from 62,022 ha in 2018 to 86,982 ha 
in 2019. Compared with 2018, the actual harvested area 
increased by as much as 589 per cent in Spain, 505 per 
cent in Hungary, 118 per cent in Slovakia, 46 per cent in 
India, 33 per cent in France and 25 per cent in Turkey, 
and it decreased by 45 per cent in Australia. India is the 
only opium-producing country included in the present 
analysis. Australia and Spain were the only two countries 
that cultivated opium poppy rich in codeine in 2019. The 
area harvested with this variety decreased slightly in 
Australia, from 2,683 ha in 2018 to 2,300 ha in 2019, but 
in Spain it decreased by almost half, from 1,990 ha in 
2018 to 863 ha in 2019. 
161. The global production of morphine-rich opiate raw 
materials in the main producing countries increased sig-
nificantly, to 421 tons in morphine equivalent, in 2019 
(see figure X), compared with 304 tons in 2018. Spain, in 
which production increased almost threefold compared 
with 2018, became the largest producer in 2019, and was 
followed by Turkey, Australia, France, India and Hungary. 
Those six countries accounted for 96 per cent of global 
production in 2019. 
162. At the end of 2019, the global stock of opiate raw 
materials rich in morphine, which includes poppy straw, 
concentrate of poppy straw and opium, amounted to 
about 645 tons in morphine equivalent, an increase from 
564 tons at the end of 2018. Those stocks were considered 
to be sufficient to cover 18 months of expected global 
demand by manufacturers, on the basis of advance data 
for the level of demand in 2020. In 2019, Turkey continued 
to be the country with the largest stocks of opiate raw 
materials rich in morphine, with 207 tons in morphine 
equivalent, followed by France (96 tons), Spain (87 tons), 
India (80 tons, all in the form of opium), Australia (54 tons), 
the United States (43 tons), the United Kingdom (21 tons), 
Hungary (18 tons), Japan (16 tons), Slovakia (15 tons) and 
Belgium (7 tons). Together, those 11 countries accounted 
for 99 per cent of the global stock of opiate raw materials 
rich in morphine. The remaining stocks were held in 
other producing countries and in countries importing 
opiate raw materials.
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Figure X Supply of and demand for opiate raw 
materials rich in morphine, in morphine 
equivalent, 2016–2021
a Data for production and demand for 2020 are based on advance data 
(dotted line) submitted by Governments.
b Data for 2021 are based on estimates (dotted line) submitted by 
Governments.
163. At the end of 2019, global stocks of morphine-
based opiates, mainly in the form of codeine and 
morphine, amounted to 531 tons in morphine equivalent 
and were sufficient to cover global demand for those 
opiates for about 19 months. On the basis of data reported 
by Governments, total stocks of opiates and opiate raw 
materials are fully sufficient to cover demand for medical 
and scientific purposes for morphine-based opiates for 
more than a year. 
164. From 2009 until 2016, the global production of 
opiate raw materials rich in morphine exceeded global 
demand. As a result, stocks increased during that period, 
with some fluctuations. In 2017 and 2018, global produc-
tion was lower than global demand, which led to a decline 
in global stocks. However, in 2019, production was again 
higher than demand; consequently, stocks also increased 
(to 645 tons in morphine equivalent). 
Thebaine 
165. The total actual harvested area of opium poppy 
rich in thebaine more than halved, from 9,755 ha in 2018 
to 3,455 ha in 2019. The area decreased by 97 per cent 
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Australia. Hungary did not cultivate that variety of opium 
poppy in 2019.
166. In 2019, the global production of opiate raw mate-
rials rich in thebaine amounted to 119 tons in thebaine 
equivalent, a drop of almost half compared with the 
230 tons produced in 2018 (see figure XI). Australia 
accounted for nearly 97.5 per cent of global production 
of those opiate raw materials and India accounted for the 
remaining 2.5 per cent (with thebaine being extracted 
from opium). Australia reported a significant decrease in 
production compared with 2018.
167. Stocks of opiate raw materials rich in thebaine 
(poppy straw, concentrate of poppy straw and opium) 
decreased to 188 tons in thebaine equivalent at the end 
of 2019, from 235 tons at the end of 2018. Those stocks 
were considered to be sufficient to cover the expected 
demand by manufacturers worldwide for about 10 months 
at the 2020 level of demand. 
168. Global stocks of thebaine-based opiates (oxycodone, 
thebaine and a small quantity of oxymorphone) decreased 
slightly, to 241 tons in thebaine equivalent at the end of 
2019, from 248 tons in 2018. Those stocks were sufficient 
to cover global demand for thebaine-based opiates for 
medical and scientific purposes for more than two years.
Figure XI Supply of and demand for opiate 
raw materials rich in thebaine, in thebaine 
equivalent, 2016–2021
a Data for production and demand for 2020 are based on advance data 
(dotted line) submitted by Governments.
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169. Despite the reduction in global production of 
opiate raw materials rich in thebaine, demand grew, from 
144 tons in 2018 to 164 tons in 2019. This led to a 
decrease in the quantity of stocks, from 235 tons at the 
end of 2018 to 188 tons at the end of 2019. The stocks at 
the end of 2019 were sufficient to cover global demand 
for 10 months.
Noscapine
170. Even though noscapine is not under international 
control, a significant amount of morphine can be extracted 
from opium poppy rich in noscapine. Cultivation of 
noscapine-rich opium poppy plants for the purpose of 
opiate production was reported by France in 2019. France 
sowed 2,298 ha and harvested 1,974 ha of noscapine-rich 
opium poppy in 2019 and produced noscapine-rich 
poppy straw with a gross weight of 1,493 tons.
C. Overall treaty compliance
1. Evaluation of overall treaty 
compliance
171. The 1961 Convention as amended, the 1971 
Convention and the 1988 Convention create a series of 
obligations incumbent upon States parties that require 
them to adopt legislative and policy measures in a variety 
of areas to ensure effective implementation of the 
conventions. 
172. These areas include the adoption of regulatory 
frameworks for the monitoring of licit production and 
manufacture of and trade in narcotic drugs, psychotropic 
substances and precursor chemicals and for the permitted 
uses for controlled substances; the development of a legal 
framework to combat trafficking in and diversion of 
drugs, and related conduct; and the taking of all practicable 
measures for the prevention of illicit drug use and for the 
early identification, treatment, education, aftercare and 
social reintegration of persons affected by illicit drug use.
173. In carrying out its mandate of ensuring the execu-
tion of the provisions of the three international drug con-
trol conventions, the Board reviews developments in 
States parties with the aim of identifying possible short-
comings in the implementation of those conventions by 
States with a view to recommending remedial action.
174. The Board’s evaluation of the status of implementa-
tion by States of their legal obligations pursuant to the 
international drug control conventions is guided by its 
ongoing dialogue and exchange of information with 
Governments, including through extensive correspond-
ence, meetings with Government representatives, country 
missions and participation in INCB initiatives, and 
through the submission of statistical reports by 
Governments to the Board. In the period under review, 
the Board reviewed the drug control situation in Australia, 
Italy, Luxembourg, Mexico, the Philippines, Trinidad and 
Tobago, and Uruguay.
(a) Australia
175. The Board notes that new cannabis cultivation and 
possession rules came into effect in the Australian Capital 
Territory on 31 January 2020, as a result of the passage 
in September 2019 of the Drugs of Dependence 
Amendment Act. According to the new rules around per-
sonal use of cannabis for non-medical purposes, people 
in the Australian Capital Territory over the age of 18 are 
permitted to possess up to 50 grams of dried cannabis or 
up to 150 grams of fresh cannabis and adults may grow 
up to two cannabis plants per person, with a maximum 
of four plants permitted per household. Also under the 
rules, personal use of cannabis for non-medical purposes 
is permitted in people’s homes. 
176. Under the changes to the cannabis rules in the 
Australian Capital Territory, the following have been 
established as offences: (a) using cannabis in a public 
place; (b) exposing a child or young person to cannabis 
smoke; (c) storing cannabis in reach of children; (d) 
growing cannabis using hydroponics or artificial cultiva-
tion; and (e) growing plants where they could be accessed 
by the public. Rules pertaining to the use of cannabis for 
non-medical purposes that have not been changed include 
that it is illegal to sell, share or give cannabis as a gift to 
another person and it is illegal for people to drive with 
cannabis in their system.
177. The government of the Australian Capital Territory 
describes these new regulations as decriminalization and 
explains that cannabis is not legal in the Australian 
Capital Territory. Rather, the territory has removed penal-
ties for adults who possess or use small amounts of can-
nabis so that they can receive support without fear of 
being sanctioned through the justice system. 
178. The Board takes note of the indicated purposes of 
the amendment. However, the text of the amendment 
states that cannabis is not considered a “prohibited sub-
stance”. While the amendment does create new offences, 
such as use of cannabis around children, the effect of it 
is the legalization of cannabis for personal and non-medical 
use by adults. 
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179. Despite the restrictions with regard to the place 
and minimum age of consumption, the amendment does 
not meet the requirement found in article 36, paragraph 
1 (a), of the 1961 Convention as amended that possession 
of drugs contrary to the Convention shall be a punishable 
offence. It is further specified, in article 4, paragraph (a), 
of the Convention, that parties shall take such legislative 
and administrative measures as may be necessary to give 
effect to and carry out the provisions of the Convention 
within their own territories. 
180. The Board recognizes that the possession or culti-
vation of cannabis with the intention to sell continues to 
be an offence in Australia, in line with the Commonwealth 
Criminal Code of 1995. Further, the Board understands 
that the federal Government does not give effect at the 
federal level to the amended cannabis regulations in the 
Australian Capital Territory and that federal law will 
continue to be enforced throughout Australia.
181. The Board will continue to monitor these develop-
ments in the Australian Capital Territory and will also 
continue to monitor the application of the federal law (the 
Commonwealth Criminal Code), which includes the 
offence of possession or cultivation of cannabis.
(b) Italy
182. During the period under review, the Board continued 
to monitor drug-related developments in Italy. In 
December 2019, the Supreme Court of Italy issued a 
ruling removing small-scale cultivation of cannabis for 
private use from the definitions in article 73 of the 
Consolidated Law included in Presidential Decree 
309/1990 that criminalizes illicit activities with controlled 
substances. In its ruling, the Court declared that the 
offence of “cultivating narcotic drugs” should not include 
small amounts grown domestically for the exclusive use 
of the grower. Although the cultivation and sale of can-
nabis remain illegal under the drug legislation, there has 
been some uncertainty in the interpretation of this pro-
hibition following previous court decisions on the matter.
183. The Board is engaged in close dialogue with Italian 
authorities to ascertain the details of the Supreme Court 
ruling and its impact on the prohibition of the cultivation 
and sale of cannabis for non-medical purposes under 
current Italian legislation and to facilitate the country’s 
compliance with its international legal obligations as a State 
party to the three international drug control conventions. 
In the context of that dialogue, the Board has reiterated 
that the legalization of the non-medical and non-scientific 
use of controlled narcotic drugs is a violation of the 1961 
Convention as amended, which restricts the use of con-
trolled substances to medical and scientific purposes, and 
of the 1988 Convention, which obliges States parties to 
establish as criminal offences a wide range of conduct 
related to the production and commercial distribution of 
controlled substances in a manner inconsistent with the 
1961 Convention as amended.
(c) Luxembourg
184. The Board continued to follow closely the drug-
related developments in Luxembourg, in particular those 
related to control of cannabis in the country, and engaged 
in active dialogue with the national authorities to facilitate 
compliance with the international drug control treaties.
185. The governing coalition in Luxembourg released 
its policy positions in December 2018, which included its 
plans to introduce legislation to regulate the use of can-
nabis for non-medical purposes within the following five 
years. According to the Government, the stated objective 
of the plan is to move from a repressive to an innovative 
approach, through: (a) the reduction of demand on the 
black market; (b) the reduction of psychological and 
physical harms; and (c) the reduction of criminal activity 
at the supply level. The Board engaged with the 
Government of Luxembourg during a series of meetings 
to gain a broader understanding of these developments 
and to ensure that Luxembourg remains in compliance 
with the provisions of the 1961 Convention as amended.
186. During those meetings, the representatives of the 
Government of Luxembourg informed the President of 
the Board about the potential plans for the regulation of 
the use of cannabis for non-medical purposes in the 
country, including certain planned measures to prevent 
trafficking in or personal cultivation of cannabis, such as 
the introduction of strict punishments for cannabis-
related activity outside the planned programme, notably 
for sale to minors (those aged under 18) or to 
non-residents of the country, and to ensure that con-
sumption of cannabis in public and personal cultivation 
remained illegal. 
187. The Board has continued to emphasize that, 
although the initiative to regulate non-medical use of can-
nabis is still at the planning stage in Luxembourg, any 
and all legislative or regulatory measures aimed at the 
legalization of the use of cannabis for non-medical 
purposes would be inconsistent with the provisions of the 
1961 Convention as amended, in particular article 4, 
paragraph (c), which requires States parties to take such 
legislative and administrative measures as may be 
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necessary to limit the use of narcotic drugs exclusively to 
medical and scientific purposes, and article 3, paragraph 
1 (a) (i), of the 1988 Convention, which creates the obli-
gation for States to establish as criminal offences, when 
committed intentionally, the production, manufacture, 
extraction, preparation, offering, offering for sale, distri-
bution, sale, delivery on any terms whatsoever, brokerage, 
dispatch, dispatch in transit, transport, importation or 
exportation of any narcotic drug or psychotropic sub-
stance contrary to the provisions of the 1961 Convention, 
the 1961 Convention as amended or the 1971 Convention.
(d) Mexico
188. As a result of a jurisprudential ruling of the 
Supreme Court of Mexico in 2018, which required that 
personal cannabis use be made legal in the country, draft 
legislation on the matter is pending in the country’s 
Senate. The Supreme Court ruling came after five appeals 
were resolved in favour of the personal possession and 
consumption of cannabis for non-medical purposes. The 
Supreme Court found that the refusal of the Federal 
Commission for Protection against Health Risks to grant 
permits to adults for the consumption of cannabis for 
non-medical purposes violated the country’s constitu-
tional principle of the right to free development of the 
personality. 
189. The Supreme Court of Mexico did not authorize, 
in its 2018 ruling, the commercial sale, supply or 
distribution of cannabis or the consumption of any other 
narcotic drugs and psychotropic substances. In order to 
comply with the ruling of the Supreme Court, the 
Congress of Mexico is required to develop legislation that 
would include new guidelines and modalities to regulate 
the possession and use of cannabis for non-medical 
purposes by adults. 
190. In March 2020, the Senate of Mexico began 
deliberations in committees on the amendments to the 
country’s cannabis regulations. Although work was 
initially paused owing to the COVID-19 pandemic, on 
19 November 2020, the Senate of Mexico approved 
legislation that would legalize and regulate the personal 
use and possession of cannabis for non-medical purposes. 
To enter into force, the legislation still needs to be passed 
by the Chamber of Deputies and signed into law by the 
President. The Supreme Court extended the deadline for 
passage of the legislation to 15 December 2020. 
191. The Board takes note of these proposed changes to 
the drug laws of Mexico and will continue to engage with 
the Government on developments pertaining to amended 
regulations on cannabis consumption for non-medical 
purposes, as well as other matters pertaining to the coun-
try’s implementation of its international legal obligations 
as a State party to the three international drug control 
conventions. 
(e) Philippines
192. During the reporting period, the Board continued 
to closely monitor developments in the Philippines related 
to drug control. In March 2020, the President of the 
Board held a meeting with the delegation of the Philippines 
to the Commission on Narcotic Drugs at its sixty-third 
session, during which the implementation by the 
Philippines of its laws and policies related to drug control, 
including allegations of extrajudicial targeting of persons 
suspected of drug-related activities and the plans of the 
Government to reinstate the death penalty for drug-
related offences, was discussed.
193. During that meeting, the President of the Board 
was informed of the Government’s plan of action, which 
was revised in 2018 and contains actions on demand-
reduction advocacy, community-based drug rehabilitation 
programmes and supply-reduction operations. Information 
was also provided on the introduction of a points-based 
system, whereby those receiving drug treatment were 
assessed and monitored, and on the provision of incen-
tives to administrative divisions in the Philippines that 
demonstrated tangible progress in implementing drug-
related reforms.
194. The Board also held consultations with a high-level 
delegation of the Philippines at its 129th session, held in 
November 2020, during which those issues were further 
discussed.
195. The Board has taken note of concerns put forward 
by the Office of the United Nations High Commissioner 
for Human Rights and of the fact that a preliminary 
examination has been initiated by the Office of the 
Prosecutor of the International Criminal Court in The 
Hague with regard to allegations of extrajudicial killings 
of persons for reasons related to their alleged involvement 
in illegal drug use or dealing.
196. The Board has also taken note of information pro-
vided by the Government of the Philippines in response 
to allegations of extrajudicial targeting of drug users, 
including on the establishment of oversight mechanisms 
over police operations and the systematic review of any 
deaths resulting from anti-drug operations. The Board 
has further taken note of the stated position of the 
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Government that it does not condone extrajudicial target-
ing and that the Constitution of the Philippines provides 
for the right of due process. 
197. The Board, while acknowledging the stated efforts 
of the Government to introduce measures to prevent any 
coercive or punitive actions against individuals suspected 
of involvement in drug-related activities without due 
process, and also acknowledging the continued engage-
ment of the Government in dialogue with the Board, 
wishes to reiterate its call to the Government of the 
Philippines to condemn any extrajudicial actions against 
individuals suspected of involvement in the illicit drug 
trade or of drug use, to introduce more robust measures 
to prevent any such actions and to ensure that the per-
petrators of such acts are brought to justice in full obser-
vance of due process and the rule of law.
198. Calls by senior government officials of the 
Philippines to reinstate the death penalty for drug-related 
offences in the Philippines continued during the reporting 
period, although opinion seemed to be divided on the 
matter in the legislature. As repeatedly stated in its annual 
reports, although the determination of sanctions applicable 
to drug-related crime remains the prerogative of States 
parties to the conventions, the Board encourages States 
that retain capital punishment for that category of offence 
to commute death sentences that have already been 
handed down and to consider the abolition of the death 
penalty for drug-related offences.
199. The Board continues to actively seek the accept-
ance of the Government of the Philippines of an INCB 
country mission, which was initially proposed by the 
Board in 2017, in order to seek further clarification on 
the implementation of the three international drug 
control conventions by the Philippines from senior drug 
control stakeholders in the country. It reiterates its call to 
the Government of the Philippines to facilitate the hold-
ing of the mission at the earliest opportunity. 
(f ) Trinidad and Tobago
200. During the period under review, Trinidad and 
Tobago passed the Dangerous Drugs (Amendment) Bill 
to amend the regulation of cannabis use for non-medical 
purposes. The amendment will decriminalize the posses-
sion of not more than 30 grams of cannabis or not more 
than 5 grams of cannabis resin and create offences 
restricting the use of cannabis in specific instances, such 
as in a public place.
201. The text of the amendment to the Dangerous Drugs 
Act, which came into force on 23 December 2019, includes 
the provision that the offence and related liability will no 
longer apply to those possessing the specified amounts of 
cannabis. The Board notes that the stated aim of the 
Government of Trinidad and Tobago is to decriminalize 
the possession of cannabis and enable the expungement of 
criminal records and the pardoning of past convictions for 
possession of limited quantities of cannabis. 
202. However, without the establishment of an offence 
or liability attached to the consumption by adults of 
cannabis for non-medical purposes, the Dangerous Drugs 
(Amendment) Bill might not be a sufficient legislative and 
administrative measure to limit the use and cultivation 
of cannabis to medical and scientific purposes in line with 
article 4, paragraph 1 (c), of the 1961 Convention as 
amended and article 3, paragraph 1 (a) (i), of the 1988 
Convention. 
203. The Board will continue monitoring these develop-
ments in Trinidad and Tobago and engage in dialogue with 
the Government to support the full and effective imple-
mentation of the international drug control treaties.
(g) Uruguay
204. During the reporting period, the Board followed 
closely the implementation by Uruguay of law No. 19172, 
which legalized the production, distribution, sale and 
consumption of cannabis and its derivatives for non-
medical purposes in the country, through three access 
routes: domestic cultivation, membership of a cannabis 
club and dispensing by registered pharmacies. 
205. According to a February 2020 report on the regu-
lated cannabis market in Uruguay, published by the coun-
try’s Institute for the Regulation and Control of Cannabis, 
there has been an upward trend in the number of people 
entering the cannabis market for non-medical purposes. 
The 2020 report confirms that, as at February 2019, by 
which time the law had been implemented for two years 
and seven months, 53,399 people were authorized to 
access cannabis through the Government’s regulated 
market. That represented an increase of 7.5 per cent, or 
3,720 people, in the number of cannabis users registered 
with pharmacies, as home growers or as members of can-
nabis clubs since the previous report, published in 2019. 
Of the three routes for accessing cannabis through the 
Government’s regulated market, membership of cannabis 
clubs showed the greatest growth, with 18 per cent more 
ChaPTER II. fuNCTIONINg Of ThE INTERNaTIONal dRug CONTROl sysTEm   33
members reported in October 2019, largely due to the 
formation of new clubs. 
206. As part of its close monitoring of these developments 
in Uruguay, the Board held consultations with a high-
level delegation from Uruguay on 12 November 2020. The 
Board will continue its engagement with the Government 
of Uruguay to promote the effective implementation of 
the drug control treaties and enhance understanding of 
convention requirements, particularly article 4, paragraph 
(c), of the 1961 Convention as amended, which requires 
States parties to take such legislative and administrative 
measures as may be necessary to limit the use of narcotic 
drugs exclusively to medical and scientific purposes. 
2. Country missions
207. Under normal circumstances, the Board under-
takes several country missions each year in order to assist 
it in monitoring compliance by States parties with their 
legal obligations under the three international drug con-
trol conventions and to promote the effective implemen-
tation of those treaties.
208. The Board utilizes these country missions to engage 
in dialogue with relevant national authorities on a range 
of drug control issues, including legislative, institutional 
and practical measures implemented at the national level 
in the areas of licit manufacture of and trade in controlled 
substances with a view to facilitating the availability of 
those substances for medical and scientific purposes 
while preventing their diversion into illicit channels. The 
Board also discusses with national stakeholders mecha-
nisms for preventing and addressing the illicit manufac-
ture of, trafficking in and illicit use of narcotic drugs and 
psychotropic substances.
209. Following its missions, the Board adopts a series 
of recommendations aimed at improving the implementa-
tion of the international drug control conventions that 
are communicated confidentially to the Governments in 
question. 
210. Owing to the COVID-19 pandemic, the Board has 
suspended its country missions until the global public 
health situation permits. Accordingly, during the period 
under review, no country missions were undertaken. The 
Board continues to consider country missions as an 
essential tool in facilitating its dialogue with States and 
looks forward to resuming them at the earliest opportunity.
3.  Evaluation of the implementation 
by Governments of 
recommendations made by the 
Board following its country 
missions
211. As a follow-up to its country missions, the Board 
reviews developments in countries that have hosted Board 
delegations two to three years previously. In order to do 
so, the Board requests the Governments in question to 
provide it with relevant information on any developments 
since the missions, including any legislative or policy 
actions taken to implement the Board’s post-mission 
recommendations. 
212. In 2020, the Board invited the Governments of 
Australia, Egypt, Guyana, the Russian Federation and 
Switzerland, countries to which missions had been con-
ducted in 2017, to report on any drug policy-related 
developments that had resulted from the Board’s post-
mission recommendations. During the period under 
review, the Board also received a report from the 
Government of Afghanistan on the status of implementa-
tion of the Board’s recommendations following its mis-
sion to the country in 2016.
213. The Board wishes to express its appreciation to the 
Governments of Afghanistan, Egypt, the Russian 
Federation and Switzerland for submitting timely 
responses and renews its call to the Governments of 
Australia and Guyana to provide the information 
requested at the earliest opportunity.
(a) Afghanistan
214. In May 2016, the Board undertook a mission to 
Afghanistan to review the implementation of the inter-
national drug control treaties by Afghanistan and continue 
the consultations with the Government of Afghanistan 
that it had initiated in 2001. At that time, INCB con-
cluded that the situation in the country, if left unattended, 
would seriously endanger the aims of the 1961 Convention 
as amended and decided to invoke the relevant measures 
under article 14 of that Convention with a view to 
promoting cooperative action at the international level.
215. During the mission, the Government of Afghanistan 
informed the Board that it remained committed to com-
bating the illicit cultivation, production and manufacture 
of, trafficking in and illicit use of drugs. The Board 
expressed concern that the illicit cultivation of opium 
poppy in Afghanistan, regardless of fluctuations, had 
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continued to increase over the previous two decades. The 
Board observed that, in the light of reports of increasing 
illicit cultivation and production of cannabis, as well as 
the emergence of illicit methamphetamine manufacture 
in the country, there was a need to strengthen the 
Government’s efforts to address those challenges. The 
Board also expressed concern over the level of illicit drug 
use in the country. Issues of the availability of drugs for 
medical purposes and precursor control challenges in the 
country were also on the agenda of the mission. 
216. The Board continues to monitor drug-related 
developments in Afghanistan and engage in close 
dialogue with the Government with a view to promoting 
compliance with the international drug control treaties. 
More detailed information on the cooperation of the 
Board with Afghanistan is provided in chapter II, part E, 
of the present report. 
(b) Egypt
217. The Board notes that the Government of Egypt has 
made progress in the implementation of the recommen-
dations of the Board following the mission in 2017. Egypt 
reported that, since the mission, it had taken substantial 
law enforcement measures to prevent narcotic drugs and 
psychotropic substances from being trafficked into the 
country. Egyptian law enforcement authorities had been 
monitoring official border crossings in cooperation with 
the competent national authorities to prevent drug 
trafficking. Joint commissions had regularly brought 
together the border guard intelligence forces, the navy 
and the air force, as well as other anti-drug agencies, to 
tackle trafficking in a unified manner. 
218. With respect to the expansion of drug law 
enforcement capacity, Egypt reported that its police and 
customs authority were strengthening their cooperation 
to establish government control over legal points of entry 
into the country in order to determine the best admin-
istrative and legislative mechanisms for controlling the 
movements of containers, goods and parcels, as well as 
the movement of persons, thereby consolidating the 
country’s policy on combating cross-border trafficking 
offences.
219. The Government of Egypt updated the Board on 
the measures it had taken since 2017 to combat the 
misuse of precursor chemicals and psychotropic sub-
stances. A tripartite commission composed of representa-
tives of the Ministry of Justice, the Ministry of Health 
and the Ministry of the Interior, which monitor the legal 
use of precursor chemicals, had been strengthened. New 
types of drugs that had been appearing on the illicit 
market in Egypt were being monitored and studied by 
the Government with a view to adopting necessary measures. 
Illicit activities resulting from the improper distribution 
of certain psychotropic drugs by pharmacies had also 
been targeted and efforts had been made to keep those 
drugs from being trafficked.
220. Egypt also reported that the Ministry of the Interior 
had been coordinating with the relevant entities in the 
Ministry of Health, the Ministry of Industry and the 
Ministry of Investment to assess actual need and deter-
mine the amounts of precursor chemicals required for 
legal use in the health and manufacturing industries in 
order to prevent such chemicals from being trafficked. 
Egypt noted that a laboratory would be established within 
the Administration for the analysis of narcotic substances, 
in order to detect and identify new psychotropic sub-
stances and their ingredients and expedite the addition 
of new substances to the country’s drug schedules. 
221. The Board was informed that the Government of 
Egypt was cooperating closely with neighbouring countries 
and countries in the region and that Egypt had participated 
in regional cooperation efforts to combat the country’s 
drug problem. Egypt reported that it had strengthened its 
frameworks for the exchange of information, such as on 
where drugs were produced, trafficking routes, means of 
trafficking, patterns of illicit use, new developments and 
challenges, related criminal activities and the persons 
involved in those illicit activities. Egypt had also been 
coordinating with the UNODC Regional Office in Cairo 
to support multilateral cooperation on training. It had 
cooperated and coordinated with liaison officers in 
international and regional anti-drug agencies and had 
participated in all relevant coordination meetings, including 
with the Mediterranean Area Anti-Drug Enforcement 
Coordination Centre, in support of inter national anti-
drug operations and early targeting of offences involving 
the import and smuggling of drugs into the country. 
Egypt had also taken part in the high-level meeting of 
the heads of the anti-drug agencies of the Mediterranean 
Area Anti-Drug Enforcement Coordination Centre held 
in Paris in November 2019.
222. The Government of Egypt stated that it continued 
to face difficulties, including with regard to the scientific 
advancements that were being misused to produce new 
synthetic and psychotropic drugs. Criminal networks had 
been resourceful in using non-scheduled substances as 
substitutes and, therefore, the types of substances had 
multiplied significantly and their spread on the illicit 
market had accelerated. Taking advantage of political 
instability and insecurity, criminal networks used 
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neighbouring countries to cultivate, produce and manu-
facture narcotic substances and to traffic them into other 
countries in the region. The Government of Egypt 
reported that the information technology and social 
media revolution had facilitated the digital promotion of 
drug trafficking and drug use. 
223. With regard to the mechanisms established to 
overcome difficulties relating to drug law enforcement 
capacity, the Government of Egypt provided information 
to the Board that: (a) trafficking routes, persons involved 
in trafficking operations and areas where drug shipments 
were stored had been targeted; (b) the main hubs and 
routes through which shipments of drugs transited and 
were then trafficked onward had been monitored; (c) air, 
sea and land ports had been monitored more closely in 
order to crack down on trafficking operations; (d) new 
technologies had been deployed to detect, screen for and 
confiscate drugs at ports and the capacity of law enforcement 
agencies to perform those tasks had been enhanced; (e) 
anti-drug personnel had been trained and new methods of 
trafficking and means of concealment had been studied; 
(f) cutting-edge investigative methods such as controlled 
delivery had been used to track the activity of and 
apprehend high-level drug traffickers; and (g) officials in 
neighbouring countries had met to exchange intelligence 
on the activities of the networks involved in drug trafficking.
224. With respect to the progress made by Egypt since 
2017 in implementing the Board’s post-mission recom-
mendations, the Board has requested further information 
from the Government of Egypt on treatment and reha-
bilitation, reporting obligations, the submission of data to 
INCB and ensuring the adequate availability of opioids 
for medical purposes. Egypt has made substantial efforts 
to implement the Board’s recommendations pertaining to 
strengthening and expanding law enforcement capacity, 
and the Board acknowledges the effective cooperation of 
the Government of Egypt in fulfilling the country’s 
obligations under the international drug control treaties.
(c) Russian Federation
225. The Board undertook a mission to the Russian 
Federation in November 2017 in order to review the 
implementation of the international drug control treaties 
by the country and to examine drug control develop-
ments since its last mission to the country, in 2005. 
226. During the mission, the Board noted that the 
Government of the Russian Federation remained com-
mitted to the objectives of the international drug control 
treaties. The intention of the Government to cultivate 
opium poppy for medical and scientific purposes to sat-
isfy the domestic need for opiate raw materials was one 
of the main subjects discussed during the mission. In 
addition, the delegation of the Board reviewed the avail-
ability of drugs for medical purposes and other matters 
concerning the implementation of the international drug 
control treaties, as well as drug use and drug treatment, 
including in penitentiary facilities, and trafficking in 
drugs, precursors and new psychoactive substances. 
227. The Board notes that the Government has imple-
mented several initiatives aimed at removing regulatory 
and other barriers towards better access to controlled 
substances for rational medical use, which has resulted in 
an increase in the consumption of such drugs. The coun-
try has also significantly improved and extended its 
system of drug use treatment, which is available in all 
parts of the country and in prison facilities.
(d) Switzerland
228. The Board undertook a mission to Switzerland in 
November 2017 in order to review the implementation 
of the international drug control treaties by the country 
and to examine drug control developments since its last 
mission to the country, in 2000. 
229. During the mission, the Board observed close 
communication and coordination among various stake-
holders in the area of drug control (competent national 
authorities, law enforcement agencies, representatives of 
pharmaceutical and chemical industries, related academic 
institutes and non-governmental organizations) within 
the country. 
230. The Board was informed that the Government of 
Switzerland wished to adapt the legislative framework 
governing cannabis in order to adequately respond to the 
opportunities and risks associated with the substance. In 
this regard, the Board notes that the Government has 
submitted two legislative changes to Parliament in order 
to facilitate access to cannabis for medical purposes and 
to permit scientific studies to be conducted on the rec-
reational use of cannabis. The Board understands that, on 
the basis of the legislation currently in place, various 
applications for research licences to study the potential 
non-medical use of cannabis were denied by the Federal 
Office of Public Health.
231. The Board was informed that Switzerland had been 
using “drug consumption rooms” for over 30 years and 
that, according to the Government, they had proved to 
mitigate risks and maintain public safety in the country. 
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The Board notes that the Government is participating in 
an EMCDDA project in order to better understand the 
use of “drug consumption rooms” in Europe and to ana-
lyse the demand for, trends in and evolution of “drug 
consumption rooms” in a more in-depth manner. 
232. The Board recognizes the fruitful collaboration 
between the Government and the industrial sector, which 
has led to the control of three other classes of substances 
(namely fentanyl, derivatives of lysergic acid, and deriva-
tives of nitazene). In particular, cooperation with the 
relevant authorities has resulted in a balanced approach 
to ketamine, by countering trafficking on the one hand 
and avoiding restrictions for medical use on the other.
233. The Board notes that the Government is conducting 
an assessment on the development of pain medication 
following a change in consumption patterns in recent 
years. The Government recognizes the importance of 
ensuring that no unjustifiable barriers exist to the overall 
availability and accessibility of controlled drugs intended 
for medical purposes. In this regard, the Government 
intends to analyse and conduct research to determine 
whether there is a need to improve the availability and 
accessibility of more affordable drugs in the country.
234. The Government confirmed its commitment to the 
development of networks for bilateral and multilateral 
cooperation. The Board commends the commitment of 
Switzerland to a global approach to drug-related problems 
and to the three international drug control conventions.
D.  Action taken by the Board to 
ensure the implementation of 
the international drug control 
treaties
1. Action taken by the Board pursuant 
to article 14 of the Single Convention 
on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol and article 19 of 
the Convention on Psychotropic 
Substances of 1971
235. In situations where the Board has objective reasons 
to believe that the aims of the international drug control 
treaties are being seriously endangered by the failure of 
a party, country or territory to comply with the obliga-
tions contained therein, or there is a serious situation 
requiring cooperative action at the international level, the 
Board can pursue specific courses of action under the 
conventions to facilitate compliance and/or international 
assistance. These courses of action are set out in articles 
14 and 14 bis of the 1961 Convention as amended, article 
19 of the 1971 Convention and article 22 of the 1988 
Convention. Under these articles, the Board engages in a 
formal dialogue with the States in question, as well as 
with the international community, with a view to facilitat-
ing compliance with the conventions. 
236. In the past, INCB has invoked article 14 of the 
1961 Convention as amended and/or article 19 of the 
1971 Convention with respect to a number of States and 
has engaged in a close dialogue with them with a view 
to bringing about compliance with the treaties. In line 
with the requirements of the relevant provisions of the 
treaties, the names of the States concerned are not publicly 
disclosed and the related consultations with the Board 
remain confidential, unless the Board decides to bring the 
situation to the attention of the parties, the Economic and 
Social Council or the Commission on Narcotic Drugs 
following its consultations with the Government in 
question or if the country in question consents to the 
invocation of the provisions being publicly disclosed. 
237. The present section contains information on meas-
ures taken by the Board in relation to Afghanistan. In 
2001, the Board determined that a serious situation 
existed that called for cooperative action at the inter-
national level and with the authorities of any future 
governing body in Afghanistan, whether transitional or 
permanent, and decided to call the attention of the 
parties, the Economic and Social Council and the 
Commission on Narcotic Drugs, through its annual 
report, to the situation in Afghanistan, under the provi-
sions of article 14, paragraph 1 (d), of the 1961 Convention 
as amended. 
238. One of the recommendations of the Board follow-
ing its high-level mission to Afghanistan in May 2016 
concerned the importance of the invocation of article 
14 bis of the 1961 Convention as amended with respect 
to the country. That article is concerned with the provision 
of technical and financial assistance to the country in 
respect of which the article has been invoked. It states 
that “in cases which it considers appropriate and either 
in addition or as an alternative to measures set forth in 
article 14, paragraphs 1 and 2, the Board, with the agree-
ment of the Government concerned, may recommend to 
the competent United Nations organs and to the special-
ized agencies that technical or financial assistance, or 
both, be provided to the Government in support of its 
efforts to carry out its obligations under this Convention”. 
On 28 March 2018, the Board received a letter from the 
Government of Afghanistan in which the Government 
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expressed its agreement to invoking article 14 bis of the 
1961 Convention as amended, in addition to the meas-
ures already invoked by the Board under article 14. At its 
122nd session, in May 2018, the Board decided to invoke 
article 14 bis with regard to Afghanistan.
2. Consultation with the Government 
of Afghanistan pursuant to articles 14 
and 14 bis of the 1961 Single 
Convention on Narcotic Drugs as 
amended by the 1972 Protocol
239. During the reporting period, the Board continued 
to pursue consultations with the Government of 
Afghanistan under articles 14 and 14 bis of the 1961 
Convention as amended. Several important meetings 
were held with the Government of Afghanistan in that 
regard. One of the highlights of the consultations was the 
participation of the delegation of Afghanistan in the 
127th session of the Board, in February 2020, in order to 
hold consultations with the Board under article 14 bis. 
The Government of Afghanistan was represented by the 
Deputy Minister of the Interior for Counter-Narcotics, 
the Director for Coordination of Counter-Narcotics 
Efforts of the Ministry of the Interior and the Permanent 
Representative of the Islamic Republic of Afghanistan to 
the United Nations (Vienna).
240. The consultations held on 7 February 2020 with 
the delegation of Afghanistan, during the 127th session 
of the Board, provided an opportunity to discuss the cur-
rent challenges and needs of Afghanistan in terms of 
addressing the serious drug control situation in the coun-
try. The Government cited several specific areas in which 
assistance by the international community, including 
United Nations organs and specialized agencies, as well 
as other donors and partners, was still needed. In par-
ticular, the Government of Afghanistan called for urgent 
and sustained technical and financial support by the 
international community in the following broad areas:
 (a) Building upon the success of existing alternative 
livelihood programmes, in particular through further 
supporting developing agricultural infrastructure, and 
strengthening marketing opportunities for goods and 
products produced under those initiatives;
 (b) Addressing linkages between terrorism, insur-
gency, corruption and drug trafficking through integrated 
crime prevention and criminal justice technical assistance 
initiatives;
 (c) Strengthening law enforcement capacities in inter-
diction and investigation of domestic and cross-border 
drug-related offences through increased provision of 
training and necessary border control and other 
equipment;
 (d) Facilitating regional cooperation in addressing 
drug control challenges, on the basis of common and 
shared responsibility;
 (e) Addressing the trafficking in chemical precursors 
used in illicit drug production through effective cooper-
ation among source, transit and destination countries;
 (f) Increasing health-care opportunities for the treat-
ment and rehabilitation of drug users, in particular for 
women and youth.
241. On 10 February 2020, the Board issued a press 
release outlining the details of the consultations held with 
the Government of Afghanistan under article 14 bis of 
the 1961 Convention as amended. In the press release, 
the Board reiterated its readiness to further facilitate 
support to Afghanistan through continuous engagement 
with the United Nations and other agencies, and with 
members of the international community at large, while 
highlighting that efforts to stabilize the country would 
not be sustainable unless the country’s illicit drug economy 
was effectively addressed.
242. In his statement during the opening meeting of the 
sixty-third session of the Commission on Narcotic Drugs, 
held in Vienna from 2 to 6 March 2020, the President of 
INCB addressed the drug control situation in Afghanistan 
and reported on the outcome of the consultations with 
the Government of Afghanistan held during the 127th 
session of the Board. He noted that the urgent needs in 
drug control that could be addressed through technical 
and financial assistance from the competent organs and 
specialized agencies of the United Nations had been 
identified.
243. In March 2020, the President of the Board held 
further consultations with the delegation of Afghanistan 
to the sixty-third session of the Commission on Narcotic 
Drugs, led by the Deputy Minister of the Interior for 
Counter-Narcotics. During the meeting, the delegation 
informed the President that government agencies, 
including the Ministry of the Interior, were developing a 
new opium poppy eradication plan and noted the decrease 
in opium poppy cultivation in 2019. Issues of increased 
trafficking in methamphetamine in Afghanistan were also 
discussed. The President noted that the Board would take 
further steps, in consultation with the Government of 
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Afghanistan, as and when appropriate, to communicate 
the matters raised by the delegation of Afghanistan to the 
organs and specialized agencies of the United Nations, for 
the purposes of facilitating the provision of technical and 
financial assistance to Afghanistan to assist it in meeting 
its obligations under the 1961 Convention as amended.
United Nations action
244. On 10 March 2020, the Security Council adopted 
resolution 2513 (2020), in which it welcomed accelerated 
efforts to make progress towards reconciliation and also 
welcomed and encouraged the continuation of the efforts 
of all regional and international partners to support 
peace, reconciliation and development in Afghanistan. 
Also in the resolution, the Council called upon the 
Government of Afghanistan and the Taliban to pursue, 
in good faith, additional confidence-building measures to 
create conditions conducive to a swift beginning and the 
success of intra-Afghan negotiations and a durable peace. 
The Council recalled the urgent need for all Afghan 
parties to counter the world drug problem with the goal 
of combating the traffic in opiates originating in Afghanistan.
Situation in Afghanistan
245. The political and security situations in Afghanistan 
during the reporting period were dominated by develop-
ments related to the presidential elections and to the 
peace talks with the Taliban.
246. After being re-elected as President, Mohammad 
Ashraf Ghani announced his intention to form a strong 
and united Government, noting that the participation of 
women would be vital. Amid claims from opposition par-
ties regarding the legality of the results of the presidential 
elections and their intention to form an alternative gov-
ernment, UNAMA and other international actors in the 
country called upon all parties to address grievances 
through dialogue and respect for the constitutional order.
247. Despite an announcement by the President of the 
United States on the withdrawal of the United States from 
peace negotiations with the Taliban in September 2019, 
the post-electoral period was marked by the accelerated 
efforts of the United States to re-engage in peace talks 
with the Taliban. The United States Special Representative 
for Afghanistan Reconciliation restarted his close engage-
ment with national and regional stakeholders and partici-
pated in peace talks with the Taliban in Doha, claiming 
that the negotiations had led to an agreement on a “sig-
nificant and nationwide reduction of violence across 
Afghanistan” from 22 February 2020. Despite the initial 
criticism by the Government of Afghanistan of the peace 
process led by the United States owing to the lack of the 
involvement of the national Government in those nego-
tiations, in February 2020, Mr. Ghani welcomed the 
developments in the talks between the United States and 
the Taliban and noted that Afghanistan would manage 
the next steps in a manner that positively supported the 
overall peace process. On 28 February 2020, an agreement 
was signed between the United States and the Taliban on 
the reduction in the number of United States military 
forces to 8,600 troops and the proportional reduction in 
the number of coalition forces over the subsequent 135 
days. That was to be followed by a reduction in the 
number of all international forces within another nine 
and a half months, which would be conditional on the 
Taliban’s commitment to reducing violence.
248. The security situation, meanwhile, remained unsta-
ble. Between 8 November 2019 and 6 February 2020, 
UNAMA recorded 4,907 security-related incidents, a 
number similar to that recorded during the same period 
in the previous year. The highest number of incidents 
occurred in the southern region, followed by the northern 
and eastern regions. Fighting decreased during the winter 
(at the end of 2019 and in early 2020) and an overall 
reduction in violence was noted from February 2020, 
although it is yet to be seen how long-lasting that reduc-
tion will be.
249. On 22 February 2020, UNAMA and the Office of 
the United Nations High Commissioner for Human 
Rights released a joint report entitled Afghanistan: 
Protection of Civilians in Armed Conflict – 2019, in which 
the continuing record-high levels of civilian casualties in 
the ongoing conflict were described. According to the 
report, a documented 3,403 civilians were killed and 
6,989 were injured, with the majority of the civilian casu-
alties in 2019 caused by anti-government elements. It was 
also noted in the report that 2019 was the sixth year in 
a row that the number of civilian casualties had exceeded 
10,000. The figures represent a 5 per cent decrease over 
the previous year, mainly owing to a decrease in civilian 
casualties caused by Islamic State in Iraq and the Levant-
Khorasan Province. The number of civilian casualties 
caused by other parties increased, in particular those 
inflicted by the Taliban (21 per cent increase) and the 
international military forces (18 per cent increase), mainly 
as a result of an increase in improvised explosive device 
attacks and airstrikes. In total, more than 100,000 civilians 
have been killed or injured since the United Nations 
began its systematic documentation of civilian casualties, 
in 2009. The report contains several recommendations, 
including the need to comply with the key principles of 
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distinction, proportionality and precaution to prevent 
civilian casualties, and also contains a reminder to the 
parties that attacks deliberately targeting civilians and 
civilian objects are serious violations of international 
humanitarian law that may amount to war crimes, which 
need to be promptly and transparently investigated.
250. Afghanistan continued to report seizures of sub-
stantial amounts of illicit substances, including heroin, 
opium, cannabis resin, methamphetamine, “ecstasy” and 
precursor chemicals, through its counter-narcotics opera-
tions. Those seizures were accompanied by the arrests of 
many suspects and the confiscation of assets and weap-
ons. There have been many reports of officers of the 
Afghan Counter-Narcotics Police being killed or wounded 
while carrying out their operations. More detailed infor-
mation regarding the drug-related trends in Afghanistan 
can be found in chapter III, part D, of the present report.
251. With the support of the United Nations, the Drug 
Demand Reduction Department of the Ministry of Public 
Health opened five drug treatment centres in Afghanistan, 
which provide services for the prevention and treatment 
of drug use disorders to children and their families. In 
February 2020, the delegation of Afghanistan to the 127th 
session of the Board called for support in the area of drug 
treatment and highlighted that the Afghanistan national 
drug use survey for 2015 had shown a presence of 
2.9 million to 3.6 million drug users across the country, 
representing about 11.1 per cent of the entire population 
of Afghanistan. The same survey had found that, in 2015, 
the total number of drug treatment centres in the country 
was 123, with a total annual treatment capacity of 32,170 
patients.
252. The return of many Afghans from Iran (Islamic 
Republic of) and Pakistan owing to the outbreak of the 
COVID-19 pandemic threatens a greater outbreak in 
Afghanistan that could overwhelm its already inadequate 
health infrastructure. As at 13 August 2020, the 
International Organization for Migration had recorded 
more than 672,000 returnees to Afghanistan since January 
2020 (about 430,000 from the Islamic Republic of Iran 
and 242,000 from Pakistan). The removal of many staff 
of international non-governmental organizations from 
Afghanistan owing to the pandemic has put additional 
stress on the fragile health-care system in Afghanistan, 
which does not have the capacity to test, take the tem-
peratures of or quarantine the returnees. Afghan officials 
have emphasized that, if no urgent action is taken, up to 
80 per cent of the country’s total population of 35 million 
could be infected.
253. As the Board continues its close consultations with 
the Government of Afghanistan, in particular, with a view 
to effectively implementing article 14 bis of the 1961 
Convention as amended, it looks forward to facilitating 
further support to Afghanistan through ongoing engage-
ment with the United Nations and other agencies in 
addressing the complex drug control challenges in 
Afghanistan and in supporting the pursuit of peace and 
sustainable development.
3. Supporting Government compliance 
with the treaties
INCB Learning
254. In 2016, in order to increase the effectiveness of its 
work to ensure the availability of internationally 
controlled substances for medical and scientific purposes, 
the Board launched the INCB Learning project. Under 
the project, assistance is provided to Member States by 
promoting the implementation of and full compliance 
with the international drug control conventions through 
awareness-raising and training. One of the objectives of 
the project is to address the barriers to the adequate avail-
ability of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, while 
preventing their abuse and diversion into illicit channels. 
Timely and accurate national reports of estimated 
requirements, statistical data for controlled substances 
and submissions of the estimates of annual legitimate 
requirements for precursors to the Board are essential 
for achieving this objective. 
255. Through capacity-building, INCB Learning 
supports Governments in estimating and assessing their 
specific needs for internationally controlled substances. 
Activities include regional training seminars, availability 
workshops, e-learning modules, bilateral consultations 
and, since mid-2020, online training sessions.
256. The ninth regional INCB Learning training semi-
nar was held in Moscow from 2 to 4 December 2019. It 
was attended by 38 drug control officials from Armenia, 
Azerbaijan, Kazakhstan, Kyrgyzstan, the Russian 
Federation, Tajikistan, Turkmenistan and Uzbekistan. 
Hosted by the Government of the Russian Federation and 
with the participation of WHO representatives, the train-
ing seminar provided, over three days, specialized train-
ing on the requirements of the three international drug 
control conventions relating to the regulatory control and 
monitoring of licit trade in narcotic drugs, psychotropic 
substances and precursor chemicals. Participants also 
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received hands-on training on the Board’s global online 
tools: I2ES, PEN Online, PICS and IONICS.
257. Following the seminar, on 5 December 2019, an 
awareness-raising regional workshop on the availability 
of narcotic drugs and psychotropic substances for medical 
and scientific purposes was held in Moscow. The event, 
which was co-organized and hosted by the Ministry for 
Foreign Affairs of the Russian Federation, brought 
together participants from national authorities, inter-
national organizations and civil society to discuss the 
importance of ensuring access to medicines containing 
internationally controlled substances.
258. Between April 2016 and December 2019, in-person 
training was provided through INCB Learning to 274 
officials from 95 countries and territories in nine regional 
training seminars and four workshops. Between June and 
November 2020, 76 officials from 11 countries were 
provided with online training, in line with the restrictions 
put in place to combat the COVID-19 pandemic. 
259. Webinars were offered to provide online training on 
the implementation of the international drug control 
conventions with a focus on treaty compliance and 
exchange of best practices among countries. Between 8 and 
15 June 2020, 26 government officials from Costa Rica, the 
Dominican Republic, El Salvador, Guatemala, Honduras 
and Panama participated in nine online sessions focused 
on internationally controlled substances. Participants had 
the opportunity to increase their knowledge of the 
international drug control framework and to receive 
hands-on training on the technical reporting requirements 
of the conventions relating to narcotic drugs, psychotropic 
substances and precursor chemicals and on the use of 
I2ES. This was the first time that webinars had been offered 
through INCB Learning. The aim of the webinars is to 
continue supporting Governments through the provision 
of capacity-building activities while complying with 
measures designed to prevent the spread of COVID-19. 
260. An anonymous online evaluation of the INCB 
Learning webinars revealed that 95 per cent of partici-
pants had found the content to be relevant to their daily 
work. Furthermore, 84 per cent of participants indicated 
that the sessions had met their expectations and 95 per 
cent considered that webinars should play a role in 
capacity-building in the future. The activity received an 
overall rating of 4.71 out of 5. Following the webinars for 
Spanish-speaking countries, a series of bilateral meetings 
were scheduled between July and September 2020 with 
officials from the competent national authorities of Costa 
Rica, the Dominican Republic, El Salvador, Honduras, 
Guatemala and Panama to address national issues related 
to narcotic drugs.
261. Webinars for the competent national authorities of 
Belize and Guyana took place from 16 to 23 June 2020. 
The participation of Panama in the Spanish webinar and 
of Belize and Guyana in the English webinar marked an 
important milestone, as none of those three countries had 
received training under INCB Learning before.
262. A second series of webinars in Spanish took place 
from 28 September to 1 October and on 25 and 
26 November 2020 for 43 officials from three countries: 
Colombia, Ecuador and Peru. The webinars were tailored 
to assist Governments in estimating and providing accu-
rate data to ensure the availability of controlled substances 
while preventing diversion and abuse.
263. On 3 March 2020, INCB Learning launched Spanish 
versions of its e-learning modules at a side event during 
the sixty-third session of the Commission on Narcotic 
Drugs. The side event, organized by the Government of 
El Salvador in cooperation with INCB and the Governments 
of Australia, Belgium, Chile, the Dominican Republic, 
Ecuador, Guatemala, Honduras, Mexico, the Netherlands, 
Paraguay, Peru, the Russian Federation and Singapore, 
provided an opportunity for beneficiaries of and contributors 
to INCB Learning to highlight the importance of capacity-
building for competent national authorities. The importance 
of such capacity-building had been recognized by Member 
States in the outcome document entitled “Our joint 
commitment to effectively addressing and countering the 
world drug problem”, adopted at the thirtieth special 
session of the General Assembly, and reiterated by the 
Commission on Narcotic Drugs in its resolutions 62/5 
and 62/8.
264. In its resolution 63/3, adopted in March 2020, the 
Commission on Narcotic Drugs highlighted the work of 
INCB Learning for a second year in a row and encouraged 
its continuation. In implementing the mandates con-
tained in Commission resolutions 63/3, 62/5 and 62/8, 
INCB is seeking further donor support to expand and 
continue carrying out activities under INCB Learning.
265. The demand for INCB Learning online training 
modules has increased since the outbreak of COVID-19 
and the introduction of restrictions that have affected the 
ability to carry out face-to-face training. As at 2 November 
2020, INCB Learning had received access requests to the 
e-learning modules from 812 government officials from 
101 countries and territories. Upon completion of the 
INCB e-learning modules, participation is acknowledged 
with a certificate of completion. As at 2 November 2020, 
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a total of 680 certificates had been issued. Access to the 
modules can be requested by email (incb.learning@un.org). 
266. Available in English and Spanish since March 2020, 
the three INCB e-learning modules provide interactive 
training on the estimates system for narcotic drugs, the 
assessment system for psychotropic substances and the 
estimates of annual legitimate requirements for imports 
of precursors of amphetamine-type stimulants. These 
modules were developed to assist competent national 
authorities build capacity and maintain continuity of rel-
evant knowledge despite staff turnover.
267. The Board is pleased to note the positive reception 
of the e-learning modules and continues to encourage all 
Governments to register pertinent officials of their 
competent national authorities to benefit from them. It 
also invites Governments to provide feedback and 
suggestions for the development of further training. The 
Board is looking forward to reaching a larger audience 
through the development of additional modules and the 
translation of the modules into other official languages of 
the United Nations.
268. The Board is grateful for the contributions to 
INCB Learning made by the Governments of Australia, 
Belgium, France, the Russian Federation, Thailand and 
the United States, and reiterates its invitation to 
Governments to consider actively supporting INCB 
Learning by participating in its activities and providing 
the resources required to ensure the project’s continua-
tion and expansion.
International Import and Export 
Authorization System
269. Pursuant to article 31 of the 1961 Convention as 
amended, article 12 of the 1971 Convention and relevant 
resolutions of the Economic and Social Council, inter-
national trade in narcotic drugs and psychotropic 
substances requires both import and export authorizations. 
Given the growing volume of licit trade in internationally 
controlled substances, which leads to an increasing work-
load for competent national authorities, it is essential to 
modernize the import and export authorization system 
in order to reduce the risk of diversion while continuing 
to ensure the adequate availability of and access to those 
substances. 
270. I2ES, a web-based electronic system developed by 
the Board together with UNODC, with financial and 
technical support from Member States, was designed to 
promote paperless trade in internationally controlled 
substances by facilitating the online exchange of import 
and export authorizations.
271. Available to all Governments at no cost, I2ES 
serves as a safe and secure platform for generating and 
exchanging import and export authorizations between 
trading countries while ensuring full compliance with all 
provisions of the 1961 Convention as amended and the 
1971 Convention. The system helps competent national 
authorities to reduce errors in data entry and save time 
and communication costs. 
272. The estimates of requirements of narcotic drugs 
and the assessments of psychotropic substances estab-
lished by States parties and endorsed by the Board are 
automatically synchronized with I2ES. After an import 
authorization has been approved, the system calculates in 
real time the remaining balance of the estimates or 
assessments available to the importing country. Trading 
partners registered with the platform can access that 
information at any time. Authorities of the trading 
countries can also use the system to securely communi-
cate and exchange information directly with their coun-
terparts if further clarification relating to a transaction 
request is required.
273. Unlike paper-based systems, in which authoriza-
tions can be further processed only after their physical 
delivery and receipt, the online exchange of import and 
export authorizations using I2ES enables the instantaneous 
transfer of data between trading countries, thus facilitating 
a much faster approval process. To provide a fully 
electronic and paperless international trade system, the 
Board established the possibility for Governments to use 
electronic signatures along with the import and export 
authorizations processed using the system.
274. In the outcome document of the thirtieth special 
session of the General Assembly, Heads of State and 
Government recommended expediting the process of 
issuing import and export authorizations for licit inter-
national trade on narcotic drugs and psychotropic 
substances by using I2ES.
275. In its resolutions 55/6, 57/10, 58/10 and 61/5, the 
Commission on Narcotic Drugs set out actions to further 
the establishment of an import and export authorization 
system and invited the secretariat of INCB to administer 
and monitor I2ES and report on the progress made on 
its implementation. 
276. The emergence of the COVID-19 pandemic in 
early 2020 further highlights the important role that I2ES 
plays in the international drug control system. The Board 
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notes that many countries have initiated emergency 
procedures to expedite the authorization process for the 
trade in narcotic drugs and psychotropic substances in 
order to respond to heightened demand, stemming from 
the pandemic, for medicines containing controlled 
substances. Several countries already registered with I2ES 
were able to leverage the advantages of the platform to 
rapidly respond to their needs.
277. In addition, the secretariat of the Board has 
expedited the registration of Governments to allow them 
to use I2ES and has made available a secure forum in the 
platform so that competent national authorities can 
exchange information regarding their respective special 
measures to ensure the availability of controlled 
substances during the COVID-19 pandemic.
278. The Board notes that, in the 12-month period to 
1 November 2020, nearly six years after the launch of 
I2ES, 23 Governments registered with I2ES, bringing the 
total to 87 Governments that have registered with the 
system. Of those, 68 Governments have an active admin-
istrator account. Of those with an active account, 
24 entered data into the system during 2020.
279. In order to encourage the further adoption of I2ES 
among Member States, INCB carried out multiple activities 
to raise awareness of the system and improve the technical 
capabilities of competent national authorities. 
280. In December 2019, several technical webinars were 
held to introduce the competent national authorities of 
Denmark, Latvia, Norway and Sweden to the functions 
of I2ES. In February 2020, a technical introduction was 
conducted through a webinar with representatives from 
the competent national authority of Lithuania. A similar 
webinar was held for representatives from Luxembourg 
in March. In May, a webinar was held for Bhutan, 
Bulgaria, Mozambique and Oman to introduce repre-
sentatives of their competent authorities to the technical 
functions of I2ES.
281. In the light of the travel restrictions still in place 
in countries that require technical assistance on I2ES, 
further Member States have expressed an interest in 
online training activities. Accordingly, more online train-
ing sessions are planned. 
282. The efforts made by the Board can be reinforced 
and complemented only with the ongoing commitment 
of Member States in supporting the adoption of I2ES as 
the unequivocal choice of a digital international trade 
system for controlled substances. In its resolution 61/5, 
the Commission on Narcotic Drugs invited Member 
States to consider providing extrabudgetary resources for 
the maintenance and promotion of I2ES.
283. Following the recommendations contained in 
Commission resolutions 58/10 and 61/5, the Board has 
continually expressed the need for extrabudgetary 
resources to increase awareness of I2ES, improve the 
capacity of Governments to use it and expand the 
functionalities of the system to address the challenges 
faced by Member States.
284. A multilingual user interface would facilitate the 
adoption of I2ES in more countries and regions. The 
possibility of adding nationally controlled substances to 
the import authorizations processed using I2ES would 
enable competent national authorities to comply with 
domestic legal obligations and avoid the burden at the 
operational level of running two parallel systems, one for 
nationally controlled substances and another for inter-
nationally controlled substances. In addition, the trading 
data stored in I2ES could be exported for post-processing 
purposes, which would help competent authorities to 
expedite reporting to INCB on substances controlled 
under the international drug control treaties.
285. At the same time, know-how at the operational 
level and commitment to using I2ES at the decision-
making level continue to be significant barriers to be 
overcome. The Board reiterates its commitment to working 
hand in hand with Member States on activities that 
encourage the wider adoption of the system and greater 
user engagement.
286. The Board encourages all Member States to contact 
its secretariat to discuss challenges they face in imple-
menting the system and jointly setting out the specific 
steps to achieve a road map that integrates I2ES into 
nationwide governmental procedures and policies for 
supervising the control of narcotic drugs and psycho-
tropic substances.
287. The Board invites Member States that are already 
using I2ES to share their experiences and expertise with 
the Board and other Member States, in particular, their 
trading partners that are not currently using the platform. 
Member States are invited to express their views on I2ES 
in regional meetings for drug control and health monitoring 
and engage with their counterparts to facilitate active 
cooperation that expands adoption of the system.
288. It is essential for Governments and the Board to 
continue their cooperation to implement I2ES in order 
to fully realize the benefits of the platform and facilitate 
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the more rapid trade of internationally controlled 
substances. 
289. INCB encourages Governments that have not yet 
done so to request the assistance of the INCB secretariat 
in implementing and integrating I2ES into their national 
systems, including through the provision of guidance on 
first steps and initial training. 
290. The Board wishes to reiterate to Member States 
the need for continual support, including extrabudget-
ary resources, to expand the functionality of I2ES, 
address technical issues identified by Governments and 
provide expanded training to further support countries 
in adopting and implementing the platform. 
Global Rapid Interdiction of Dangerous 
Substances Programme
291. The GRIDS Programme focal point networks form 
the core of activities under the Board’s operational 
projects on dangerous substances, namely Project Ion and 
the OPIOIDS project. These networks comprise an infra-
structure that enables the rapid exchange of information 
and alerts, facilitates bilateral and multilateral operational 
actions that assist with investigations, and provides 
participating agencies with practical solutions to stop 
trafficking in non-scheduled substances. As at 1 October 
2020, there were 1,421 Project Ion focal points representing 
471 agencies from 176 Governments and 1,398 OPIOIDS 
project focal points from 165 Governments.
292. IONICS, established in 2014, has 773 law and 
regulatory enforcement users from 138 Governments and 
15 international organizations who receive its trafficking 
notifications. Information communicated through and 
intelligence derived from IONICS represent more than 
13,000 incidents involving 209 unique types of new 
psychoactive substances, of which 15 per cent are non-
medical synthetic opioids and dangerous fentanyl-related 
substances. The Board encourages the Governments of 
Algeria, Andorra, Azerbaijan, Belarus, Burkina Faso, 
Burundi, Cabo Verde, the Central African Republic, 
Chad, Comoros, the Congo, the Democratic People’s 
Republic of Korea, the Democratic Republic of the 
Congo, Djibouti, Equatorial Guinea, Eritrea, Eswatini, 
Gabon, the Gambia, Guinea-Bissau, the Holy See, 
Honduras, Iran (Islamic Republic of), Kazakhstan, 
Kuwait, Kyrgyzstan, Lesotho, Liberia, Liechtenstein, 
Madagascar, Malawi, Maldives, the Marshall Islands, 
Mauritania, Micronesia (Federated States of), Monaco, 
Mongolia, Morocco, Nauru, Nepal, Niue, North 
Macedonia, Oman, Panama, the Republic of Moldova, 
Samoa, San Marino, Sao Tome and Principe, Serbia, 
Seychelles, Sierra Leone, Slovenia, Somalia, South 
Sudan, the Syrian Arab Republic, Tajikistan, Timor-
Leste, Togo, Tonga, Turkmenistan, Tuvalu, Uganda, 
Vanuatu, Yemen, Zambia and Zimbabwe, as well as the 
government of Kosovo,68 to nominate both law and 
regulatory enforcement focal points to exchange 
communications using IONICS. 
293. In 2020, 11 confidential global alerts and special 
notices were circulated to GRIDS Programme focal 
points, including a notification in May 2020 on the 
emergence of and increased reporting on encounters 
involving isotonitazene, a potent synthetic opioid and one 
of the etonitazene analogues not under international 
control. Isotonitazene was subsequently placed under 
temporary scheduling in the United States, effective 
August 2020; the European Commission initiated the 
process to ban it across the European Union in September; 
and the WHO Expert Committee on Drug Dependence 
reviewed it for international control at its forty-third 
meeting, held in October 2020.
294. The GRIDS Programme continued to provide officers 
worldwide with access to and training on the Board’s 
intelligence tools throughout the ongoing COVID-19 
pandemic, through distance-learning technologies. 
Between 1 January and 1 October 2020, 50 training 
sessions were held under the Programme on topics 
including information exchange using IONICS, intelli-
gence development, awareness of new psychoactive sub-
stances, and safe handling and interdiction methods for 
opioids. A total of 1,108 law and regulatory enforcement 
officers representing 104 Governments and international 
organizations took part in those training sessions. 
295. In 2020, the GRIDS Programme convened several 
expert group meetings and events that brought together 
leading global private sector partners, including Internet 
domain name registries and registrars, Internet search 
engine companies, social media companies, private postal 
and express mail operators and express courier services, 
to collaborate with Member State Governments and, 
through them, the Board. The Board continues to assist 
Governments in their efforts to foster voluntary coopera-
tion with private sector partners to prevent the exploita-
tion of legitimate industries by traffickers of fentanyls and 
other dangerous substances. 
296. The Board released its updated list of fentanyl-
related substances with no known legitimate uses on 
68 References to Kosovo shall be understood to be in the context of 
Security Council resolution 1244 (1999).
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September 2020 to Governments, their private sector 
partners and international organizations. The list identi-
fies 144 fentanyl-related substances that have been 
trafficked or seized, encountered in illicit Internet sales, 
manufactured and found in toxicology or related incident 
reports. Of those listed substances, 122 are not scheduled 
under any of the international drug control treaties. Since 
the list’s initial introduction in June 2018, more than 50 
additional substances have been identified and added to 
it. The Board circulated the list by letter to all Governments, 
provided it to all GRIDS Programme focal points, circu-
lated it, through Governments, to private sector partners 
and posted it on the Board’s OPIOIDS project web page. 
The Board encourages Governments and industry 
partners to refrain, on a voluntary basis, from manu-
facturing, marketing, importing, exporting and 
distributing any of the substances listed.
297. Under the GRIDS Programme, INCB facilitates 
access by law and regulatory enforcement officers to the 
Board’s proprietary IONICS platform for the secure 
exchange of real-time information related to trafficking 
in dangerous substances and the communication plat-
form for INCB-coordinated intelligence-gathering opera-
tions. In 2019, INCB coordinated two operations, 
Operation Fast Forward and Operation Trance. 
298. Operation Fast Forward, launched in January 2019, 
was aimed at identifying key sources and re-distribution 
points involving fentanyl, fentanyl analogues and related 
substances trafficked using international post, express 
mail and courier services. The operation involved 
45 Governments and two international agencies and 
resulted in 53 communications on target substances, with 
seizures of more than 29 kg and the dismantling of a 
fentanyl distribution operation by authorities in Canada. 
299. Operation Trance, launched in December 2019, 
targeted traffickers of non-medical ketamine and tramadol 
and involved cooperation with 131 officers from 74 
Governments, as well as INTERPOL, the Oceania 
Customs Organization, the Universal Postal Union and 
WCO. Governments communicated 91 incidents through 
IONICS involving 35 countries and territories, and over 
470 kg of ketamine and 957,000 tablets of tramadol were 
reported seized. Authorities from India reported dis-
mantling their first darknet vendor operating a global 
distribution operation, with subsequent investigations 
leading to seizures of 135 kg and 112,000 tablets of 
psychoactive substances and the arrests of four suspects.
Project Prism and Project Cohesion
300. Project Prism and Project Cohesion are two inter-
national initiatives led by INCB that bring together opera-
tional focal points from more than 140 Governments 
worldwide to address the diversion of chemicals used in 
the illicit manufacture of synthetic drugs (Project Prism) 
and heroin and cocaine (Project Cohesion).
301. Participating Governments have provided and 
received information on emerging trafficking trends, 
identified modi operandi and exchanged data on activi-
ties related to the diversion of precursors and non-
scheduled chemicals. The Board continues to assist those 
Governments on a regular basis by serving as a focal 
point for the exchange of such information, including 
through PICS and through the dissemination of special 
alerts. During the reporting period, 10 special alerts 
were circulated to all participating Governments, includ-
ing on: (a) illicit manufacture of methamphetamine in 
Afghanistan; (b) precursor trends in the illicit manufac-
ture of fentanyl; (c) trends in increasing the efficiency 
of P-2-P-based methamphetamine manufacture; (d) sus-
picious shipments of chemicals destined for Myanmar; 
and (e) awareness-raising interventions for the sale of 
equipment for illicit drug manufacture over e-commerce 
platforms.
302. Both projects are steered by the INCB Precursors 
Task Force, which met twice in 2020 to exchange 
information on the latest operational trends in precursor 
trafficking in different regions of the world and to discuss 
options to address the proliferation of non-scheduled 
chemicals and designer precursors for heroin, cocaine 
and synthetic drugs. The Task Force also discussed issues 
related to public-private partnerships, including concerns 
about the vulnerability of chemical manufacturing 
companies with economic difficulties as a result of the 
COVID-19 pandemic, and measures for the early 
identification of such manufacturers to prevent their 
premises being targeted for illicit activity. 
303. Since January 2019, INCB has trained 313 regu-
latory and law enforcement officers from 34 countries 
and territories (Antigua and Barbuda, Austria, Bahamas, 
Barbados, Belize, Bermuda, Cambodia, Cayman Islands, 
China, Dominica, Egypt, Grenada, Guyana, Haiti, India, 
Indonesia, Iraq, Jamaica, Libya, Malaysia, Montserrat, 
Myanmar, Philippines, Qatar, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines, Saudi Arabia, 
Singapore, Slovakia, Suriname, Trinidad and Tobago, 
Tunisia and Viet Nam). The training focused on providing 
support for the sharing of intelligence, including through 
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PICS, the secure online platform developed by INCB for 
enhanced real-time communication and information-
sharing between national authorities on precursor 
incidents.
304. In 2020, cooperation between INCB, Europol and 
the authorities of Bulgaria, Iran (Islamic Republic of), the 
Netherlands and Turkey resulted in the identification of 
suspected links between six seizures of acetic anhydride 
made in Europe and West Asia since 2017. The six cases, 
involving almost 22,000 litres of acetic anhydride, repre-
sent the largest number of interlinked seizures of precur-
sors identified so far on the basis of analysis of intelligence 
communicated through a Project Cohesion alert and 
PICS. Investigations are ongoing.
305. INCB encourages all Governments to make use 
of the existing global cooperation mechanisms under 
Project Prism and Project Cohesion to gather and 
exchange information on new precursor trafficking 
trends and on the criminal organizations involved and 
how they operate, and to use that knowledge to develop 
specific risk profiles and conduct joint operations to 
prevent future diversions. INCB also reiterates its 
recommendations to all Governments to ensure that the 
contact details of their focal points for Project Prism 
and Project Cohesion are always up to date and that 
those focal points actively participate in the relevant 
operations under Project Prism and Project Cohesion 




Analysis of the world situation
A. Global issues
1.  Ensuring access to and availability 
of controlled substances for 
medical and scientific purposes 
during the COVID-19 pandemic and 
the effect of the pandemic on drug 
trafficking and the illicit economy 
Ensuring access to and availability of controlled 
substances for medical and scientific purposes 
during the COVID-19 pandemic 
306. Since the beginning of 2020, the COVID-19 
pandemic has brought forth unprecedented challenges to 
the economies and public health systems of all countries. 
The lockdowns, border closures and social-distancing 
measures adopted by most countries to reduce the 
number of infections and contain the further spread of 
the virus have put to the test the ability of the international 
community to ensure adequate access to and availability 
of internationally controlled drugs for those in need.
307. The global supply chain of medicines has been 
affected since February 2020 as a result of both the dis-
ruption in the manufacturing of key starting materials of 
active pharmaceutical ingredients and of the ingredients 
themselves in some major manufacturing countries and 
the logistical challenges arising from border closures and 
other social-distancing policies adopted by a number of 
countries.
308. On top of challenges in sourcing active pharma-
ceutical ingredients for further processing and generic 
medicines for consumption, the surge in demand for 
medicines necessary for the treatment of patients with 
COVID-19 further reduced the availability of some medi-
cines containing controlled substances. In particular, the 
Board was aware of and concerned about news regarding 
shortages of medicines containing controlled substances 
such as fentanyl and midazolam in some countries, largely 
driven by significant increases in the need to provide pain 
relief and sedation for patients admitted into intensive 
care units with COVID-19.
309. In the light of lower supply and greater demand, a 
number of contingency measures have been put in place 
by some countries, including increasing stocks to provide 
a greater buffer, resorting to alternative drugs, imple-
menting temporary export bans, which have in turn led 
to shortages of certain medicines in other countries, and 
importing medicines containing controlled substances 
registered in other countries. 
310. The heightened demand for certain substances has 
been reflected in part by a number of requests by 
Governments since March 2020 to increase their estimates 
and assessments and by a greater number of countries 
deciding to issue electronic import and export authoriza-
tions instead of hard copies of such authorizations. Several 
Governments also permitted the electronic submission of 
applications for import and export authorizations for 
narcotic drugs and psychotropic substance and notifica-
tions of no objection for precursor chemicals. 
311. Alongside the difficulties faced by most countries 
in the procurement and sourcing of controlled substances, 
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disruption in the treatment and service delivery for 
people with mental health problems and substance use 
disorders since the onset of COVID-19 warrants specific 
concern and attention. Based on the rapid assessment of 
WHO, more than 40 countries experienced disruption in 
their services for people with mental health problems and 
substance use disorders, including those related to life-
saving emergencies. Community-based outpatient ser-
vices, services to raise awareness of and prevent mental 
health problems, and services targeted at older adults and 
children were among those that were most adversely 
affected. The lack of access to such essential treatment 
services as a result of COVID-19 is extremely worrisome, 
as prolonged social distancing and the associated social 
isolation impose greater emotional strain on people with 
mental health problems and substance use disorders and 
may further increase the number of people suffering from 
such conditions. 
312. Research from UNODC has further confirmed the 
impact and health consequences of COVID-19 on people 
who use drugs. Specifically, the mobility restrictions 
imposed by most Governments caused considerable 
disruption to access to drug treatment services, clean 
drug-using equipment and substitution therapy. The lack 
of access to treatment services and safe practices increased 
not only the risk of aggravating drug use disorders, but 
also risks with regard to the health and survival of drug 
users. For instance, heroin users who could not access 
opiate-substitution therapy were reported to have suffered 
severe withdrawal symptoms. Meanwhile, shortages in the 
supply of drugs also led to the use of alternative means 
of administration (e.g., injection) by some users, incur-
ring additional risks such as the spread of blood-borne 
diseases (e.g., HIV/AIDS and hepatitis C).
Measures taken by the Board to ensure 
access to and availability of controlled 
substances for medical and scientific 
purposes during the COVID-19 pandemic
313. In line with its mandate, the Board strives to raise 
awareness of the importance of ensuring the availability 
of medicines containing controlled substances during this 
challenging time. In April 2020, the President of INCB 
joined a call made in an article in The Lancet to extend 
palliative care during and after the COVID-19 pandemic. 
On 26 June 2020, to mark the International Day Against 
Drug Abuse and Illicit Trafficking, he also emphasized 
the importance of Governments ensuring continued 
access to controlled medicines for all medical needs 
related to COVID-19. In addition to joining other 
United Nations entities as part of the United Nations 
COVID-19 response, on 14 August 2020, the Board 
issued a statement, together with UNODC and WHO, on 
access to internationally controlled substances during the 
COVID-19 pandemic. 
314. Since the beginning of the pandemic, INCB has 
conducted further research and enhanced its contact with 
competent national authorities to ensure the availability 
of controlled substances. In May 2020, the Board 
contacted major manufacturing countries to identify 
challenges encountered in the supply of controlled 
psycho tropic substances. Several manufacturing countries 
noted a considerable increase in the demand for drugs 
containing controlled psychotropic substances and the 
logistical challenges involved in the international trade 
therein. Most of them, however, did not anticipate further 
disruptions to their manufacturing activities. 
315. The Board also conducted a survey among users 
of PEN Online to ascertain the impact of the pandemic 
on legitimate activities related to precursors. Most 
respondents reported no major effect on the legitimate 
supply of such substances, apart from the general “lock-
down” effect, such as border closures affecting trade in 
general. This is corroborated by the information available 
to the Board through the number of pre-export notifica-
tions submitted, which showed a decline of 17 per cent 
for the period January–June 2020 when compared with 
the same period in previous years.
316. Since March 2020, an increased number of 
supplementary estimates for narcotic drugs and modifica-
tions to assessments for psychotropic substances have 
been submitted by Governments as a result of COVID-19. 
They were processed expeditiously and the assessment 
system for psychotropic substances continues to be 
updated on a weekly basis. The INCB secretariat has also 
facilitated communication between importing and exporting 
countries and assisted in the verification of the legitimacy 
of import and export authorizations to ensure that inter-
national trade is unaffected as much as possible by 
measures put in place in response to the pandemic. 
317. The Board has repeatedly expressed its commit-
ment to supporting Governments in using I2ES and 
enhancing their knowledge of the international drug 
control framework through INCB Learning. Such activi-
ties have taken on heightened importance during the 
COVID-19 crisis, as paperless trade and online training 
become the norm. 
318. Since the end of March 2020, Governments have 
been encouraged to share updates through the I2ES 
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forum on contingency measures taken as a result of 
COVID-19 so that trading partners are informed in a 
timely manner of the latest measures to minimize 
disruptions to trade. Furthermore, the secretariat 
conducted several webinars to strengthen the operational 
capacity of the I2ES community. Between March and June 
2020, representatives of the competent national authorities 
of Bhutan, Bulgaria, Costa Rica, the Dominican Republic, 
El Salvador, Guatemala, Honduras, Luxembourg, Mozambique, 
Oman and Panama attended a series of INCB Learning 
webinars to receive hands-on training on the technical 
reporting requirements of the international drug control 
conventions.
319. INCB has been in touch with Member States and 
international organizations to review the need to update 
the Model Guidelines for the International Provision of 
Controlled Medicines for Emergency Medical Care69 as 
the impact of COVID-19 continues to unfold, casting 
uncertainties on the ability of the international commu-
nity to ensure the adequate availability of medicines con-
taining controlled substances during emergency and 
other crisis situations. 
320. Looking ahead, the Board will continue to monitor 
the impact of COVID-19 on the availability of medicines 
containing internationally controlled substances and 
treatment services for mental health problems and 
substance use disorders, particularly in low- and middle-
income countries. To ensure uninterrupted manufacturing 
and delivery of those medicines for the treatment of 
patients with COVID-19, and all others in urgent need 
of them, the Board recommends that countries review 
their forecasts for the demand of medicines containing 
internationally controlled substances and streamline all 
the necessary administrative and logistical requirements. 
Countries are also urged to continue the provision of 
treatment services for mental health problems and 
substance use disorders as part of essential services. At 
the international level, the Board encourages all Member 
States to continue working closely with each other and 
the Board to ensure the global availability of medicines 
containing controlled substances, especially for those 
who are most in need during emergency situations. 
Effect of the COVID-19 pandemic on drug 
trafficking and the illicit economy
321. The measures introduced by Governments to pre-
vent the spread of COVID-19 have inevitably influenced 
illicit drug markets, from the manufacture and movement 
69 WHO, document WHO/PSA/96.17.
of drugs to the consumption thereof. Thus far, three 
developments in drug markets and, in particular, in inter-
national drug trafficking, can be identified: (a) a decrease 
in the availability of drugs and an increase in pricing; (b) 
an impact on law enforcement capacities; and (c) a change 
in the modi operandi of drug trafficking organizations.
Impact on the availability and pricing of 
drugs on the illicit market
322. Recent studies suggest that the measures imple-
mented by Governments to address the COVID-19 
pandemic have led (at least temporarily) to a shortage of 
numerous types of drugs at the retail level, coupled with 
an increase in prices. These impacts vary depending on 
the type of substance and the geographical location of 
production, but they affect in particular those substances 
that are transported alongside licit goods and services. 
The availability and prices of synthetic and semi-synthetic 
drugs are also affected by the availability of the requisite 
precursor chemicals. Wherever illicit drug manufacture 
is dependent on the cross-border and, in particular, inter-
regional flow of precursors, the decline in international 
trade, which traffickers use to mask illicit shipments of 
precursors, will inevitably lead to lower availability of 
those substances and consequent drug manufacture. 
323. Unsurprisingly, drug trafficking by air passengers 
decreased dramatically in the first months of 2020 as most 
planes for private passenger transport were grounded 
owing to COVID-19 restrictions. However, the transpor-
tation of commercial goods has not seen the same wide-
spread disruption as passenger transport. Therefore, the 
trafficking of drugs by maritime shipping or commercial 
air freight has likely continued at similar levels to those 
before the outbreak of the pandemic. For example, there 
are indications that international trafficking in heroin, a 
substance that is primarily transported by land, has been 
disrupted more than, for instance, trafficking in cocaine, 
which relies to a large extent on sea routes. Seizures of 
relatively large amounts of cocaine in European ports 
confirm the ongoing international trafficking in cocaine.
324. Furthermore, some countries in the European 
Union noted an increase in drug distribution using post 
and parcel services. This increase is substantiated by the 
data uploaded from law enforcement authorities to 
IONICS, the Board’s global intelligence exchange platform 
for synthetic opioids and new psychoactive substances: of 
3,298 seizures communicated within the first five months 
of 2020, 86 per cent were made in relation to postal 
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services, compared with 46 per cent the year before. 
Overall, within the European Union, the logistics of drug 
trafficking generally appear to be most affected in relation 
to the movement of bulk quantities of drugs between 
member States, owing to the introduction of border 
controls. 
325. Information from community-based drug preven-
tion and treatment workers suggests that there have been 
some shortages related to heroin that, in some cases, may 
have led to heroin being substituted with other dangerous 
substances. For instance, in Czechia, reports have emerged 
that heroin has fully disappeared from the street-level 
drug market owing to COVID-19, which has led to 
concerns of a potential increase in the use of fentanyl or 
alcohol in combination with benzodiazepines. Another 
consequence of these drug shortages is that, in some 
countries, the purity of local drug supplies has decreased 
over time as dealers add bulking agents in order to 
continue to meet persistently high demand. There are also 
instances where adulterants are used to artificially increase 
the perceived purity. The most common of these adulterants, 
in particular in North America, is fentanyl and its many 
analogues, which could significantly increase overdose 
and death rates. Some reports show that benzodiazepines 
have also been used as adulterants, in particular in Canada.
326. Thus, regarding the availability and pricing of 
drugs, there is evidence that the COVID-19 restrictions 
have, in some countries, led to a disruption in the 
availability of drugs and to an increase in prices. 
Depending on the substance, people who use drugs may 
have either reduced their overall consumption or switched 
to even more harmful substitutes. The consumption of 
drugs typically connected to nightlife and party scenes, 
such as “ecstasy”, has decreased, given the restrictions on 
gatherings and the closure of nightclubs and other venues 
imposed as a measure to control the pandemic.
Impact on law enforcement capacities
327. The shift in operational focus towards duties related 
to the enforcement of social-distancing requirements, 
border controls and the fight against falsified medical 
products has temporarily reduced the availability of law 
enforcement personnel to conduct investigations into 
other types of crimes. In countries with already limited 
law enforcement capacity, this change makes drug traf-
ficking and manufacture less risky and therefore more 
attractive to criminal organizations.
328. During the first six months of 2020, the number 
of seizures of new psychoactive substances communicated 
through IONICS totalled 3,501, which was a decrease of 
25 per cent compared with the same period in 2019, when 
4,721 incidents were communicated. Similarly, with 
regard to precursors, the number of incidents commu-
nicated through PICS was about one third less in the 
same time period (the period most likely to have been 
affected by the pandemic) as compared with the same 
period in 2019.
Changes in the modi operandi of drug 
trafficking organizations
329. Evidence shows that one of the approaches of drug 
traffickers to dealing with challenges is to change existing 
trafficking routes, modi operandi and, in some cases, even 
substances, looking for ways to minimize cost and risk 
and maximize profit.
330. Several reports have revealed that criminals have 
used falsified certificates, commercial vehicles and corporate 
uniforms to impersonate food delivery and other key 
workers in order to deliver drugs. In April 2020, INTERPOL 
issued an alert warning that criminal organizations were 
using food delivery services to transport drugs, such as 
cocaine, cannabis, ketamine and “ecstasy”. Even the 
increasing demand for supplies such as gloves, masks and 
hand sanitizer has been exploited in that way by drug 
traffickers, perhaps in the belief that border controls for 
those types of goods may be less rigorous.
331. Moreover, open web and darknet markets, social 
media, secure encrypted communications applications 
and online forums seem to be playing a more prominent 
role in the sourcing of drugs at the user level. Home deliv-
eries, less face-to-face dealing and less reliance on cash 
as a form of payment seem to be trends in individual 
transactions and it is possible that these behavioural 
changes, once established, will persist over the longer 
term. Although the rapid devaluation of cryptocurrencies 
such as bitcoin at the beginning of the pandemic caused 
some vendors to pull out of darknet marketplaces, 
according to the National Cyber-Forensics and Training 
Alliance of the United States, listings in almost all dark-
net marketplaces increased between the end of March 
and the end of April 2020. Drug traffickers and trafficking 
organizations remain resilient and are adapting their 
modi operandi to the current situation in many ways, 
further exploiting online and secure communication 
channels, as well as adapting transportation modes and 
trafficking routes. 
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Measures taken by the Board to counter 
current developments on the illicit drug 
market
332. As a practical response to the COVID-19 pandemic 
and utilizing opportunities for increased connectivity 
while moving to online work environments, the Board 
hosted, inter alia, a series of interactive hybrid (in-person 
and online) webinars, discussion sessions and expert 
group meetings to raise awareness of the new trafficking 
trends outlined above, exchange experiences and provide 
practical approaches for law and regulatory enforcement 
focal points, information exchange being vital for joint 
efforts to tackle current challenges in drug trafficking. 
333. Given that pandemic-related measures are likely to 
persist for the foreseeable future, accompanied by uncer-
tainty in circumstances affecting both domestic and inter-
national travel and an increase in express consignments 
and home deliveries for vital supplies, which provide 
ample opportunities for traffickers to hide substances, it 
has been proved vital for law enforcement authorities to 
utilize new strategies for dangerous substance interdiction, 
which the Board’s GRIDS programme provides. Evaluation 
statistics relating to the GRIDS Programme webinars on 
trafficking trends and approaches during the COVID-19 
pandemic, held in May 2020, showed that, overall, 
87 per cent of the participants considered the event to be 
highly valuable for their work in combating global drug 
trafficking. 
334. As drug manufacturers, traffickers and distributors 
seem to gradually overcome the difficulties initially caused 
by COVID-19, it is of great importance that law enforce-
ment authorities, which have already been operating with 
limited counter-narcotics resources during the pandemic, 
identify these developments and find new ways to counter 
changes in the nature of trafficking in dangerous 
substances.
2.  Effective drug control as a means of 
fostering peace and security
335. INCB, within its mandates, continues to support 
Member States in the implementation of the three inter-
national drug control conventions in a comprehensive, 
integrated and balanced way with a view to achieving the 
Sustainable Development Goals, in particular Goal 16 
(Promoting peaceful and inclusive societies for sustain-
able development, providing access to justice for all and 
building effective, accountable and inclusive institutions 
at all levels).
336. In this regard, the Board notes that the provisions 
of the international drug control conventions related to 
supply reduction, which include measures and strategies 
to reduce the quantities of illicit drugs on illicit markets 
while ensuring the availability of narcotic drugs and 
psycho tropic substances for medical and scientific needs, 
together with the provisions of the conventions pertaining 
to reducing demand for illicit drugs, constitute some of 
the essential elements of such a comprehensive, integrated 
and balanced approach. The Board wishes to highlight 
that the provisions of the international drug control 
treaties related to criminal justice, covering issues such as 
penal provisions, international judicial and law 
enforcement cooperation, asset forfeiture and confiscation, 
can serve as effective legal instruments in addressing not 
only drug-related offences, but also any associated 
criminal activity, such as organized crime, corruption and 
money-laundering.
337. Target 16.1 of the Sustainable Development Goals is 
to significantly reduce all forms of violence and related 
death rates everywhere. In this regard, the Board recognizes 
that, under the pretext of the “war on drugs”, policies in 
some countries have led to disproportionate and overly 
repressive responses without respect for due process and 
the rule of law. Such responses contribute to an increase 
in violence and related death rates. The Board has called, 
on numerous occasions, for national drug control systems 
to be based on the international drug control conventions, 
the Political Declaration and Plan of Action on International 
Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem and the Ministerial 
Declaration on Strengthening Our Actions at the National, 
Regional and International Levels to Accelerate the 
Implementation of Our Joint Commitments to Address 
and Counter the World Drug Problem, in all of which 
Member States expressed their commitment to 
implementing a comprehensive, integrated and balanced 
approach, principles of proportionality in the determination 
of penalties and response measures, shared responsibility 
and respect for human rights and liberties and the rule of 
law. The Board continues to engage in close dialogue with 
all Member States, as well as the non-governmental sector 
and academia, with a view to promoting those commitments.
338. Target 16.4 of the Sustainable Development Goals 
is to significantly reduce, by 2030, illicit financial and 
arms flows, strengthen the recovery and return of 
stolen assets and combat all forms of organized crime. 
The Security Council, in its resolution 2482 (2019), 
acknowledged that terrorists could benefit from organ-
ized crime, whether domestic or transnational, such as 
trafficking in drugs, and called upon Member States to 
strengthen their efforts, as well as international and 
52  INCB REPORT 2020
regional cooperation, to counter the threat to the inter-
national community posed by the illicit cultivation and 
production of, trafficking in and consumption of narcotic 
drugs and psychotropic substances, which could signifi-
cantly contribute to the financial resources of terrorist 
groups, and to act in accordance with the principle of 
common and shared responsibility in addressing and 
countering the world drug problem, including through 
cooperation against trafficking in illicit drugs and 
precursor chemicals. 
339. The outcome document of the thirtieth special 
session of the General Assembly, entitled “Our joint com-
mitment to effectively addressing and countering the 
world drug problem”, also reflects the international com-
munity’s commitment to addressing the links between 
drug-related crimes and other forms of organized crime, 
including money-laundering, corruption and other crimi-
nal activities, in line with the international drug control 
conventions and the United Nations Convention against 
Transnational Organized Crime, the United Nations 
Convention against Corruption and the international 
instruments on countering terrorism. In the outcome 
document, Member States recommend improving the 
availability and quality of statistical information and analysis 
on illicit drug cultivation, production and manufacturing, 
drug trafficking, money-laundering and illicit financial 
flows, including for appropriate reflection in reports of 
UNODC and INCB, in order to better evaluate the impact 
of such crimes and further enhance the effectiveness of 
criminal justice responses in that regard.
340. In a statement on 18 December 2013 (S/PRST/ 
2013/22), the President of the Security Council highlighted 
the Council’s concern over the increasing links between 
drug trafficking and other forms of transnational 
organized crime, including trafficking in arms and in 
persons, and terrorism, as well as its concern over the 
growing violence resulting from activities of criminal 
organizations involved in drug trafficking in West Africa 
and the Sahel region. The Council emphasized the need 
to enhance interregional cooperation and coordination in 
order to develop inclusive and effective strategies to 
combat, in a comprehensive and integrated manner, 
transnational organized crime, including trafficking in 
drugs and arms, and activities of terrorist groups. The 
Council called for increased international cooperation, 
including with UNODC and INCB, and encouraged 
Member States to ratify and implement the international 
drug control treaties.
341. In Colombia, despite the signature of the peace 
agreement with the Revolutionary Armed Forces of 
Colombia-People’s Army (FARC-EP) in 2017 and the 
continued efforts of the national Government to combat 
drug trafficking, illicit coca bush cultivation continued, 
and with it the financing of illegal activities by criminal 
groups. Despite the efforts of national agencies, the coun-
try continues to face threats from other activities related 
to drug trafficking, such as trafficking in arms, terrorism, 
money-laundering and corruption. There has also been 
an increase in violence, resulting in the deterioration of 
the security situation in some cities of Colombia.
342. Linkages between insurgency and terrorism and 
drug trafficking in Afghanistan have been repeatedly 
highlighted by the United Nations and the Board. Despite 
the fact that the gross value of the Afghan opiate economy 
fell by two thirds, from between $4.1 billion and 
$6.6 billion in 2017 to between $1.2 billion and 
$2.2 billion in 2018, the opiate economy still accounted 
for 6–11 per cent of the country’s gross domestic product 
and exceeded the value of its officially recorded licit 
exports of goods and services. With a view to supporting 
the efforts of Afghanistan to address the illicit drug economy 
and other drug-related challenges, and to mobilize global 
support in that regard, the Board invoked article 14 bis 
of the 1961 Convention as amended in May 2018, which 
allowed it to recommend to the competent United Nations 
organs and to the specialized agencies that technical or 
financial assistance, or both, be provided to the Government 
of Afghanistan in support of its efforts to carry out its 
obligations under that Convention.
343. The strong financial “incentives” offered by drug 
trafficking to organized criminal groups were highlighted 
by UNODC in its 2011 report entitled Estimating Illicit 
Financial Flows Resulting from Drug Trafficking and 
Other Transnational Organized Crimes. In that report, it 
was pointed out that the largest income for transnational 
organized criminal groups came from illicit drugs, which 
accounted for some 20 per cent of all crime proceeds, 
about half of transnational organized crime proceeds and 
0.6–0.9 per cent of global gross domestic product. In turn, 
drug-related proceeds available for money-laundering 
through the financial system were equivalent to between 
0.4 per cent and 0.6 per cent of global gross domestic 
product.
344. In its statements regarding the situation in 
Afghanistan, which are applicable to any country or region 
seriously affected by drug trafficking and use and associ-
ated criminality, the Board has highlighted the fact that 
drug control is a cross-cutting issue and that, unless local, 
national, regional and international efforts to address it are 
effectively pursued, poverty, insurgency, terrorism and 
obstacles to development will remain unaddressed.
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345. In this regard, the Board wishes to call upon 
Member States to counter drug trafficking and related 
violence through comprehensive and balanced meas-
ures. These measures include effective prevention and 
criminal justice responses and alternative development 
initiatives. Member States should also ensure that 
responses to drug-related criminal conduct are propor-
tionate and founded upon respect for human rights and 
dignity, in line with the three international drug control 
conventions, international human rights instruments 
and the rule of law. 
3.  Collective approaches to drug 
terminology
346. Strengthening international cooperation in drug 
control requires a collective understanding of common 
challenges and the identification of mutual approaches to 
key concepts and issues. Some challenges in promoting 
the consistent application of the international drug 
control treaties have resulted from shifts over time in the 
terminology used to describe issues related to drug con-
trol. The Board routinely takes note of changes to drug-
related lexicons and developments in the terminology 
used by Member States, intergovernmental organizations, 
academia and civil society in relation to the world drug 
problem. 
347. Since the drafting of the most recent international 
drug control convention, the 1988 Convention, there have 
been changes to the terminology commonly used to 
describe various aspects of the world drug problem. These 
changes have resulted from major advancements in 
science, as well as substantial societal developments and 
increased understanding of drug use and drug dependence. 
348. Some terminology, although not found in the 
international drug control conventions, has been used by 
the international community and included in intergov-
ernmental processes to reflect both advancements in sci-
ence and evolving societal approaches to drug control, in 
particular from the perspectives of prevention, treatment 
and rehabilitation. Changes to drug-related terminology 
have come from changes in the broader societal context, 
such as the increasing awareness of the importance of 
inclusivity in language. For example, although the pream-
ble to the 1961 Convention includes a reference to con-
cern for the health and welfare of mankind, the Board 
keeps within the full spirit of the Convention when it 
replaces the term “mankind” with “humankind” or 
“humanity”, which are also translations of the terms used 
in other languages in which the Convention was written. 
The principles in the conventions continue to be upheld, 
even as certain word choices are avoided in the interests 
of gender-inclusive language.
349. The drug terminology used in resolutions and 
decisions of the Economic and Social Council and the 
Commission on Narcotic Drugs and in publications in 
the field of international drug control has changed over 
time. The Board notes that some changes to terminology 
have been based on new and evolving challenges or the 
need to better safeguard human rights protections and 
place people and their needs at the centre of drug control 
policies. The term “drug use”, for example, has been 
mostly preferred in recent publications over the term 
“drug abuse”, owing to perceptions that the word “abuse” 
can, in some instances, result in the further stigmatization 
of people who consume drugs. 
350. The careful use of terminology can therefore aid in 
preventing the stigmatization of drug use and dependence. 
Those working in the field of drug control have had to 
take a cautious approach to the use of terms in order to 
be mindful of the possible effects of language on the 
protection of human rights. The Board takes note of 
Commission on Narcotic Drugs resolution 61/11, entitled 
“Promoting non-stigmatizing attitudes to ensure the 
availability of, access to and delivery of health, care and 
social services for drug users”, and affirms the Commission’s 
guidance that Member States can prevent social margin-
alization and promote non-stigmatizing attitudes, includ-
ing in the development and implementation of scientific 
evidence-based policies. 
351. The Board regularly and carefully examines the use 
of drug-related concepts and other lexicons, such as the 
lexicon used by WHO. In its report for 2017, for example, 
the Board specifically indicated that precision was 
required in the use of terminology concerning the medi-
cal use of cannabinoids. Such precision and the collective 
aim of standardization can help the Board in the coming 
years with data collection across countries and periods of 
time and facilitate the effective monitoring of treaty 
compliance. 
352. In line with the Ministerial Declaration on 
Strengthening Our Actions at the National, Regional and 
International Levels to Accelerate the Implementation of 
Our Joint Commitments to Address and Counter the 
World Drug Problem,70 the Board seeks to promote the 
collection, analysis and sharing of quality and comparable 
data. This will require the continued identification of any 
scientific or legal ambiguities in the terminology chosen 
70 See Official Records of the Economic and Social Council, 2019, 
Supplement No. 8 (E/2019/28), chap. I, sect. B.
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in the drafting of drug policies and laws. Member States 
draw distinctions in drug terminology on the basis of 
their own national and local understandings and inter-
pretations of the conventions and public health priorities. 
353. In this context, the Board urges Governments to 
continually examine any drug terminology that has 
ambiguous usage, or potentially stigmatizing effects, 
and that might have an impact on the ability of the 
international community to cooperate effectively on and 
jointly counter the world drug problem. 
4.  Genetic engineering and its 
implications for the cultivation of 
cannabis and production of 
cannabis derivatives in the context 
of the international drug control 
conventions
354. Selective breeding techniques have been used for 
centuries in the agricultural sector to maximize desirable 
traits in plants and animals. However, they require careful 
cultivation or breeding of multiple generations in order 
to maximize certain traits and minimize others. The rise 
of genetic engineering has, for several decades now, 
allowed the agricultural sector to modify crops to increase 
their yield, improve their resilience to pests and enable 
them to grow in harsh environments. Although many 
genetic engineering techniques may be unreliable, expen-
sive or difficult to execute, recent advancements in genetic 
engineering technologies now allow for highly accurate, 
effective and cheaper genetic engineering of organisms. 
These new technologies are also being applied to the can-
nabis plant and the production of cannabinoids.
355. In article 1, paragraph 1 (b), of the 1961 Convention 
as amended, cannabis is defined as the flowering or fruit-
ing top of the cannabis plant (excluding the seeds and 
leaves when not accompanied by the tops) from which 
the resin has not been extracted. These portions of the 
plant contain the most THC and other cannabinoids. 
Moreover, studies of the cannabis plant over the last few 
years have found that, beyond THC and CBD, over 100 
cannabinoids are found naturally in the plant.
356. As more jurisdictions permit the cultivation and 
use of cannabis for medical purposes, researchers and the 
private sector are investigating the use of genetic 
engineering technologies to modify the cannabis plant to 
optimize industrial processes and more precisely adjust 
the yields of the types of cannabinoids being produced. 
Research is also being undertaken on modifying other 
organisms to produce cannabinoids that they would not 
otherwise produce naturally.
357. As the flowering top represents only a fraction of 
the cannabis plant’s biomass, cultivators are seeking ways 
to increase yields of cannabinoids from the plant. To this 
end, patents have already been filed using recently devel-
oped technologies to modify the cannabis plant to grow 
trichomes or produce cannabinoids in other parts of the 
plant beyond the flowering top, leaves or seeds, effectively 
making the entire cannabis plant a producer of 
cannabinoids.
358. In addition to the modification of the cannabis 
plant, some technologies may allow the production of 
cannabinoids without using the cannabis plant at all. 
Through initial research conducted in 2019, a method 
was found of modifying a kind of yeast that could allow 
for the large-scale fermentation of cannabinoids from 
simple sugars, independent of cannabis cultivation. 
359. Research into both the genetic modification of the 
cannabis plant and the yeast-based method of cannabinoid 
production has also indicated the possibility of using 
these technologies to produce cannabinoids such as 
cannabigerol, cannabichromene and cannabinol in far 
larger quantities than can be produced through selective 
cultivation.
360. As the system of control established under the 1961 
Convention as amended includes controls of the flowering 
top, with limited control on the leaves and seeds, these 
developments pose questions with regard to the control 
of the cannabis plant if it were modified to produce 
cannabinoids throughout the plant and beyond the 
flowering top. 
361. Advances in technology also allow for the possibil-
ity for its abuse, in particular, through the misuse of these 
new genetic engineering technologies to illicitly produce 
drugs. The method of cannabinoid production through 
genetically modified yeast makes the need for large “grow 
houses” or clandestine cultivation of cannabis unnecessary. 
362. The Board calls upon Governments to take note 
of the advances in genetic engineering and biotechno-
logy in the cultivation of cannabis, as well as other 
technologies that can allow for the manufacture of 
cannabinoids through non-conventional means. The 
Board also calls upon Governments to ensure that these 
technologies are appropriately used with respect to the 
international drug control conventions and to take steps 
to prevent the misuse of such technologies in the illicit 
manufacture of drugs.
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B. Africa
a growing number of countries in africa are now permit-
ting the cultivation and export of cannabis for medical 
and scientific purposes, and some countries have author-
ized the use of cannabis for medical purposes. 
The lack of data from many countries in africa on the 
trafficking in and use of drugs remains a major impedi-
ment to fully assessing the drug situation in the region 
and hinders the ability of countries and the international 
community to respond to these challenges.
1. Major developments
363. Four countries in Africa have estimates approved 
by INCB on the cultivation of cannabis for medical 
purposes. Some other countries in Africa have enacted 
legislative and policy changes with regard to cannabis. 
Most of those changes would allow for the cultivation of 
cannabis for medical purposes, although in some cases 
only for export, not domestic use. In addition, some 
countries have modified their schedules of control to 
reduce or remove restrictions on the use of certain 
cannabis-based preparations for medical purposes.
364. The Board wishes to recall that Governments that 
permit the cultivation of cannabis have an obligation to 
establish control measures in accordance with the 1961 
Convention as amended. Such measures include the 
establishment of an agency responsible for designating 
areas and issuing licences for cultivating, purchasing 
and taking physical possession of such crops as soon as 
possible and having the exclusive right of importing, 
exporting and wholesale trading and maintaining stocks 
other than those held by manufacturers.
365. ECOWAS released the report of the West African 
Epidemiology Network on Drug Use in late 2019, the 
first-ever report on drug trafficking and drug use in West 
Africa, with the support of UNODC and the European 
Union. The report provides an analysis of drug trafficking 
and drug use data provided by the Network’s focal points 
for the period 2014–2017.
366. The Ministry of Health of Morocco released a 
national protocol to address drug overdoses by persons 
who inject drugs in the country. The protocol is aimed at 
providing information for health officials, officials outside 
the health sector and other relevant actors across the 
country who might have to deal with a drug overdose 
situation.
367. Following the adoption of the Narcotic Control 
Commission Bill 2019, Ghana has decriminalized some 
minor drug use offences and refocused its drug control 
efforts using a health-based approach for persons who 
use drugs.
368. In August 2020, the Government of South Africa 
submitted to the Parliament the Cannabis for Private 
Purposes Bill of 2020, amending its Drugs and Drug 
Trafficking Act (1992) to allow the cultivation and use of 
cannabis by adults for personal use following a 2018 
decision of the country’s Constitutional Court. Combined 
with the amendments made to the Medicines and Related 
Substances Act of 1965 in May 2020, the non-medical use 
and cultivation of cannabis by adults in private spaces is 
decriminalized in South Africa. Public use of and 
trafficking in cannabis remain punishable offences.
369. Despite the lack of data from many countries, the 
information that is available suggests that Africa contin-
ues to face major challenges regarding trafficking in 
drugs. Countries in West and North Africa continue to 
seize shipments of cocaine trafficked from South America 
destined for Europe. Cannabis continues to be widely 
trafficked within Africa, while cannabis resin is heavily 
trafficked in North Africa, both for sale in the subregion 
and for trafficking onward to Europe. Trafficking in 
heroin remains a major concern for African countries in 
the Indian Ocean region, whereas countries in other parts 
of Africa seize only small quantities of the drug. While 
no major seizures of illicitly manufactured or falsified 
tramadol have been reported in the region, available drug 
use prevalence data suggest that the substance continues 
to be trafficked.
370. During the COVID-19 pandemic, a number of 
countries and international organizations took measures 
to ensure that persons affected by drug use disorders were 
able to continue receiving treatment and to reduce the 
risk of COVID-19 transmission during such treatment. 
371. In Nigeria, UNODC partnered with health workers 
across the country, establishing a network to provide 
assistance by telephone to drug users. In addition, the 
European Union, through the UNODC project entitled 
“Response to drugs and related organized crime”, pro-
vided personal protective equipment to 25 drug treatment 
centres across Nigeria to ensure that health workers and 
patients were protected while services are provided.
372. The Ministry of Health of Algeria, in cooperation 
with UNODC and UNAIDS, provided material support, 
including personal protective equipment, to several non-
governmental organizations, allowing them to reach drug 
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users individually while minimizing their risk of contract-
ing COVID-19 at hospitals and treatment centres. 
Similarly, UNODC supplied personal protective equip-
ment to a major drug treatment centre in Dakar so that 
patients were protected while receiving treatment.
373. The Government of Kenya opened an additional 
methadone dispensary in Shimo Le Tewa Prison to relieve 
congestion and reduce the risk of COVID-19 transmission 
among prisoners being treated for drug use. The Moroccan 
Association of Addictology issued guidelines for drug 
treatment professionals to ensure that drug treatment 
services continued during the COVID pandemic.
2. Regional cooperation
374. The Peace and Security Council of the African 
Union, at its 905th meeting, in January 2020, issued a 
statement regarding the political and security situation in 
Guinea-Bissau. While noting the political progress made 
in the country, the Council appealed to the international 
community to support Guinea-Bissau in confronting 
drug trafficking, which could threaten efforts to ensure 
stability, democratic governance and the rule of law in 
the country.
375. As part of a review of the political and security 
situation in Guinea-Bissau, the Security Council, on 
28 February 2020, adopted resolution 2512 (2020), in 
which, inter alia, it called upon authorities in the country 
and the international community at large to step up 
efforts to combat drug trafficking and other transnational 
crimes. In that resolution, the Council also requested the 
Secretary-General, through collaboration with inter-
national donors, to ensure that the UNODC country 
office in Guinea-Bissau be sufficiently resourced in order 
to assist the country in its efforts to counter drug 
trafficking following the withdrawal of the United Nations 
Integrated Peacebuilding Office in Guinea-Bissau.
376. As of February 2020, three additional countries 
had signed the treaty for the establishment of the African 
Medicines Agency, bringing the number of signatories of 
the treaty to 14 countries, 1 less than the 15 required for 
the treaty to enter into force. Once established, the Agency 
is expected to coordinate the regulatory system for medi-
cines and drugs among States members of the African 
Union, provide regulatory guidance to countries and 
facilitate further cooperation among countries to ensure 
access to safe and effective medical products in the region.
377. The third annual meeting of the African 
Medicines Quality Forum took place in Abuja from 
25 to 28 February 2020. The meeting was hosted by the 
National Agency for Food and Drug Administration and 
Control of Nigeria in collaboration with the African 
Union and other international organizations. The meeting 
brought together drug control organizations from many 
African countries and scientists and stakeholders from 
various health- and drug-related agencies to deliberate on 
a quality-assurance model for drugs and medicines for 
countries in Africa. 
378. During the second half of 2020, INCB coordinated 
access to IONICS and GRIDS intelligence and conducted 
10 training sessions for law and regulatory enforcement 
officers from 11 countries in the region. A total of 113 
officers from Benin, Burkina Faso, Egypt, Ghana, Libya, 
Mali, Namibia, Nigeria, South Africa, the Sudan and 
Tunisia participated in training on monitoring new psy-
choactive substances and emerging synthetic opioids, as 
well as training in the safe handling of fentanyl-related 
substances and interdiction approaches. The officials also 
received practical training on the Board’s secure commu-
nications platforms that allow for the exchange of infor-
mation on dangerous substances that are not internationally 
controlled.
3.  National legislation, policy and 
action
379. Several countries in Africa have revised their 
national legislation to permit the cultivation of cannabis 
for medical purposes for export or to permit the import 
and use of certain cannabis preparations for medical use. 
In some cases, control measures for cannabis plant have 
changed, and some countries have changed the placement 
of THC and CBD in their schedules of control. 
380. In addition to cannabis-related legislative and 
policy reforms, several countries have launched new 
national drug control plans to better address their respec-
tive drug control problems. Further, Ghana has updated 
its legislation, revising its penal code to decriminalize 
minor drug use offences. 
381. At the end of 2019, Togo launched a new five-year 
plan for the period 2020–2024 to counter drug use and 
trafficking in the country, allocating financing to 
implement the plan. The plan is aimed at strengthening 
coordination among drug control bodies in the country 
and enabling authorities to freeze and seize the assets 
of criminal organizations.
382. The President of Seychelles launched the country’s 
new National Drug Control Master Plan 2019–2023 in 
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December 2019. The plan is focused on improving the 
well-being and safety of the population at large. The 
President noted that demand reduction and treatment for 
persons who use drugs were of critical importance in 
combating the country’s drug problem.
383. In February 2020, the Government of Seychelles 
adopted the Misuse of Drugs (Cannabidiol-based Products 
for Medical Purposes) Regulations 2020, amending the 
country’s drug control legislation to permit the use of 
CBD for medical purposes. Under the amendment, duly 
authorized medical practitioners are permitted to 
prescribe CBD-based medicines for qualifying medical 
conditions. The amendment does not specify which quali-
fying medical conditions may be treated with CBD but 
empowers the country’s Public Health Commissioner to 
determine them by decree.
384. The Parliament of Malawi approved the Cannabis 
Regulation Bill of 2020, in February 2020, permitting the 
cultivation of cannabis for medical, industrial and scien-
tific purposes. The bill also establishes a national cannabis 
agency to issue licences to cultivate cannabis and regulate 
the industry within Malawi. According to official reports, 
the cultivation of cannabis under the framework of the 
Cannabis Regulation Bill could be permitted as early as 
2021.
385. In March 2020, the Parliament of Ghana approved 
the Narcotics Control Commission Bill 2019, which 
introduces a major overhaul of the country’s drug control 
legislation and policy. Under the bill, a health-based 
approach is emphasized in addressing drug use, and some 
minor drug use offences are decriminalized. In addition, 
the bill alters the country’s institutional framework for 
drug control by giving the country’s Narcotics Control 
Board the status of a Commission, with enhanced powers. 
Also under the bill, the cultivation of cannabis for the 
production of CBD for medical purposes is permitted, 
and CBD is removed from national control. 
386. In an official communication to the Board in April 
2020, Uganda reported that it had begun permitting the 
cultivation of cannabis for medical purposes. The 
Government had drafted guidelines to assist the Minister 
of Health in determining which cultivators should be 
granted licences to cultivate cannabis. However, final 
approval of the guidelines and the establishment of the 
national cannabis agency were delayed due to lockdown 
measures related to the COVID-19 pandemic.
387. In May 2020, the Minister of Health of South 
Africa issued Notice R586, further amending the schedules 
of the country’s Medicines and Related Substances Act of 
1965 and codifying changes in the control of cannabis-
related substances made by the Minister in May 2019. 
Under the Notice, cannabis plant, THC and dronabinol 
were removed from schedule 7 (the country’s highest level 
of control) of the Act. Certain low-dose CBD prepara-
tions from raw plant material were descheduled entirely. 
Also under Notice R586, cannabis plant raw material was 
descheduled if it is cultivated, possessed or consumed by 
an adult, in private for personal consumption. According 
to the Ministry of Health, those amendments bring the 
Act into line with a 2018 decision of the Constitutional 
Court of South Africa.
388. In a related development, on 5 August 2020, the 
South African Cabinet submitted to Parliament the 
Cannabis for Private Purposes Bill of 2020. The bill, 
together with the above-mentioned changes made to the 
Medicines and Related Substances Act of 1965, amends 
the country’s Drugs and Drug Trafficking Act of 1992 
(Act No. 140 of 1992) in relation to the personal cultiva-
tion of cannabis. The Cannabis for Private Purposes Bill 
of 2020 is aimed at bringing the country’s drug control 
legislation into line with a decision by the Constitutional 
Court of South Africa in 2018 that struck down portions 
of that legislation. The Court suspended its ruling for 24 
months to give the Government time to amend the coun-
try’s drug control laws to permit the private cultivation 
and consumption of cannabis by adults. At present, pri-
vate personal cultivation and consumption of cannabis is 
decriminalized in South Africa. The sale of cannabis and 
consumption of the drug in public remain illegal and 
subject to punishable offences.
389. In June 2020, South Africa launched the country’s 
new National Drug Master Plan for the period 2019–
2024, the fourth such plan put into effect in the country. 
The Plan was developed following an evaluation of the 
country’s plan for the period 2013–2017, which had led 
to recommendations for key authorities at several levels 
of government in the country to be strengthened and for 
a focus on evidence-based interventions to prevent and 
treat substance use. The National Drug Master Plan 
includes seven goals to address the country’s drug prob-
lem, including ensuring the availability of controlled sub-
stances for licit medical use and countering the expanding 
use of new psychoactive substances. In addition, the 
Master Plan contains a reference to the 2018 ruling by 
the Constitutional Court of South Africa permitting the 
private use of cannabis, and it is noted therein that, while 
the Government would modify national legislation to 
comply with the ruling, the Master Plan remained a 
framework to curb cannabis use in the country.
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4.  Cultivation, production, 
manufacture and trafficking
390. Available information suggests that Africa remains 
a major transit region for drug trafficking, as well as a 
growing market for drugs. Seizure data suggest that, as 
has been the trend in recent years, West and North Africa 
continue to be a key hub for the trafficking of cocaine 
from South America to Europe. Seizures of cannabis and 
cannabis resin are reported by all countries for which data 
are available, and there is significant trafficking in those 
drugs in North Africa, both for sale within the subregion 
and for trafficking onward to Europe. The seizures of 
falsified and non-pharmaceutical tramadol, an opioid 
analgesic not under international control, reported by 
some countries in West Africa suggest that the trafficking 
in that drug continues to be a challenge for the subregion.
391. Law enforcement authorities in Algeria, Côte 
d’Ivoire, Morocco and Tunisia each reported multiple sei-
zures of cocaine in 2020, seizures being effected in ports 
or on ships in their territorial waters. In one significant 
seizure in February 2020, the naval forces of Côte d’Ivoire 
seized more than 400 kg of cocaine from a ship in the 
country’s coastal waters. Several other countries in other 
parts of Africa also reported seizures in the first part of 
2020, although of small quantities. In comparison with 
2019, when Algeria, Burkina Faso, Mauritius, Morocco, 
Mozambique, Senegal, the United Republic of Tanzania 
and Zambia provided official reports regarding their sei-
zures of cocaine, the lack of seizure data for 2020 from 
some parts of Africa has made it difficult to determine 
the trend for trafficking in cocaine. Notably, although 
several significant seizures were made in West and North 
Africa in 2020, they were not as large as the multi-ton 
seizures of cocaine effected by the authorities of Cabo 
Verde in January and August 2019.
392. Cannabis continues to be the most-trafficked drug 
in Africa and is also trafficked to Europe, mostly from 
North Africa, with reports that in some cases the trafficking 
route goes through countries of the western Sahel. As in 
previous years, most trafficking in cannabis resin occurred 
in North Africa, with Morocco reporting seizing a total of 
more than 75 tons of that substance, the result of numerous 
interdictions in the first half of 2020. Similarly, authorities 
in Algeria conducted several interdictions, seizing a total 
of more than 18 tons of cannabis resin since late 2019. 
Senegal reported a significant seizure of 5.1 tons of cannabis 
resin. The National Drug Law Enforcement Agency of 
Nigeria reported seizing a total of 7.4 tons of cannabis in 
2020. Regarding trafficking in cannabis herb, Benin, 
Burkina Faso, Gabon, Ghana, Mauritius, Namibia, Senegal, 
Seychelles, the United Republic of Tanzania and Zambia 
reported seizures ranging from several hundred kilograms 
to hundreds of tons, quantities that are comparable to those 
seized in previous years.
393. Seizure data suggest that trafficking in heroin con-
tinues to be a major issue in African countries of the 
Indian Ocean region, including Mauritius, Mozambique, 
Seychelles and the United Republic of Tanzania, but traf-
ficking in that drug is reported in other parts of Africa 
as well. Côte d’Ivoire, Ghana and Morocco all reported 
total seizures of heroin ranging from a few kilograms to 
several hundred kilograms in 2019. The lack of data 
makes it difficult to determine year-to-year trends in the 
trafficking in heroin in Africa, as the amounts seized have 
risen somewhat in a few countries but fallen in others. 
394. For countries in the region, there are only very 
limited official data on trafficking in other drugs for the 
present reporting period. Several countries in Africa 
reported seizures of amphetamine-type stimulants, related 
precursor chemicals and other substances, although in 
smaller quantities than the other drugs discussed above. 
Seizures of “ecstasy” and other hallucinogens were 
reported by Morocco and Tunisia. 
395. Trafficking in tramadol, a synthetic opioid not 
under international control, including illicitly manufac-
tured non-pharmaceutical preparations containing that 
substance, continues to pose a challenge for the region. 
Few official data are available regarding trafficking in 
tramadol during the reporting period. However, data on 
the prevalence of use of tramadol, both pharmaceutical 
and falsified tramadol, suggest that trafficking in the sub-
stance remains an issue for the region.
5. Prevention and treatment
396. The lack of prevalence data and information on 
drug use in Africa continues to be an impediment to 
determining the extent of drug use. It also hinders 
Governments and the international community as they 
seek to respond effectively by means of evidence-based 
drug use prevention and treatment programmes. 
Nonetheless, on the basis of the limited information avail-
able, drug use in the region appears to be increasing, and 
some countries report drug use rates for some drugs that 
are higher than the global prevalence rate. Cannabis con-
tinues to be the main drug used in Africa, along with 
tramadol, which is used in some parts of Africa.
397. The Board reiterates its call upon all States in the 
region to develop mechanisms to improve the collection 
of information on drug use prevalence with the aim of 
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developing drug control and treatment strategies that 
are evidence-based and tailored to each country’s 
specific needs.
398. In 2019, the Ministry of Health of Morocco 
released a national protocol to prevent and manage drug 
overdoses by persons who use drugs. The goal of the pro-
tocol is to provide guidance to health practitioners, emer-
gency responders and non-health professionals who may 
be faced with an overdose situation. Implementation will 
be dependent on the provision of training for relevant 
people, information-sharing, the distribution of naloxone 
and the granting of authority for non-health-care profes-
sionals to administer naloxone in response to an overdose 
situation outside a hospital setting. The protocol is dis-
tributed to relevant stakeholders in Morocco, together 
with a supporting information kit. Following the outbreak 
of the COVID-19 pandemic, the Ministry of Health mod-
ified the protocol in line with the guidelines of the 
Moroccan Association of Addictology to ensure ease of 
access to treatment services during the pandemic.
399. In late 2019, ECOWAS released the first-ever 
report of the West African Epidemiology Network on 
Drug Use, for the period 2014–2017, which was produced 
with the assistance and support of UNODC and the 
European Union. The report provides an analysis of the 
data provided by the Network’s focal points on drug 
trafficking and drug use in States members of ECOWAS. 
As stated in the report, in the reporting period, 7 of every 
10 persons accessing drug treatment services (not 
counting cases related to alcohol use) indicated that 
cannabis was their primary drug of use. Further, cocaine 
was the most common stimulant used. The rapid rise of 
opioid use in the subregion was also noted in the report, 
with tramadol use driving the phenomenon, along with 
significant use of heroin in some ECOWAS countries.
400. According to the UNODC World Drug Report 2020, 
cannabis is the most-used drug in Africa; approximately 
45 million people have used the drug in the past year. 
Pharmaceutical opioids, in particular tramadol, constitute 
the next most-used category of substances; prevalence 
data are available only for North Africa but they show 
that approximately 7.4 million people in that subregion 
used tramadol in the past year. Despite major gaps in 
prevalence data, the World Drug Report 2020 noted that 
cocaine, amphetamine, “ecstasy” and other drugs were 
used in the region, but in limited amounts compared with 
cannabis and tramadol.
401. In March 2020, the Ministry of Health of Ethiopia, 
in collaboration with UNODC, organized a workshop on 
the national implementation of drug policy commitments. 
More than 40 participants, including high-level 
representatives of the federal Government and regional 
governments of Ethiopia and representatives of the Office 
of the United Nations Resident and Humanitarian 
Coordinator, the African Union, civil society and non-
governmental organizations with mandates related to drugs 
and substance use. One important topic discussed during 
the meeting was the fact that Ethiopia was being targeted 
by drug traffickers as a destination and transit country for 
illicitly manufactured drugs. The workshop concluded with 
the establishment of a new national multisectoral technical 
working group on drugs, to be led by the Ethiopian Food 
and Drug Administration.
402. Burkina Faso strengthened its capacity to treat 
people who use drugs by deploying 20 specialists from 
its Ministry of Health and from civil society groups to 
each district in the country, in line with the ECOWAS 
Universal Treatment Curriculum of the Colombo Plan 
Drug Advisory Programme. The health authorities of 
Burkina Faso opened a new specialized unit for drug 
treatment in Yalgado Ouédraogo University Hospital in 
Ouagadougou.
403. Mauritius has been experiencing a rise in the use 
of synthetic drugs for several years. The number of 
offences related to synthetic drugs has doubled since 
2015, reaching 1,059 cases in 2018. The most-used syn-
thetic drugs in Mauritius include synthetic cannabinoids, 
seizures of which increased from approximately 1 kg in 
2015 to 224 kg in 2018. 
404. The United Republic of Tanzania reported that, by 
the end of 2019, the country had established eight opiate 
substitution therapy centres using methadone to treat 
people who inject drugs and 65 recovery homes to 
support people who use drugs. The Government is also 
in the process of establishing an opiate substitution 
therapy programme in the country’s prisons, with the 
support of UNODC.
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C. Americas
Central America and the Caribbean
The region of Central america and the Caribbean remains 
a transit route for cocaine being trafficked to North 
america, Europe and rest of the world. Crime and drug-
related violence continue to be key issues of concern in 
Central american countries. 
In addition to cocaine use, there is concern regarding the 
use of amphetamines and pharmaceutical stimulants by 
local communities. 
1. Major developments
405. Central America and the Caribbean remains a 
major trans-shipment area for illicit drugs, in particular 
cocaine, trafficked from countries in South America to 
destination markets in North America and Europe. Owing 
to their geographical location along the cocaine route, 
countries in Central America have also been used for the 
refinement of cocaine. 
406. Drug trafficking and other types of transnational 
crime continue to be a cause of corruption, violence and 
social and political instability in deprived areas in the 
region. In Central America, maras (street gangs) continue 
to be associated with drug trafficking. A criminal gang 
known as “Bagdad”, composed of a number of smaller 
criminal gangs, is expanding its criminal activities, includ-
ing trafficking in illicit drugs, in Panama. In El Salvador, 
Guatemala and Honduras, the countries that make up the 
so-called “Northern Triangle”, the street gangs Mara 
Salvatrucha (MS13) and Barrio 18 have continued their 
illicit activities, including drug trafficking and the collection 
of extortion payments, which have a corrosive impact on 
the lives of citizens and the economies of the countries. 
407. The restrictive measures implemented by Governments 
at the borders in response to the COVID-19 pandemic have 
resulted in the disruption of drug trafficking routes by air, 
as well as a significant decrease in trafficking by land. 
Nonetheless, traffickers’ attempts to transport large amounts 
of cocaine by sea via Central America and the Caribbean 
have continued, as corroborated by significant seizures of 
the substance in the region in 2020. 
408. To address the increasing presence of transnational 
criminal organizations and their alliances with local crim-
inal groups in countries and territories of the Caribbean, 
drug control experts from the region point to the need 
to further increase maritime domain awareness in the 
Caribbean and enhance cooperation with international 
partners, as well as to the importance of developing and 
implementing national and regional maritime security 
strategies to counter drug trafficking and other related 
crimes.
409. Synthetic drugs and new psychoactive substances 
that have become prevalent in Latin America and the 
Caribbean in the past decade now warrant the same level 
of monitoring and surveillance as cannabis, cocaine and 
other common drugs under international control. The 
Board noted that Barbados and Trinidad and Tobago have 
established national early warning systems to gather and 
disseminate information on emerging drugs and related 
drug threats and that other countries in the region, 
including Costa Rica and Jamaica, have taken steps towards 
the creation of their own early warning systems.
2. Regional cooperation
410. In October 2019, representatives of Antigua and 
Barbuda, Bahamas, Barbados, Belize, Dominica, Grenada, 
Jamaica, Saint Kitts and Nevis, Saint Lucia, Saint Vincent 
and the Grenadines, and Trinidad and Tobago were 
invited to attend the first Caribbean Youth Forum on 
Drug Use Prevention. The main aim of the Forum, hosted 
by the Executive Secretariat of CICAD, was to promote 
youth leadership in drug demand reduction by develop-
ing youth-led initiatives.
411. A number of countries from Central America and 
the Caribbean, including Belize, Costa Rica, the 
Dominican Republic, El Salvador, Guatemala, Honduras, 
Jamaica, Nicaragua, Panama, and Trinidad and Tobago, 
participated in the Orion V International Naval Campaign 
to Combat Drug Trafficking carried out in the Pacific, the 
Atlantic and the Caribbean in 2020.
412. In 2020, CICAD and UNODC continued providing 
a number of workshops and training sessions, including 
online courses, to the competent national authorities of 
the countries in the region. The training activities were 
focused, among others, on measures to care for front-
line officers during the COVID-19 pandemic; the impact 
of COVID-19 on the structures of organized crime; 
illicit traffic using air cargo and courier services; and 
HIV prevention, treatment and support for people who 
use drugs.
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413. In June 2020, under INCB Learning, regional 
online seminars were held on the assessment of national 
needs for internationally controlled substances for medi-
cal and scientific purposes and overall implementation of 
the provisions of the international drug control conven-
tions, including compliance with reporting requirements. 
The seminars, which form part of the ongoing dialogue 
between the Board and national competent authorities, 
were attended by representatives of eight countries from 
Central America and the Caribbean and South America 
(Belize, Costa Rica, Dominican Republic, El Salvador, 
Guatemala, Guyana, Honduras and Panama). 
414. In July 2020, INCB coordinated access to and 
training on IONICS for intelligence officers from the 
Caribbean Community’s regional communications cen-
tres, enhancing the exchange of information that supports 
international investigations into trafficking in dangerous 
substances. In August 2020, INCB provided training to 
over 240 law and regulatory enforcement officers from 
Central America and the Caribbean and South America 
(Antigua and Barbuda, Bahamas, Barbados, Belize, 
Bermuda, Cayman Islands, Dominica, Grenada, Guyana, 
Haiti, Jamaica, Montserrat, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines, Suriname, and 
Trinidad and Tobago) on emerging new psychoactive 
substances, opioids and fentanyl-related substances, and 
precursors information exchange. In a separate event 
facilitated by the Caribbean Customs Law Enforcement 
Council, over 70 officers from Anguilla, Antigua and 
Barbuda, Bahamas, Barbados, Belize, Bermuda, British 
Virgin Islands, Curaçao, Dominica, Grenada, Jamaica, 
Montserrat, Saint Kitts and Nevis, Saint Lucia, and 
Trinidad and Tobago received training about the chang-
ing situation with regard to trafficking in emerging new 
psychoactive substances, opioids and fentanyls and infor-
mation exchange using the INCB global secure commu-
nication platforms. 
415. In 2020, the Cooperation Programme between 
Latin America, the Caribbean and the European Union 
on Drugs Policies II (COPOLAD II), financed by the 
European Commission, concluded its activities, which 
had spanned four and a half years and had been focused 
on the exchange of information, experiences, good prac-
tices and lessons learned, with the aim of consolidating 
effective policies on the basis of scientific evidence. 
3. National legislation, policy and action
416. In 2019 and 2020, several countries in the region 
reviewed or adopted national drug control strategies. The 
Government of Antigua and Barbuda adopted the National 
Anti-Drug Strategy Plan for the period 2019–2023, 
the aims of which are to reduce demand for illicit drugs, 
delay the onset of drug use and strengthen cooperation 
between key stakeholders. To respond to drug use in the 
country, Barbados has revised its plan of action for the 
period 2020–2025. The Government of Costa Rica 
approved its National Strategy on Drugs and Associated 
Crimes for the period 2020–2030 and its National Plan 
on Drugs, Money-Laundering and Financing of Terrorism 
for the period 2020–2024. The Government of Saint Lucia 
has reviewed a new drug strategy for the period 2020–2024 
that is aimed at discouraging the early onset of alcohol 
and drug use and to facilitate effective treatment for and 
the rehabilitation and reintegration of drug users. The 
Board noted that Trinidad and Tobago passed the 
Dangerous Drugs (Amendment) Bill to amend the 
regulation of cannabis use for non-medical purposes.
417. In December 2019, the National Anti-Drug 
Commission of El Salvador released its National Strategy 
for Institutional Strengthening in the Interdiction of 
Drugs and Chemical Precursors. The strategy is aimed at 
strengthening compliance with the objectives and goals 
of the National Anti-Drug Strategy for the period 2016–
2021. A new strategy for the strengthening of drug and 
precursor interdictions was also adopted by the 
Government of Costa Rica in 2019. 
418. Several countries in Central America and the 
Caribbean, including Jamaica and Nicaragua, expressed 
concern with respect to the proliferation and marketing 
of illicit drugs and new psychoactive substances, as well 
as trafficking in precursors over the Internet, the dispatch 
of such substances in postal services, and the use of cryp-
tocurrencies to pay for them. The importance of assessing 
the risk posed by e-commerce enterprises to international 
trade in the context of preventing drug trafficking was 
noted. In that regard, the Board noted efforts by Antigua 
and Barbuda to develop national legislation to regulate 
the use of virtual currencies to comply with recommenda-
tions of the Financial Action Task Force. 
4.  Cultivation, production, manufacture 
and trafficking
419. Since 2015, a number of countries in Central 
America and the Caribbean, including the Bahamas, 
Belize, Costa Rica, El Salvador, Guatemala, Honduras, 
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Nicaragua, and Trinidad and Tobago, have reported 
outdoor illicit cannabis cultivation in their territories. In 
Guatemala, the methods used to grow cannabis have been 
refined in recent years, which has resulted in a higher 
quality of the drug, as well as an increased price on the 
black market. In Honduras, cannabis is often cultivated 
by farmers with a low level of education who are recruited 
by criminal organizations. Locally produced cannabis 
herb is mostly trafficked and consumed within the region. 
In recent years, the most frequently mentioned country 
of origin, departure and transit of seized cannabis herb 
within Central America was Guatemala. In the Caribbean, 
it was Jamaica. In 2019, seizures of cannabis herb were 
reported by Costa Rica (16.8 tons), Honduras (16 tons), 
Panama (12.9 tons), Nicaragua (3.6 tons), Guatemala 
(1.9 tons) and El Salvador (1.3 tons). Costa Rica reported 
the eradication of a total of 11.6 ha of illicit cannabis 
cultivation in 2019, which was approximately the same as 
that eradicated in 2018.
420. According to the National Strategy for Institutional 
Strengthening in the Interdiction of Drugs and Chemical 
Precursors of El Salvador, about 84 per cent of the cocaine 
(base and hydrochloride) produced in South America is 
transported from south to north on the eastern Pacific 
Ocean. The main destinations for drugs transported by 
sea are the coasts of Guatemala and Mexico or Costa Rica 
and Panama, before their final overland transport to the 
United States. In the Caribbean, fast boats continue to be 
the primary method of trafficking in drugs. According to 
authorities in El Salvador, trafficking in cocaine by land 
in the country is minimal. 
421. In 2019, the eradication of small areas under illicit 
cultivation of coca bush and opium poppy (totalling 
37.3 ha) and the destruction of six clandestine cocaine-
processing laboratories were reported by Guatemala. 
Small areas under coca bush cultivation (2.3 ha) were also 
eradicated in Honduras.
422. In 2018, seizures of cocaine in Panama and Costa 
Rica accounted for 4 per cent and 2 per cent, respectively, 
of a total of 1,311 tons of cocaine seized worldwide. By 
contrast, the amounts reported seized by countries in the 
Caribbean accounted for 0.5 per cent of the total global 
quantity of cocaine intercepted, mostly reflecting seizures 
made by the Dominican Republic. 
423. In 2019, Costa Rica seized 31.1 tons of cocaine, an 
increase of 10 per cent compared with 2018. Seizures of 
cocaine in Nicaragua nearly doubled in 2019 compared 
with 2018, reaching 5.9 tons. Panama seized 78 tons of 
cocaine in 2019, 20.4 tons more than in 2018. In 2019, 
seizures of cocaine were also reported by Guatemala 
(18.9 tons), Honduras (2.8 tons) and El Salvador (0.1 tons). 
The National Directorate for Drug Control of the 
Dominican Republic reported that the total amount of 
illicit drugs seized in the country in the first five months 
in 2020 amounted to almost 3.4 tons (2.3 tons of cocaine 
and 1.1 tons of cannabis herb), an increase of 18 per cent 
compared with the same period in 2019. 
424. Container vessels continued to be used by traffick-
ers to transport large amounts of cocaine, as evidenced 
by a seizure of 5 tons of cocaine in Costa Rica in February 
2020. Seizures of 5 tons of unspecified illicit drugs and 
0.7 tons of cocaine from semi-submersibles in Panama in 
February and June 2020, respectively, confirmed the 
increased use of non-conventional vessels reported by 
CICAD member States. 
425. In 2019, Guatemala seized a total of 16.9 tons of 
amphetamine. The drug was allegedly destined for local 
markets and Mexico. In addition, authorities in Guatemala 
seized sizeable amounts of ephedrine and pseudoephed-
rine, which are precursors of methamphetamine. The 
country has also been mentioned as a source of metham-
phetamine seized in El Salvador. A comprehensive review 
of the situation with respect to the control of precursors 
and chemicals frequently used in the illicit manufacture 
of narcotic drugs and psychotropic substances can be 
found in the report of the Board for 2020 on the imple-
mentation of article 12 of the 1988 Convention. 
5. Prevention and treatment
426. In 2018, the annual prevalence of use of cocaine 
in Central America and the Caribbean was 0.66 per cent 
and 0.63 per cent, respectively. Those rates were below 
the average in North America (2.13 per cent), Western 
and Central Europe (1.36 per cent) and South America 
(0.96 per cent).
427. The annual prevalence of cannabis use in the 
Caribbean (3.39 per cent) in 2018 was similar to that in 
South America (3.49 per cent) and considerably lower 
than that in North America (14.56 per cent).
428. Cannabis continued to be the drug most com-
monly used by the school-aged population, in particular 
boys, in El Salvador. According to a drug situation report 
published by the National Drug Commission of 
El Salvador in December 2019, the average age of first-
time use ranged from 13 to 15.
429. Cannabis was the primary drug for which people 
sought treatment in El Salvador, Guatemala and Honduras; 
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in Costa Rica, it was cocaine. In Honduras, among per-
sons receiving treatment for cannabis use, 90 per cent 
were receiving treatment for the first time.
430. In contrast to the use of cocaine, the annual preva-
lence of use of amphetamine, methamphetamine and 
pharmaceutical stimulants in Central America (0.98 per 
cent) and the Caribbean (0.9 per cent) was considerably 
higher than that of South America (0.27 per cent). In 
several Central American countries, the non-medical use 
of pharmaceutical stimulants, including weight loss pills, 
was reportedly more common than the use of other 
amphetamines, in particular among women.
431. The Board noted the continued efforts of the coun-
tries of Central America and the Caribbean to establish 
systematic monitoring of new psychoactive substances. 
While the total number of alerts on the emergence and 
presence of new psychoactive substances in Central 
America and the Caribbean and South America may cur-
rently be comparatively small, there is an increasing 
awareness by Governments in the region of the problems 
related to those substances and the associated adverse 
health effects of the use of those drugs.
432. According to the best estimates from the latest 
UNODC data, published in 2020, about 20,000 people in 
Central America and 100,000 people aged 15–64 in the 
Caribbean inject drugs. The joint 2018 UNODC/WHO/
UNAIDS/World Bank estimate of the global prevalence 
of HIV among people who inject drugs was 12.6 per cent. 
In Central America and the Caribbean, where HIV preva-
lence data were available for one third of all people who 
inject drugs, this prevalence was estimated at 3.4 per cent 
and 14 per cent, respectively.
433. People who use drugs may be particularly vulner-
able to COVID-19 owing to underlying health issues, 
stigma, social marginalization and higher economic and 
social vulnerabilities, including a lack of access to housing 
and health care. The Board wishes to encourage all com-
petent national authorities to continue providing compre-
hensive prevention and treatment services for those with 
a drug use disorder during difficult times, including the 
COVID-19 pandemic. 
North America
during the COVId-19 pandemic, North america suffered 
from an increased number of overdose deaths and chal-
lenges in providing treatment to people who use drugs. 
Cannabis legalization measures and decriminalization 
initiatives in North america continued to evolve and 
shape the regional market for cannabis.
1. Major developments
434. Deaths from illicit drug use are increasing in North 
America. Use of and trafficking in fentanyl, cocaine and 
methamphetamine increased in the past year, which had 
an impact on the lethality of drug overdoses in North 
America, owing in part to the use of fentanyl in many 
drugs sold on the region’s illicit markets. 
435. The public health emergencies surrounding the 
COVID-19 pandemic altered the region’s drug trafficking 
landscape and affected the ability of Governments to 
respond to drug use threats and provide treatment for 
people who use drugs, including access to medications 
for opioid use disorders.
436. Mexico reported that it is undergoing a national 
drug policy transition on the basis of the principles of 
public health, scientific evidence and respect for human 
rights, based in the National Development Plan for the 
period 2019–2024. The Government of Mexico has indi-
cated that new policies are designed to take a preventive 
and responsive approach to the needs of vulnerable popu-
lations, especially those in prison settings, women and 
adolescents, and other groups disproportionately affected 
by drug use and associated health conditions.
2. Regional cooperation
437. North American cooperation on drug control is 
focused on addressing the complex problems pertaining 
to trafficking, the opioid crisis and the multifaceted 
regional drug crisis. The trilateral efforts are embodied in 
the Annual North American Drug Dialogue, the fourth 
iteration of which was held in December 2019. The dis-
cussions among law enforcement and health officials 
solidified the region’s collective understanding that efforts 
to combat synthetic drugs, including fentanyl and meth-
amphetamine, should be intensified. 
438. In December 2019, a bilateral meeting was held 
between Mexico and the United States to advance security 
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collaboration. Officials from the two countries agreed to 
strengthen the United States-Mexico High-level Security 
Group to combat organized crime and cross-border 
crime. The Group has a drug policy sub-group that focuses 
on counter-narcotics issues including maritime container 
control, the mail-based fentanyl supply chain and the 
tracking and safe destruction of precursor chemicals. 
439. Officials from the Governments of Canada and the 
United States held a meeting in Washington, D.C., on 
31 January 2020 on their Joint Action Plan on Opioids. 
The Steering Committee of the Joint Action Plan on 
Opioids established working groups and a framework for 
bilateral exchanges on the law enforcement, border security 
and health challenges facing the two countries.
3.  National legislation, policy and 
action
440. In February 2020, the United States Office of 
National Drug Control Policy released the National Drug 
Control Strategy for 2020. The Strategy is focused on 
three areas: (a) preventing initiates to drug use through 
education and evidence-based prevention; (b) lowering 
barriers to treatment services; and (c) reducing the 
availability of illicit drugs through law enforcement and 
cooperation with international partners. It was confirmed 
in the strategy that the top priority for the Government 
was addressing the current opioid crisis and reducing 
the number of people in the United States dying from 
synthetic opioid overdoses. 
441. The Drug Enforcement Administration of the 
United States released the 2019 National Drug Threat 
Assessment in February 2020. The assessment contains an 
outline of the threats faced by the United States from 
domestic and international drug trafficking, including the 
opioid threat, which is described as continuing at 
ever-increasing epidemic levels. According to the assess-
ment, threats from methamphetamine and cocaine are 
also increasing. Fentanyl-involved overdose deaths are 
highest in the Great Lakes, Midwest and north-east 
regions, with Ohio having among the highest age-adjusted 
rates of fentanyl-involved overdose deaths. The availabil-
ity and new varieties of new psychoactive substances con-
tinue to be a challenge; and the domestic cannabis 
situation is evolving as legalization of cannabis for medi-
cal and non-medical purposes at the state level continues 
to spread.
442. In February 2020, the United States Office of 
National Drug Control Policy issued the Northern Border 
Counternarcotics Strategy, which contains specific goals 
for reducing the availability of illicit drugs in the United 
States. It is explained in the Strategy that the border 
between the United States and Canada, the longest in the 
world between two countries, offers many opportunities 
for transnational criminal organizations to traffic drugs, 
including through exploitation of the mountain valleys in 
the States of Washington and Idaho, as well as the water-
ways on the border that are conducive to moving contra-
band. Implementation of the Strategy will include 
coordinated drug interdiction efforts driven by improve-
ments to information-sharing processes, procedures and 
technology. Stakeholders from the two countries will be 
integrated into the law enforcement operations of the other, 
with coordinated investigative and operational efforts.
443. The Justice in Policing Act of 2020 was passed on 
25 June 2020 by the House of Representatives of the 
United States, although it remained under consideration 
in the Senate. The legislation includes a section prohibit-
ing so-called “no-knock warrants” in federal drug cases. 
This would amend section 509 of the Controlled 
Substances Act to include that a search warrant author-
ized under that section may be executed by a law enforce-
ment officer only after providing notice of his or her 
authority and purpose. Law enforcement funding would 
also be conditioned on state and local prohibitions on 
“no-knock warrants”. While no action was taken on the 
legislation before the end of 2020, the bill could still form 
the framework for legal changes that take place during 
2021.
444. In response to the COVID-19 pandemic, the Drug 
Enforcement Administration of the United States has 
taken efforts to support more flexible prescribing prac-
tices, such as through telemedicine and without an in-
person medical evaluation. The Drug Enforcement 
Administration has reported that it is working with its 
federal United States partners to ensure an adequate 
supply of controlled substances and medications during 
the pandemic. For example, owing to the public health 
emergency, authorized practitioners were granted the 
authority to prescribe buprenorphine for opiate use dis-
order by telemedicine, without conducting in-person 
examinations of the patient.
445. As a result of the COVID-19 pandemic, there were 
reports in the United States of shortages of critical medi-
cines needed for placing patients on ventilators and of 
other essential prescription drugs. According to a 
December 2019 report from the United States Senate 
Committee on Homeland Security and Governmental 
Affairs, even before the pandemic affected the supply 
chain, the number and duration of drug shortages in the 
United States had continued to rise in 2019. It was noted 
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in the report that more than 80 per cent of the active 
pharmaceutical ingredients for prescription drugs sold in 
the United States came primarily from China and India. 
The American Hospital Association released information 
in June 2020 explaining that, owing to COVID-19 treat-
ments, the demand for certain drugs such as sedatives 
had increased, but the supply of those drugs had 
decreased, at least partly as a result of a fracturing of the 
supply chains.
446. Local and national governments in North America 
continued to adopt new measures for the legalization and 
decriminalization of the use of cannabis for non-medical 
purposes. In Mexico, the Supreme Court granted an 
extension to the Congress to approve draft legislation on 
a cannabis law, which would amend the cannabis 
regulations and permit consumption for non-medical 
purposes. 
447. In Canada, as of 1 January 2020, the legal age to 
buy or possess cannabis in Quebec was raised to 21. The 
province amended its regulations to prohibit possession 
of cannabis for non-medical purposes by anyone under 
21, and individuals younger than 21 are not permitted on 
any premises where cannabis is sold. The government of 
Quebec further banned food items containing cannabis 
that could be considered attractive to people under the 
age of 21. In addition, it is forbidden in Quebec to smoke 
or vape cannabis in any public place, whether indoors or 
outdoors. 
448. In July 2020, the Canadian Association of Chiefs 
of Police released a report of its special purpose commit-
tee on the decriminalization of illicit drugs. The findings 
of the committee include the recognition of substance use 
disorder as a public health issue and the recommendation 
that decriminalization of simple possession of drugs 
would be an effective way to reduce the negative health 
consequences of drug use. Also in the report, the 
Association endorsed alternatives to criminal sanctions 
for simple possession and access to diversion measures.
449. Under the 2018 United States Farm Bill, the 
commercial production of hemp, limited to no more than 
0.3 per cent of THC, was legalized and the United States 
Department of Agriculture was directed to establish a 
national regulatory framework for hemp production. 
Hemp and hemp seeds were removed from the schedules 
of the Controlled Substances Act. Through an interim 
rule that became effective on 31 October 2019, the 
Agricultural Marketing Service established provisions for 
the approval of the plans of states and Indian tribes 
related to the domestic production of hemp, including 
use of the plant to extract cannabidiol. In this 
connection, the Board calls upon States parties to ensure 
that the cultivation of cannabis for industrial purposes 
is undertaken in line with the requirements of the 1961 
Convention as amended, which limits the cultivation of 
cannabis for industrial purposes to fibre and seed. 
450. The Commonwealth of Virginia passed a law to 
decriminalize the simple possession of cannabis that pro-
vided for a civil penalty of no more than $25. The law 
came into force on 1 July 2020. Violations of the law 
would result in a summons, in the same way as a motor 
vehicle law violation, with no liability for court costs for 
the offender. In addition, a working group was established 
under the law to study the potential impact of the legali-
zation of cannabis for personal, non-medical use.
451. On 7 October 2020, the Governor of the State of 
Vermont allowed legislation on the commercial regulation 
of cannabis to go into effect. The law allows for the 
creation of a regulated market for the sale of cannabis for 
non-medical purposes. The legislation requires cities and 
towns to take further action before retail establishments 
may open and ensures that local zoning applies to 
cannabis cultivation and production. Up to 30 per cent 
of the tax revenue collected from commercial sales will 
go towards substance use education and prevention 
programming. 
452. Following the elections of 3 November 2020 in the 
United States, in which a number of ballot measures were 
voted upon, there are now 34 states in which the use of 
cannabis for medical purposes is permitted and 11 states, 
in addition to Washington, D.C., in which cannabis pos-
session and use for non-medical purposes have been 
legalized. 
453. As a result of the 2020 ballot measures, the States 
of Arizona, Montana, New Jersey and South Dakota legal-
ized the possession and use of cannabis by adults for non-
medical purposes. In the States of Mississippi and South 
Dakota, measures were approved by voters to permit the 
use of cannabis for medical purposes.
454. In the State of Oregon, two ballot measures per-
taining to drug control were approved by voters during 
the 2020 election. Measure 109 was approved to create a 
programme to permit licensed service providers to 
administer psilocybin-producing mushroom and fungi 
products to individuals aged 21 or older. Measure 110, 
which was also approved by voters in the State of Oregon, 
will decriminalize possession of all currently controlled 
substances and reclassifies the penalties for possession 
offences from a misdemeanor crime to a violation, 
subjecting offenders to a $100 fine or a health assessment. 
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The manufacture and distribution of controlled sub-
stances in Oregon will continue to be subject to criminal 
penalties. 
455. In Washington, D.C., voters approved, in the 
November 2020 election, a ballot measure that makes the 
investigation and arrest of adults for the non-commercial 
planting, cultivating, purchasing, transporting or posses-
sion of or engaging in practices with entheogenic plants 
and fungi among the lowest law enforcement priorities of 
the area’s police department. These species of plants and 
fungi are defined as containing ibogaine, dimethyl-
tryptamine, mescaline, psilocybin or psilocyn.
456. The Board is concerned that legalization measures 
or regulations that permit the use of any controlled sub-
stance, including cannabis, for non-medical purposes 
are inconsistent with the obligations of States parties, in 
particular those included in article 4, paragraph (c), of 
the 1961 Convention as amended. The Board calls upon 
all States to respect their Convention obligations in the 
development of their national drug control policies.
4. Cultivation, production, 
manufacture and trafficking
457. Illicit drug supply and trafficking patterns in North 
America have changed over the course of 2020 owing to 
the impacts of COVID-19. The social-distancing measures 
and societal challenges caused by the pandemic have led 
to shifting drug trafficking patterns and changes in illicit 
drug manufacturing. 
458. According to preliminary research from the 
Canadian Community Epidemiology Network on Drug 
Use, undertaken on the basis of information collected 
between 31 March 2020 and 10 May 2020, the illegal drug 
supply in Canada has been affected by business closures, 
border closures and social distancing. A decrease in the 
availability of different drugs, increased prices of drugs 
and increased drug adulteration were all noted. The full 
impact of COVID-19 on the illicit cultivation, production 
and manufacture of and trafficking in drugs in Canada 
continues to be a subject of research and analysis.
459. In Mexico, the COVID-19 pandemic and the 
related health emergency has had profound impacts on 
society and the economy. The pandemic is expected to 
affect the way in which transnational organized crime and 
illicit markets operate. Changes to the way in which 
organized criminal activity affects the economy could 
have long-term consequences, based on the Government’s 
identification of three significant impacts: (a) an increase 
in armed violence linked to organized crime; (b) diversi-
fication of criminal acts owing to a reduction in income 
from the drug market; and (c) a strengthening of criminal 
groups. 
460. In July 2020, during a visit to the Port Complex of 
Manzanillo, one of the ports through which a large 
amount of precursors and fentanyl is trafficked to Mexico 
from Asia, the President of Mexico announced that, in 
response to the violence and corruption resulting from 
trafficking in drugs and precursors at ports in Mexico, 
the country’s armed forces would be responsible for cus-
toms and addressing the problem of insecurity and drug 
trafficking at ports. 
461. The Drug Enforcement Administration of the 
United States explained, in an intelligence report pub-
lished in January 2020, that the flow of illicitly manufac-
tured fentanyl into the United States had become more 
diverse since the start of the opioid crisis, in 2014, with 
new source and transit countries emerging. It was noted 
in the report that India was emerging as a source for 
finished fentanyl powder and chemicals used for illicit 
fentanyl manufacture, alongside the identified primary 
source countries of China and Mexico. The explanation 
provided in the report for the shift of production from 
China to India was the restrictions in China on the illicit 
manufacturing of all forms of fentanyl. The change in 
legislation in China in 2019, to place all fentanyl ana-
logues under control, has resulted in substantially fewer 
detections at the border of fentanyl entering the United 
States from China.
462. In November 2019, the Drug Enforcement 
Administration of the United States issued a warning over 
counterfeit prescription pills containing fentanyl that 
were being trafficked from Mexico. According to the 
Drug Enforcement Administration, drug trafficking 
organizations were sending bulk shipments of counterfeit 
pills mixed with fentanyl that were disguised as real 
pharma ceutical products to the United States. Furthermore, 
the results of “Project Python”, an operation targeting the 
Jalisco New Generation Cartel, were announced in March 
2020 by the Department of Justice of the United States. 
According to the Department, the cartel was responsible 
for moving tons of cocaine, methamphetamine and fentanyl- 
laced heroin into the United States. Methamphetamine 
labs operated by the cartel are reportedly procuring 
precursors from China and India, as well as producing 
their own precursors.
463. In April 2020, the Canadian Community 
Epidemiology Network on Drug Use published a bulletin 
describing the content of drugs on the illicit market in 
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Canada. According to the bulletin, fentanyl and its ana-
logues are common in the country’s illicit drug supply 
and were present in nearly two thirds of samples contain-
ing opioids studied by the Drug Analysis Service of 
Health Canada. Nationally, up to 3 per cent of samples 
containing stimulants contained fentanyl or its analogues. 
Data from the Province of British Columbia included in 
the bulletin suggested that between 14 and 36 per cent 
of fentanyl exposure was unknown or unintentional. The 
British Colombia Coroners Service in Canada reported 
extremely high fentanyl concentrations in post-mortem 
toxicology results from April to June 2020 compared with 
previous months. 
464. In 2019, the INCB Operation Fast Forward 
identified interdictions of new pre-precursors (N-phenyl- 
piperidin-4-amine and 4-piperidone), which could be 
used in the illicit manufacture of fentanyl. The substances 
were seized by Mexico arriving from China and India by 
express post and courier services. Operation Fast Forward, 
launched in January 2019, was aimed at identifying key 
sources and redistribution points involving fentanyl, fen-
tanyl analogues and related substances trafficked using 
international post, express mail and courier services. The 
operation involved 45 Governments and two interna-
tional agencies and resulted in 53 communications on 
target substances, with seizures of more than 
29 kg. It also resulted in the identification and subsequent 
dismantling of a fentanyl-distribution operation in Canada.
465. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in North America can be 
found in the report of the Board for 2020 on the imple-
mentation of article 12 of the 1988 Convention.
466. Concurrently, a number of emerging, potent, 
fentanyl-like synthetic opioids are increasingly appearing, 
including isotonitazene. Isotonitazene is a highly potent 
synthetic opioid and one of several analogues of etonitazene. 
It is structurally different from fentanyl, but INCB open 
net monitoring found that it is being marketed online as 
a legal replacement for internationally scheduled opioids. 
In May 2020, a special notification on the substance 
was sent through the INCB GRIDS Programme to all 
Project Ion and OPIOIDS project focal points. Numerous 
communications related to seizures of the substance were 
subsequently received through IONICS. Through the 
GRIDS Programme, information relating to isotonitazene 
trafficking has been provided to the relevant focal points 
in North America. In June 2020, the United States added 
it to schedule I of the Controlled Substances Act under its 
emergency procedure.
467. In February 2020, the Drug Enforcement 
Administration of the United States initiated Operation 
Crystal Shield to focus efforts on stopping the growing 
methamphetamine threat in the country, to reduce the 
supply of methamphetamine and to respond to the 
trafficking in methamphetamine across the south-west 
border. The operation was designed to focus enforcement 
efforts on eight methamphetamine distribution hubs 
throughout the country, namely Atlanta, Los Angeles, 
Phoenix, El Paso, Dallas, Houston, St. Louis and New 
Orleans. Those cities are reportedly used by Mexican drug 
trafficking organizations to distribute methamphetamine. 
468. In a summary of findings related to methampheta-
mine published in March 2020 by the Canadian Centre 
on Substance Use and Addiction, significant increases 
were highlighted in the rates of criminal violations involv-
ing methamphetamine between 2010 and 2018. Violations 
for possession of methamphetamine increased by 626 per 
cent over that period, and there was an expansion in the 
illicit manufacture of methamphetamine in small labora-
tories throughout North America. 
469. In 2019, Public Safety Canada released a study 
entitled “Patterns in cannabis cryptomarkets in Canada 
in 2018”. In that study it was noted that, following the 
legalization of cannabis for non-medical purposes in 
Canada, sales by Canadian dealers of cannabis on cryp-
tomarkets appeared to be increasing in number. It was 
concluded that the increase was ostensibly owing to sales 
for the international market. When comparing cannabis 
sales on cryptomarkets from July 2018 with those from 
November 2018, it was noted in the study that Canada 
had moved from eighth to fourth position in the world. 
470. According to Statistics Canada, the price gap 
between cannabis for non-medical purposes purchased 
legally and illegally is increasing, with overall price 
increases attributable to the higher costs of cannabis sold 
legally. Based on data released by Statistics Canada on 
21 February 2020, sales of cannabis totalled 1.2 billion 
Canadian dollars in 2019. Following a statistical analysis 
of voluntary responses to the National Cannabis Survey 
on the effects of legalization, Statistics Canada reported 
that, after the Cannabis Act, more consumers obtained 
cannabis from legal sources and fewer reported obtaining 
it from illegal sources or from family and friends.
471. In March 2020, officials from Colombia and the 
United States developed a bilateral agenda and joint 
action plan to reduce the levels of coca bush cultivation 
and cocaine manufacture by 50 per cent by the end of 
2023; the levels of coca bush cultivation and cocaine 
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manufacture in Colombia stabilized in 2018 and 2019 for 
the first time since 2012.
472. In March 2020, UNODC and the Government of 
Mexico published the third technical monitoring report on 
illicit opium poppy cultivation following a study conducted 
between July 2017 and June 2018. The area under opium 
poppy cultivation in Mexico was estimated at 28,000 ha, 
with a statistical range of 21,200 to 34,800 ha. Compared 
with the period 2016–2017, the area under opium poppy 
cultivation decreased slightly, by 9 per cent, or 2,600 ha. 
The national average yield of opium gum was estimated at 
16.1 kg per hectare; the potential national production of 
dry opium gum was estimated at 450 metric tons; and the 
morphine concentration in opium gum during the 
reporting period was 16.2 per cent. 
5. Prevention and treatment
473. North America continued to be affected by opioid-
related harms and deaths in 2019. In June 2020, the Public 
Health Agency of Canada reported that there had been 
more than 21,000 suspected opioid-related overdoses 
between January and December 2019. There had been 
3,823 opioid-related deaths during the same period, of 
which 94 per cent were unintentional; 77 per cent of the 
cases involved fentanyl or fentanyl analogues. The 
COVID-19 pandemic has reportedly exacerbated the 
vulnerability of drug users to negative health impacts, with 
higher levels of concern about the drug supply and the 
quality, degree of contamination, potency and cost of drugs.
474. At the start of the COVID-19 pandemic, in 
response to the opioid overdose crisis, the Government 
of Canada issued a temporary exemption to the Controlled 
Drugs and Substances Act to facilitate prescribing through 
flexible treatment options, creating an alternative and 
safer supply than the illicit drugs available to users. The 
exemption has been extended until 30 September 2021. 
Prescription-grade heroin (diacetylmorphine) was added 
to the List of Drugs for an Urgent Public Health Need 
and safer supply pilot projects have been developed in 
cities across Canada. According to Health Canada, the 
early findings from the pilot projects have shown that 
using pharmaceutical-grade medications such as hydro-
morphone and diacetylmorphine can help save lives and 
improve outcomes for people at risk of overdose. 
475. In April 2020, the United States National Center 
for Health Statistics published data showing that deaths 
from drug overdoses were an increasing public health 
burden in the United States. The Substance Abuse and 
Mental Health Services Administration of the United 
States has stated that it expects the COVID-19 crisis to 
contribute to increasing numbers of people struggling 
with mental health problems and substance use, coupled 
with corresponding increases in depression, anxiety, 
trauma and grief.
476. In Canada, on 21 May 2020, as a result of the 
increased toxicity of illicitly manufactured drugs, British 
Columbia issued a provincial overdose alert following an 
increase in fatal and non-fatal overdoses resulting from 
smoking and injecting illicit drugs. According to the 
British Columbia Coroners Service, 170 people died of 
illicit drug overdoses in May 2020, compared with 76 in 
February 2020. In May 2020, a new resource was launched, 
called the “Lifeguard App”, to help respond to the over-
dose crisis. The application is designed to be activated 
before a person administers a dose of drugs. An alarm 
will be sounded after 50 seconds and, if user does not 
respond after 75 seconds, emergency medical services are 
alerted to a potential overdose.
477. According to provisional data from the Centers for 
Disease Control and Prevention of the United States that 
were available as at 8 June 2020, there were 3 per cent 
more drug overdose deaths in the United States during 
the period November 2018–November 2019 than during 
the year before.
478. The Director of the United States National Institute 
on Drug Abuse has raised concerns about the impacts of 
COVID-19 and the potentially heightened risks and com-
plications for people who smoke, vape or use opioids or 
methamphetamine. In an article in the Annals of Internal 
Medicine, the Director wrote that people with substance 
use disorder may be especially susceptible to COVID-19 
and find it harder to get care. Social distancing during 
the pandemic could further increase the possibility of 
opioid overdoses if there are fewer people available to 
administer naloxone. 
479. The potential health risks associated with using 
methamphetamine during the COVID-19 pandemic were 
outlined in an evidence brief issued by the Canadian 
Centre on Substance Use and Addiction. In the light of 
increases in Canada of methamphetamine-related visits 
to emergency departments, hospitalizations and overdose 
deaths, it was noted that people who regularly use drugs, 
including methamphetamine, may be at higher risk of 
COVID-19 infection. 
480. The United States “Monitoring the Future Survey” 
for the period 1975–2019 found a dramatic increase in 
vaping among adolescents, including vaping of concen-
trated cannabis. During the period 2017–2019, the 30-day 
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prevalence of vaping of cannabis rose among students in 
the twelfth grade (usually 17- and 18-year olds), from 
4.9 per cent in 2017 to 14.0 per cent in 2019. The rate of 
past-year prevalence of cannabis vaping among twelfth 
graders was 20.8 per cent. Daily cannabis use rates 
increased significantly in some grades, rising to 4.8 per 
cent among tenth graders and 1.3 per cent among eighth 
graders. These figures represent an increase of 85.7 per 
cent compared with 2018.
481. According to the National Drug Control Strategy 
of the United States for 2020, prior to COVID-19, the 
historically low prices for some synthetic drugs, such as 
methamphetamine, had led to increasing trends of poly-
drug use across the country. Addressing the increasing 
availability and use of cocaine in the United States is 
called for in the Strategy. Also in the Strategy, efforts are 
outlined to strengthen the capacity of state, local and 
tribal communities to identify and prevent substance 
misuse. The enhancement of research and the development 
of evidence-based prevention programmes, including 
through the “Drug Free Communities Support Program”, 
which is aimed at preventing youth substance use at the 
community level, are also called for.
482. In Mexico, there are indications of a growing 
methamphetamine epidemic. At the sixty-sixth regular 
session of CICAD, held in Miami, United States, from 
19 to 21 November 2019, the National Commissioner 
against Addictions of Mexico stated that lifetime preva-
lence of methamphetamine use had increased from 
0.1 per cent to 0.9 per cent of the general population 
between 2002 and 2016. Cannabis remained the main 
drug for which people sought treatment in Mexico. The 
National Commissioner noted that treatment in Mexico 
should respond better to the needs of women and youth 
and that hospital and forensic medical service registration 
systems needed improvement.
483. In a study, commissioned by the Government of 
Mexico, of heroin and crystalline methamphetamine 
users in the northern border cities of Mexico, tests of 
drug paraphernalia samples showed that 93 per cent of 
white powder heroin, 40 per cent of black tar heroin and 
100 per cent of “speedball” (a combination of heroin and 
crystalline methamphetamine) contained fentanyl. The 
drug users who provided the paraphernalia were unaware 
that their drugs were combined with fentanyl. Therefore, 
although heroin use in Mexico is not high, except for in 
marginalized communities on the northern border, heroin 
users in Mexico have been unknowingly exposed to fen-
tanyl. These findings also explain the overdoses among 
drug users in parts of Mexico in recent years. 
484. In June 2020, the Department of Health and 
Human Services of the United States published a guide 
on the treatment of stimulant use disorders. The Assistant 
Secretary for Mental Health and Substance Use explains 
in the guide that stimulant use, including misuse of pre-
scription stimulants, is on the rise in the United States. 
The risk of overdose and death has increased substantially 
owing to illicitly manufactured stimulants containing 
unknown amounts of fentanyl. The treatment guide is 
meant to address a public health crisis involving cocaine 
and amphetamines, which have become more accessible, 
purer and cheaper.
485. In January 2020, the Office of the Inspector General 
of the Department of Health and Human Services issued 
a report on the geographical disparities in the United 
States affecting access to buprenorphine services for 
opioid use disorder. According to the study, access to 
treatment is vital, but only a small percentage of people 
who need treatment in the United States actually receive 
it. The findings of the Inspector General concluded that 
40 per cent of counties in the United States did not have 
a single health-care provider with a waiver permitting the 
prescription of buprenorphine in an office setting. The 
providers were also not necessarily located in the areas 
in which the need for such medication-assisted treatment 
was most critical.
486. Facing challenges of drug use, manufacture and 
trafficking in rural areas, the United States launched the 
Rural Community Toolbox in June 2020 to connect rural 
leaders with funding, data and information from 16 fed-
eral government departments. The aim of the Toolbox is 
to provide rural communities with the resources needed 
to overcome the opioid epidemic and drug use crisis 
through evidence-based prevention and treatment ser-
vices. It provides rural leaders with data about drug over-
dose deaths and factors that are driving drug use trends, 
such as those relating to education and unemployment 
levels. In January 2020, the Rural Community Action 
Guide was released, which contains recommended 
practices and action steps to increase the stability of rural 
communities.
487. In October 2020, the Department of Justice of the 
United States announced the resolution of its criminal 
and civil investigations into the opioid manufacturer 
Purdue Pharma and the conclusion of its civil investiga-
tions into the company’s individual shareholders. Purdue 
Pharma agreed to plead guilty in federal court to charges 
of conspiracy to violate the Federal Anti-Kickback Statute, 
with a criminal fine of over $3.5 billion and $2 billion in 
criminal forfeiture. A settlement in the amount of 
$2.8 billion will resolve the civil liability under the False 
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Claims Act for opioid prescription practices that were 
unsafe, ineffective and medically unnecessary, resulting in 
abuse and diversion. The resolution does not resolve other 
claims that states may have against the company.
488. In 2020, the Canadian Centre on Substance Use 
and Addiction published a report on the costs and harms 
associated with substance use during the period 2015–
2017. It contains updates to the previous figures, from the 
period 2007–2014, found in the 2018 report. As set out 
in the latest publication, substance use cost Canada 
almost 46 billion Canadian dollars in 2017 and led to 
over 275,000 hospitalizations. While nearly 63 per cent 
of the total costs were due to alcohol and tobacco use, 
opioids accounted for $5.9 billion Canadian dollars, or 
12.9 per cent of the total costs. Cocaine accounted for 
$3.7 billion Canadian dollars, or 8.1 per cent of the total 
costs. 
489. A socioeconomic review of supervised consumption 
sites in the Province of Alberta, Canada, was released in 
March 2020. Since 2019, the government of the province 
had frozen funding for any new supervised consumption 
sites until a review of the impact of existing sites was 
carried out. The Health Authority of the province advised 
the committee reviewing the sites that, since October 
2017, there had been about 6,541 adverse events at the 
sites, and that death rates in their vicinity had increased. 
The committee was concerned about issues of transparency 
and accountability surrounding how overdose reversals 
were tracked and reported. Non-opioid substance use, 
such as methamphetamine, also reportedly increased at 
some of the sites and, in most areas, crime in the 
immediate vicinity increased.
490. On 6 January 2020, the Council of Chief Medical 
Officers of Health of Canada issued a statement on can-
nabis extracts, edibles and topical products. Released 
through the Public Health Agency of Canada, the Council 
advised, in the statement, that cannabis was not harmless 
and that it carried risks. Evidence continued to emerge 
on the longer-term health effects of cannabis use, which 
highlighted the importance of ongoing research. It was 
further indicated in the statement that the safest approach 
for people who use cannabis was to avoid smoking or 
vaping cannabis extracts, and that side effects from can-
nabis products should be reported to Health Canada. 
491. Mexico reported to the Board that, owing to the 
COVID-19 pandemic, the National Institute of Psychiatry 
had enacted a series of remote intervention programmes 
for drug users. Guidance is provided to people, at any 
time, over the Internet. Mexico reported on its drug abuse 
and depression assistance programme, which provides 
brief online psychological treatment from a professional 
counsellor to encourage a reduction in drug use and 
address symptoms of depression. Mexico also reported on 
additional programmes that had been designed to 
strengthen social, emotional and parenting skills to help 
prevent the use of drugs. 
South America 
The COVId-19 pandemic has affected trafficking routes, 
supply of and demand for drugs, and microtrafficking 
modalities in south america.
Total cocaine manufacture potential in Colombia 
increased by 1.5 per cent in 2019 despite a decrease in 
the area under coca bush cultivation.
The manufacture and presence of synthetic drugs is on 
the rise in south america, in particular in Chile.
1. Major developments
492. The COVID-19 pandemic has greatly affected 
South America, with significant repercussions for the cul-
tivation and manufacture of, trafficking in and consump-
tion of drugs in the region. As lockdowns of varying 
degrees were imposed across South America, criminal 
organizations again demonstrated their capacity to adapt 
to new circumstances. This was noted in particular with 
regard to the channels used for the illicit movement of 
drugs: alternative routes were created to circumvent 
border closures and road and air travel restrictions; mari-
time routes acquired a prominent role, with traffickers 
taking advantage of the limited capacity in some coun-
tries in the region to detect and seize controlled sub-
stances trafficked along river and sea routes; and there 
was an increase in the use of light aircraft, flown at low 
altitude to avoid radar, to transport drugs between Bolivia 
(Plurinational State of), Brazil and Peru. 
493. Changes in supply and demand as a result of 
border closures have also had an impact on drug prices 
in the region. In Brazil, there was an increase in cocaine 
prices and, in Colombia, a similar trend was observed 
with regard to the price of coca paste. No official data 
have been made available yet to calculate the exact 
increase in the price of cocaine for consumer markets. 
Between January and April 2020, the price of coca leaf 
dropped by 46 per cent in Peru and by 58 per cent in the 
valley of the rivers Apurímac, Ene and Mantaro, one of 
the major coca bush-growing areas in the country, as a 
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result of the impact of COVID-19 on demand for cocaine. 
The prices of cocaine hydrochloride and coca paste also 
decreased in Peru, by 25 per cent and 23 per cent, 
respectively. 
494. Organized criminal groups that control more 
resources were better able to anticipate and overcome the 
repercussions of the lockdown on their illegal businesses 
by stockpiling drugs. Reduced economic activities and 
restrictions on transport also had an impact on the 
procurement of chemical precursors. As such, while some 
criminal organizations have relied on the reserves of 
chemicals that they had on hand to produce cocaine 
hydrochloride, others have tried to produce their own 
precursor chemicals. Although a trend towards self-
reliance in the manufacture of cocaine was observed 
before the COVID-19 pandemic, restrictions related to 
the pandemic have increased the interest of organized 
criminal groups in developing and manufacturing their 
own chemical precursors to sustain their production in 
difficult circumstances.
495. Lockdowns related to the COVID-19 pandemic 
have also prompted changes in microtrafficking practices 
across the region, with drug traffickers taking increased 
advantage of existing licit services, such as food delivery, 
Internet platforms and emergency services, or emulating 
such services as a cover for their operations. In July 2020, 
24 people were detained in Chile for using a fake food 
delivery service as a front for delivering cocaine, cannabis 
and clonazepam. Other drug traffickers have taken advan-
tage of the transportation of essential equipment during 
the pandemic to smuggle drugs. In March 2020, authori-
ties in Brazil found 1.1 tons of cocaine hidden in surgical 
gloves that were being transported by truck, and police 
officers in Peru seized over 1 kg of drugs in boxes con-
taining protective masks destined for Hong Kong, China.
496. In June 2020, the border between the city of 
Salvador Mazza in Argentina and the Plurinational State 
of Bolivia was closed to prevent the spread of COVID-19 
and stop trafficking in goods and drugs between both 
countries. Controls at the border between the two coun-
tries have increased as drug traffickers appear to be taking 
advantage of the influx of people from the Plurinational 
State of Bolivia seeking medical assistance in Argentina 
to smuggle their drugs. 
497. It is expected that the economic crisis triggered by 
the COVID-19 pandemic will move the patterns of drug 
use and trafficking towards cheaper and more addictive 
substances. The Chilean Observatory on Drugs has noted 
a possible increase in the illicit market of synthetic drugs 
that are cheaper to manufacture and easier to transport 
and distribute. This comes at a time when the presence 
of synthetic drugs such as “ecstasy” is becoming more 
evident in the region. 
498. The pandemic has also evidenced the role that car-
tels and organized criminal groups have in the region. At 
times, they have filled the void left by Governments by 
implementing lockdown measures when and where the 
Government was not acting or was unable to enforce such 
measures. 
499. According to a report from Fundación Paz y 
Reconciliación (Peace and Reconciliation Foundation), 
the presence of cartels and drug trafficking groups from 
Mexico has increased in Colombia. Although their pres-
ence dates back to previous decades, their activity has 
become more prominent. They have increased the fund-
ing and arming of Colombian drug trafficking groups, 
presumably to ensure that cocaine continues to reach 
Mexico as the Revolutionary Armed Forces of Colombia-
People’s Army (FARC-EP) relinquishes control of drug-
producing areas in Colombia. 
500. In March 2020, the President of the Bolivarian 
Republic of Venezuela, together with government officials 
and members of FARC, were indicted in the United States 
on counts of narco-terrorism and international cocaine 
trafficking. The Government of the Bolivarian Republic 
of Venezuela immediately denounced the charges against 
its President as baseless, highlighting the aggressive action 
it had taken to fight drug trafficking and condemning 
what it considered attacks against its country. In April 
2020, in response to the occurrence of maritime drug 
smuggling from the Bolivarian Republic of Venezuela, the 
Government of the United States launched a counter-
narcotics operation in the Caribbean Sea, which involved 
the deployment of warships. 
501. In the Andean region, the area under illegal coca 
bush cultivation has been increasing since 2016, together 
with the potential for cocaine manufacture. Until 2017, 
the Board and other United Nations entities could carry 
out comparative analyses of the trends in illicit coca bush 
cultivation and cocaine manufacture in Bolivia 
(Plurinational State of), Colombia and Peru on the basis 
of the crop monitoring activities carried out by UNODC 
and the Governments concerned. While reports for 
Bolivia (Plurinational State of) and Colombia continued 
to be published, since 2017 there have been no official 
figures for Peru. This absence of updated information 
impairs the comprehensive assessment of coca cultivation 
trends in the Andean region. The Board expresses its 
concern about the lack of measurement of the area 
under illegal coca bush cultivation in Peru during 2018 
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and 2019 and urges the country to complete and present 
the studies for the missing years and to renew its long-
standing commitment to crop monitoring activities 
and to the promotion of comprehensive and sustain-
able alternative development.
2. Regional cooperation
502. In 2020, several new initiatives were developed to 
overcome the challenges that drugs pose to the region. 
On 4 and 5 March 2020, the first meeting of the intelli-
gence agencies of Latin America was held in La Paz, with 
the participation of Bolivia (Plurinational State of), Brazil, 
Chile, Colombia, Ecuador and the United States. 
Participating countries agreed to cooperate and exchange 
information to identify the persons involved and the 
modi operandi used in the production and manufacture 
of and trafficking in drugs in each country.
503. From 1 April to 15 May 2020, 26 countries from 
Europe and the Americas, including Argentina, Brazil, 
Colombia, Chile, Guyana, Peru, Suriname and Uruguay, 
collaborated in the Orion V International Naval Campaign 
to Combat Drug Trafficking, the operational aspects of 
which were coordinated by Colombia. As a result of the 
campaign, 50.3 tons of cocaine, 7.3 tons of cannabis, 
10 kg of heroin, 12 kg of amphetamines, 10 kg of “ecstasy” 
and 13 kg of methamphetamine were seized. Also as part 
of the operation, 38 vessels, two submarines and four air-
craft were seized and 72 laboratories were dismantled. 
Activities under the Orion V naval campaign were 
initiated in 2018; from January to May 2020, a total of 
180.3 tons of cocaine and 22.6 tons of cannabis were 
seized as part of it.
504. In April 2020, CICAD published the first informa-
tion bulletin of the newly established early warning 
system for the Americas. The system was created in 2019 
in the context of a growing need to monitor the presence 
of new psychoactive drugs in the States members of OAS. 
The system collects information from national early 
warning systems in the region. As of April 2020, 
Argentina, Chile, Colombia and Uruguay had operation-
alized their national early warning systems for emerging 
drugs and related threats, while Brazil, Paraguay and Peru 
had taken steps toward the creation of such systems.
505. Between 28 September and 1 October 2020, offi-
cials of the competent national authorities of Bolivia 
(Plurinational State of), Colombia, Ecuador and Peru 
participated in the webinars delivered by the INCB 
Learning project. The webinars provided an opportunity 
to enhance participants’ understanding of the drug con-
trol and reporting requirements as established by the 
international drug control conventions and offered a plat-
form for the exchange of best practices among South 
American authorities.
506. In November 2019, INCB participated in the 
International Conference on Synthetic Drugs in Santiago, 
which strengthened the capacity of law enforcement 
agencies to identify and interdict new psychoactive 
substances and non-medical synthetic opioids and to 
exchange intelligence on trafficking in those substances. 
More than 130 international experts and front-line officers 
from Brazil, Chile, China, Germany, Italy, New Zealand 
and Spain, as well as representatives of INTERPOL and 
INCB, participated in the event, which was hosted by the 
Government of Chile. Following the event, INCB provided 
training to 21 officials from the Ministry of Interior, the 
Ministry of Public Health, the police and the postal and 
customs agencies of Chile on awareness-raising and safe-
handling approaches for emerging substances and 
information exchange using IONICS. In August 2020, as 
part of its public-private partnership initiatives to counter 
trafficking in dangerous substances, the GRIDS programme 
participated in an online regional event organized by the 
Postal Union of the Americas, Spain and Portugal, during 
which 150 postal security officers from 18 countries 
received awareness-raising training on emerging new 
psychoactive substances, non-medical synthetic opioids 
and fentanyl-related substances trafficked through the 
international mail and express mail services.
3.  National legislation, policy and 
action
507. On 28 February 2020, the National Council on the 
Fight against Illicit Drug Trafficking of the Plurinational 
State of Bolivia released the 2020–2025 National Strategy 
Against Drug Trafficking and the Illicit Drug Economy, 
under the slogan “United, Free of Drugs”. The strategy is 
composed of six thematic areas: (a) public health; (b) 
socioeconomic inclusion; (c) sustainable development; (d) 
regional and international cooperation; (e) tackling the 
financial foundations of drug organizations; and (f) 
enhancing the rule of law and governance on counter-
narcotics. This strategy moves away from the “social con-
trol” approach of the previous Government and embraces 
direct coca bush eradication techniques. It is acknowl-
edged in the strategy that the Plurinational State of Bolivia 
is not only a producing country, but also part of the drug 
market, with traffickers connected to regional and inter-
national networks involved in trafficking in drugs and 
gold, as well as trafficking in persons.
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508. In March 2020, eight police officers were detained 
in the Plurinational State of Bolivia for involvement in 
the smuggling of cocaine that had been seized during an 
operation. The interim Government began investigating 
members of the former Administration for their involve-
ment in drug trafficking and other illegal activities in the 
country. The former Minister of the Interior and the 
former National Director of the Special Force to Combat 
Drug Trafficking were placed under investigation for drug 
trafficking and corruption.
509. In June 2020, Peru adopted its Strategic Institutional 
Plan for the period 2020–2024. The Plan is aimed at, 
among other things, combating the criminal networks 
operating in the country. One of the objectives of the Plan 
is reducing trafficking in drugs.
510. In June 2020, the Government of Chile presented 
a draft bill to increase penalties related to drug trafficking, 
in particular for individuals who involve children under 
the age of 14 in activities related to drug trafficking, and 
to enable the use of seized assets for the national fight 
against drugs.
511. In June 2020, the National Assembly of Ecuador 
approved a bill on combating the consumption of and 
microtrafficking in drugs. The bill introduces administra-
tive sanctions such as fines and community work for drug 
use in public spaces and at public events. It allows the 
placement of video cameras in and around educational 
institutions and, where not possible, the presence of law 
enforcement officers outside such institutions at peak 
hours, to ensure the security of students. Higher educa-
tion institutions will have to include compulsory pro-
grammes on drug prevention in their curricula. The bill 
also creates a National Fund for the Comprehensive 
Prevention of Drugs, which will be partially financed by 
assets seized as part of prosecutions for drug trafficking 
and will support treatment and rehabilitation programmes 
for drug users.
512. Some Governments in South America have 
progressed further in regulating the cultivation and 
production of and trade in cannabis for medical and 
scientific purposes. In December 2019, the Brazilian 
regulatory agency for medicine issued new regulations on 
the use, production, commercialization, prescription, 
dispensing, monitoring and control of cannabis derivatives 
for medical purposes. Under the regulations, the cultiva-
tion of cannabis for medical purposes is not authorized in 
the country.
513. On 7 and 8 January 2020, the Government of 
Uruguay published two new laws (law No. 19845 and law 
No. 19847) on the use of cannabis for medical and 
scientific purposes. Law No. 19845 is focused on the pro-
motion of scientific research on cannabis and it establishes 
a national research centre on cannabis to contribute to 
research, technology transfer and training. The law also 
establishes a national research fund for cannabis, which 
will be partially funded by revenue obtained from the sale 
of cannabis for non-medical purposes. Law No. 19847 
was passed to protect, promote and improve public health 
through quality-controlled cannabis-based products. It 
provides for the creation of a national programme to 
access cannabis for medical and therapeutic purposes, a 
commission to integrate cannabis businesses into the 
banking system of Uruguay and a commission to promote 
small and medium-sized manufacturers of cannabis.
514. In February 2020, the first licences to cultivate and 
manufacture medicinal cannabis were granted to 12 com-
panies in Paraguay. The Government has stipulated that 
2 per cent of the amount produced is to be transferred 
to the Ministry of Health, which will distribute the can-
nabis products free of charge to patients with a medical 
prescription. Paraguay, together with Argentina, Brazil, 
Chile, Colombia, Peru and Uruguay, currently allows the 
use of cannabis for medical purposes.
515. In March 2020, the National Council on the Fight 
against Illicit Drug Trafficking of the Plurinational State 
of Bolivia announced that the Secretary of the Committee 
for the Fight Against Drug Trafficking of the Chamber of 
Deputies had produced a draft bill to permit the use of 
cannabis for medical purposes, with the ultimate inten-
tion of permitting the production of medical cannabis-
based products in the country.
516. Through its resolution 315 of March 2020, the 
Ministry of Health of Colombia updated its list of sched-
uled substances and established a mechanism to allow the 
National Narcotics Fund to authorize new activities, such 
as research and development, involving internationally 
controlled substances. The resolution also includes provi-
sions under which medicines containing cannabinoids 
can be sold. Medicines containing more than 2 mg of 
delta-9-THC are subject to control and monitoring by the 
National Narcotics Fund. According to information from 
the Ministry of Health, an inter-institutional project is 
currently being developed to reformulate the regulatory 
framework in relation to safe and informed access to can-
nabis for medical and scientific purposes.
517. Suriname has also begun talks to address the use 
of cannabis for medical purposes. In May 2020, the 
Surinamese Standards Bureau shared with other minis-
tries its cannabis standards for medical and scientific 
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purposes, which are aimed at regulating the cannabis 
industry for medical and scientific purposes.
518. The Board reiterates its view that, while the 
cultivation, production and use of cannabis for medical 
purposes are permitted by the 1961 Convention as 
amended, such activities must be carried out in a 
manner that is consistent with articles 23 and 28 of that 
Convention.
4.  Cultivation, production, 
manufacture and trafficking
519. Colombia, Peru and the Plurinational State of 
Bolivia accounted for 70 per cent, 20 per cent and 10 per 
cent, respectively, of the global area under coca cultiva-
tion in 2017, the latest year for which comparable esti-
mates are available. According to the UNODC World 
Drug Report 2020, following an increasing trend during 
the period 2013–2017, the total area under coca bush 
cultivation remained stable in 2018.
520. According to UNODC, Colombia reported a 
decrease of 9 per cent in the total area under coca 
cultivation, from 169,000 ha in 2018 to 154,000 ha in 
2019, a continuation of the decreasing trend observed in 
the previous year. In spite of this decrease, the total 
manufacture potential of pure cocaine hydrochloride was 
1,137 tons, which represents an increase of 1.5 per cent 
in relation to 2018. This increase could be explained by 
improvements in cultivation techniques, which have 
resulted in an increase in the size of the coca leaf harvest, 
and the higher performance of cocaine manufacture sites. 
Estimated coca leaf production in 2019 was 993,107 tons, 
representing an increase of 1.6 per cent compared with 2018.
521. Increasingly sophisticated efforts by drug traffick-
ers in terms of the illicit manufacture of cocaine could 
also explain the increase in the manufacture of cocaine 
hydrochloride in Colombia. In recent years, drug traffick-
ers appear to be becoming more self-sufficient by produc-
ing their own chemical precursors, such as potassium 
permanganate. This goes against a previously observed 
trend of some drug traffickers moving the manufacture 
of cocaine hydrochloride outside Colombia.
522. In 2018, the Government of Colombia proposed a 
zoning system based on the characteristics of the territo-
ries affected by coca bush cultivation, to design public 
policy in a way that was more responsive to local condi-
tions. UNODC noticed that 48 per cent of the coca 
detected in 2019 was concentrated in 3 of the 12 zones: 
(a) forest reserve areas (18 per cent); (b) black community 
land (16 per cent); and (c) areas of strategic interest for 
productive integration (14 per cent).
523. According to data from the Ministry of Defence of 
Colombia, from 1 January to 12 July 2020, 44,905 ha 
under illicit cultivation had been eradicated. The eradica-
tion target for 2020 is 130,000 ha of coca bush, 30 per 
cent higher than that of 2019. After a meeting between 
the President of Colombia and the President of the United 
States in March 2020, discussions were launched on the 
use of aerial spraying of glyphosate to increase the effec-
tiveness of the eradication plan. Colombia had suspended 
aerial spraying in 2015, following a recommendation by 
WHO indicating that its use could have serious repercus-
sions for human health and the environment. The 
Colombian Constitutional Court has blocked aerial spray-
ing until the Government can meet various health and 
environmental requirements, including undertaking an 
inclusive consultation process with all affected communi-
ties. Given COVID-19 prevention requirements, the con-
sultations were to have taken place online, but many of 
the affected communities have limited or non-existent 
Internet access. In 2019, 94,606 ha of illicit crops were 
manually eradicated. This represents an increase of 58 per 
cent compared with 2018, when a total of 59,978 ha were 
manually eradicated.
524. In the Plurinational State of Bolivia, the 5.7 per 
cent decrease in the area under coca bush cultivation 
from 2017 to 2018 was reversed in 2019, when the area 
under cultivation increased by 8.2 per cent, to 25,000 ha, 
from 23,100 ha in 2018. Political instability in 2019, 
border permeability and the country’s location near the 
largest consumers and manufacturers of illicit drugs in 
South America are factors that could have led to the 
increase in cultivation.
525. As a consequence, the Plurinational State of Bolivia 
registered an increase in cocaine manufacture that could 
also have been caused by the large amount of coca leaf 
circulating on the illegal market. In 2018, an estimated 
55,168 tons of coca leaf were produced in the country, 
according to the Directorate-General for Coca Leaf 
Commercialization and Industrialization. UNODC 
reported that, in 2019, authorities in the country disman-
tled 50 illicit cocaine laboratories and 841 factories. In 
2018, authorities recorded an increase in the number of 
cocaine laboratories in remote, difficult-to-access areas in 
the eastern part of the country.
526. In October 2020, the National Drug Directorate of 
the Peruvian National Police published a report on trends 
in criminal drug trafficking networks in Peru. The report 
was based on available data from national anti-drug 
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operations, the Drug Enforcement Administration of the 
United States, the European Union and UNODC, and 
validated the estimates, made by the United States Office 
of National Drug Control Policy, of 52,100 ha under illicit 
coca cultivation in 2018. This would represent an increase 
of 4.4 per cent in the area under cultivation in the country 
compared with 2017.
527. In July 2020, authorities in Peru dismantled six 
laboratories used to process coca paste and disabled 17 
clandestine airstrips intended for use in drug trafficking. 
The laboratories served an area of over 70 ha of coca leaf 
cultivation and some 16 tons of coca leaf debris were 
seized. According to data from the Government of Peru 
released in May 2020, 25,526.31 ha under illicit coca bush 
cultivation were eradicated in 2019, surpassing the target 
for the year by 2.11 per cent. For 2020, the eradication 
goal remains 25,000 ha.
528. In the Bolivarian Republic of Venezuela, the 
number of clandestine airstrips and suspected drug flights 
increased in 2019. The Government reported the confis-
cation of 23 light aircraft and the destruction of 36 clan-
destine airstrips in 2019. Most of the country’s clandestine 
airstrips are located in the State of Zulia, which borders 
the Catatumbo region in Colombia, a significant area for 
cocaine manufacture. However, the number of airstrips 
in Zulia might be bigger. According to reports from vari-
ous organizations monitoring the matter, some 400 air-
strips have been identified for the landing and departure 
of aircraft bound for the Caribbean islands and Central 
America. It appears that drugs flown from the Bolivarian 
Republic of Venezuela are primarily bound for El Salvador 
and Honduras. The Mexican cartel Sinaloa has also been 
detected in Zulia, where it has taken advantage of the 
airstrips to build centres of transit and collection of nar-
cotic drugs with the support of the Colombian National 
Liberation Army, which has expanded its activities in the 
Bolivarian Republic of Venezuela.
529. Uruguay reported two historic seizures of cocaine 
and coca paste in 2019 and 2020. In December 2019, 
6 tons of cocaine were seized at the Port of Montevideo 
in containers bound for Togo. In February 2020, Operation 
Bagdad-Bangui resulted in the record seizure of 347 kg 
of coca paste and 206 kg of cocaine that had been smug-
gled by light aircraft, a recurring and increasingly 
common technique used by drug traffickers. Uruguay is 
gradually becoming a country for the trans-shipment of 
illicit drugs. In 2019, the country seized 12 tons of 
cocaine, the highest amount reported to date and a con-
siderable increase from 2018, when only 782 kg of cocaine 
were seized. At the same time, the corruption of law 
enforcement officers by drug traffickers is becoming more 
visible as the country plays an increasingly significant role 
in the international market for illicit drugs. In January 
2020, four Uruguayan navy officers were accused of 
assisting drug trafficking organizations.
530. Brazil remains a significant transit hub and a key 
departure point for the cocaine that enters Asia and 
Africa. In April 2020, 555 kg of cocaine destined for Côte 
d’Ivoire were seized in the Port of Paranagua. Data from 
UNODC show that, between 2014 and 2018, most of the 
cocaine trafficked to Africa and smuggled onwards to 
Europe had departed from Brazil.
531. In May 2020, in the course of Operation Tsunami, 
authorities in Ecuador seized 3 tons of sodium hydroxide, 
a chemical controlled in Ecuador that can be used for the 
processing of cocaine, in the Province of Esmeraldas. 
Esmeraldas has seen a rise in the presence of drug 
trafficking organizations from Colombia in recent years. 
In the past decade, Ecuador has become a significant 
exporter of cocaine that is produced primarily in southern 
Colombia. The drug is usually bound for Europe and for 
Central America, from where it is trafficked onwards to 
North America.
532. In May 2020, Paraguay reported an increase in the 
amount of cocaine seized. In the first few months of 2020, 
the amount seized totalled approximately 4,300 kg. 
According to the National Anti-Drug Secretariat, that was 
a record amount for the country: in recent years, the 
annual average has been approximately 1,500 kg.
533. In 2018, South America accounted for 43 per cent 
of the quantity of cannabis herb seized globally. In May 
2020, authorities in the Plurinational State of Bolivia 
destroyed over 46 tons of cannabis plant. In November 
2019, a joint operation between Brazil and Paraguay 
(Operation Alianza 21), in the territory of the latter, led 
to the dismantling of 85 cannabis cultivation and produc-
tion sites, the eradication of 160 ha of cannabis plant and 
the seizure of 19,480 kg of dried cannabis and 377 kg of 
pressed cannabis. In August 2020, the continued coopera-
tion of the two countries under Operation Alianza 22 led 
to the dismantling of 63 cannabis sites, the eradication of 
127 ha of cannabis plant and the seizure of 89.6 tons of 
chopped and processed cannabis. Brazil reported the sei-
zure of 261 tons of cannabis herb in 2019 and, between 
January and May 2020, 141 tons of cannabis herb were 
seized. In May 2020, the Federal Police of Brazil carried 
out the biggest drug seizure in the country to date: 28 tons 
of cannabis herb being transported in a truck were inter-
cepted in a city on the border with Paraguay.
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534. Different cannabis varieties are appearing on the 
illicit cannabis market in Chile. Seizures of “creepy” can-
nabis, a genetically modified cannabis variety that con-
tains high levels of THC and is popular among drug 
traffickers for its profitability, have increased sevenfold in 
the country in the past three years.
535. The overwhelming presence of cannabis and 
cocaine in the region often overshadows the presence of 
synthetic drugs. According to the UNODC World Drug 
Report 2020, the quantities of “ecstasy” seized in South 
America declined between 2017 and 2018. Nonetheless, 
a growing presence of the drug has been noted in the 
region since 2019. At the end of 2019, the Plurinational 
State of Bolivia announced the seizure of 1.5 kg of 
“ecstasy” tablets that had come from Spain. The most 
recent seizure of “ecstasy” in the country prior to that 
had been in 2006.
536. Chile also experienced a worrying influx of 
synthetic drugs in 2019. In 2010, the country reported 
the seizure of some 2,000 doses but, by 2019, the number 
had increased to up to 1.5 million. Chilean authorities 
are alarmed by the increasing presence of these drugs, a 
growing trend that can also be observed in the number 
of seizures and of laboratories dismantled. In 2010, the 
number of “ecstasy”-type substances seizures was 7 (1,501 
doses) and by 2019 it was 444 (456,741 doses). The latest 
data from the Chilean Observatory on Drugs show that, 
in 2019, 15 clandestine drug manufacturing laboratories, 
largely dedicated to the manufacture of synthetic drugs, 
were discovered.
537. Brazil has reported an increase since 2019 in the 
domestic manufacture of “ecstasy”. Between 2018 and 
2020, at least eight clandestine laboratories for the manu-
facture of the substance were dismantled. According to 
the UNODC regional office in Brazil, this is a new phe-
nomenon in the country. Previously dismantled facilities 
were usually focused on the cutting and retableting of 
imported “ecstasy”; however, recently discovered labora-
tories in south Brazil have been dedicated to the entire 
manufacturing chain.
5. Prevention and treatment
538. Consistent with past years, cannabis and cocaine 
continue to be the most-used drugs in South America 
according to UNODC. The region has witnessed a steady 
increase in the use of cannabis, which appears to be more 
predominant among people from poorer socioeconomic 
backgrounds. UNODC reported that, in 2018, 2 per cent 
of the population of the Plurinational State of Bolivia 
were past-year users of cannabis, compared with 1.3 per 
cent in 2014.
539. In Uruguay, 8.9 per cent of the population aged 
between 15 and 65 reported past-month cannabis use in 
2018. Since 2011, the country has witnessed a rise in the 
number of regular and frequent cannabis users, to the 
extent that more than a third of those users were consid-
ered to be dependent. According to the seventh national 
survey of Uruguay on drug use in the general population, 
undertaken in 2019, the average age of first cannabis use 
is 20, an increase from previous years that has been attrib-
uted to the increased number of adults using cannabis. 
In 2011, the age of first use was 18.3 and by 2018 it had 
reached 20.1. In the ninth regulated cannabis market 
report, published by the Institute for the Regulation and 
Control of Cannabis in February 2020, it was reported 
that, as at 29 February 2020, a total of 53,399 people were 
authorized to access cannabis: 40,604 people had 
registered to acquire cannabis from pharmacies, 8,120 
had registered for domestic cultivation and 4,675 had a 
membership of a cannabis club. UNODC, in the World 
Drug Report 2020, noted that users who accessed 
cannabis only through authorized means represented a 
small proportion of the cannabis users in the country.
540. The Board notes the efforts of the Government of 
Uruguay to monitor and provide information on the 
manufacture, distribution and consumption of cannabis 
for non-medical purposes. However, the Board expresses 
concern regarding the increase of cannabis consumption 
as reported by the Government of Uruguay and wishes 
to reiterate that legalization measures or regulations 
that permit the use of any controlled substance, includ-
ing cannabis, for non-medical purposes are inconsistent 
with the obligations of States parties, namely those 
included in article 4, paragraph (c), of the 1961 
Convention as amended. The Board calls upon all States 
to respect their international legal obligations in the 
development of their national drug control policies.
541. Treatment for substance use disorder in which 
cocaine is the primary drug of concern represents a large 
share of drug treatment in South America. It was esti-
mated that, in 2018, 2.8 million people aged 15–64 were 
past-year users of cocaine in South America. In particu-
lar, in 2018 in Uruguay, 2 per cent of the adult population 
were past-year users of cocaine, 43 per cent of whom were 
suffering from cocaine use disorder.
542. In addition, a growing pattern of use of coca paste 
has been observed in the region. While the use of cocaine 
seems to be more prevalent among young adults from 
high- and middle-income backgrounds, coca paste is 
ChaPTER III. aNalysIs Of ThE wORld sITuaTION  77
more widespread among older users (36–45) from low-
income groups. Uruguay has reported a decline in the use 
of cocaine base paste among young adults but an increase 
in such use among adults, as the users who initiated use 
at the age of 18 during the period 2002–2004 have con-
tinued using the drug over the years.
543. In the past, the use of coca paste predominantly 
took place in the countries where cocaine was manufac-
tured. However, according to UNODC, it has spread to 
other countries in South America where the manufacture 
of cocaine does not take place. Nevertheless, it is difficult 
to provide accurate estimates on such use as cocaine base 
paste is commonly consumed by marginalized groups, 
which are not reached by treatment services and national 
surveys.
544. During the coronavirus pandemic, access to drugs 
such as cocaine has been limited because of a lack of 
movement across borders and a considerable rise in 
prices owing to limited stocks. However, this has not 
halted the consumption of cocaine or cannabis. On 
14 July 2020, the Service for the Prevention and Treatment 
of Drug and Alcohol Use in Chile presented the results 
of an online survey on the effects of the COVID-19 pan-
demic on the use of alcohol and other drugs in the coun-
try. According to the survey, cannabis consumption has 
remained more stable than cocaine during the pandemic. 
Since the beginning of the pandemic, respondents had 
had more access to cannabis (84.3 per cent) than cocaine 
(5.5 per cent). One third (33.3 per cent) of the partici-
pants said that they had consumed more cannabis during 
the pandemic, whereas 27.7 per cent said that they had 
consumed less. By contrast, 29.9 per cent said that they 
had consumed more cocaine during the pandemic and 
49.2 per cent had reduced their consumption of cocaine.
545. A report published by CICAD and the Uruguayan 
National Drug Board in February 2020 showed a marginal 
prevalence of opioid use in the population (0.9 per cent 
lifetime use and 0.3 per cent in the past 12 months). This 
is consistent with the limited presence of opioids on the 
illicit market in Uruguay. However, the Government has 
noted that continued monitoring of this trend is required.
546. UNODC and WHO estimate that only 1 in 11 
people in Latin America have access to drug treatment 
programmes. Reports from the Plurinational State of 
Bolivia indicate a general lack of public treatment centres; 
the centres that do exist are located only in urban areas. 
In its recently published national strategy on combating 
drug trafficking and the illegal economy for drugs, the 
Government of the Plurinational State of Bolivia noted 
that there were only two drug dependence treatment 
facilities managed by the Government.
547. Brazil is the largest cocaine market in South 
America, according to information from the World Drug 
Report 2020. In July 2020, resolution 03/2020 was issued 
by the Ministry of Health of Brazil allowing therapeutic 
communities to provide treatment to adolescents (aged 
12–18) suffering from drug use disorders. According to 
a national study from 2017, 95 per cent of such thera-
peutic communities use non-evidence-based approaches 
to treat patients. In June 2019, the Government approved 
law No. 13840, to enable the compulsory hospitalization 
of drug users. This law modifies federal law No. 11343 of 
August 2006, which established the National System of 
Public Policy on Drugs. Under the new law, treatment of 
patients suffering from drug use disorders could take 
place without the consent of the patient, at the request of 
a family member or legal guardian or, in the absolute 
absence of a guardian, a public servant in the field of 
health who verifies the existence of reasons that justify 
the measure.
548. The Board discourages the use of compulsory 
treatment for the rehabilitation of patients suffering 
from drug use disorders and recalls the report of the 
Special Rapporteur on the right of everyone to the 
enjoyment of the highest attainable standard of physical 
and mental health submitted to the Human Rights 
Council at its forty-fourth session, held from 30 June to 
17 July 2020 (A/HRC/44/48), in which the Special 
Rapporteur warned that medical rationales should 
never be used as a defence or justification for policies 
and practices that violate the dignity and rights of 
people who use drugs. The Board calls upon the 
Government of Brazil to implement voluntary, evidence-
based treatment services with due respect for patients’ 
human rights, in line with the UNODC-WHO 
International Standards for the Treatment of Drug Use 
Disorders and Commission on Narcotic Drugs resolutions 
46/1 and 59/4.
549. Governments of the region have continued to work 
on raising awareness among youth of the adverse conse-
quences of drug consumption and on the prevention of 
drug use. In the Plurinational State of Bolivia, the 
Ministry of Education and the Ministry of the Interior 
signed a memorandum of understanding in June 2020 to 
address the prevention of and fight against the use of 
drugs in schools by providing information materials for 
students, educators and families through the country’s 
schools.
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550. Taking note of the heavy toll that the COVID-19 
pandemic has had on the most vulnerable sectors of 
society, especially people suffering from drug use 
disorders, Argentina and Uruguay developed action plans 
to assist those populations. In Argentina, the Secretariat 
for Comprehensive Drug Policies activated a contingency 
plan to guarantee the provision of essential services 
through community structures and call centres that are 
available 24 hours a day, seven days a week. In Uruguay, 
the National Drug Board started the implementation of 
Project Paradores, which offers places in daytime shelters 
to people living on the street who have a high risk of 
marginalization and social exclusion. National data from 
Uruguay show that 87 per cent of its citizens living on the 
streets consume some type of illicit drug. As such, Project 
Paradores has been promoted as part of a comprehensive 
initiative: while focusing on the prevention and containment 
of the transmission of COVID-19, trained personnel assist 
people with drug dependence issues.
551. While the economic impact of the COVID-19 pan-
demic is expected to lead to an increase in rates of sub-
stance use disorder, spending on drug prevention and 
treatment services is in long-term decline in the region. 
Access to drug treatment services might be disrupted as 
Governments divert their attention to address the eco-
nomic crisis in the aftermath of the global pandemic.
D. Asia
East and South-East Asia
The continued increase in the illicit manufacture of, 
trafficking in and use of synthetic drugs, in particular 
methamphetamine in increasingly purer forms, remained 
a major concern for East and south-East asia. The drug 
problem has had serious health, human rights, security 
and economic implications for the countries of the region.
It seems that the decision by China in 2019 to schedule 
fentanyl-related substances as a class-wide group has, 
over the course of the year, resulted in a sharp drop in 
the amount of those substances of alleged Chinese origin 
seized globally. however, it also seems that traffickers 
have now moved to fentanyl precursors as a way of 
manufacturing these substances, which calls for greater 
collaboration to deal with this trafficking challenge.
The Board has repeatedly expressed its concerns over 
serious human rights violations, especially with regard to 
extrajudicial actions, committed in purported pursuit of 
drug control objectives. These violations contravene 
internationally recognized human rights standards and 
are inconsistent with the obligations of governments 
under the three international drug control conventions.
1. Major developments
552. More than any other part of the world, the coun-
tries in East and South-East Asia continue to see an 
increase in the illicit manufacture of, trafficking in and 
use of synthetic drugs, in particular methamphetamine. 
The price of methamphetamine decreased to its lowest in 
a decade, while purity remained stable or increased. 
UNODC estimates that the manufacture of and traffick-
ing in methamphetamine and heroin in the region gener-
ated annual revenues of more than $54 billion, with 
methamphetamine accounting for $44.9 billion. 
553. In early 2020, major seizures of synthetic drugs 
took place in a number of countries of the region, including 
China, Malaysia, Myanmar and Thailand.
554. In its annual report for 2019, the Board noted that, 
to further strengthen its drug control system, China had 
decided to schedule, as a class-wide group, all fentanyl-
related substances as of 1 May 2019. Available data by the 
end of 2019, including as reflected in presentations by 
representatives of national agencies at INCB-hosted semi-
nars for subject-matter experts, suggested that the number 
of interdictions of fentanyl-related substances of alleged 
Chinese origin had dropped markedly.
555. Effective regulatory mechanisms, as well as border 
management and control and forensic capacity with 
regard to precursors and other chemicals frequently used 
in illicit drug manufacture, continue to be of particular 
importance given that the chemical industry has a sub-
stantial presence in the region and the region’s increas-
ingly improved infrastructure has further enhanced 
connectivity among countries. Effective regional coopera-
tion among the countries of the region through collabora-
tion, joint operations and the sharing of information 
remains crucial. In particular, given the apparent effec-
tiveness of the decision by China to schedule fentanyl-
related substances as a class, traffickers have moved to 
precursors as a way of continuing to provide those 
substances to illicit markets, a development described in 
the Board’s report on precursors for 2019, which gives 
even greater impetus to the need to work regionally to 
deal with this trafficking challenge.
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556. Most countries continue to lack comprehensive 
drug use prevalence data and evidence-based drug 
dependence treatment programmes. In particular, in view 
of the COVID-19 pandemic, attention should be paid, 
and resources devoted, to continued drug use prevention 
and treatment efforts, in order to sustain progress made 
and to prevent an increase in additional vulnerabilities 
among the region’s population. 
2. Regional cooperation
557. The countries of the region have a long-standing 
history of cooperation, bilaterally as well as regionally. In 
November 2019, signatories to the Mekong Memorandum 
of Understanding on drug control (Cambodia, China, the 
Lao People’s Democratic Republic, Myanmar, Thailand, 
Viet Nam and UNODC) endorsed the Bangkok Declaration 
on effectively responding to the drug problem in the 
Mekong. In addition, the signatories endorsed their 
eleventh subregional action plan on drug control (May 
2019–May 2021), in which the joint commitment of 
signatory countries to addressing the subregion’s drug 
problem was reaffirmed. The action plan comprises four 
key areas of cooperation: drugs and health; law enforcement 
cooperation; legal and judicial cooperation; and sustainable 
alternative development. 
558. In December 2019, ASEAN agreed to add the Food 
and Drug Administration of the Philippines to its current 
list of inspection services, which also includes similar 
authorities in Indonesia, Malaysia, Singapore and 
Thailand. Under the ASEAN Sectoral Mutual Recognition 
Arrangement for Good Manufacturing Practice, certifi-
cates on good manufacturing practices are mandatory for 
the registration of medicinal products in each ASEAN 
member State. 
559. To complement the Board’s treaty-mandated pro-
gramme of work on precursors, which is further described 
in the Board’s 2020 report on precursors, countries in 
the region agreed to increase cooperation on precursor 
control. In December 2019 and February 2020, with the 
assistance of UNODC, intelligence specialists from East, 
South and South-East Asia, as well as Australia, Canada 
and the United States, met in China and Myanmar, 
respectively, to exchange information on recent diversion 
and trafficking cases.
560. In Hanoi in December 2019, INCB hosted its 
second international workshop on public-private partner-
ships preventing exploitation of legitimate e-commerce. 
Participants discussed voluntary partnerships with indus-
try to make the marketing and sale of non-medical 
fentanyl and other dangerous substances more difficult 
throughout the region. Seventy participants from 
21 countries and territories and four international 
organizations and nine representatives from private-
sector partners exchanged experiences and practical 
advice on building legitimate e-commerce while addressing 
trafficking in dangerous substances over the Internet. In 
addition, in-person and online training was delivered to 
law and regulatory enforcement officers in the region on 
countering trafficking, including through awareness-
raising on emerging new psychoactive substances, non-
medical synthetic opioids and safe handling approaches 
to fentanyl, and on information exchange, in partnership 
with international partners.
561. Owing to the COVID-19 pandemic, a number of 
regional meetings were postponed. Others, such as the 
third meeting of the Advisory Council on Dangerous 
Drugs of the ASEAN Inter-Parliamentary Assembly, were 
held online. Countries participating in that meeting 
adopted a resolution entitled “Turning words into actions 
towards a drug-free ASEAN community”, defining the 
scope of future activities within the Council. 
3.  National legislation, policy and 
action
562. In 2020, the Government of Thailand initiated a 
legislative amendment to the Narcotics Act which would 
remove kratom (Mitragyna speciosa), a plant-based 
psycho active substance not under international control, 
from category V of the country’s list of narcotics. In con-
trast, Indonesian authorities are considering whether to 
place kratom under national control as a category I nar-
cotic, which would make it illegal in the country. Before 
taking such a decision, during the period 2020–2024, 
Indonesia will undertake further research on the issues, 
including health, sociological, socioeconomic, ecological 
and alternative development considerations, surrounding 
such a scheduling decision. 
563. The Government of Thailand is considering a pro-
posal to remove cannabis from the narcotics list by means 
of a ministerial regulation of the Ministry of Public 
Health, under which research would be conducted on the 
effects of cannabis in medicines, cosmetics and herbs, in 
line with the Government’s policy of boosting the coun-
try’s competitiveness in the production of cannabis-based 
products. This regulation would allow for the cultivation 
of the cannabis plants specified in the regulation by indi-
viduals and corporations, subject to conditions on trade 
and possession. The Food and Drug Administration of 
Thailand joined the country’s national network of medical 
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cannabis cultivators to organize a training course on 
planting techniques for farmers, community enterprise 
groups and agricultural cooperatives. 
564. The President of Indonesia mandated the National 
Narcotics Agency to implement a new national action 
plan for the prevention and eradication of narcotic drug 
abuse and circulation for the period 2020–2024. The 
action plan builds upon the previous one, which was 
implemented during the period 2018–2019. Actions 
included in the plan are the provision and dissemination 
of information related to the dangers of drugs, the establish-
ment of an anti-drug task force and the inclusion of relevant 
topics in educational materials and training materials for 
officials. The plan is to be implemented in cooperation with 
various ministries and authorities in the country. 
565. In January 2020, the Government of Indonesia 
adopted a 15-action point resolution addressing the drugs 
situation in correctional facilities in the country. The 
action points include the provision of medical assistance 
and social rehabilitation to over 21,000 prisoners who use 
drugs, as well as addressing overcrowding in order to 
prevent the circulation of illegal drugs within prisons. 
566. The Ministry of Home Affairs of Indonesia issued 
ministerial regulation No. 12, 2019 (replacing a previous 
regulation from 2013), pursuant to which provincial and 
local governments and village heads are permitted to con-
duct demand-reduction activities within their jurisdic-
tions. Such activities may be focused on raising awareness, 
early detection, community empowerment or providing 
medical treatment and/or rehabilitation services.
567. In the Philippines, allowing the use of cannabidiol-
based medications with no more than 0.1 per cent THC 
content is being considered for the treatment of certain 
forms of epilepsy, such as Lennox-Gastaut and Dravet 
syndrome. The national Dangerous Drugs Board informed 
the public that cannabis use remained illegal in the coun-
try for both recreational and medical use. 
568. In June 2020, pursuant to Human Rights Council 
resolution 41/2, the United Nations High Commissioner 
for Human Rights issued a comprehensive report on the 
situation of human rights in the Philippines (A/HRC/44/22). 
In the report, the High Commissioner concluded that the 
heavy focus on countering national security threats and 
drug use in the country had resulted in serious human 
rights violations, including killings and arbitrary detentions, 
as well as in impunity for those killings, and a failure of 
domestic mechanisms to ensure accountability thus far. 
Also in the report, the High Commissioner stressed the 
need for independent, impartial and effective investigations 
into all allegations of serious violations of human rights 
and international humanitarian law. The Office of the 
Prosecutor of the International Criminal Court in The 
Hague is undertaking a preliminary examination of the 
situation in the Philippines, analysing crimes allegedly 
committed in the country in the context of its “war on 
drugs” since 1 July 2016.
569. The Board reminds all Governments that extra-
judicial action, taken in purported pursuit of drug con-
trol objectives, is inconsistent with their obligations 
under the three international drug control conventions. 
All drug control actions taken to comply with these obli-
gations should be taken with full respect for the rule of 
law and due process of law.
570. In February 2020, the Prime Minister of Viet Nam 
announced measures to address the drug situation in the 
country, outlining nine key tasks. As part of those 
measures, attention and priority should be given to drug 
use prevention, including at the family, commune and 
district levels and among high-risk groups. Viet Nam will 
focus on enhancing the detection of large-scale, 
transborder drug trafficking, preventing Viet Nam from 
becoming a transit country, and will introduce strict 
controls on the import, export and manufacture of 
controlled substances and precursors. Viet Nam intends 
to collect data on the number of people with drug use 
disorders in order to prepare resources for early 
intervention and improve the effectiveness of treatment 
and rehabilitation programmes, as well as to draft legal 
documents on drug prevention and control and related 
legislative amendments. Cooperation among the Ministry 
of Public Security, the Ministry of Health, the Ministry 
of Labour, War Invalids and Social Affairs and other 
relevant agencies was outlined as crucial. 
571. In line with that, in March 2020, the Ministry of 
Public Security of Viet Nam introduced amendments to 
the national law on drug prevention and control, with a 
view to improving the effectiveness of the State’s manage-
ment of drug prevention and control, as well as of com-
pulsory and voluntary rehabilitation. Other aims of the 
amendments were to improve and ensure safety in society 
and decrease the number of deaths and illnesses caused 
by crime and drug use. The Ministry of Health requested 
its agencies to enhance the implementation of activities 
for drug prevention and control and to set up plans and 
programmes in that regard. June was declared the national 
action month for drug use prevention and control.
572. The Government of Myanmar adopted a new 
national strategic plan for the period 2020–2024 and is 
in the process of developing a two-year action plan for 
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the states and regions of the country in order to imple-
ment the national drug policy that was formally approved 
in 2018. The national policy was seen as a move from a 
law enforcement to a health-oriented approach, with 
areas covering supply reduction and alternative develop-
ment, demand reduction, international cooperation, 
research and analysis, and compliance with human rights. 
For the first time, the Government of Myanmar formally 
included in its national policy measures to reduce the 
negative consequences of drug use. 
573. Effective in May 2020, Singapore expanded the 
national list of controlled substances by adding 17 new 
psychoactive substances to its schedules. Currently, 
Singapore classifies 12 generic groups of new psychoac-
tive substances and 160 individually listed new psychoac-
tive substances as class A drugs. In addition, three 
non-fentanyl novel synthetic opioids were added to the 
country’s national schedules of controlled substances on 
the basis of literature reviews from overseas science jour-
nals in which the presence of those substances on illicit 
drug markets and their structural similarities to sub-
stances shown to be liable to abuse and with limited licit 
use had been highlighted. In April 2020, seven precursors 
were put under national control in Myanmar. 
574. Following reports of increased drug trafficking in 
Cambodia, in 2020, the Government adopted a seven-
point strategy to combat illegal drugs. The strategy 
includes education and dissemination of information 
related to the negative consequences of drug use among 
the population, monitoring drug use and continued 
construction of treatment and rehabilitation centres. The 
strategy is also aimed at encouraging private sector support 
for the country’s national movement to combat drugs and 
drug-related crime, including in its border areas. 
4.  Cultivation, production, 
manufacture and trafficking
575. The illicit manufacture of, trafficking in and use of 
heroin, which is reported as the second most-frequently 
trafficked drug in South-East Asia, continued to pose 
challenges for most countries in the region, although 
most illicit manufacture of heroin in the region takes 
place in northern Myanmar.
576. In the UNODC Myanmar opium survey for 2019, 
the total area under opium poppy cultivation in Myanmar 
in 2019 was estimated at 33,100 ha, representing a 
decrease of 11 per cent in comparison with 2018, 
continuing a downward trend that started in 2014. Despite 
decreasing demand for opiates, the estimated domestic 
heroin consumption of 6 tons was valued at between 
$152 million and $290 million, while exports to 
neighbouring countries were estimated to have generated 
$1 billion. 
577. Countries of the region have been seizing an 
increasing amount of methamphetamine over the last 
10 years, more than in any other part of the world. 
According to UNODC, marked increases in the amounts 
seized were seen in Thailand, although they also decreased 
in China, where wastewater analysis showed a significant 
decline in methamphetamine consumption. 
578. The quantities of methamphetamine seized annu-
ally by the Republic of Korea remained high in 2019, and 
nearly 80 per cent of the total amount seized was being 
trafficked by air travellers. The amount of crystalline 
methamphetamine seized was the second largest on 
record in 2019, while seizures of methamphetamine tab-
lets and cocaine reached a record high in that year. 
579. Also in 2019, a record amount (2.3 tons) of crystal-
line methamphetamine was seized in Japan, driven mainly 
by maritime interdictions by the national authorities of 
large amounts. Similarly, seizures of “ecstasy” tablets 
increased sixfold between 2018 and 2019, reaching a 
record high. In 2018, over 71 per cent of arrests for 
alleged drug-related offences were related to metham-
phetamine and over 63 per cent of all smuggling cases 
were cases of smuggling by air travellers. The number of 
cannabis-related arrests in 2018 in Japan reached a record 
high, accounting for over 25 per cent of all drug-related 
arrests in the country. 
580. Methamphetamine in its crystalline form has been 
more persistent recently on the illicit market, with higher 
purity and a lower price. In Indonesia, Thailand and Viet 
Nam, retail prices of methamphetamine more than halved 
while, at the same time, the purity of the drug rose to 
around 95 per cent in 2019 in Thailand. Similar develop-
ments were seen in other countries of the region. 
581. The discrepancy between the amount of metham-
phetamine seized and the comparatively low amount of 
key precursors and pre-precursors seized continues to 
characterize the situation in the region. A comprehensive 
review of the situation with respect to the control of pre-
cursors and chemicals frequently used in the illicit manu-
facture of narcotic drugs and psychotropic substances can 
be found in the report of the Board for 2020 on the 
implementation of article 12 of the 1988 Convention.
582. The Board expresses its concern over the continuous 
increases in the illicit manufacture of, trafficking in and 
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use of synthetic drugs, in particular methamphetamine, 
and urges countries of the region to take further action 
at the domestic and regional levels to address this 
alarming situation. 
583. According to UNODC, by the end of 2019, a total 
of 461 different new psychoactive substances had been 
reported by countries in East and South-East Asia, almost 
half of the total number reported at the global level. Japan 
reported the largest number (366 substances), followed 
by China (201), Singapore (118) and the Republic of 
Korea (93). 
584. In Viet Nam, during the first half of 2020, over 
11,000 drug-related cases were investigated, with nearly 
16,000 arrests and 235 kg of heroin seized, in addition to 
nearly 1.6 tons and 850,000 tablets of synthetic drugs, 
according to the Counter-Narcotics Police Department of 
the Ministry of Public Security. While the quantity of 
drugs seized decreased in comparison with the same 
period in 2019, there was an increase of nearly 10 per 
cent in the number of drug-related cases, despite the lock-
down in place over part of the period owing to the 
COVID-19 pandemic. 
585. According to the Government of China, Yunnan 
Province remained the main transit point for overseas 
drugs being trafficked inland, commonly through express 
delivery services, owing to the low costs and low risks. 
Online drug trafficking has been emerging, with a total 
of nearly 7,000 drug-related cyber cases in 2019. The 
increasing use of the Internet for illicit trade and drug-
related activities has also been reported by other countries 
of the region. The Government also reported that new 
forms and new types of drugs had been emerging. In the 
course of 2019, 41 new psychoactive substances were 
detected in the country, of which 5 were newly detected.
5. Prevention and treatment
586. Many countries in the region continue to lack a 
mechanism for gathering information on the scope and 
nature of drug use. Systematic and quantitative data 
would allow for the development of an evidence-based 
drug policy tailored to each country’s specific needs. 
587. For a number of years, the primary drug of use 
within the region has been methamphetamine. According 
to the World Drug Report 2020, in Brunei Darussalam, 
Cambodia, Malaysia, the Philippines and Singapore, the 
majority of people seeking treatment for drug use sought 
such treatment for the use of crystalline methampheta-
mine, while in the Lao People’s Democratic Republic and 
Thailand, the majority were primarily seeking treatment 
for the use of methamphetamine tablets. Overall, people 
receiving treatment for the use of methamphetamine 
account for more than three quarters of those in 
treatment in Brunei Darussalam, Cambodia, the Lao 
People’s Democratic Republic, the Philippines, Singapore 
and Thailand. 
588. The Government of China estimated that, in 2019, 
there were 2.14 million drug users registered in the 
country, accounting for 0.16 per cent of the total 
population of China, slightly less than the year before. 
Meth amphetamine remained the primary drug of use 
(accounting for 55.2 per cent, or 1.18 million drug users), 
followed by heroin (37.5 per cent of users) and ketamine 
(2.3 per cent of all drug users). The number of cannabis 
users remained stable in comparison with 2018. In 2019, 
the Government reported that 220,000 persons had 
undergone compulsory treatment and that 300,000 
persons had received community-based treatment and 
rehabilitation. 
589. In Indonesia, according to the 2019 national survey 
on drug abuse and illegal trafficking, which had been 
undertaken by the Indonesian Institute of Sciences in 
cooperation with the National Narcotics Agency and 
covered all 34 provinces of the country, the rate of past-
year drug use in the country reached 1.80 per cent, 
equivalent to approximately 3.5 million people aged 15–64, 
of whom 3.2 per cent were students. The most widely used 
drugs were crystalline methamphetamine, cannabis, 
amphetamine-type stimulants and other psycho tropic 
substances. 
590. In 2020, the Ministry of Public Health of Thailand 
opened a series of cannabis clinics, providing patients 
with access to cannabis oil for medical treatment. Four 
types of preparations, containing different combinations 
of CBD and THC, were given to patients to treat migraine, 
insomnia, neck pain and muscle stiffness.
591. In 2019, a total of 232 patients underwent inpatient 
treatment at the Al-Islah Treatment and Rehabilitation 
Centre, the only approved centre for the treatment of 
drug use disorders in Brunei Darussalam. Of those, 201 
(87 per cent) were men. Of the total patients, 209 were 
first-time patients, 50 per cent of whom were admitted 
on the basis of a minister’s order following a failed urine 
test, 34 per cent on the basis of a court order and 16 per 
cent on a voluntary basis. 
592. According to the National Anti-Drugs Agency of 
Malaysia, the most-used drug in the country in 2019 was 
methamphetamine (nearly 60 per cent), followed by heroin 
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(28 per cent) and other amphetamines (10 per cent). The 
majority of users were people aged between 19 and 39. 
Approximately 4,000 cases of crystalline methampheta-
mine use were recorded in the country in 2014, but nearly 
14,000 were recorded in 2019. In addition, the use of 
amphetamine-type stimulants more than doubled, from 
1,152 cases registered in 2018 to 2,872 in 2019.
593. In June 2020, the Ministry of Labour, War Invalids 
and Social Affairs of Viet Nam issued a plan for the 
review of detoxification and post-detoxification manage-
ment activities undertaken during the period 2016–2020. 
The plan was aimed at reviewing the implementation and 
outcomes of measures put in place during that period, 
with a view to proposing new measures for the period 
2021–2025. According to the Ministry, as of November 
2019, there were over 200,000 people with a drug use 
disorder, representing an increase of more than 10,000 in 
comparison with 2018. As of April 2020, a total of 97 
public treatment facilities and 16 centres for treatment on 
a voluntary basis had been licensed to operate, providing 
treatment for nearly 35,000 people. The existing opioid 
substitution therapy programme, using both methadone 
and buprenorphine, has provided services for 54,000 
patients to date. In addition, opioid substitution therapy 
programmes using methadone have been implemented in 
compulsory settings in two provinces and piloted in a 
prison setting.
594. The National Authority for Combating Drugs of 
Cambodia, in cooperation with relevant ministries and 
provincial drug control committees, continued to work 
on reducing the negative consequences of drug use and 
provided opioid substitution therapy with methadone 
maintenance services to 108 people, including 17 women, 
in two hospitals. In addition, the national programme on 
the exchange of syringes was used by 668 people who inject 
drugs in 2019. Cambodia had 20,091 registered drug users, 
a small increase in comparison with 2018. The increase 
was attributed by the national authorities to an increase in 
admissions to treatment centres on a voluntary basis.
595. In 2019, the 29 treatment centres and 56 clinics in 
Myanmar treated over 10,000 people, over 80 per cent of 
whom were using heroin. Altogether, 11 treatment cen-
tres, operating under the Ministry of Social Welfare, 
Relief and Resettlement, provide services to reintegrate 
people who have undergone treatment for drug use.
596. The Drug Dependence Treatment and Research 
Unit of the Ministry of Health and Sports of Myanmar 
has taken measures to ensure the continuity of medically 
assisted treatment services for people who use drugs since 
March 2020, including the provision of take-home doses 
of methadone for extended periods of time, the provision 
of hygiene measures at centres and education for service 
providers and the use of online communication tools by 
clinicians. In 2019, over 7,000 drug users were provided 
opioid substitution therapy with methadone.
597. As part of a campaign launched by the Ministry of 
Public Health of Thailand in June 2020, free HIV tests 
are being made available, including for youth under the 
age of 18. Under the new measures, people can voluntarily 
request free HIV testing twice a year at all hospitals that 
provide services under the national health coverage 
scheme.
598. Drug use in Singapore continues to be measured 
by the number of people arrested for using drugs. In 
2019, the Central Narcotics Bureau arrested 3,526 people 
for drug use (representing 41 per cent of all arrests), of 
whom 62 per cent were aged under 30. While there was 
a decrease in the number of persons arrested for heroin 
use, there was an increase in those arrested for use of 
new psychoactive substances (12 per cent of arrests) and 
methamphetamine (63 per cent of arrests). Throughout 
the year, the Central Narcotics Bureau has continued to 
enhance preventive drug education efforts, using aug-
mented reality technology, social media, schools, parents 
and anti-drug advocates to reach out to the country’s 
young people. 
599. The 2019 nationwide survey on the nature and 
extent of drug abuse in the Philippines was undertaken by 
the Dangerous Drugs Board, in cooperation with the 
Department of Social Welfare and Development. Altogether, 
55 facilities (53 residential and 2 outpatient) participated 
in the survey, and reported a total of nearly 5,300 
admissions for 2019, representing a decrease of 4 per cent 
compared with 2018. The decrease could be attributed to 
the community-based drug rehabilitation programme in 
place. A total of 89 per cent of the patients were men, with 
a mean age of 32. According to the survey, the most 
commonly used drug was methamphetamine hydrochloride, 
which was the main drug of use for 94 per cent of the 
patients. 
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South Asia
south asia continued to experience a rise in drug traf-
ficking over the reporting period, as evidenced by signifi-
cant increases in the amounts of opiates and cannabis 
herb seized in the region, as well as an increase in the 
use of methamphetamine pills (“yaba”). from early 2020, 
the challenges related to combating such trafficking and 
use were exacerbated by the COVId-19 pandemic.
The Internet, in combination with postal and courier 
parcel services, is being exploited more and more for 
drug trafficking within south asia, in particular for 
trafficking in psychotropic substances.
Trafficking in heroin and methamphetamine is increasing, 
in particular along the maritime routes in south asia.
1. Major developments
600. Major drug-related challenges facing South Asia 
include increased trafficking in heroin and methampheta-
mine, especially along maritime routes. During the 
reporting period, a shift from trafficking in narcotic drugs 
to trafficking in synthetic drugs, including amphetamine-
type stimulants, and chemical precursors was reported. 
The smuggling of heroin from Afghanistan over land and 
subsequently along maritime routes continued. An 
increased use of courier services, as well as the darknet 
and Internet pharmacies, was also reported.
601. South Asia has been identified as a major supplier 
of pharmaceutical preparations containing ephedrine and 
pseudoephedrine, which are substances that are diverted 
and used in the clandestine manufacture of methamphet-
amine within the region and in other countries in Asia.
602. In the UNODC World Drug Report 2020, a global 
rise in substance use disorders was noted, both in overall 
numbers and in the proportion of the world’s population. 
Drug use increased more rapidly in developing countries 
over the period 2000–2018. Adolescents and young adults 
account for the largest share of those using drugs and are 
also the most vulnerable to the negative health effects of 
drugs. This trend is mirrored in South Asia, where youth 
constitute about 50 per cent of the region’s population. 
2. Regional cooperation
603. In October 2019, UNODC convened a regional 
workshop in Manipur, India, for senior drug law enforce-
ment officials and policymakers from South Asian 
countries, to foster collective action and develop recom-
mendations to counter trafficking in opiates and amphet-
amines in South Asia. The consultation was attended by 
officials from Bangladesh, Bhutan, India, Maldives, Nepal 
and Sri Lanka. 
604. In December 2019, UNODC participated in and 
presented key areas of concern on drug trafficking and 
money-laundering at the regional customs enforcement 
meeting attended by customs administrators from 
21 countries of the Asia-Pacific region and by representa-
tives of INTERPOL.
605. In February 2020, the high-level National 
Conference on Combating Drug Trafficking and Abuse 
of Narcotics Drugs and Psychotropic Substances of the 
Bay of Bengal Initiative for Multi-Sectoral Technical and 
Economic Cooperation71 was held in New Delhi. UNODC 
was invited to convene a special session on interdictions 
related to drug trafficking involving the darknet and 
postal and courier services. 
606. In May 2020, the UNODC Regional Office for 
South Asia organized an online training session for 
doctors and technical staff from Bangladesh and India on 
preventing and responding to drug overdose. 
3.  National legislation, policy and 
action
607. Addressing challenges in the prison sector in Sri 
Lanka, UNODC provided materials to support the refur-
bishment of a specialized voluntary drug rehabilitation 
centre designed to reduce concentration in the overall 
prison population. On 26 June 2020, the UNODC 
Regional Office for South Asia participated in an event 
to mark the launch of the Nawadiganthaya drug treat-
ment facility in Colombo, which was also attended by 
high-level representatives of the Ministry of Defence, the 
National Dangerous Drugs Control Board, the Sri Lanka 
Navy, the Sri Lanka Police and the State Intelligence 
Service. 
608. Also on 26 June 2020 (International Day Against 
Drug Abuse and Illicit Trafficking), the Ministry of Social 
71 The Bay of Bengal Initiative for Multi-Sectoral Technical and 
Economic Cooperation is a regional organization comprising seven 
member States located in the littoral and adjacent areas of the Bay of 
Bengal. Five member States (Bangladesh, Bhutan, India, Nepal and Sri 
Lanka) are located in South Asia and two (Myanmar and Thailand) are 
located in South-East Asia. The Initiative provides a communication plat-
form for countries in South and South-East Asia and enables the sharing 
of information and techniques to counter the drug problem affecting 
countries of those regions. 
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Justice and Empowerment of India launched a campaign 
called “Nasha Mukt Bharat” (Addiction-free India). The 
campaign was aimed at providing information regarding 
drug use and related problems across the 272 districts of 
India that had been identified by the Narcotics Control 
Bureau of India, on the basis of the findings of the most 
recent national survey on substance use, as the districts 
most affected by drug use.
4.  Cultivation, production, 
manufacture and trafficking
609. Methamphetamine remains the main drug of con-
cern in many countries in the region. In 2020, Bangladesh 
continued to see significant seizures of “Yaba” tablets, 
which are a mix of methamphetamine and caffeine and 
come in different flavours and colours, despite a ban on 
pseudoephedrine, the main substance used to manufacture 
them, being in place since 2017. According to UNODC, 
the average annual quantity of amphetamine-type stimu-
lants, mainly methamphetamines, seized in South Asia 
during the period 2014–2018 was 2 tons. 
610. South Asia, in particular, India, Maldives and 
Sri Lanka, has seen an increase in the number of seizures 
and the amount of heroin seized owing to the growing 
use by drug traffickers of the southern route, which goes 
from Afghanistan, through the Islamic Republic of Iran 
and Pakistan and then by sea or air either directly to 
Europe or through South Asia, Africa and/or the Gulf 
States: 218 kg of heroin were seized along the western 
coast of India in May 2019; 155 kg were seized in 
Sri Lanka in July and August 2019; 70 kg were seized in 
Maldives in October 2019; and 224 kg were seized in 
Sri Lanka in November 2019. All of those seizures were 
made on boats, some of which were on their way from 
Pakistan, as part of maritime operations that were largely 
joint operations by law enforcement agencies of India, 
Maldives and Sri Lanka. During the reporting period, a 
considerable increase in maritime trafficking in heroin 
was reported by South Asian countries. 
611. Law enforcement authorities in India seized more 
than 3,212 kg of heroin in 2019, mostly in the Arabian 
Sea and Bay of Bengal, along the southern route. Areas 
close to the international borders in the north-western and 
north-eastern parts of India have reported a far higher 
prevalence of heroin use than the national average.
612. Another concerning trend in the reporting period 
was the increase in trafficking in heroin from Myanmar 
to India. In March 2019, 44.5 kg heroin sourced from 
Myanmar was seized in Delhi and, in April 2019, 50 kg 
of heroin, also sourced from Myanmar, was seized in Delhi. 
613. Trafficking in methamphetamine tablets from 
Myanmar to Bangladesh and India was reported during 
2019. In September 2019, the Indian Coast Guard inter-
cepted a boat in the Andaman and Nicobar Islands that 
had come from Myanmar and had 1.1 tons of meth-
amphetamine onboard. Another seizure of 370 kg of 
methamphetamine and ketamine took place in December 
2019 in the same area, from a boat also coming from 
Myanmar. Methamphetamine precursor trafficking flows 
from India into Myanmar have also been reported. In 
June 2020, about 78 kg of crystalline methamphetamine 
washed ashore in the State of Tamil Nadu, in southern 
India. The methamphetamine in its crystalline form had 
been concealed in packaging bearing the label of a 
Chinese tea brand and sealed inside a drum. 
614. A large amount of methamphetamine originating 
in Myanmar was seized in Bangladesh during 2019, by 
virtue of the two countries being neighbours and the 
regular movement across their shared border. According 
to the Government of Myanmar, about one third of all 
methamphetamine tablets seized in 2019 were found in 
Rakhine State, indicating large flows of the drug from 
Myanmar to Bangladesh.
615. Recent ketamine manufacturing and trafficking 
cases indicate that Indian drug trafficking organizations 
may be playing an increasingly large role in the ketamine 
market in the East and South-East Asian regions. For 
instance, in June 2020, Indian authorities dismantled a 
synthetic drug laboratory in Chennai and seized about 
110 kg of ketamine destined for Malaysia, together with 
55.5 kg of pseudoephedrine.
616. The greater use of land routes and improved con-
nectivity between Myanmar and north-east India has led 
to a rise in methamphetamine trafficking in the region. 
Indian police reported a seizure of 3.9 million tablets in 
February 2020. In February 2020, the Ministry of Home 
Affairs reported increased use of digital platforms and 
darknet markets. Through further investigations following 
the seizure of 55 kg of cocaine, which had been trafficked 
to Australia concealed in a plasma cutting machine shipped 
from India, Australian authorities were able to seize another 
200 kg of methamphetamine in Australia and Indian 
authorities were able to seize 20 kg of cocaine in India. 
617. In 2019, in India, a total of 3,212 kg of heroin was 
seized, compared with 1,258 kg in 2018. Similarly, in 
2019, the total amount of opium seized was 4,542 kg, 
which was marginally more than the 4,307 kg recorded 
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in 2018. In addition, an increase in the amount of cocaine 
seized, from 35 kg in 2018 to 62 kg in 2019, was recorded.
618. In 2019, 70 kg of heroin were seized from a vessel 
inside the Maldives exclusive economic zone during a 
controlled delivery operation. In March 2020, the 
Maldives Police Service seized 61.06 kg of heroin and 
arrested 11 Maldivians during one operation. Heroin 
worth approximately 72 million rufiyaa ($466,900) was 
confiscated from a fishing vessel docked at Male in 
March 2020. 
619. In Sri Lanka, 7,071 kg of cannabis herb, 15.16 kg 
of cannabis resin, 1,741 kg of heroin, 10.84 kg of cocaine 
and 35.45 kg of methamphetamine were seized in 2019. 
The total number of persons arrested for drug-related 
crimes was 89,321 in the same year. Of those, 45,923 per-
sons (51.41 per cent) were detained for cannabis posses-
sion, 40,970 persons (45.87 per cent) for crimes related 
to heroin possession and trafficking and 2,073 persons 
(2.32 per cent) for methamphetamine trafficking. The 
amount of drugs seized between 1 November 2019 and 
30 June 2020, as reported by different law enforcement 
agencies in Sri Lanka, totalled 1,713 kg of heroin, 7,088.7 kg 
of cannabis, 1,389 kg of cocaine, 2,295 kg of cannabis 
resin and 775.2 kg of synthetic drugs (in capsule and 
tablet form).
620. During the 12-month reporting period 2019/20, 
seven export consignments, including 20.8 million tablets 
of tramadol, an opioid analgesic not under international 
control (equivalent to 2,980 kg of tramadol base), in four 
consignments were stopped by Indian authorities following 
the identification of forged import certificates.
621. A comprehensive review of the situation with 
respect to the control of precursors and chemicals 
frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances in South Asia can be 
found in the report of the Board for 2020 on the imple-
mentation of article 12 of the 1988 Convention. 
5. Prevention and treatment
622. Approximately 20 per cent of the world’s popula-
tion aged 15–64 live in South Asia and the region accounts 
for more than one third of the estimated number of 
opioid users worldwide. According to UNODC, in South 
Asia, among the population aged 15–64, the average 
annual prevalence in 2018 was 2.82 per cent for cannabis 
use, 2.04 per cent for opioid use, 0.1 per cent for cocaine 
use and 0.18 per cent for amphetamine and pharmaceuti-
cal stimulant use. 
623. South Asian countries have also seen an increase 
in the use of inhalants among street children. This is a 
particularly concerning trend as abusing inhalants or 
other solvents in early stages of life increases vulnerability 
to the use of other illicit drugs later in life. As shown in 
the 2019 national survey on substance use in India, inhal-
ants were the only category of substances for which the 
prevalence of current use among children and adolescents 
(1.17 per cent) was higher than that for adults 
(0.58 per cent). At the national level, an estimated 460,000 
children and about 1.8 million adults need support for 
inhalant use disorders. Similar problems have been 
reported in Bangladesh and Nepal. In Bhutan, the use 
of solvents, particularly among school children, has been 
on the rise.
624. In South Asia, health systems and providers of sub-
stance use disorder treatment face challenges posed by 
the emergence of new drugs and polydrug use, for which 
treatment is not always readily available. Furthermore, 
there are difficulties in tackling comorbidities, such as 
HIV and hepatitis C, associated with drug use. The most 
noteworthy development in terms of data on drug use 
prevalence in South Asia during the reporting period was 
the publication of the results of the 2019 national survey 
on substance use in India. The survey was a combination 
of household sampling and respondent-driven sampling 
and had over 500,000 respondents from all states in the 
country. The survey found that there were 31 million can-
nabis users in the country among those aged 10–75, 
which translates into an annual prevalence of 2.83 per 
cent. The number of opiate users in that age group was 
reported to be 23 million (annual prevalence of 2.1 per 
cent). However, “problem use” was associated with opiates 
(7.7 million persons) more than cannabis (7.2 million 
persons).
625. India has a multipronged National Action Plan for 
Drug Demand Reduction. During the 12-month report-
ing period 2019/20, India conducted more than 1,300 
awareness-raising programmes for 150,000 young people 
and conducted capacity-enhancement programmes for 
more than 1,500 specialized staff. School-based interven-
tions, under the name “Navchetna”, or “New Awakening”, 
with a primary role given to teachers, peers and parents, 
were also created.
626. In Sri Lanka, the total number of reported drug 
users who received treatment in 2019 was 70,862; 2,497 
people received treatment for cannabis use disorder and 
2,769 people received treatment for opioid use disorder. 
During the reporting period, 869 beds were available in 
impatient treatment facilities in Sri Lanka. 
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627. Also in Sri Lanka, cannabis use among youths 
increased during the reporting period. An estimated total 
of 301,898 Sri Lankans are registered as cannabis users. 
Cannabis is the most commonly used illicit drug, with an 
annual prevalence of 1.9 per cent among the total popula-
tion aged over 14. In Sri Lanka, an estimated 92,540 per-
sons, or 0.6 per cent of the population aged over 14, are 
heroin users. Of those, 70,862 persons, or 77 per cent, 
are regular heroin users. The prevalence of heroin use 
among males aged over 14 is estimated at 1.2 per cent. 
A total estimated 178,643 persons are regular cannabis 
users and the total number of persons who received treat-
ment for cannabis use in the country in 2019 was 3,613, 
a 19 per cent decrease compared with 2018. Of the total 
number of those with drug use disorders in the country, 
19 per cent were living in prison settings. 
628. Initial data from the latest drug use survey in 
Nepal, launched in June 2020, showed that the average 
age of first use of inhalants in Nepal was below 19. In 
Nepal, the number of people receiving drug treatment for 
opioid use disorder increased from 902 in February 2020 
to 936 in April 2020. 
629. On 26 June 2020 (International Day Against Drug 
Abuse and Illicit Trafficking), the Government of Maldives 
confirmed its decision to return to providing opioid sub-
stitution therapy with methadone in its State-run reha-
bilitation programmes, after a gap of almost three years. 
630. In 2019 and 2020, UNODC successfully 
implemented the universal family skills training 
programme in Bangladesh. The main objective of the 
programme is to decrease the risk of drug use and other 
negative health and social outcomes among young people 
through evidence-based prevention focused on improving 
family functioning, bonding and communication. The 
programme reached and benefited 80 families and 
83 adolescents in Bangladesh. UNODC-trained facilitators 
presented a report on the implementation of the initiative, 
in the presence of the Education Minister and senior 
officials from the Ministry of Education, in Dhaka on 
1 January 2020.
631. The non-medical use of tramadol has been reported 
by Bhutan, India, Nepal and Sri Lanka. In Sri Lanka, 
about 0.2 per cent of the population aged 14 and older 
are estimated to have misused pharmaceutical preparations 
in the past year. The non-medical use of tramadol is the 
most common, although the misuse of morphine has also 
been reported. The Board notes the growing problem of 
methamphetamine trafficking and use and the increased 
use of narcotic drugs and psychotropic substances in the 
region. A central component in the design of effective 
prevention and treatment programmes throughout 
South Asia remains the collection of drug-related data 
by centralized agencies mandated to assess that 
information. Although the amount and quality of 
information regarding drug use patterns in the region 
have greatly improved, more research on consumption 
patterns and trends is needed to tailor treatment 
initiatives to local needs. The Board reiterates the need 
for capacity-building in the field of treatment and 
rehabilitation of people with drug use disorders in the 
region.
West Asia
In afghanistan, despite the decrease in the area under 
opium poppy cultivation in 2019, the production of 
opium in the country remained almost the same in 2019 
as in 2018, with afghanistan remaining the country in 
which the vast majority of the world’s illicit opium poppy 
cultivation and opium production take place.
The measures introduced to contain the COVId-19 pan-
demic and the resulting drug shortages on the illicit 
market reported in countries of south-west asia may 
have resulted in increased consumption of harmful 
domestically produced substances and pharmaceutical 
drugs, and other more harmful patterns of drug use by 
people with drug use disorders.
1. Major developments
632. The area under opium poppy cultivation in 
Afghanistan decreased for the second year in a row in 
2019, declining by almost 47 per cent, from 263,000 ha 
in 2018 to 163,000 ha in 2019. However, UNODC has 
estimated that the production of opium in 2019 remained 
at almost the same level as in 2018, possibly owing to 
higher yields. The low price of opium during planting 
time was one of the main drivers of the decline in cultiva-
tion. Afghanistan has accounted for almost 84 per cent 
of global opium production over the past five years and, 
to date, there have been no indications of a reduction in 
the supply of heroin of Afghan origin to consumer mar-
kets globally. The Board notes with concern that contin-
ued large-scale opium poppy cultivation and opium 
production in Afghanistan, coupled with limited eradi-
cation efforts, further undermine the efforts of 
Afghanistan and its partners to promote peace, security 
and sustainable development in the country. The Board 
reiterates its call for further technical and financial 
assistance to address the drug control challenges in the 
country.
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633. Trafficking in opiates has continued during the 
COVID-19 pandemic along the traditional northern, 
Balkan and southern routes, and the transportation of 
commercial goods is in many cases used as a cover-up 
for transporting opiates. However, air travel restrictions 
and border controls introduced as a result of the pan-
demic may have had a strong impact on heroin trafficking 
by land and air, with a shift towards increased trafficking 
using maritime transport.
634. The substantial increase in 2019 in trafficking in 
methamphetamine in Afghanistan, continuing an upward 
trend observed in the country since 2014 and potentially 
resulting from increased manufacture of the substance in 
Afghanistan, has become a matter of great concern to the 
countries of the region and the global community. 
635. Afghanistan continued to be one of the main 
sources of cannabis resin globally; it was cited as a source 
of the substance by 19 per cent of the countries worldwide 
that reported seizures of cannabis resin in the period 
2014–2018. 
636. The Board reiterates its concern with regard to the 
trafficking in and manufacture of “captagon”72 affecting 
the countries of the Middle East, which are not only des-
tination markets for that substance, but are also increas-
ingly becoming a source for it.
637. Central Asian countries continued to report an 
increase in trafficking in synthetic drugs, including new 
psychoactive substances, which are increasingly sold 
online or through social media platforms.
638. The Board shares the concern raised by others that 
the measures introduced to contain the COVID-19 pan-
demic and the resulting drug shortages on the illicit 
market reported in countries of South-West Asia, includ-
ing shortages of illicitly manufactured heroin, may have 
resulted in an increase in the consumption of harmful 
domestically produced substances and pharmaceutical 
preparations containing narcotic drugs and/or psycho-
tropic substances, and other harmful patterns of drug use.
72 Captagon was originally the official trade name for a pharmaceu-
tical preparation containing the substance fenethylline, a synthetic stim-
ulant. As encountered in seizures across West Asia today and referred to 
in the present report, “captagon”, is a falsified drug compressed into pills 
or tablets that are similar in appearance but distinct from the earlier phar-
maceutical preparation Captagon. The active ingredient in counterfeit 
“captagon” is amphetamine, which is typically cut with multiple adulter-
ants, such as caffeine.
2. Regional cooperation
639. In line with the Anti-Drug Strategy for 2018–2023 
of SCO and the programme of action to implement the 
Strategy, an international counter-narcotics operation 
named Web was conducted in SCO member States 
(China, India, Kazakhstan, Kyrgyzstan, Pakistan, Russian 
Federation, Tajikistan and Uzbekistan) in July 2019. The 
operation, which was coordinated by staff based at 
CARICC in Almaty, Kazakhstan, was aimed at suppress-
ing the channels of supply and distribution of new psy-
choactive substances and synthetic and other drugs, 
including those involving the use of the Internet and 
electronic payment systems. Representatives of counter-
narcotics agencies, internal affairs and public security 
bodies, national security agencies, and customs and 
border services of the SCO member States, as well as an 
SCO observer State (Afghanistan) and international 
organizations (UNODC and CARICC) contributed to the 
conduct of the operation.
640. In accordance with the plan for the main organi-
zational activities for 2019 of the Coordination Council 
of Heads of Competent Authorities for Countering Drug 
Trafficking of the Collective Security Treaty Organization 
(CSTO), the Ministry of Internal Affairs of the Russian 
Federation, in cooperation with the CSTO secretariat, 
conducted a subregional counter-narcotics operation 
named Channel-Caucasus Redoubt in September 2019, 
during which 18 tons of drugs were seized.
641. In addition, in August 2019 in Balykchy, Kyrgyzstan, 
special units of the anti-drug agencies of CSTO member 
States conducted a tactical exercise named Thunder-2019 
to identify and investigate transnational criminal groups; 
seize and destroy places of storage, production and pack-
aging of drugs; and destroy drug laboratories.
3.  National legislation, policy and 
action
642. On 26 February 2020, the Parliament of Uzbekistan 
adopted amendments to the Law on Narcotic Drugs and 
Psychotropic Substances of 1999 permitting legal entities 
with a relevant licence to cultivate and trade in cannabis 
for industrial purposes. In accordance with the amend-
ments, cannabis may be grown, processed and sold only 
for industrial purposes that are not related to the produc-
tion or manufacture of narcotic drugs and psychotropic 
substances. Another condition set out in the legislation 
is the THC content of the varieties of cultivated cannabis, 
which should not exceed 0.2 per cent. The varieties of 
cannabis permitted for cultivation by legal entities are to 
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be determined by the Cabinet of Ministers of Uzbekistan. 
Prior to the adoption of the amendments, section 6 of 
the Act on Narcotic Drugs and Psychotropic Substances 
had provided for the maintenance of a State monopoly 
over cultivation and other activities involving plants con-
taining narcotic drugs, which could be undertaken only 
for scientific purposes.
643. On 3 October 2019, the Cabinet of Ministers of 
Uzbekistan adopted a resolution aimed at improving 
measures to prevent, diagnose and treat diseases related 
to drug use, strengthening the material, technical and 
human capacities of drug treatment services and enhanc-
ing the effectiveness of the work of drug treatment insti-
tutions. In the resolution, the Cabinet of Ministers 
provided for the construction and renovation of buildings 
and premises, the provision of medical equipment, tools 
and other inventory for those institutions, the introduc-
tion of modern methods and technologies for prevention, 
diagnosis and treatment, and related scientific research.
644. On 21 April 2020, the Parliament of Lebanon 
adopted a law allowing for the cultivation of, trade in, 
study and use of cannabis for medical purposes. The law 
allows for the cultivation of cannabis with a maximum 
THC content of 1 per cent. In addition, it provides for 
the establishment of an authority for managing the can-
nabis industry, namely, the Regulatory Authority for the 
Cultivation of Cannabis Plants for Medical and Industrial 
Use, and for a committee responsible for the review of 
licensing applications and compliance with the law and 
for developing instructions issued by the Regulatory 
Authority.
645. In December 2019, the mini-Dublin Group for 
Afghanistan, which is dedicated to the fight against drug 
trafficking, held a meeting that was hosted by the French 
Embassy in Kabul and was attended by the acting Interior 
Minister of Afghanistan, the Special Representative of the 
Secretary-General for Afghanistan, and representatives of 
19 countries and organizations, including the European 
Union, NATO and UNODC. In their statement, 
the members of the mini-Dublin Group reiterated that 
they remained committed to continuing to work in 
close cooperation with the Afghan authorities and 
would take actions to enhance the effectiveness of the 
fight against drugs.
646. One of the factors defining the situation with 
regard to drugs in Kazakhstan is the influx of new types 
of synthetic drugs into the illicit drug market. Legislative 
amendments were adopted in 2019 to improve State con-
trol over the circulation of new psychoactive substances 
and counter trafficking therein. As a result of the 
amendments, the Government is now empowered to 
approve the list of controlled substances and to determine 
the threshold quantities that define criminal liability. 
Previously, any changes to that list and the threshold 
quantities of drugs could be introduced only through a 
legislative process. In July 2019, the Government adopted 
a resolution in which it approved the updated list of nar-
cotic drugs, thereby increasing the number of controlled 
synthetic drugs in the country, including fentanyl and its 
possible analogues. The measures adopted also allowed 
for the rapid inclusion of new types of drugs in the list 
and the timely establishment of State control over them. 
647. During the reporting period, Kazakhstan intro-
duced amendments to its Criminal Code to classify the 
sale of and inducement to use drugs over the Internet 
and other electronic information resources as particularly 
serious offences. Criminal liability for the sale of drugs 
in public places by an official misusing his or her official 
position was increased, the advertising and promotion of 
drugs was introduced as a new category of crime and the 
definitions of drug advertising and drug promotion 
were amended in the legislation in order to exclude 
unintentional acts.
648. Kyrgyzstan reported that it was currently develop-
ing a new draft law on narcotic drugs, psychotropic sub-
stances and their analogues and precursors. In addition, 
measures were being taken to update the existing national 
Anti-Drug Programme, including by developing an action 
plan for the coming five-year period.
649. To prevent violations of its rules on the legal cir-
culation of controlled substances, the Drug Control 
Agency of Tajikistan held seminars in Dushanbe and in 
the country’s regions for employees of State agencies, 
organizations, institutions and enterprises whose activi-
ties were related to the legal circulation of narcotic drugs, 
psychotropic substances and precursors. Participants in 
the seminars discussed the requirements of the legislative 
framework of Tajikistan regarding licit drug control in 
the country. 
650. To address problems relating to the availability of 
and access to narcotic drugs and psychotropic substances 
and to ensure that sufficient stocks are available in the case 
of a complete closure of its borders in connection with the 
COVID-19 pandemic, the Ministry of Health and Social 
Protection of the Population of Tajikistan officially applied 
for permission from the Drug Control Agency of Tajikistan 
to import such drugs and substances by air. In 2019, the 
Islamic Republic of Iran launched several drug control 
strategy documents, including the "Comprehensive docu-
ment to combat the drug supply” and the “Comprehensive 
90  INCB REPORT 2020
document to adopt a community-based approach", which 
served as strategic and scientific road maps to counter the 
illicit use of drugs and psychotropic substances.
651. With a view to addressing the increasing challenges 
of trafficking in and consumption of new psychoactive 
substances, in 2019, Turkey placed 69 such substances 
under national control.
652. From 2 to 4 December 2019, as part of the INCB 
Learning project, specialized training on the requirements 
of the three international drug control conventions relating 
to the regulatory control and monitoring of the licit trade 
in narcotic drugs, psychotropic substances and precursor 
chemicals was provided in Moscow to 38 drug control offi-
cials from Armenia, Azerbaijan, Kazakhstan, Kyrgyzstan, 
the Russian Federation, Tajikistan, Turkmenistan and 
Uzbekistan. The participants also received hands-on train-
ing on the Board’s global online tools, including I2ES, the 
PEN Online system, PICS and IONICS. These systems are 
available free of charge to Member States. 
653. Following the aforementioned training, on 
5 December 2019, the INCB Learning project held an 
awareness-raising workshop on the availability of narcotic 
drugs and psychotropic substances for medical and 
scientific purposes. The event was co-organized with and 
hosted by the Ministry of Foreign Affairs of the Russian 
Federation and brought together participants from 
national authorities, international organizations and civil 
society to discuss the importance of ensuring access to 
medicines containing internationally controlled substances.
654. Initiated by UNODC, a meeting of experts from 
Azerbaijan, Armenia, Georgia, Kazakhstan, Kyrgyzstan, 
the Russian Federation, Tajikistan and Uzbekistan was 
held in Vienna on 29 and 30 January 2020. The meeting 
was attended by independent scientific experts and by 
representatives of CARICC and UNODC. The partici-
pants discussed the current drug situation and recent 
trends in opiate trafficking along the northern route. In 
addition, concern was raised about increased trafficking 
in synthetic drugs and new psychoactive substances in 
CARICC member States.
4. Cultivation, production, 
manufacture and trafficking
655. According to UNODC, the area under opium 
poppy cultivation in Afghanistan decreased for the second 
year in a row in 2019, declining by almost 47 per cent in 
2019 compared with 2018. Despite that decline, UNODC 
has estimated that the production of opium in 2019 
amounted to 6,400 tons, almost the same amount as 
reported in 2018. That could be explained by the higher 
yields reported in the main opium-producing provinces 
in Afghanistan, which were attributed to favourable 
weather conditions. The low price of opium during plant-
ing time was one of the main drivers of the reduction in 
cultivation. In the main opium production areas in 
Afghanistan, the price of opium declined by an average 
of 37 per cent in 2018 and 24 per cent in 2019. Prices 
for high-quality heroin also declined in those areas, by 
11 per cent in 2018 and 27 per cent in 2019.
656. Afghanistan has accounted for about 84 per cent 
of global opium production (global opium production 
was estimated at approximately 7,610 tons in 2019) over 
the past five years, supplying illicit drug markets in neigh-
bouring countries, in Europe, the Middle East, South Asia 
and Africa, and to a limited extent in North America and 
Oceania. To date, there has been no indication of a 
reduction in the supply of heroin to consumer markers 
globally, despite a decrease in opium poppy cultivation in 
Afghanistan.
657. According to UNODC, the key months for the 
opium poppy harvest in Afghanistan are March to June; 
the 2020 opium poppy harvest was thus under way during 
the COVID-19 crisis. This suggests that the opium 
harvest would be affected if the labour force needed for 
harvesting was not able or willing to travel to the areas 
where opium poppy is grown in the country owing to 
mobility restrictions imposed by the Government or non-
State actors, or to the spread of COVID-19 itself. A shortage 
of opium poppy lancers has been observed in the western 
and southern provinces of the country, mainly attributed 
to the closure of a border crossing with Pakistan. However, 
women in opium poppy-growing households and persons 
who lost their jobs as a result of the COVID-19 pandemic 
appear to be increasingly engaged in the opium poppy-
lancing process.
658. The largest quantities of opiates seized globally in 
2018 were seized in Afghanistan, Iran (Islamic Republic 
of) and Pakistan, which together accounted for 98 per cent 
of opium seized globally, 97 per cent of morphine and 
38 per cent of heroin. In total, 690 tons of opium, 42 tons 
of morphine and 37 tons of heroin were seized in those 
three countries in 2018. The Islamic Republic of Iran 
accounted for more than half (53 per cent) of the amount 
of opiates seized globally, when defined in common heroin 
equivalents; it was followed by Afghanistan (12 per cent), 
Turkey (9 per cent) and Pakistan (5 per cent). 
659. When the total amount of heroin and morphine 
seized in countries of Central Asia is combined with the 
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total amount of those substances seized in Afghanistan, 
Iran (Islamic Republic of) and Pakistan, the resulting total 
represents more than 56 per cent of the global combined 
quantity of heroin and morphine seized in 2018.
660. According to CARICC, the amount of heroin seized 
in the territories of its member States, namely, Azerbaijan, 
Kazakhstan, Kyrgyzstan, the Russian Federation, Tajikistan, 
Turkmenistan and Uzbekistan, increased by 69.6 per cent 
in 2019, compared with 2018, whereas the amount of 
opium seized decreased by 41.3 per cent. In total, 5.7 tons 
of opiates were seized in 2019, compared with 5.3 tons in 
2018. The amount of heroin seized increased most 
significantly in Kazakhstan, from 58.6 kg in 2018 to 1,522 kg 
in 2019. The amount of heroin seized also increased in 
Azerbaijan, by 73 per cent, and in Uzbekistan, by 98.5 per 
cent, in 2019, compared with 2018. In the other CARICC 
member States, decreases in the amounts of heroin seized 
ranged from 27 per cent to 39 per cent. In 2019, the 
amount of opium seized increased only in the Russian 
Federation, from 1.3 kg in 2018 to 7.6 kg in 2019, while 
the remaining CARICC member States observed decreases 
ranging from 12 per cent to 89 per cent.
661. Analysing the current and potential impact of 
COVID-19 on drug trafficking in and through the Central 
Asian region, the Russian Federation and Azerbaijan, 
CARICC noted that the closure of State borders and the 
resulting restrictions on the movement of people and 
goods had somewhat weakened the ability of transna-
tional organized criminal groups to smuggle drugs and 
precursors, as well as cash proceeds from drug-related 
crimes, across borders. However, CARICC is of the view 
that further research on the topic is required, as, during 
the initial months of 2020, an increase in the amounts of 
drugs seized overall, including drugs originating in 
Afghanistan, in the entire CARICC region was observed, 
which may have been a result of an increase in measures 
to counter drug trafficking, including measures by States 
to control the movement of cargo at borders, and not 
necessarily a result of an increase in activities of organized 
criminal groups as such. Transnational drug-related crim-
inal groups could also be exploiting deliveries of food 
supplies to the populations of those countries during the 
pandemic in order to traffic drugs. 
662. CARICC observed that, although trafficking in 
heroin of Afghan origin to illicit markets in the Russian 
Federation and beyond via Central Asian States had 
become more challenging during the COVID-19 pan-
demic, the risk of opiate trafficking continued to exist, as 
commercial cargo and food products continued to be 
transported, albeit in accordance with certain additional 
sanitation requirements. That was evidenced by a number 
of major seizures made in March 2020 in countries 
located at the beginning of the northern route and the 
beginning of a sub-branch of the Balkan route that passes 
from the Islamic Republic of Iran to the countries of the 
southern Caucasus and then onwards to Ukraine via the 
Black Sea into Eastern Europe. Two major seizures of 
drugs smuggled from the Islamic Republic of Iran to 
Azerbaijan were recorded in March 2020: more than 43 kg 
of heroin, 500 grams of opium, 1.6 kg of cannabis and 
2 kg of methamphetamine were seized during the first 
operation, and a combined total of 61 kg of heroin, opium 
and cannabis were seized during the second. Two crimi-
nal gangs involved in trafficking in drugs from the Islamic 
Republic of Iran into Tajikistan were also identified in 
Afghanistan, resulting in seizures of 10 kg of meth-
amphetamine and 2.11 kg of heroin. In addition, at the 
end of April 2020, 40 kg of heroin were seized from a 
criminal trafficking group that had smuggled the drugs 
by car from Armenia to Georgia with the intention of 
smuggling them onward into Europe.
663. During the pandemic, trafficking in heroin also 
continued along the main Balkan route, which runs from 
Afghanistan, through the Islamic Republic of Iran, Turkey 
and the Balkan countries, towards destination markets in 
Western and Central Europe. Similar to the situation 
along the northern route, the transportation of commercial 
goods was, in many cases, used as a cover. EMCDDA 
reported that seizures of significant amounts of heroin 
had been made along the Balkan route despite the COVID-19 
pandemic. For example, a joint operation between 
authorities in Bulgaria and Turkey led to the seizure of 
72 kg of heroin in Bulgaria at the end of March 2020. In 
addition, several seizures of large amounts of heroin 
reported in Turkey in the first months of 2020 and a 
further two seizures of more than 100 kg each in eastern 
Turkey in late April 2020 suggest that opiates have 
continued to flow from Afghanistan to Turkey. Moreover, 
a joint police operation at the end of February 2020 
between authorities of the Netherlands and Turkey led to 
several significant seizures of heroin, with a total of 
2,384 kg seized across five countries (1,105 kg in 
Kazakhstan, 703 kg in Germany, 350 kg in Poland, 171 kg 
in the Netherlands and 55 kg in Turkey). 
664. Although no conclusive evidence is yet available 
concerning the overall impact of the COVID-19 pan-
demic on trafficking in opiates along the southern route, 
which is used for trafficking in opiates to Europe by 
means of shipments from the Islamic Republic of Iran 
and Pakistan by air or sea, either directly or transiting 
through Gulf States and East Africa, air travel restrictions 
introduced as a result of the pandemic may have had a 
significant impact on heroin trafficking by air. In addition, 
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a recent increase in seizures of heroin in the Indian Ocean 
could support the conclusion that traffickers are using 
maritime transport and routes increasingly frequently to 
traffic heroin to Europe, which would indicate a major 
shift in the trafficking strategies of organized criminal 
groups. A recent seizure of heroin in the port of Rotterdam 
also demonstrates that trafficking in heroin by means of 
maritime transport continued during the pandemic.
665. According to a preliminary analysis of available 
data, the volume of methamphetamine seized in 
Afghanistan substantially increased, from 182 kg in 2018 
to 1,251 kg in 2019, which continued the upward trend 
observed since 2014. This emerging trend, possibly result-
ing from the increasing manufacture of methampheta-
mine in Afghanistan, is of great concern to the countries 
of the region and the global community. Rapid increases 
in recent years in the illicit manufacture of methampheta-
mine in Afghanistan have also been inferred by the sub-
stantial amounts of methamphetamine of Afghan origin 
seized by other countries. In particular, the Islamic 
Republic of Iran reported that most of the methampheta-
mine seized in its territory in 2018 had originated in 
Afghanistan. In addition, authorities in Sri Lanka 
expressed concern regarding an emerging trend whereby 
methamphetamine manufactured in Afghanistan was 
being trafficked along the already well-established south-
ern route for heroin trafficking, after having seized at sea, 
in February 2020, 100 kg of crystalline methampheta-
mine, which they believed had originated in Afghanistan. 
According to UNODC, the extent of clandestine meth-
amphetamine manufacture in the Islamic Republic of 
Iran, where the bulk of methamphetamine continues to 
be seized, appears to be declining.
666. The Board reiterates its concern with regard to 
trafficking in and production of falsified “captagon”, 
which continue to have a negative impact on the coun-
tries of the Middle East, which are not only destination 
markets for “captagon”, but are also increasingly becom-
ing sources of the substance. This can be explained in 
part by the continued political instability and unresolved 
conflicts in some parts of that subregion. In several nota-
ble seizures in the Middle East in 2019 and early 2020, 
“captagon” seized was believed to have been manufac-
tured in Lebanon or the Syrian Arab Republic. During 
the first half of 2020, the Anti-Narcotics Department of 
Jordan seized 11.5 million “captagon” pills, with most of 
the seizures being made in the northern governorates of 
Jordan, near the border with the Syrian Arab Republic, 
or in the Governorate of Aqaba, near the borders with 
Israel and Saudi Arabia. In addition, from June 2019 to 
June 2020, 2.1 kg of crystalline methamphetamine were 
seized in four seizures in Amman. Between July 2019 and 
June 2020, Lebanon seized about 1.8 million “captagon” 
pills and 2,990 “ecstasy” pills. Most of the seizures were 
accompanied by arrests of individuals from Lebanon or 
the Syrian Arab Republic. In one case, the “captagon” 
seized was destined for the Sudan, in another, for the 
United Kingdom, and in several other cases, for Saudi 
Arabia or other Gulf States. In June 2019, the Internal 
Security Forces of Lebanon dismantled a “captagon” 
smuggling network and arrested a prominent drug 
trafficker in the Biqa‘ Valley. He was suspected of smug-
gling large shipments of “captagon” to at least six coun-
tries (Egypt, Qatar, Saudi Arabia, the Sudan, the United 
Arab Emirates and Yemen). Kuwait and Oman also 
reported seizures of “captagon” pills during the first half 
of 2020. The countries of the subregion continued to face 
challenges related to trafficking in and use of tramadol, 
although official data in that regard remain scarce.
667. In July 2020, the police in Italy seized a record 
quantity of 14 tons of amphetamines, including more 
than 84 million “captagon” tablets with a value of over 
$1 billion, which the authorities of Italy suspect were 
manufactured in the Syrian Arab Republic and destined 
for European markets, with the proceeds to be used for 
financing Islamic State in Iraq and the Levant (ISIL). The 
tablets had been hidden in large paper and steel cylinders 
and transported to the port of Salerno in southern Italy, 
where they were seized by the police. According to the 
media statements of the Italian authorities, COVID-19 
may have brought the manufacture and distribution of 
synthetic drugs in Europe to a halt, leading many 
traffickers to turn to the Syrian Arab Republic, where 
such manufacture does not seem to have been affected 
by the pandemic. Although it is too early to reach any 
definitive conclusions, restrictions on the movement of 
persons, goods and services across borders related to 
COVID-19 may have disrupted the supply of precursors 
used for the illicit manufacture of synthetic drugs in the 
subregion, including in Lebanon and the Syrian Arab 
Republic.
668. Turkey, which is on the route used for trafficking 
“captagon” to different parts of the Middle East and the 
Gulf States, reported that there had been a significant 
decrease in the amount of “captagon” seized in its territory 
in recent years. Cross-border operations and increased 
security measures to eliminate security threats to Turkey 
stemming from the civil war in the Syrian Arab Republic 
were believed to be the reasons for that decrease, which 
had led smugglers to opt for alternative routes. At the same 
time, Turkey, which has observed a continued increase in 
the amount of methamphetamine seized since 2016, saw a 
sharp increase (almost twofold) in the amount of the 
substance seized in 2019, compared with 2018. The largest 
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amount of methamphetamine seized ever in Turkey was in 
2019; it totalled almost 1 ton. Experts in Turkey believe 
that the substance will become the biggest near-term threat 
to the country. Crystalline methamphetamine, which is the 
most common form of methamphetamine found in Turkey, 
is mainly seized in the regions bordering the Islamic 
Republic of Iran. Most of the methamphetamine seized in 
Turkey is believed to originate in the Islamic Republic of 
Iran and countries in Europe.
669. In 2019, in the territories of the CARICC member 
States, the total amount of cannabis and cannabis resin 
seized continued to represent the majority of overall drug 
seizures in terms of weight. Despite the travel restrictions 
and other protective measures implemented in CARICC 
member States as a result of the COVID-19 pandemic, 
CARICC experts believe that cannabis and cannabis resin 
will continue to comprise the majority of the drugs seized 
in the region in 2020. Of a total of 66.3 tons of drugs 
seized in 2019, 55 tons were cannabis and cannabis resin. 
In 2018, about 52 tons of cannabis and cannabis resin 
were seized by CARICC member States. In Azerbaijan 
and Tajikistan in 2019, opiates accounted for the majority 
of seized drugs in terms of weight, while drugs of the 
cannabis group accounted for the majority in the other 
CARICC member States.
670. A total of 4.4 tons of cannabis resin were seized in 
CARICC member States in 2019, representing a 3.8 per 
cent decline compared with seizures in 2018. The amount 
of cannabis resin seized decreased significantly in Tajikistan, 
from 1.3 tons in 2018 to 608 kg in 2019. In 2019, seizures 
of cannabis resin also decreased in Azerbaijan (from 89 kg 
in 2018 to 23 kg in 2019), Kazakhstan (from 839 kg in 
2018 to 709 kg in 2019) and Kyrgyzstan (from 205 kg in 
2018 to 170 kg in 2019) but increased in Uzbekistan (from 
61 kg in 2018 to 112 kg in 2019). 
671. Among CARICC member States, seizures of can-
nabis decreased in 2019 in Kazakhstan (from 17 tons in 
2018 to 9.6 tons in 2019), Kyrgyzstan (from 2.3 tons in 
2018 to 1.3 tons in 2019) and Tajikistan (from 496 kg in 
2018 to 60 kg in 2019) but increased in Azerbaijan (from 
756 kg in 2018 to 822 kg in 2019) and Uzbekistan (from 
600 kg in 2018 to 736 kg in 2019). 
672. Afghanistan remains one of the main sources of 
cannabis resin globally, and was reportedly a source for 
cannabis resin in 19 per cent of the countries worldwide 
that reported seizures of cannabis resin in the period 
2014–2018. Afghanistan is, in particular, the country of 
origin of cannabis bound for Central Asia, the southern 
Caucasus and Europe. Other countries reported as source 
countries were Lebanon and Pakistan. Cannabis resin 
originating in the Biqa‘ Valley of Lebanon is mainly found 
in the Middle East and, to a lesser extent, in Western and 
Central Europe.
673. The Islamic Republic of Iran reported that the can-
nabis resin seized in its territory originated mainly in 
Afghanistan and, to a lesser extent, in Pakistan. In 2018, 
about 65 per cent of the cannabis resin smuggled out of 
the Islamic Republic of Iran was destined for countries 
on the Arabian Peninsula and 15 per cent for the south-
ern Caucasus. Twenty per cent of the cannabis seized in 
the Islamic Republic of Iran was intended for domestic 
consumption.
674. Turkey reported that, as a result of successful oper-
ations carried out by law enforcement units in the coun-
try in recent years, a significant decrease had been 
observed in the availability of cannabis within Turkey, 
with the exception of “skunk”, a highly potent form of 
cannabis. That development had led drug traffickers to 
start trafficking in “skunk” in order to meet domestic 
demand. The amount of smuggled “skunk” seized 
increased by approximately 14 times in 2019 compared 
with 2017 and by 1.5 times compared with 2018.
675. Central Asian States continued to report increases 
in trafficking in synthetic drugs, including new psycho-
active substances, within their territories. From 21 October 
to 21 November 2019, the CARICC member States carried 
out an international operation, called Reflex-2019, aimed 
at countering the spread of new psychoactive substances 
and other synthetic drugs. As a result of the operation, a 
laboratory for the manufacture of synthetic drugs was dis-
mantled and members of a transnational organized crimi-
nal group engaged in distributing new types of drugs over 
the Internet in the Central Asian subregion were arrested. 
676. Tajikistan reported the emergence of new 
approaches to the sale of new psychoactive substances, 
including without hand-to-hand transfer by putting drugs 
in caches and effecting payment over the Internet. The 
assessment of Tajikistan is that, over the last two years, 
new psychoactive substances and other illicitly manufac-
tured synthetic drugs have originated mainly in Europe, 
as well as in Afghanistan.
677. Kazakhstan reported that 2019 and the first three 
months of 2020 were characterized by a substantial 
increase in the proliferation of synthetic drugs. Since the 
beginning of 2019, Kazakhstan has recorded about 380 
criminal offences related to trafficking in synthetic drugs 
in its territory, where nearly 40 kg of such substances have 
been seized, equivalent to 75,000 single doses. In 2019, 
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111 grams of fentanyl, 500 grams of MDMA and 6.9 kg 
of pyrovalerone were seized in Kazakhstan. 
678. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in West Asia can be found 
in the report of the Board for 2020 on the implementation 
of article 12 of the 1988 Convention.
5. Prevention and treatment
679. During the reporting period, with the support of 
the United Nations, the Drug Demand Reduction 
Department of the Ministry of Public Health of 
Afghanistan opened five drug treatment centres in the 
country. The centres provide services for the prevention 
and treatment of drug use disorders among children and 
their families.
680. In 2019, the Islamic Republic of Iran continued to 
carry out a range of measures for the prevention and 
treatment of drug use disorders and the rehabilitation of 
people with such disorders. The Helping Hands project 
was implemented under the auspices of the Drug Control 
Headquarters of the Islamic Republic of Iran with the aim 
of creating and strengthening the sense of individual and 
social responsibility and participation in drug use pre-
vention efforts. Under the project, various activities have 
been implemented, including cultural and sports events, 
seminars on the role of non-governmental organizations 
and vocational training programmes. 
681. In Dushanbe in November 2019, UNODC, within 
the framework of its Regional Programme for Afghanistan 
and Neighbouring Countries, and in recognition of World 
Children’s Day, convened a three-day training workshop 
entitled “Treatment of children with drug use problems, 
with special attention to synthetic drugs”. The workshop 
highlighted the importance of introducing scientific 
evidence-based interventions in relation to prevention, 
treatment and rehabilitation. During the workshop, 
participants from Afghanistan, Iran (Islamic Republic of), 
Kazakhstan, Kyrgyzstan, Pakistan, Tajikistan and Uzbekistan 
enhanced their knowledge of treatment for children with 
drug use disorders.
682. Also within the framework of the Regional 
Programme for Afghanistan and Neighbouring Countries, 
in Almaty, Kazakhstan, in December 2019, UNODC con-
ducted a regional expert group meeting on sharing expe-
riences in the implementation of the strengthening 
families programme and best practices in the prevention 
of drug use among youth. Representatives from the law 
enforcement, education and health sectors in Afghanistan, 
Iran (Islamic Republic of), Kazakhstan, Kyrgyzstan, 
Pakistan, Tajikistan, Turkmenistan and Uzbekistan dis-
cussed and shared experiences in programme delivery in 
relation to family and evidence-based interventions. The 
participants highlighted the need for data collection, 
monitoring and analysis relating to the implementation 
of evidence-based prevention interventions.
683. In February 2020, Uzbekistan conducted a month-
long campaign focusing on drug prevention among youth. 
As part of the campaign, thematic sessions involving rep-
resentatives of competent authorities, students and teach-
ers were organized, sporting events under the motto 
“We Are Against Drugs!” were held, visual aids were 
published, awareness-raising videos and television 
programmes were broadcast and relevant articles were 
published in print media. During the campaign, repre-
sentatives of the National Information-Analytical Centre 
on Drug Control and the Ministry of the Interior, together 
with regional drug control commissions, local bodies of 
the Ministry of Public Education and the Ministry of 
Higher and Secondary Specialized Education conducted 
more than 16,000 prevention interventions in educational 
institutions, covering more than 2.2 million people.
684. With the support of the OSCE Programme Office 
in Bishkek, the Service for Combating Illicit Drug 
Trafficking of the Ministry of Internal Affairs of 
Kyrgyzstan, together with Kyrgyz educational institutions, 
within the framework of a month-long campaign dedi-
cated to the International Day against Drug Abuse and 
Illicit Trafficking, held competitions among schoolchil-
dren on the theme “We are for a healthy Kyrgyzstan!”. 
Because schools and higher educational institutions in 
Kyrgyzstan were closed in March 2020 in connection with 
the COVID-19 pandemic, drug use prevention events 
have been held online since that time using social media 
networks.
685. According to UNODC, countries in South-West 
Asia have reported shortages of drugs on the illicit market 
attributed to the measures introduced to contain the 
COVID-19 pandemic, including shortages of heroin at 
the retail level, which could potentially result in the 
increased consumption of harmful domestically produced 
substances, as well as more harmful patterns of drug use 
among people with drug use disorders.
686. The Central Asian subregion also witnessed 
impacts of COVID-19 on drug use patterns. For example, 
UNODC found that, in Uzbekistan, the use of pharma-
ceutical drugs had increased significantly. The subregion 
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also saw an increase in the use of homemade opium alka-
loid, which is extracted from poppy seeds that are legally 
available and widely used by the food industry for decora-
tion and flavouring. In general, as a result of the pan-
demic, drug users have actively sought alternatives, such 
as alcohol, pharmaceutical drugs, extracted opium and 
synthetic substances, to common illicit substances.
687. According to UNODC, the COVID-19 pandemic 
and related response measures in Central Asia have 
resulted in changes in the patterns of acquisition of illicit 
substances. The Internet and related technologies, includ-
ing messaging platforms and e-wallets, have been used 
increasingly frequently to purchase psychoactive sub-
stances. An increase in drug prices has led drug users to 
join groups to purchase such substances. There has also 
been an increase in the frequency of illicit drug use at 
home, potentially provoking serious conflicts within fam-
ilies. However, UNODC has reported that some people 
who use substances have reduced such use out of fear 
that their family and friends might become aware of it.
688. Possibly as a result of significant reductions in the 
supply of drugs that have traditionally been commonly 
used in Central Asia, as well as reductions in their purity 
and increased costs, countries in Central Asia have 
witnessed an increase in the demand for treatment. At 
the same time, measures related to COVID-19, such as 
restrictions on movement, the repurposing of beds in 
drug use treatment facilities and the limitation of hospital 
admissions to emergency cases, have resulted in limited 
availability of treatment options for drug users. There 
have also been reductions in the range of services 
provided in the context of drug treatment and programmes 
to reduce the negative health and social consequences of 
drug use, and an increase in online counselling services. 
These challenges have resulted in increased demand for 
the training of relevant staff in the provision of online 
drug-related services and, owing to the increased 
prevalence of synthetic drug use disorders, for medical 
and non-medical interventions to treat those who use 
synthetic drugs.
689. In 2019, a downward trend in the number of 
people registered with drug treatment facilities continued 
in almost all CARICC member States, except Azerbaijan. 
The number in Kazakhstan decreased by 12 per cent 
(from 22,748 persons in 2018 to 20,003 in 2019), in 
Kyrgyzstan by 1.4 per cent (from 8,564 in 2018 to 8,448 
in 2019), in Tajikistan by 11.3 per cent (6,059 in 2018 to 
5,375 in 2019) and in Uzbekistan by 7.2 per cent (6,142 
in 2018 to 5,698 in 2019). In that same year, Kazakhstan, 
Kyrgyzstan and Tajikistan reported a decrease in the 
number of newly registered drug-dependent persons in 
comparison with the previous year, while Azerbaijan and 
Uzbekistan reported increases.
690. Tajikistan reported that about 55 per cent of the 
registered drug-dependent persons in the country were 
injecting drug users. The number of drug-dependent per-
sons in Tajikistan has been decreasing in recent years. 
691. A similar decreasing trend in the number of inject-
ing drug users was observed in Uzbekistan. Among the 
registered drug users in the country, persons dependent 
on cannabinoids represented the largest group (3,982 per-
sons, or 69.9 per cent of registered drug users in 2019, 
and 4,169 persons, or 67.9 per cent of registered drug 
users in 2018); the number of those who were dependent 
on opiates amounted to 1,418 persons, or 24.9 per cent 
of registered drug users in 2019, and 1,684 persons, or 
27.4 per cent of registered drug users in 2018. The number 
of heroin users decreased by 1.8 times and amounted to 
536 persons in 2019, compared with 979 persons in 2018, 
and represented 9.4 per cent of the total number of 
registered drug users in 2019, compared with 15.9 per cent 
in 2018. Uzbekistan also reported an increase in recent 
years in the consumption of synthetic cannabinoids and 
pharmaceutical preparations containing opioids.
692. Turkey reported its serious concern about the 
increasing use of new psychoactive substances, in particu-
lar among youth in recent years, and tackling that emerg-
ing threat has become one of the priority areas in the 
country’s national efforts to combat the drug problem. 
Turkey also noted the increased use of the Internet for 
the commission of drug-related crimes.
693. UNODC found that the subregional prevalence of 
HIV among people who inject drugs continued to be the 
highest by far in South-West Asia (29.5 per cent). In 
South-West Asia and the Middle East, the past-year prev-
alence of opiate use, amounting to 1.8 per cent, was 
higher than the global average of 0.6 per cent.
694. The use of methamphetamine in Afghanistan 
appears to be increasing and, similarly to the situation 
observed in the Islamic Republic of Iran, methampheta-
mine is frequently used in Afghanistan concurrently with 
opiates in order to mitigate the negative side effects of 
opiate use.
695. Iraq has witnessed an increase in the use of crystal-
line methamphetamine in recent years, in particular in 
the Province of Basrah. The types of drugs most used in 
Iraq are amphetamine-type stimulants, with metham-
phetamine (32 per cent of all amphetamine-type stimu-
lants) and fenethylline (14 per cent) being the most 
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prevalent. Several reasons have been identified for the 
prevalence of drug use in Iraq, among which are the psy-
chological pressures and severe stress suffered as a result 
of security threats and the unstable social and economic 
conditions facing the Iraqi population. 
696. Trafficking in and use of tramadol, an opioid 
analgesic not under international control, continued to 
occur in the State of Palestine, especially in Gaza, in 
addition to trafficking in and use of synthetic opioids on 
the West Bank. To address those challenges, the Palestine 
National Rehabilitation Centre for drug users was 
established in 2019. The Centre provided services to 
about 260 drug users during the reporting period. 
UNODC continued to support the work of the Centre, 
including through the provision of training. In addition, 
UNODC continued to support the Opioid Substitution 
Treatment Centre, opened in 2015, which currently serves 
about 230 drug users in community and closed settings.
697. In February 2020, the President of Afghanistan 
convened and chaired the first meeting of the High 
Commission for Counter-Narcotics and Intoxicants. 
During the meeting, the President identified action 
against drug trafficking and use as one the five priorities 
of his Government, emphasizing the need for synergies 
to be developed among the health, justice and security 
sectors. The need for greater regional cooperation was 
also highlighted during the meeting.
E. Europe
several countries in Europe took steps towards the legali-
zation of the use of cannabis for non-medical purposes, 
in contravention of the provisions of the international 
drug control treaties.
Evidence points to synthetic drug manufacture taking 
place increasingly in Eastern Europe, with both small- 
and large-scale operations dismantled in several 
countries.
a rapid assessment of the impact of COVId-19 indicated 
increasing use of the Internet and the darknet to illicitly 
buy drugs. It also indicated lower availability of treatment 
services for persons using drugs within the region; those 
services were subsequently partly supplemented by tel-
emedicine and other innovative treatment service 
models.
1. Major developments
698. The Netherlands is in the process of launching its 
four-year trial programme for the production and distri-
bution of cannabis for non-medical purposes in the coun-
try by adopting relevant domestic legislation, thereby 
becoming the first European country to legalize, on a 
temporary basis, the cultivation and sale of an inter-
nationally controlled narcotic drug for non-medical 
purposes in parts of its territory. Switzerland approved a 
long-term study to examine the possible effects of intro-
ducing a similar approach. Luxembourg continued to 
work on draft legislation to the same effect. 
699. Beyond the traditional origin countries for 
amphetamine-type stimulants in Northern and Western 
Europe, countries in Eastern Europe are increasingly 
detecting illicit synthetic drug manufacture in their 
territories. Ukraine disrupted half a dozen sizeable illicit 
drug manufacturing operations in 2019, among them two 
large-scale methamphetamine manufacturing sites and 
trafficking networks. Belarus detected four small-scale 
clandestine laboratories, while the Russian Federation 
eliminated a few small- to medium-scale meth-
amphetamine manufacturing sites and discovered numerous 
others, involving a variety of end products such as mephe-
drone, methadone and alpha-pyrrolidinovalerophenone 
(α-PVP). Cyprus dismantled a clandestine methampheta-
mine laboratory for the first time in 2020.
700. Based on data gathered through an online survey 
and intelligence received from law enforcement authorities, 
EMCDDA and Europol produced a joint paper containing 
a rapid assessment of the impact of the COVID-19 
pandemic on the drug market in the European Union, 
entitled “EU drug markets: impact of COVID-19”. Travel 
restrictions and other social-distancing measures seemed 
to have resulted in shortages of and higher prices (mostly 
noted at the retail level) for some drugs. Trafficking activi-
ties related to the wholesale supply of drugs, however, did 
not seem to have been interrupted. Adaptations made by 
organized criminal groups to ensure uninterrupted supply 
encouraged the growth of online drug dealing through 
encrypted communications, posing additional challenges 
for law enforcement entities.
2. Regional cooperation
701. The European Commission adopted the European 
Union Agenda and Action Plan on Drugs for the period 
2021–2025 on 24 July 2020, in which the political frame-
work and priorities for action for the coming five years 
are set out. Eight strategic priorities are outlined, under 
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the following three areas: (a) enhanced security (focused 
on all aspects of trafficking in drugs); (b) increased 
prevention (of the adverse effects of drugs, including links 
to violence); and (c) addressing drug-related harms 
(through access to treatment, risk and harm reduction, 
and a balanced approach to the issue of drugs in 
prisons). 
702. In view of a wider use of encrypted communica-
tions technologies by organized drug trafficking syndi-
cates in the region, a joint investigation team was formed 
among French and Dutch law enforcement and judicial 
authorities, Europol and Eurojust to dismantle an 
encrypted telephone network used by criminal networks. 
The considerable amount of information obtained by the 
operation enabled authorities to disrupt planned criminal 
activities and trigger new criminal investigations into 
organized criminal groups across Europe and beyond.
703. The INCB secretariat presented updates concerning 
seizures of newly available fentanyl-related substances in 
Europe and opioid-related overdose deaths in several 
OSCE participating States during the OSCE conference 
on the theme “Evolving threat of synthetic drugs”, held 
in Vienna on 3 and 4 June 2019. In January 2020, the 
INCB secretariat also conducted a training workshop in 
Slovakia to strengthen the capacity of law enforcement 
agencies in Austria and Slovakia to counter trafficking in 
new psychoactive substances, chemicals and non-
scheduled dangerous substances. In February 2020, an 
overview of the INCB multi-agency global IONICS plat-
form was provided to nearly 260 law and regulatory 
enforcement officers from more than 30 European coun-
tries during a webinar organized by the European Union 
Agency for Law Enforcement Training. 
3.  National legislation, policy and 
action
704. Since March 2019, Cyprus has permitted the 
prescription of cannabis by physicians for any medical 
condition. The related regulations that amend the Narcotic 
and Psychotropic Substances Law L29/77 also provide the 
basis for the issuance of licences for the cultivation of 
cannabis for medical purposes, which is expected to be 
subjected to monitoring and control by a governmental 
office dedicated to the country’s cannabis programme for 
medical purposes. According to the official communica-
tion received on the matter, this office has yet to be 
established. 
705. Several acts introduced the option of using 
cannabis for medical purposes in Czechia. The conditions 
for prescribing, preparing, distributing, supplying and 
using the substance for medical use are laid out in Decree 
No. 236/2015 Coll. In October 2019, the Parliament 
approved an amendment to the Public Health Insurance 
Act that allows 90 per cent coverage by insurance companies 
of cannabis for medical use. The amendment came into 
force on 1 January 2020 and has set a limit of 30 grams 
per month for cannabis for medical use covered by public 
health insurance. 
706. In Luxembourg, the two-year pilot programme on 
cannabis for medical purposes, launched in 2018, the 
budget for which had been tripled in late 2019, was 
approaching its first evaluation in 2020. It was expected 
that the programme would be continued and would 
include training for medical practitioners on handling 
cannabis for medical purposes, while also lifting current 
restrictions that allow only selected hospital pharmacies 
to sell cannabis for medical purposes, on prescription.
707. In France, a decree providing details of the regula-
tory framework of an experiment on the use of cannabis-
based medical products (approved by the Parliament in 
2019) was issued in October 2020. The decree specifies 
the therapeutic indications or clinical situations under 
which the cannabis-based drugs can be used, the speci-
fications of permissible cannabis-based drugs and the 
conditions of their availability. The two-year programme 
will be implemented by the Ministry of Solidarity and 
Health. Participating companies are required to supply 
the products to the patients free of charge, and the prod-
ucts concerned must comply with pharmaceutical stand-
ards, including good manufacturing practices.
708. The Board recommends that Governments that 
allow the use of cannabinoids for medical purposes 
should monitor and evaluate the potential for diversion 
to trafficking or other unintended consequences of those 
programmes.
709. In November 2019, the Netherlands passed legisla-
tion allowing a pilot programme for the production and 
commercial distribution of cannabis for non-medical 
purposes, referred to as the “closed cannabis supply chain 
experiment”. The legislation became effective on 1 July 
2020. Under the programme, the local cultivation and 
wholesale supply of cannabis to “coffee shops” was legal-
ized in 10 municipalities for a trial period of four years, 
to be followed by an evaluation of the experiment and its 
effects on public health, public order, safety and crime. 
Within the 10 selected municipalities (which exclude the 
4 largest municipalities of Amsterdam, Rotterdam, The 
Hague and Utrecht), “coffee shops” will be required to 
limit sale exclusively to cannabis sourced from 
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Government-licensed Dutch producers. The official prep-
aration phase of the experiment includes a public tender 
to select a limited number of producers, which are not 
required to be from the selected municipalities and will 
be designated in accordance with specific criteria. The 
earliest harvest of locally sourced cannabis for non-medical 
use is expected in 2021. In municipalities that do not 
participate in the trial, applicable Dutch laws will 
continue to be enforced. Those laws generally prohibit the 
cultivation, distribution and use of cannabis, with the 
option of tolerating (i.e., not enforcing the prohibition of) 
the sale and purchase of small amounts for personal use 
in “coffee shops” under certain conditions.
710. In June 2020, Switzerland approved legislation 
permitting a long-term pilot study to be conducted on 
the effects of the possible legalization of cannabis for 
non-medical purposes, with the involvement of several 
large Swiss cities. As part of the study, the market, both 
licit and illicit, for cannabis, as well as the anticipated 
social impact of legalization in a controlled setting, will 
be examined. In the same month, the Government of 
Switzerland submitted a draft amendment to the legisla-
tion on cannabis for medical purposes, containing a 
proposal to ease access to the substance by no longer 
requiring special authorization of prescriptions by the 
Federal Office of Public Health. 
711. Luxembourg continued to explore modalities for 
the legalization of the production, distribution and use of 
cannabis for non-medical purposes. 
712. The Board wishes to remind all parties to the 
1961 Convention as amended that, under article 4, para-
graph (c), of that Convention, the production, manu-
facture, export, import, distribution of, trade in, use 
and possession of drugs are limited exclusively to medical 
and scientific purposes and that any measures allowing 
for the non-medical use of cannabis are in violation of 
the legal obligations incumbent upon parties.
713. The European Commission approved the inclusion 
of seven precursors in its list of scheduled substances in 
annex I to regulation (EC) No. 273/2004 of the European 
Parliament and the Council and the annex to Council 
regulation (EC) No. 111/2005, including those precursors 
recently recommended for international control 
(3,4-MDP-2-P methyl glycidic acid, 3,4-MDP-2-P methyl 
glycidate, APAA and MAPA), as well as two additional 
amphetamine designer precursors (P-2-P methyl glyci-
date and P-2-P methyl glycidic acid). These chemicals, 
which can be easily transformed to support the produc-
tion of amphetamines and “ecstasy”, will be listed in cat-
egory 1 of the regulations. Red phosphorus, which has 
considerable legitimate use but is frequently diverted for 
the illicit manufacture of methamphetamine, will be listed 
in category 2A and will be subject to less stringent control 
than those substances listed in category 1. The new regu-
lations were to enter into force in December 2020.
714. Legislative changes concerning new psychoactive 
substances were enacted in some European countries. The 
United Kingdom revised the generic definitions for a 
range of synthetic cannabinoids permanently controlled 
as class B drugs under the 1971 Misuse of Drugs Act and 
as schedule 1 compounds under the Misuse of Drugs 
Regulations 2001. The definitions came into effect on 
15 November 2019. In Hungary, with amendments to the 
Criminal Code on New Psychoactive Substance, people 
who commit criminal offences involving new psycho-
active substances will face the same penalty as those who 
commit offences involving other controlled substances. In 
addition, Governmental Decree No. 22/2012 (on the pro-
cedure for listing new psychoactive substances and on 
licit activities involving narcotic drugs and psychotropic 
substances and new psychoactive substances) has been 
amended, so as to speed up the listing procedure for new 
psychoactive substances within the country. In Sweden, 
the updated 1992 Narcotic Drug Controls Act and the 
1999 Prohibition of Certain Goods Dangerous to Health 
Act have provided the police with the authority to make 
anonymous purchases of new psychotropic substances on 
behalf of the Public Health Agency of Sweden or the 
Swedish Medical Products Agency since 1 January 2019. 
It is envisaged that such changes will facilitate a faster 
classification of substances dangerous to health that are 
or may be made available on the Swedish market. 
715. The Russian Federation added 14 new psychoactive 
substances, as well as kratom (Mitragyna speciosa), to its 
national schedules for drug control in August 2019, plac-
ing 12 of them on the schedule of prohibited substances 
(catalogue I) and 2 on the schedule of substances of 
restricted circulation (catalogue II). An additional 15 sub-
stances were added in March 2020 (11 to catalogue I and 
4 to catalogue II), and 10 precursors were placed under 
national control in February 2020. 
716. Bulgaria, one of the countries with flexible legisla-
tive measures on allowing new substances to be put under 
control, listed eight new substances under the ordinance 
on the procedure for classifying plants and substances as 
narcotic. 
717. In 2019, an increasing number of notifications 
regarding mephedrone were registered by the drug early 
warning system of Belgium and the new synthetic opioid 
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isotonitazene was detected. Formal notification was sent 
to EMCDDA and UNODC.
718. An action plan for the period 2019–2020 to limit 
the use and spread of drugs was approved by the 
Government of Latvia in 2019, which paved the way for 
shifting responsibility for the development and coordina-
tion of drug policy from the Ministry of the Interior to 
the Ministry of Health by the end of 2020. The plan is 
aimed at reducing demand for and supply of drugs and 
includes 28 measures divided into three areas of action: 
(a) promoting the quality and availability of drug preven-
tion, addiction treatment, social rehabilitation and harm 
reduction interventions; (b) reducing drug supply and 
availability; and (c) promoting effective drug policy coor-
dination, data collection, research and evaluation.
719. In December  2019, the Supreme Court of Italy 
issued a ruling removing small-scale cultivation of can-
nabis for private use from the definitions in article 73 of 
the Consolidated Law included in Presidential Decree 
309/1990 that criminalizes illicit activities with controlled 
substances. In its ruling, the Court declared that the 
offence of “cultivating narcotic drugs” should not include 
small amounts grown domestically for the exclusive use 
of the grower.
720. Italy has taken measures to strengthen cooperation 
among different stakeholders on drug-related policies. 
Specifically, the Department of Drug Policies of the 
Presidency of the Council of Ministers signed agreements 
with the police, universities and other institutions to 
increase monitoring of online activities related to new 
psychoactive substances and cryptocurrency payments 
related to international drug trafficking, and to analyse 
wastewater in major cities to identify the use of drugs 
among the general population.
4.  Cultivation, production, 
manufacture and trafficking
721. The latest EMCDDA reports state that some of the 
recent trends are: (a) growing availability and illicit use 
of high-purity cocaine; (b) more diverse drug production 
within the region; and (c) the continuing availability of 
high-strength MDMA products.
722. Albania, Belarus, the Republic of Moldova, the 
Russian Federation and Ukraine reported the eradication 
of illicitly cultivated cannabis on their territories in 2019. 
Opium poppy was also illicitly cultivated in all of those 
countries, with the exception of Albania, but the amount 
of land affected had decreased (significantly, in the case 
of the Republic of Moldova), while illicit cannabis cultiva-
tion was reported to be on the rise in Albania and the 
Republic of Moldova.
723. Despite an overall decrease in the flow of opiates 
trafficked along the northern route, which goes from 
Afghanistan, through Central Asia to the Russian 
Federation and Europe, the Russian Federation observed 
attempts by international organized criminal groups to 
use the country’s territory for the transit of heroin des-
tined for European markets. Belarus and the Baltic States 
were named as possible transit points for cocaine entering 
the Russian Federation from Latin American countries, 
through Europe. 
724. Belarus reported that the illicit manufacture of 
amphetamine, α-PVP and methadone had taken place in 
its territory during the reporting period, although in sig-
nificantly lower amounts than in preceding years. Four 
manufacturing sites set up in private homes had been 
dismantled by law enforcement agencies, with laboratory 
equipment and unspecified precursor chemicals seized.
725. Some authorities in the region noticed that the 
domestic illicit drug markets changed and grew in 2019, 
driven by greater use of the Internet to share information 
and to communicate. In Sweden, buyers and sellers using 
the darknet and social media, together with traditional 
modi operandi for drug distribution, drove a trend of 
polydrug smuggling. Meanwhile, considerable numbers 
of online purchases of cannabis seeds and equipment for 
illegal cultivation were detected in Latvia, as the amounts 
of cannabis herb seized and unauthorized cannabis cul-
tivation rose. Authorities believe that factors such as the 
legalization and public tolerance of cannabis use, as well 
as the ease of online purchase, have promoted this growth. 
The Republic of Moldova reported that 12 per cent of 
organized drug trafficking groups operating from within 
the country were using the darknet for drug distribution, 
targeting mainly domestic consumers. Fewer than one in 
four criminal groups were believed to operate interna-
tionally. Authorities in Belgium also observed the grow-
ing role of the darknet in retail sales and the emergence 
of “mobile” cannabis plantations, which comprise con-
tainers with cannabis planted inside.
726. According to EMCDDA, there was greater activity 
on the darknet, driven mostly by retail sales of cannabis, 
in some European countries during the first quarter of 
2020. Restrictions on freedom of movement and social-
distancing measures reduced access to street dealers, 
resulting in an increase in drug trafficking activities over 
the Internet and shipments by post. In mid-2020, Bulgaria 
noted a considerable decline in drug and precursor 
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trafficking, as a result of the travel restrictions and social-
distancing measures adopted by most European Union 
countries. The distribution of drugs within the country 
also decreased, as nightclubs, discos, ski resorts, 
restaurants, hotels and schools were closed. However, 
authorities believe that online purchasing and small-scale 
delivery continued. 
727. Spain reported a considerable reduction in the 
amount of cocaine seized in 2019 (down by 22 per cent 
compared with 2018). The use of maritime shipping con-
tainers remained the main method for cocaine trafficking. 
Owing to its geostrategic location and proximity to Africa, 
Spain was once again the European country in which the 
greatest amount of cannabis resin was seized in 2019 
(about 350 tons), mainly originating in Morocco (94 per 
cent). The majority (85 per cent) of cannabis resin 
seizures took place in Andalusia, the province closest to 
Morocco. About 1.5 million cannabis plants, mainly 
cultivated indoors, were also seized in the same year. The 
amount of heroin seized (about 230 kg in 2019) remained 
close to that of the previous year, but the amount of meth-
amphetamine in powder or crystalline form reached 
historic highs of almost 1.6 tons.
728. The amount of heroin smuggled into the United 
Kingdom, mainly in air freight, through express courier 
services and the post and by air travellers, registered a 
considerable increase in 2019. Meanwhile, authorities 
noted the continued trend of trafficking on board yachts 
across the Atlantic and the rising amounts of cannabis 
seized that originated in North America. Demand for 
synthetic drugs also expanded further, with increasing 
imports of chemicals required for their manufacture and 
greater seizures, alongside a widening geographical 
market for amphetamine. 
729. Considerable amounts of cocaine continued to be 
seized by some countries, including Portugal (10.5 tons 
in 2019), Belgium (6.5 tons in 2019), Romania (1.6 tons 
in 2019) and Finland (223 kg in 2019). Notably, the 
amount seized in Portugal was twice that seized in 2018. 
In Finland, one batch of 176 kg of cocaine with purity of 
between 95 and 100 per cent was found in a container. 
The container had been sent to the harbour in Helsinki 
from South America, with the prohibited substances 
hidden among legal cargo. Authorities indicated that the 
trafficking of large amounts of cocaine in sea containers 
originating in South America was a recent phenomenon. 
730. One of the most commonly used synthetic drugs in 
France is “ecstasy”; more than 1 million tablets of the sub-
stance were seized in the country in 2019. For the second 
year in a row, the total amount of meth amphetamine seized 
in 2019 (562 kg) exceeded that of amphetamine (92 kg).
731. The continued emergence of new psychoactive 
substances remained a considerable challenge for Europe. 
Bulgaria identified 18 new psychoactive substances in 
about 120 cases during 2019, with synthetic cannabinoids 
being the most commonly identified group and 5F-ADB 
being the most frequently identified type of synthetic can-
nabinoid. In 2019, the new psychoactive substances mon-
itoring system in Denmark detected the emergence of 
new psychoactive substances containing a high content 
of “ecstasy” and a very small share of amphetamine ana-
logues (a worrying trend given that methamphetamine 
has been found only rarely in Denmark in the past). In 
Sweden, about 40 substances were detected for the first 
time in 2019 and reported to EMCDDA through the 
country’s early warning system. 
732. The Republic of Moldova noted that diversion of 
clonazepam by medical professionals had taken place 
during the reporting period. Also during the same period, 
clonazepam, phenazepam, tramadol and pseudoephed-
rine had been diverted on a small scale, mainly through 
friends and family and through the use of falsified pre-
scriptions in Belarus.
733. Cyprus dismantled three clandestine methamphet-
amine laboratories on its territory in 2020, marking the 
first discovery of illicit methamphetamine manufacture in 
the country. Ukraine dismantled six illicit drug manufac-
turing operations in 2019, among them the biggest clan-
destine laboratory for the production of psychotropic 
substances (amphetamine, α-PVP and mephedrone) in 
the history of the country, and an interregional drug 
trafficking network specialized in the manufacture of 
1-phenyl-2-nitropropene, a precursor for amphetamine 
and methamphetamine. Another large-scale metham-
phetamine laboratory dismantled in Ukraine in 2020 led 
to the seizure of large quantities of pseudoephedrine. 
Organized criminal groups said to involve Polish nationals 
are reported to be involved in the supply of that precursor. 
Belgian authorities also detected methamphetamine pro-
duction sites and the first morphine-to-heroin conversion 
site in the country.
734. The Russian Federation dismantled numerous 
clandestine laboratories involving amphetamine and 
α-PVP, as well as methamphetamine and mephedrone, 
and reported a marked increase in illicit synthetic drug 
manufacture using simple synthesis methods with instruc-
tions obtained from the Internet.
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5. Prevention and treatment
735. Most European countries have high-quality data on 
the prevalence of drug use, which helps the monitoring of 
trends in the region. According to the European Drug 
Report 2018, in 2018, more than 92 million individuals 
aged 15–64 (over 25 per cent of the population of the 
European Union) were estimated to have tried illicit 
drugs during their lives. Cannabis remained the most 
commonly used illicit drug in the region, with an esti-
mated annual prevalence of 5.4 per cent in 2018. In 
Western and Central Europe, the prevalence of past-year 
cannabis use among the population aged 15–64 has fluc-
tuated around 6 and 7 per cent over the past decade. 
However, some countries (particularly those with larger 
populations, such as Germany, Italy and the United 
Kingdom) have registered an increase in cannabis use in 
recent drug use surveys. The rise in the prevalence rate 
over the past decade seems to suggest greater social 
acceptance of the use of cannabis.
736. Drug-related mortality remained a concern in 
most European countries during the reporting period. Of 
concern in several countries, including Cyprus, was the 
increased presence of opioids other than heroin in cases 
of drug-related deaths. Some countries, for example, 
Ukraine, reported a rise in cases of drug-related deaths 
involving tranquillizers, specifically benzodiazepines and 
barbiturates, but also unidentified sedatives and anti-
epileptic substances. Also in Ukraine, the second-highest 
number of drug-related deaths was associated with hal-
lucinogens (after opioids and before tranquillizers), rep-
resenting a marked increase over previous years’ figures. 
In the United Kingdom, large increases in drug-related 
mortality rates were observed across all drug classes, 
except cannabis, over the reporting period. 
737. Eastern Europe continued to be the subregion with 
the highest worldwide prevalence of people who inject 
drugs among those aged 15–64 (1.26 per cent in 2018, 
roughly 5.5 times higher than the global average). The 
unsafe use of needles and syringes contributes to the high 
subregional rates of HIV and hepatitis B infection. 
738. Some countries in Europe have reported an increase 
in the use of substances not under international control. 
The Netherlands reported that nitrous oxide (“laughing 
gas”), a substance widely used in the medical and 
gastronomical fields, was the fourth most prevalent drug 
used in 2019, particularly among youth (after tranquillizers, 
cannabis and amphetamine-type stimulants, in that order). 
The use of drugs containing psilocybine, among other 
hallucinogens, significantly increased in several countries, 
such as Luxembourg and the United Kingdom. A new 
development during the reporting period was the use of 
benzodiazepines among youth in Liechtenstein and the 
United Kingdom. Codeine use was also observed in 
Liechtenstein and the highest prevalence rate on record to 
date of ketamine use among adults was registered in the 
United Kingdom.
739. The increased use of stimulants (such as cocaine 
and methamphetamine) among drug users was reported 
by several European countries, including Cyprus, the 
Netherlands, Switzerland, Ukraine and part of the United 
Kingdom (England); in the latter, the increase of 4.4 per 
cent in the estimated number of people who use “crack” 
cocaine and/or opiates over a two-year period was con-
sidered statistically significant. The use of hallucinogens 
was also reported to have increased significantly in 2019 
in several European countries, including Ukraine. 
740. According to UNODC, cocaine is the second most-
popular illicit drug used in Europe, and Western and 
Central Europe registered a past-year prevalence rate of 
1.4 per cent for cocaine in 2018. The growing number of 
users receiving specialized treatment also points to an 
increase in substance use disorder associated with this 
increased prevalence. Results from wastewater analyses 
within the region indicated an increase in cocaine use of 
more than 50 per cent in 136 cities in 29 European coun-
tries between 2011 and 2019. 
741. Europe was estimated to have a prevalence rate of 
0.5 per cent for the use of amphetamines in the past year 
among the population aged 15–64 (or 2.5 million people) 
in 2018. Household survey data suggest that Czechia has 
one of the highest levels of methamphetamine use, and 
increasing use of the substance is now being reported in 
Cyprus, Germany, Slovakia, Spain and parts of Northern 
Europe. 
742. While opioid use remains comparatively rare and 
its prevalence rate was estimated at 0.4 per cent of the 
adult population of the European Union (about 
1.3 million users), the high number of problematic heroin 
users continues to be of concern. In Europe, opioid use 
is the main reason for receiving specialized drug treat-
ment and related studies suggest that there is an ageing 
cohort of opioid users in the region. Meanwhile, greater 
non-medical use of pharmaceutical opioids in Western 
and Central Europe has been noted, as reflected in the 
higher share of treatment admissions for the use of those 
substances. According to UNODC, users of pharmaceuti-
cal opioids accounted for 22 per cent of total users enter-
ing drug treatment in Western and Central Europe for 
opioid use disorders. 
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743. Results from the 2019 school survey on drug use 
among youth aged 15–16 in five countries (Finland, 
Latvia, Lithuania, Spain and Sweden) revealed similar 
drug use patterns, although considerable differences in 
prevalence rates. Cannabis was the most commonly used 
drug, although the lifetime prevalence rate varied from 
34 per cent in Spain to 6.3 per cent in Sweden. Identified 
as the second most-commonly used drug type, tranquil-
lizers and sedatives registered a much higher lifetime 
prevalence in Latvia and Lithuania (20 per cent) than 
Sweden (3.8 per cent). Young women reported a higher 
lifetime prevalence rate of tranquillizer and sedative use, 
while young men had a higher lifetime prevalence rate of 
cannabis use. 
744. Similar drug use patterns have been confirmed by 
a series of drug use surveys carried out in 2019 in 
Romania, Slovakia and the United Kingdom. Cannabis 
was the most commonly used drug, with a lifetime 
prevalence ranging from 30.3 per cent in the United 
Kingdom to 17 per cent in Slovakia and 6.1 per cent in 
Romania. While tranquillizers and sedatives were 
identified as the second most-commonly used drug type 
in Slovakia and had a lifetime prevalence of 8.5 per cent, 
cocaine (10.8 per cent) and new psychoactive substances 
(6.3 per cent) ranked second in the United Kingdom and 
Romania, respectively. Men reported a higher lifetime 
prevalence rate of illicit drug use than women in both 
countries. 
745. Over the last five years, the Russian Federation has 
significantly increased the domestic availability of nar-
cotic drugs and psychotropic substances for pain relief 
through a variety of measures. These include identifying 
a range of pharmaceutical preparations containing nar-
cotic drugs for the diversification of available medicines 
by 2024; expanding palliative care; and allowing subsi-
dized imports of as yet unregistered foreign medications 
for children into the country while domestic manufacture 
is established. As a result, the estimated number of 
patients receiving adequate pain relief increased sevenfold 
by the end of 2019. Accordingly, in 2019, 80 per cent of 
the estimated number of patients in need of pain relief 
during their last month of life were adequately supplied 
with medication, compared with only 12 per cent of 
patients five years earlier.
746. During the reporting period, Belarus was in the 
process of transitioning from the use of methadone to 
buprenorphine in its medication-assisted treatment pro-
gramme. Possibilities for self-drug testing, including the 
increased availability from pharmacies of express tests, 
were being expanded in the country. In addition, Belarus 
introduced several initiatives over the course of 2019 
aimed at complementing the existing treatment and rein-
tegration support infrastructure under the country’s com-
pulsory social reintegration programme. One such 
initiative involved the establishment of an “experimental 
centre” that would provide a combination of medical, 
psychological and psychotherapeutic support; it is planned 
that the initiative will be replicated across the country. 
Also, in 2019, Belarus signed into law an interministerial 
measure (resolution No. 5/8/2) whereby the social reha-
bilitation of persons suffering from substance use disor-
ders would entail their obligatory involvement in work. 
Since 2019, drug users in Belarus have also been required 
by law to undergo a mandatory preventive psychiatric 
evaluation.
747. The Board urges Governments to ensure the con-
tinued provision of treatment services for mental health 
and substance use disorders as part of essential services. 
Governments are recommended to look at existing best 
practices and develop effective strategies to ensure that 
prevention and evidence-based treatment, rehabilita-
tion, aftercare and social reintegration services continue 
to operate. In that regard, Governments are encouraged 
to refer to chapter I of the Board’s annual report for 
2017, entitled “Treatment, rehabilitation and social 
reintegration for drug use disorders: essential compo-
nents of drug demand reduction”, and the UNODC-
WHO International Standards for the Treatment of Drug 
Use Disorders.
748. Several European countries reported on the impact 
of COVID-19 on illicit drug use in their territories. 
Luxembourg reported an increase (by 10–25 per cent) in 
the retail price of cannabis, cocaine and heroin during 
the lockdown period. More significant changes were 
observed in relation to the purity of drugs: the ratio of 
active ingredients to cutting agents was observed to have 
decreased, in particular in the case of cocaine. The provi-
sion of face-to-face health care and other services, in 
particular, counselling, remained uninterrupted, but was 
reduced and moved largely to remote means (including, 
for example, the delivery of medication-assisted treatment 
doses to patients) on account of the measures introduced 
to contain the spread of COVID-19. Luxembourg has also 
launched a study among health-care providers and a 
survey of drug users to assess the impact of COVID-19 
and related measures on the availability of services and 
the needs of drug users, both retrospectively and with a 
view to preparing for subsequent outbreaks.
749. A survey of national focal points carried out by 
EMCDDA during April 2020 suggested that the impact 
of COVID-19 and related national containment measures 
appeared to have caused a reduction in the availability 
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and provision of treatment and services to reduce the 
negative health and social consequences of drug use in 
most European countries. Specialized outpatient facilities 
that could not implement the required social-distancing 
measures were closed in some countries. On the other 
hand, mobile or online platforms and other innovations, 
such as greater flexibility associated with medication-
assisted treatment service models and the use of telemedi-
cine, were increasingly adopted to provide drug treatment 
services across the region.
750. Another survey focusing on the impact of COVID-19 
on patterns of drug use suggested that there had been 
some reduction in illicit drug use during the early period 
of the COVID-19 pandemic (from March to May 2020). 
Respondents to the EMCDDA online survey provided 
different explanations, from the lack of social opportunities 
to reduced drug availability and access to sources of drug 
supply. Income loss and financial uncertainty were also 
cited as major reasons for the reduction in illicit drug use. 
751. The closure of the night-time economy was 
commonly considered as the primary reason for decreases 
in the illicit use of “ecstasy” and cocaine, although increases 
in the illicit use of amphetamines were reported in some 
Northern European countries during the lockdown period. 
On the other hand, cannabis use seemed to be less affected 
by the lockdown, with occasional users reducing their use 
and some frequent users consuming more. A reduction in 
heroin use among high-risk opioid users was observed in 
Czechia, Germany, Ireland, the Netherlands, Portugal and 
Slovakia. Increased “digitalization” of the drug market and 
more flexible distribution systems were also cited as some 
of the adaptations employed for continued access to drugs. 
F. Oceania
drugs continue to be trafficked in large quantities through 
Pacific island countries and territories en route to 
australia and New Zealand, and there is increased traf-
ficking in methamphetamine from asia. at the same time, 
domestic demand for methamphetamine and cocaine is 
growing in Pacific island countries, and there has been 
an increase in the number of drug-related offences 
recorded. however, data on the extent of drug use and 
treatment demand in Pacific Island countries remain vir-
tually non-existent.
In New Zealand, a proposed cannabis legalization and con-
trol bill, which would have allowed people to possess and 
consume cannabis in certain circumstances, was rejected 
by voters in a referendum held on 17 October 2020. 
 In australia, legislation came into force in the australian 
Capital Territory in January 2020 permitting the cultiva-
tion of cannabis plants for personal non-medical use; 
however, the use of cannabis for non-medical purposes 
remains a criminal offence under australian federal law.
The 2019 australian National drug strategy household 
survey found that the proportion of people who had used 
codeine for non-medical purposes in the previous 12 
months had halved, from 3.0 per cent in 2016 to 1.5 per 
cent in 2019. since 2018, medications containing codeine 
can no longer be purchased from a pharmacy without a 
prescription.
1. Major developments
752. The secretariat of the Oceania Customs Organization 
noted that measures such as border closures and import 
and export restrictions taken by Governments of Pacific 
island States in response to the COVID-19 pandemic had 
hindered the movement of medical supplies and medical 
teams needed to assist countries. In a guidance document 
on COVID-19, members of the Oceania Customs 
Organization were asked to consider expedited clearance 
of essential goods and workers to support national 
responses. They were also asked to consider granting all 
medical supplies and equipment needed to provide relief 
in relation to the pandemic first priority to cross borders, 
where practicably possible. 
753. Pacific island countries and territories continue to 
be used as transit points for drug trafficking; however, 
they are increasingly becoming destinations for synthetic 
drugs such as methamphetamine, with domestic demand 
growing, and becoming locations for illicit manufacture. 
Recognizing that national capacities in the region are 
inadequate to respond to this threat, the Board recom-
mends that the international community provide sup-
port to enhance the capacities of Pacific island States to 
address these new challenges and to safeguard their 
citizens’ health. 
754. Not all Pacific island States have signed and ratified 
the three international drug control conventions.73 The 
absence of this international legal framework, coupled 
with growing domestic demand for drugs and the limited 
national and regional capacities of Pacific island countries 
73 Of the 10 States yet to accede to the 1961 Convention as amended, 
7 are in Oceania: Cook Islands, Kiribati, Nauru, Niue, Samoa, Tuvalu 
and Vanuatu. Of the 13 States not party to the 1971 Convention, 8 are in 
Oceania: Cook Islands, Kiribati, Nauru, Niue, Samoa, Solomon Islands, 
Tuvalu and Vanuatu. Of the seven non-parties to the 1988 Convention, four 
are in Oceania: Kiribati, Papua New Guinea, Solomon Islands and Tuvalu.
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and territories, renders these countries and territories 
more vulnerable to drug trafficking, illicit drug manufac-
ture and related crimes, including money-laundering and 
corruption. The Board recalls that the treaties are recog-
nized as the cornerstone of the international drug control 
system and that they provide countries with a framework 
to address the challenge of drug trafficking, for example 
through the provisions on extradition and mutual legal 
assistance, as well as export pre-notification. However, 
some non-parties in the region are reporting to the Board 
and participating in the international system for monitor-
ing licit trade in controlled substances on a voluntary 
basis. The Board is engaged with the countries of the 
region, for example in the framework of the memoran-
dum of understanding signed between the Board and the 
Oceania Customs Organization in 2019, and activities 
have been held in the region over the past year under the 
Board’s GRIDS Programme (see below for further details). 
The Board welcomes the recommendation made at the 
forty-eighth Pacific Islands Chiefs of Police Conference, 
held in Pago Pago, American Samoa, from 21 to 
23 August 2019, that, among other important measures, 
non-parties should accede to the international drug con-
trol conventions. The Board urges all Pacific island States 
that are not parties to all three international drug 
control conventions to accede to them as rapidly as 
possible and offers its support to this end. The Board 
encourages the international community to support 
non-parties in the region towards treaty accession and 
implementation.
2. Regional cooperation
755. Participants at the fiftieth Pacific Islands Forum, 
held in Funafuti, Tuvalu, from 13 to 16 August 2019, 
endorsed the Boe Declaration Action Plan as a framework 
to implement the Boe Declaration on Regional Security, 
including through the establishment of a subcommittee 
of the Forum Officials’ Committee on Regional Security. 
The Plan includes an affirmation of an expanded concept 
of security, with an increasing emphasis on, inter alia, 
transnational crime. The Plan also includes recognition 
of the substantial geographical area of the region, its 
extensive and porous jurisdictional boundaries, and its 
differences in governance and law enforcement capacity 
that further exacerbate its susceptibility to illicit threats, 
markets and activities. The Plan sets out a series of 
actions, including many aimed at disrupting the flow of 
illicit drugs, such as methamphetamine and cocaine, and 
strengthening national capacities to address demand and 
minimize the harm associated with the illicit use of drugs 
through a comprehensive government approach including 
health, education and social services.
756. In November 2019, UNODC provided training to 
law enforcement and customs officers of Solomon Islands 
and Vanuatu in the use of drug and precursor test kits. 
The training followed two years of national training work-
shops for technical officers from the law enforcement and 
health authorities on the challenge of synthetic drugs. 
UNODC also held meetings with officials from the two 
countries to review progress made in implementing the 
practical recommendations developed in the national 
training workshops.
757. In December 2019, the Oceania Customs 
Organization delivered training on dangerous substances 
trafficked in the region and the use of INCB systems 
during a two-day event at its headquarters in Suva. The 
training covered awareness-raising, safe handling and 
interdiction, precursors and synthetic drug trafficking, 
and intelligence exchange and was attended by officers 
from the Oceania Customs Organization, the Fiji Police 
and the Fiji Revenue and Customs Service. It was held in 
the framework of the memorandum of understanding 
between INCB and the Oceania Customs Organization 
signed in 2019. A similar training event was held by the 
Board in Wellington on 9 December 2019 for the New 
Zealand Customs Service and the National Drug 
Intelligence Bureau. In February 2020, INCB delivered 
training in Nadi, Fiji, during a regional workshop on cus-
toms intellectual property rights enforcement organized 
by the Oceania Customs Organization. At the workshop, 
participants were provided access to and training on the 
Board’s secure global communications platforms that 
allow for the exchange of information and alerts to sup-
port domestic and international cooperation and investi-
gations into trafficking in dangerous substances not under 
international control. The workshop was also delivered 
within the framework of the memorandum of under-
standing between the Board and the Oceania Customs 
Organization and was attended by customs officers from 
Australia, Fiji, Guam, Kiribati, Marshall Islands, Nauru, 
Niue, Northern Mariana Islands, Palau, Papua New 
Guinea, Solomon Islands, Tonga and Tuvalu. Under the 
Board’s GRIDS Programme, an informal meeting of 11 
experts on the topic of trafficking in dangerous substances 
throughout Oceania was held on 3 March 2020 on the 
margins of the sixty-third session of the Commission on 
Narcotic Drugs.
758. INCB was represented at the New Zealand Annual 
Drug and Organized Crime Conference, held at the Police 
College in Porirura, Wellington, on 9 December 2019. 
Consultations were held between a representative of 
INCB and representatives of the Pacific Islands Chiefs of 
Police in Wellington on 10 December 2019 and the Pacific 
Island Forum Secretariat in Suva on 13 December 2019 
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to determine practical ways in which the GRIDS 
Programme tools and partnerships could be further 
leveraged to counter transnational crime through 
enhanced cooperation and information-sharing to disrupt 
the flow of illicit drugs in response to the region’s recently 
adopted Boe Declaration Action Plan.
759. In August 2020, the Pacific Islands Chiefs of Police 
five-year strategic plan for the period 2020–2024 was 
launched. In the plan, it is recognized that transnational 
crime remains at the forefront of concern, with growing 
local markets for methamphetamine posing a threat to 
local communities. The plan includes provision for the 
rapid sharing of information and resources, the develop-
ment of prevention approaches, the building of intelli-
gence capability and the enhancement of investigations 
capability.
3.  National legislation, policy and 
action
760. In January 2020, legislation came into force in the 
Australian Capital Territory permitting the cultivation for 
non-medical purposes of up to two cannabis plants per 
person, or four plants per household. Under the legisla-
tion, it is an offence to use cannabis in a public place, 
expose a child or young person to cannabis smoke, store 
cannabis where children can reach it, cultivate cannabis 
hydroponically or with the application of artificial light 
or heat sources, and grow plants where they can be 
accessed by the public. The sale, sharing and gifting of 
cannabis remain unlawful, as do the possession, cultiva-
tion and use of cannabis by people aged under 18 and 
the driving of a vehicle with any amount of cannabis in 
the body. Guidance by the Australian Federal Police states 
that cannabis is not legal in the Australian Capital 
Territory, only that amendments have been made that 
exempt individuals from criminal liability in certain lim-
ited circumstances. The use of cannabis for non-medical 
purposes remains illegal under Australian federal law. 
Further information on this development is contained in 
chapter II of the present report.
761. The Board recalls that developments permitting 
the non-medical use of cannabis are in contravention of 
the provisions of the 1961 Convention as amended and 
the 1988 Convention, to both of which Australia is a 
party. Consistent with article 9, paragraph 5, of the 1961 
Convention as amended, the Board remains engaged in 
dialogue with the Government of Australia with a view 
to facilitating effective national action to attain the aims 
of that Convention. 
762. During the general election in New Zealand in 
October 2020, a referendum was held on the proposed 
cannabis legalization and control bill. The bill was rejected 
by voters. 
763. In November 2019, “Law Week”, on the theme 
“Fighting illicit drugs through awareness”, was held in 
Tonga by the Office of the Attorney General in coopera-
tion with the Tonga Police and other ministries and agen-
cies. Activities included an outreach programme led by 
the Tonga Police Safety Team. Also in November 2019, 
cannabis identification training was provided to police 
officers in Tonga by the New Zealand Institute of 
Environmental Science and Research. The Tonga National 
Illicit Drugs Policy was approved by Cabinet in October 
2019; it promotes a whole-of-society approach through 
harm reduction, supply reduction and demand reduction. 
764. In November 2019, WCO, in collaboration with 
the Australian Border Force and the Fiji Revenue and 
Customs Service, conducted training for customs officers 
in Suva and Nadi under the UNODC/WCO Container 
Control Programme. In December 2019, the Fiji Revenue 
and Customs Service and the Republic of Fiji Military 
Forces signed a memorandum of understanding formal-
izing a commitment to cooperate through the provision 
of training, the sharing of information and the undertak-
ing of joint operations to combat transnational illicit 
activities. 
765. In March 2020, the Community Affairs References 
Committee of the Senate of Australia issued a report 
entitled Current Barriers to Patient Access to Medicinal 
Cannabis in Australia, in which it made a series of 
recommendations to address such barriers. The Export 
Control Legislation Amendment (Certification of Narcotic 
Exports) Bill 2020 was passed by the Parliament of 
Australia in June 2020. It amends the Export Control Act 
1982 and Export Control Act 2020 to allow for the licit 
export of certain narcotic drugs, such as medicinal 
cannabis and low-THC hemp products.
766. In August 2020, the Criminal Code and Customs 
Legislation Amendment (Precursors and Drugs) Regulations 
2020 came into effect in Australia, listing additional 
substances as controlled precursors and specifying 
commercial and marketable quantities for those substances. 
The commercial and marketable quantities for phenyl-2-
propanone were reduced, reflecting changes in the methods 
for illicitly manufacturing methamphetamine from the 
substance. Further information pertaining to the control 
of precursor chemicals can be found in the report of the 
Board for 2020 on the implementation of article 12 of the 
1988 Convention. The legislation also placed under 
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national control the substances recently added to the 
schedules of the 1961 and 1971 Conventions pursuant to 
the 2019 and 2020 scheduling decisions of the Commission 
on Narcotic Drugs. In 2019, the synthetic cannabinoids 
5F-MDMB-PINACA (5F-ADB) and AMB-FUBINACA 
(FUB-AMB) were placed under national control in New 
Zealand.
767. The Medical Cannabis Scheme of New Zealand 
came into effect on 1 April 2020, pursuant to the Misuse 
of Drugs (Medicinal Cannabis) Regulations 2019. 
Medicinal cannabis products are available to patients only 
on prescription from a doctor. Manufacturers and import-
ers are required to provide evidence to the Medicinal 
Cannabis Agency that they meet minimum standards of 
quality, and any person wishing to work in the industry 
must hold a medicinal cannabis licence or work for a 
company holding such a licence.
4. Cultivation, production, 
manufacture and trafficking
768. In addition to the continuing use of Pacific island 
countries and territories as trans-shipment points for 
drug trafficking to Australia and New Zealand, evidence 
points to those countries and territories increasingly 
becoming locations of illicit manufacture and domestic 
use. In Fiji, for example, the number of drug-related 
offences increased by more than 560 per cent from 2013 
to 2018. The authorities of Fiji noted a substantial increase 
during the same period in seizures of parcels containing 
drugs, including methamphetamine, originating in China, 
the United States and countries of South America. 
Seizures of methamphetamine and cocaine, in addition 
to cannabis, continue to be made in Tonga. From April 
2018, when the Drug Enforcement Taskforce commenced 
operation, to November 2019, a total of 42.56 kg of meth-
amphetamine, 2.49 kg of cocaine and 3.48 kg of cannabis 
were seized in Tonga. In the UNODC publication 
Synthetic Drugs in East and Southeast Asia: Latest 
Developments and Challenges, it was noted that the 
amount of methamphetamine seized in Tonga was sub-
stantial, considering that the population is estimated at 
just over 100,000 people. In July 2020, a seizure of over 
500 kg of cocaine, destined for Australia, was made in 
Papua New Guinea. 
769. The amount of cocaine seized in Oceania almost 
tripled from 2014 to 2018, to 2.1 tons; 97 per cent of the 
cocaine seized over the period was accounted for by 
Australia. Over the same period, the quantity of cocaine 
seized in New Zealand increased from 10 kg to 213 kg. 
However, the amount of cocaine reported seized by New 
Zealand decreased in 2019, with an increasing proportion 
seized in connection with air transportation and a 
decreasing proportion in connection with sea 
transportation. 
770. Seizures of large amounts of amphetamine-type 
stimulants continue to be made in Australia. For example, 
in April 2020, a yacht carrying approximately 1 ton of 
methamphetamine was intercepted in Australia, following 
an investigation in cooperation with authorities of New 
Caledonia and the United Kingdom. In March 2020, 
authorities in Australia reported the seizure of over 1 ton 
of “ecstasy” suspected to have originated in Europe, 
trafficked via the Republic of Korea. The number of 
dismantled clandestine laboratories in Australia, most of 
which were connected to the illicit manufacture of meth-
amphetamine, continued to decline, to 308 laboratories 
in the 12-month reporting period 2018/19, reflecting a 
reduction of almost 30 per cent compared with the 
previous period.
771. The amounts of methamphetamine and “ecstasy” 
seized in 2019 increased significantly in New Zealand, by 
515 per cent and 556 per cent respectively, compared with 
the previous year, and a record seizure of more than 400 kg 
of methamphetamine was made in 2019, transported by 
sea from Thailand. Some decrease in the number of 
clandestine laboratories illicitly manufacturing meth-
amphetamine was observed in New Zealand, with 54 such 
laboratories dismantled in 2019, compared with 71 the 
previous year. However, an upward trend was observed 
in the first quarter of 2020.
772. The amounts of heroin and morphine seized in 
Oceania declined for three years in a row to the lowest 
level since 2009, with Australia accounting for more than 
99 per cent of the amount reported seized in the region. 
5. Prevention and treatment
773. There continues to be a lack of data about the 
extent and scope of drug use and treatment demand and 
delivery in Pacific island States. The Board urges the 
Pacific island States to undertake studies to collect data 
on the extent of the drug problem in order to facilitate 
the design and adoption of evidence-based drug policies 
and the provision of appropriate prevention, treatment 
and rehabilitation services. The Board encourages 
regional and international organizations and bilateral 
partners that provide assistance to the Pacific island 
States to offer their support to the countries of the 
region in this regard.
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774. Preliminary findings of a survey conducted during 
the period April–June 2020 of Australians who had regu-
larly used drugs in 2019 showed that, following the intro-
duction of measures to combat the spread of COVID-19, 
cannabis use had increased, while the use of “ecstasy”, 
cocaine and ketamine had decreased. Use of pharmaceu-
tical opioids, GHB, benzodiazepines and LSD had mostly 
remained stable. Most respondents continued to receive 
their drugs in person, although there were small increases 
in the proportion of respondents who had drugs delivered 
to them and those who did not obtain drugs following 
the introduction of restrictions. A small proportion of 
respondents reported that they had tried but been unable 
to access drug treatment and/or mental health services 
following the introduction of restrictions related to the 
pandemic. Other studies suggested some disruption to 
heroin and methamphetamine markets, evidenced in 
changes in price and availability. Preliminary findings of 
another study, on the impact of the pandemic and associ-
ated restrictions on people who use illicit stimulants in 
Australia, were similar, indicating that use of “ecstasy” 
decreased in general following the introduction of restric-
tions related to COVID-19, while use of cannabis 
increased and use of benzodiazepines and LSD remained 
unchanged. Few respondents (6 per cent) reported diffi-
culties in accessing alcohol and drug treatment services 
since March 2020. Of the respondents to a poll conducted 
in May 2020 of people who use drugs, 26 per cent 
reported a decrease in their consumption of drugs during 
the COVID-19 pandemic, while 17.6 per cent reported 
an increase. In April 2020, the Government of Australia 
announced the allocation of additional resources to sup-
port online and phone services for people experiencing 
drug and alcohol problems during the pandemic. 
775. The eleventh report of the National Wastewater 
Drug Monitoring Program, which covered about 56 per 
cent of the population, provided insights into the effect 
of the COVID-19 pandemic on drug consumption in 
Australia. Record high levels of consumption of metham-
phetamine and heroin were recorded outside of capital 
cities, while record high levels of consumption of cocaine 
and cannabis were recorded in the capital cities. In con-
trast, there was a record low level of consumption of fen-
tanyl outside of capital cities and oxycodone in the capital 
cities. Both in and outside of capital cities, population-
weighted average consumption of “ecstasy”, oxycodone 
and fentanyl decreased, while population-weighted aver-
age consumption of heroin increased. Average consump-
tion of cannabis also increased outside of capital cities 
during the pandemic. Wastewater data collected in 
October 2019, December 2019 and February 2020 (i.e., 
prior to the COVID-19 outbreak in Australia) indicated 
that methamphetamine remained the most prevalent 
illicit drug for which testing was conducted, with record 
levels recorded in capital cities. In addition, the presence 
of cocaine and “ecstasy” had also increased since August 
2016, with a significant increase in “ecstasy” since April 
2018, to a record level. From August 2016, the presence 
of heroin declined considerably outside of capital cities 
but increased in some capital cities. A decline in the pres-
ence of oxycodone and fentanyl had been observed since 
December 2018. 
776. The Australian 2019 National Drug Strategy 
Household Survey found that 16.4 per cent of people aged 
14 and over had used an illicit drug in the previous 12 
months, similar to the level of 2016 (15.6 per cent) but 
representing an increase since 2007 (13.4 per cent). 
However, the survey found a lower lifetime prevalence of 
use of illicit drugs among young people: in 2001, 38 per 
cent of those aged 14–19 had used an illicit drug at some 
time in their lives, compared with 22 per cent in 2019. 
However, among people aged 20–29, use of both “ecstasy” 
and cocaine had increased. Over the period 2016–2019, 
past-year use of the following substances had increased 
among people aged 14 and over: cannabis (from 10.4 per 
cent to 11.6 per cent), cocaine (2.5 per cent to 4.2 per 
cent), “ecstasy” (2.2 per cent to 3.0 per cent), hallucino-
gens (1.0 per cent to 1.6 per cent), inhalants (1.0 per cent 
to 1.4 per cent) and ketamine (0.4 per cent to 0.9 per 
cent). Past-year methamphetamine use had stabilized in 
2019, at 1.3 per cent of people aged over 14. Between 
2016 and 2019, the estimated number of people aged 14 
and over who had used a pharmaceutical drug for non-
medical purposes within the previous 12 months had 
declined (from 4.8 per cent to 4.2 per cent), and the pro-
portion of people using substances from the category 
“painkillers and opioids” for non-medical purposes had 
declined from 3.6 per cent to 2.7 per cent. It was consid-
ered that that decrease was likely to have been the result 
of the 2018 reclassification of medications containing 
codeine, following which products containing codeine 
could no longer be purchased from a pharmacy without 
a prescription. Indeed, the proportion of people using 
codeine in the past year for non-medical purposes halved, 
from 3 per cent in 2016 to 1.5 per cent in 2019. Past-year 
use of heroin was estimated at 0.1 per cent in 2019 and 
0.2 per cent in 2016. 
777. Interviews with people who inject drugs also 
suggested that use of methamphetamine increased in 
2019, with three quarters of respondents reporting use of 
methamphetamine in the preceding six months. On the 
other hand, one survey found that the use of “ecstasy” in 
Australia had continued to decline in 2019, with 67 per 
cent of respondents indicating use of the substance in the 
previous six months. 
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778. In Australia, between the 12-month reporting 
periods 2009/10 and 2018/19, the number of closed74 
treatment episodes increased for amphetamines (almost 
sixfold, from 10,000 to 58,200) and for cannabis (from 
31,500 to 41,200); amphetamines were the most common 
principal illicit drug of concern. Closed treatment 
episodes for which heroin was the principal drug of concern 
declined from 9.9 per cent in 2009/10 to 5.2 per cent in 
2018/19. The number of deaths in Australia involving 
amphetamines was four times higher in 2018 than in 
1999. Over the same period, the rate of drug-induced 
deaths involving cocaine doubled (0.2 deaths per 100,000 
population). Opioids were present in nearly two thirds of 
drug-induced deaths in 2018 (4.6 per 100,000 population), 
and the rate of opioid-induced deaths involving synthetic 
opioids has increased over the past decade. Over the 
period from 2014 to 2018, the proportion of drug-induced 
deaths attributed to prescription drugs decreased, from 
75 per cent to 60 per cent.
779. The New Zealand Health Survey for the 12-month 
reporting period 2018/19 indicated that 15 per cent of 
people aged 16–64 had used cannabis in the previous 
year. Among young people, aged 15–24, the annual preva-
lence was 28.6 per cent. This reflected an increase 
compared with the previous year (11.9 per cent and 
24.2 per cent respectively). A 2019 survey of secondary-
school students in New Zealand found that 4.1 per cent 
of students reported use of cannabis at least weekly, 
representing a decrease since 2001 (6.5 per cent) but not 
a substantial change since 2012.
74 A treatment episode is considered closed when treatment 
is completed or has ceased; there has been no contact between 
the client and treatment provider for three months; or there is a 
change in the main treatment type, principal drug of concern or 
delivery setting.
780. The use of methamphetamine in New Zealand 
appears to have increased in recent years, with the New 
Zealand Health Survey for the 12-month reporting period 
2018/19 showing that 1 per cent of people aged 15 or 
over had used the substance in the previous year, reflecting 
a significant increase compared with the period 2017/18. 
According to wastewater monitoring data covering 80 per 
cent of the population of New Zealand, in 2019, an 
estimated 14–16 kg of methamphetamine were consumed 
each week in the sites tested, although a decrease in 
consumption of the substance was noted in the fourth 
quarter of 2019. Some increase in the number of people 
receiving treatment for the use of amphetamine-type 
stimulants was reported by the Government of New Zealand.
781. A large increase in the use of “ecstasy”-type sub-
stances in New Zealand was reported prior to the out-
break of the COVID-19 pandemic. In the final quarter of 
2019, wastewater analysis indicated that “ecstasy” was the 
second most-commonly detected drug (tested substances 
were methamphetamine, “ecstasy”, cocaine, heroin and 
fentanyl), with average annual consumption estimated at 
426.4 kg, more than double that of the level detected in 
the first quarter of the year. It is thought that “ecstasy” is 
commonly used as a replacement for alcohol, potentially 
for everyday casual use, particularly among young people.
782. In June 2020, an early-warning system was 
launched with the aim of reducing drug-related harm in 
New Zealand. The system, called “High Alert”, is operated 
by the Drug Information and Alert New Zealand of the 
National Drug Intelligence Bureau and is designed to help 
identify where drug-related harm was occurring, provide 
evidence about outbreaks of harm and, in some cases, 
anticipate potential harm related to drug use. 
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Chapter IV. 
Recommendations to Governments, the United 
Nations and other relevant international and 
national organizations
783. Following its review of the implementation of the 
international drug control conventions, the Board would 
like to present to Governments and relevant international 
and regional organizations its main conclusions and rec-
ommendations as follows.
A hidden epidemic: the use of drugs 
among older persons
784. The emergence of increasing patterns of drug use 
and drug dependence among older persons is a phenom-
enon of increasing concern. Limited epidemiological data 
exist on the extent of substance use among older persons, 
even in countries in which regular drug use surveys are 
undertaken. Data collection on substance use has focused 
on the general population (15–65 years of age), young 
people, young adults and marginalized and at-risk groups; 
some groups, such as older persons, have been neglected 
in such data collection. The problem of substance use 
among older persons has only recently been recognized 
as such and specific studies have only recently started to 
be conducted. 
785. The general lack of data on substance use among 
older persons translates into a lack of attention to the 
issue in the development of policies and programmes. The 
limited collection of scientific evidence makes it difficult 
to identify interventions and policies that have resulted 
in positive outcomes in terms of prevention, treatment 
and rehabilitation in relation to the use of drugs among 
older persons. In that regard, research and data collection, 
combating stigma associated with use of drugs among 
older persons, and the need for integrated, holistic and 
age-appropriate care should be addressed when 
Governments develop and implement policies and pro-
grammes in this area. 
Recommendation 1: The Board urges all Governments to:
(a)  Expand the age range of the population surveyed 
in epidemiological studies beyond 65 years and 
consider using innovative assistive health tech-
nologies or innovative ways for coordinating the 
treatment of, supporting and monitoring the out-
comes for older persons who use drugs;
(b)  Establish or extend and improve existing 
prescription-monitoring systems that can help 
detect problems of overuse and related risks;
(c)  Use existing data from national health record sys-
tems, including on treatment demand, and under-
take analysis and research in order to provide 
preliminary estimates of the scale of the preva-
lence of drug use, including the misuse of pre-
scription medicines, among older persons; 
(d)  Use existing evidence-based prevention strategies 
to prevent the stigmatization of older persons 
who use drugs and involve older persons in the 
development of messaging to combat stigma at 
the community level and in the development of 
and training for professionals working in the rel-
evant support services;
(e)  Develop effective service responses and include 
older persons who use or have used drugs as part 
of the integrated care policy development process 
that is centred on the needs of individuals, their 
families and communities;
(f)  Expand or develop existing outreach services for 
people who use drugs as a point of entry to the 
continuum of integrated care for the most mar-
ginalized of older persons who use drugs;
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(g)  Ensure that health services are able to screen 
older persons for drug use and ensure that these 
services and evidence-based programmes are cul-
turally adapted for older persons from varying 
societies and backgrounds;
(h)  Ensure that any policies developed for older per-
sons who use drugs are underpinned by the prin-
ciples of independence, participation, care, 
self-fulfilment and dignity, as set out in the 
United Nations Principles for Older Persons, and 
should be developed using Active Ageing: A Policy 
Framework and the Global Strategy and Action 
Plan on Ageing and Health.
For additional recommendations and more details on pro-
posed action, please refer to chapter I of the present report.
Non-medical use of cannabis
786. The Board reiterates its concern regarding the 
legalization of cannabis for non-medical and non-scientific 
purposes in several jurisdictions, with other jurisdictions 
considering similar action. The Board reiterates that the 
1961 Convention as amended, the 1971 Convention and 
the 1988 Convention limit the use of all controlled sub-
stances to medical and scientific purposes.
787. The developments in a few countries that have 
legalized or permitted the use of cannabis for non-medical 
purposes or that have tolerated its legalization at the sub-
national level are undermining the universal adherence 
to the three international drug control conventions and 
the commitment to their implementation, which was 
re affirmed by Member States at the special session of the 
General Assembly on the world drug problem held in 
2016 and in the 2019 Ministerial Declaration on 
Strengthening Our Actions at the National, Regional and 
International Levels to Accelerate the Implementation of 
Our Joint Commitments to Address and Counter the 
World Drug Problem.
Recommendation 2: Noting that the 1961 Convention as 
amended restricts, in its article 4, the production, man-
ufacture, export, import, distribution of, trade in, use and 
possession of controlled narcotic drugs to medical and 
scientific purposes, the Board states that legalization 
measures or regulations that permit the use of any con-
trolled substance, including cannabis, for non-medical 
purposes are inconsistent with the obligations of States 
parties to that Convention. The Board calls upon all 
States to respect their Convention obligations in the 
development of their national drug control policies.
Cultivation of cannabis for medical 
purposes
788. The Board notes the increasing number of coun-
tries that are permitting the cultivation of cannabis for 
medical purposes, in some cases solely for export to juris-
dictions that permit the use of cannabis for medical pur-
poses. Any export to a jurisdiction that permits the use 
of cannabis for medical purposes is subject to an obliga-
tion to submit estimates to the Board, pursuant to the 
1961 Convention as amended. In discharging its treaty 
mandates, the Board reviews and approves annual esti-
mates provided by Governments regarding the quantities 
of cannabis to be cultivated and consumed. In addition, 
the Board’s secretariat continues to receive enquiries from 
Governments requesting clarification on treaty provisions 
regarding the cultivation of cannabis for medical pur-
poses and related control measures to ensure that can-
nabis is not diverted to illicit channels. 
Recommendation 3: The Board wishes to recall that 
Governments that permit the cultivation of cannabis for 
medical purposes have an obligation to establish con-
trol measures in accordance with article 23 of the 1961 
Convention as amended. Such measures include the 
establishment of an agency responsible for designating 
areas and issuing licences for cultivating, purchasing 
and taking physical possession of such crops as soon as 
possible and having the exclusive right of importing, 
exporting, wholesale trading and maintaining stocks 
other than those held by manufacturers.
Recommendation 4: The Board recommends that 
Governments that allow the use of cannabinoids for 
medical purposes monitor and evaluate the potential 
diversion to trafficking or other unintended conse-
quences of those programmes.
789. The Board notes the advancement of genetic engi-
neering technologies and other biotechnologies that allow 
for the modification of the cannabis plant, as well as other 
technologies that may allow for the non-conventional 
manufacture of cannabinoids. These technologies allow 
for the optimization of industrial processes and to more 
precisely adjust the yields of the types of cannabinoids 
being produced. 
Recommendation 5: The Board calls upon Governments 
to take note of the advances in genetic engineering and 
biotechnology in the cultivation of cannabis, as well as 
other technologies that can allow for the manufacture 
of cannabinoids through non-conventional means. The 
Board also calls upon Governments to ensure that these 
technologies are appropriately used with respect to the 
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international drug control conventions and to take steps 
to prevent the misuse of such technologies in the illicit 
manufacture of drugs.
Universal adherence to the international 
drug control conventions
790. The three international drug control conventions 
represent the international consensus on requirements for 
the control of licit trade in narcotic drugs, psychotropic 
substances and precursor chemicals that can be diverted, 
and on the measures needed to facilitate access to and 
availability of controlled substances for legitimate medical 
and scientific purposes. By becoming parties to the con-
ventions, States demonstrate their common and shared 
responsibility for meeting those minimum requirements 
with a view to achieving the aim of the conventions, 
which is the health and welfare of humankind. 
Recommendation 6: The Board reiterates that universal 
ratification of the international drug control conven-
tions is important for strengthening the international 
licit drug control framework and for preventing traffick-
ers from targeting non-parties owing to actual or per-
ceived weaknesses in the scope of control of scheduled 
substances. Accordingly, the Board urges all States not 
yet having become parties to one or more of these 
instruments to do so without delay and to take steps to 
ensure their full implementation within their national 
legal orders. 
Availability of and access to narcotic 
drugs and psychotropic substances, 
including during the COVID-19 
pandemic
791. Since the beginning of 2020, the COVID-19 pan-
demic has brought forth unprecedented challenges to the 
economies and public health systems of all countries. The 
measures adopted by most countries to reduce the 
number of infections and contain the further spread of 
the virus have put to the test the ability of the inter-
national community to ensure adequate access to and 
availability of internationally controlled drugs for those 
in need.
792. The Board is concerned about reported shortages 
of medicines containing controlled substances such as 
fentanyl and midazolam in some countries, largely driven 
by significant increases in the need to provide pain relief 
and sedation for patients with COVID-19 admitted into 
intensive care units.
Recommendation 7: The Board recommends that coun-
tries review their forecasts for demand and streamline 
all the necessary administrative and logistical require-
ments. To that end, all Governments are encouraged to 
continue working closely with each other and the Board 
to ensure the global availability of medicines containing 
controlled substances, especially for those who are most 
in need during emergency situations. 
Recommendation 8: The Board calls upon Governments 
that report inadequate and very inadequate levels of 
consumption of opioid analgesics to develop appropri-
ate control systems and implement balanced public 
health policies to ensure rational and adequate con-
sumption of these substances, in cooperation with civil 
society, the pharmaceutical industry and the interna-
tional community.
793. The Board has noted that inadequate availability 
and poor access to psychotropic substances represent 
threats related to the control and rational use of such 
substances, in particular for the treatment of mental 
health and neurological conditions. The lack of consump-
tion data of psychotropic substances in many parts of the 
world remains the main challenge in assessing and ana-
lysing the trends in their availability and in providing 
appropriate assistance to those countries where availabil-
ity is scarce. 
794. The Board notes with appreciation that a number 
of countries have been reporting national data on the 
consumption of psychotropic substances on a voluntary 
basis. Being aware of the difficulties some Governments 
face in this regard, the Board prepared a compilation of 
methodologies for the collection of data on the consump-
tion of psychotropic substances, with the aim of address-
ing the disparity in data collection on the consumption 
of psychotropic substances. 
Recommendation 9: The Board calls upon all Governments 
to report on the consumption of psychotropic substances 
on an annual basis, pursuant to Commission on Narcotic 
Drugs resolution 54/6, as such data are essential for an 
improved evaluation of the availability of psychotropic 
substances for medical and scientific purposes. The 
Board encourages all Governments to make use of the 
recently prepared compilation of methodologies for the 
collection of data on the consumption of psychotropic 
substances and stands ready to assist Government in 
this regard.
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Human rights and peace and security
795. The Board has recognized that policies in some 
countries, under the pretext of the “war on drugs”, have 
led to disproportionate and overly repressive responses 
without respect for due process and the rule of law. Such 
responses contribute to an increase in violence and related 
death rates. The Board reiterates that drug-related crime 
is to be addressed through formal criminal justice 
responses and strict adherence to internationally recog-
nized due process standards. 
796. With a view to achieving the Sustainable 
Development Goals, in particular Goal 16, the Board 
notes that the provisions of the international drug control 
conventions related to supply reduction, together with the 
provisions of the conventions pertaining to reducing 
demand for illicit drugs, constitute some of the essential 
elements of a comprehensive, integrated and balanced 
approach. The provisions of the international drug control 
treaties related to criminal justice, covering issues such as 
penal provisions, international judicial and law 
enforcement cooperation, asset forfeiture and confiscation, 
can serve as effective legal instruments in addressing not 
only drug-related offences, but also any associated 
criminal activity, such as organized crime, corruption and 
money-laundering.
Recommendation 10: The Board wishes to call upon 
Governments to counter drug trafficking and related 
violence through comprehensive and balanced measures. 
These include effective prevention and criminal justice 
responses and alternative development initiatives that 
target the financial incentives offered by drug trafficking. 
They should also ensure that the responses to drug-
related criminal conduct are proportionate and founded 
upon respect for human rights and dignity, in line with 
the three international drug control conventions, 
international human rights instruments and the rule of law.
Recommendation 11: The Board reminds all Governments 
that extrajudicial action in relation to persons suspected 
of drug-related offences, taken in purported pursuit of 
drug control objectives, is inconsistent with their obli-
gations under the three international drug control con-
ventions. All drug control actions taken to comply with 
these obligations should be taken with full respect for 
the rule of law and due process of law and the 
principle of proportionality.
Prevention and treatment, including 
during the COVID-19 pandemic
797. The Board has repeatedly stressed the importance 
of respecting human rights and fundamental freedoms as 
part of the effective implementation of the international 
drug control treaties. INCB continues to emphasize that, 
for prevention and treatment measures to be successful 
and sustainable, they must be consistent with interna-
tional human rights standards. The health and welfare of 
humankind is the cornerstone of the international drug 
control framework and includes ensuring that persons 
affected by drug use disorders receive services that are 
evidence-based to treat drug use disorders and potential 
related harms. 
Recommendation 12: The Board discourages the use of 
compulsory treatment for the rehabilitation of patients 
suffering from drug use disorders and calls upon all 
Governments concerned to implement voluntary, 
evidence-based treatment services with due respect for 
patients’ human rights, such as services based on the 
International Standards for the Treatment of Drug Use 
Disorders developed by UNODC and WHO and other 
relevant international standards that Member States, in 
the outcome document of the special session of the General 
Assembly on the world drug problem held in 2016, 
recommended that countries promote and implement.
798. The Board is concerned about the reported halting, 
in many parts of the world, of treatment services for 
people who use drugs and of measures to reduce the 
negative consequences of drug use, as a result of the 
COVID-19 pandemic. The ongoing provision of drug use 
treatment services during any health crisis remains of the 
utmost importance and such services should continue to 
operate, with health and safety measures in place to 
guarantee the prevention of infections among personnel 
providing services, as well as among the recipients of such 
services.
Recommendation 13: The Board urges Governments to 
ensure the continued provision of treatment services for 
mental health and substance use disorders as part of 
essential services. Governments are recommended to 
look at existing best practices and develop effective 
strategies to ensure that prevention and evidence-based 
treatment, rehabilitation, aftercare and social reintegration 
services continue to operate. In that regard, Governments 
are encouraged to refer to chapter I of the Board’s 
annual report for 2017, entitled “Treatment, rehabilita-
tion and social reintegration for drug use disorders: 
essential components of drug demand reduction”, and 
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the UNODC–WHO International Standards for the 
Treatment of Drug Use Disorders.
Data collection and reporting
799. Competent national authorities play a key role in 
consolidating the data received from pharmaceutical 
companies, importers and exporters and other authorized 
agents within their jurisdictions to ensure that complete 
and reliable data are provided in a timely manner to the 
Board. However, some Governments fail to provide the 
Board with timely and adequate estimates and assess-
ments or reliable statistical returns, including quarterly 
and annual statistics on manufacture, consumption and 
international trade. 
800. Accurate and timely reporting is an important 
indicator of the effectiveness and efficiency of drug con-
trol systems and the availability of good-quality data is 
vital for the Board to accurately carry out the monitoring 
function accorded to it under the international drug con-
trol treaties. The quality of some data is a concern for the 
Board, particularly if they are data from major producing 
and manufacturing countries, as they indicate deficiencies 
in national mechanisms for regulating and monitoring 
internationally controlled substances
Recommendation 14: The Board urges Governments to 
provide, in an accurate and timely manner, their annual 
and quarterly statistics on the manufacture of, con-
sumption of and international trade in internationally 
controlled substances as required by the treaties and rel-
evant resolutions of the Economic and Social Council 
and the Commission on Narcotic Drugs. 
Recommendation 15: The Board urges Governments to 
continue to strengthen their national mechanisms to 
monitor the cultivation, production and manufacture of 
and trade in controlled substances. This may be achieved, 
in part, by improving and developing national data- 
collection systems, training staff of the competent 
national authorities, including at times of staff turnover, 
enhancing inter-agency cooperation and ensuring close 
cooperation with companies licensed to deal with inter-
nationally controlled substances. 
801. Diversion from licit domestic channels remains a 
major source of internationally controlled substances 
used for illicit purposes; however, there remain limited 
reports to the Board from Governments on their interdic-
tion efforts. In addition, the Board stresses that, while 
diversions from international trade are rare, Governments 
should remain vigilant to attempts by traffickers to divert 
preparations containing internationally controlled sub-
stances from the licit international market.
Recommendation 16: The Board acknowledges the 
interdiction efforts, by the Governments concerned, in 
relation to trafficking in internationally controlled 
substances and calls upon all Governments to furnish 
regularly to the Board, pursuant to Commission on 
Narcotic Drugs resolution 50/11, information on seizures 
of controlled substances ordered over the Internet and 
delivered through the mail. 
802. Strengthening international cooperation in drug 
control requires a collective understanding of common 
challenges and the identification of mutual approaches to 
key concepts and issues. In line with the 2019 Ministerial 
Declaration, the Board seeks to promote the collection, 
analysis and sharing of quality and comparable data. This 
requires the continued identification of any scientific or 
legal ambiguities in the terminology chosen in the drafting 
of drug policies. 
Recommendation 17: The Board urges Governments to 
continually examine any drug terminology that has 
ambiguous usage, or potentially stigmatizing effects, 
and that might have an impact on the ability of the 
international community to cooperate effectively on and 
jointly counter the world drug problem. 
Precursor chemicals
803. Since the entry into force of the 1988 Convention, 
in November 1990, there have been two major developments 
that the Board has identified as having changed the 
precursor control landscape. Firstly, there has been a shift 
in the diversion of precursors from international to 
domestic trade. This places a greater emphasis on the 
functioning of domestic control systems, which the 1988 
Convention leaves to the discretion of States parties. 
Secondly, there have been major increases in the 
sophistication and diversification of illicit drug manufacture 
and the sourcing of chemicals. The emergence and 
proliferation of designer precursors, pre-precursors and 
other non-scheduled chemicals for use in illicit activities 
have been among the focus areas of the Board for the past 
few years. 
Recommendation 18: The Board urges Governments to 
pay increased attention to establishing and implement-
ing comprehensive precursor monitoring systems at the 
national level and, in particular, to make use of the 
guidance provided in article 12, paragraph 8, of the 
1988 Convention. The Board encourages Governments 
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to improve the accuracy of estimates of annual legiti-
mate requirements for individual precursors with a view 
to ensuring that they always reflect actual market con-
ditions, and to make better use of the Board’s focal point 
network under Project Prism and Project Cohesion, 
which also offer a platform for the exchange of infor-
mation on best practices in precursor control.
Recommendation 19: The Board urges Governments to 
continue to explore various options to address the pro-
liferation and use of non-scheduled precursors for illicit 
activities. Since the timely sharing of information about 
such chemicals is essential, the Board encourages 
Governments to use PICS more actively. 
804. Over the years, the Board has observed the increasing 
use of the Internet and social media platforms for the 
sourcing of precursors and non-scheduled chemicals. 
Some Governments have been successful in countering 
diversion attempts of precursors by partnering with 
business-to-business Internet platforms (more details can 
be found in the Board’s reports since 2018 on the imple-
mentation of article 12 of the 1988 Convention). 
Recommendation 20: The Board encourages Governments 
to focus their efforts on the “clear web”, or “surface web”, 
to prevent the misuse of the Internet for the diversion 
of precursors, non-scheduled chemicals and equipment 
into illicit channels. Governments are invited to share 
successful national approaches and, in that regard, to 
refer to the approaches discussed in the Board’s reports 
on the implementation of article 12 of the 1988 
Convention. To complement these efforts, Governments 
are also encouraged to refer to the limited international 
special surveillance list, which contains chemicals for 
which substantial information exists on their use in 
illicit drug manufacture.
New psychoactive substances, emerging 
non-medical synthetic opioids and 
other dangerous substances
805. The illicit manufacture and use of and trafficking 
in non-medical synthetic opioids and new psychoactive 
substances remain significant challenges for international 
drug control efforts. Online vendors continue to use the 
Internet, the darknet and social media sites to offer these 
substances. Shipments continue to be trafficked through 
international mail and express courier services. The Board 
continues to promote partnerships among Governments, 
international organizations and the private sector to 
prevent and interdict sales of new psychoactive substances, 
emerging non-medical synthetic opioids and other 
dangerous substances. The Board notes the need to 
monitor, in particular, manufacturers of chemical 
reference and pharmaceutical products; online marketing, 
search, registries and registrars and social media platforms; 
postal, express mail, express courier, air cargo, freight 
forwarding and related transport sectors; and online 
financial, e-wallet and monetization industries.
Recommendation 21: The Board emphasizes the need for 
increased efforts to reduce trafficking in new psycho-
active substances and emerging non-medical synthetic 
opioids and invites Governments to nominate active law 
and regulatory enforcement focal points in police, drug 
control, customs, postal and regulatory agencies to par-
ticipate in INCB special intelligence-gathering opera-
tions and to make full use of the IONICS secure 
communication platform and the capacity-building and 
equipment available under its GRIDS Programme, 
Project ION and the OPIOIDS project.
Recommendation 22: The Board encourages Governments 
to work with the GRIDS Programme and its public-
private partnership initiative to establish and strengthen 
partnerships with relevant sectors, with the goal of 
voluntarily identifying, preventing and eliminating 
vendors attempting to exploit legitimate industry for the 
purposes of trafficking in dangerous new psychoactive 
substances not under international control. 
Recommendation 23: The Board continues to expand its 
list of fentanyl-related substances with no known legit-
imate medical or industrial use as a practical tool for 
use by relevant national authorities, international part-
ners and other stakeholders, including private sector 
partners, the scientific community and academia, and 
calls upon Governments to take appropriate measures 
to prevent the illicit manufacture, marketing, movement 
and monetization of those fentanyl-related substances. 
806. In the past year, the number of drug overdoses 
deaths from illicit drug use – especially fentanyl and 
methamphetamine – have increased in North America 
and in some other regions of the world. The crisis was 
further exacerbated by the COVID-19 pandemic, which 
is expected to contribute to increasing numbers of people 
struggling with mental health and substance use disor-
ders, coupled with corresponding increases in depression, 
anxiety, trauma and grief.
Recommendation 24: The Board once again encourages 
Governments to work together with public health offi-
cials, pharmacists and physicians, manufacturers and 
distributors, consumer protection associations and law 
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enforcement agencies to promote public education 
about the risks associated with the improper use of pre-
scription drugs, illicitly produced synthetic opioids and 
methamphetamine and to adopt appropriate measures 
to decrease their use and risk of overdose.
International import and export 
authorization system for narcotic drugs 
and psychotropic substances
807. The Board recognizes the efforts of Governments 
that have implemented I2ES and reiterates the advantages 
it presents to national authorities by significantly alleviat-
ing the administrative burden in the import and export 
administration process while also being a useful tool to 
help prevent the diversion of internationally controlled 
substances.
808. Having noted the challenges faced by some 
Governments in the further implementation of I2ES, the 
Board, through its secretariat, will continue to reach out 
and assist Governments in overcoming barriers such as 
know-how at the operational level and commitment to using 
I2ES at the decision-making level, to encourage a wider 
adoption of the system and greater user engagement. 
Recommendation 25: INCB encourages Governments 
that have not yet done so to request the assistance of 
the INCB secretariat in implementing and integrating 
I2ES into their national systems, including through the 
provision of guidance on first steps and additional 
initial training. 
Recommendation 26: In addition, the Board wishes to 
reiterate to Member States the need for continual sup-
port, including extrabudgetary resources, to expand the 
functionality of I2ES, address technical issues identified 
by Governments and provide expanded training to fur-
ther support countries in adopting and implementing 
the platform.
Specific countries and regions
809. The lack of official information and data regarding 
the trafficking in drugs, the prevalence rates of drug use 
as well as drug use prevention and treatment efforts in 
many regions, but specifically in Africa and Oceania, 
remains a concern for the Board. The lack of such infor-
mation hinders efforts by the international community to 
fully assess the drug problem in these regions.
810. Trafficking in drugs has increased in many Pacific 
island States, as Oceania is increasingly becoming a tran-
sit point for drug trafficking between the Americas and 
Asia. Moreover, the illicit manufacture and consumption 
of synthetic drugs are increasingly taking place in the 
Pacific island States. Many of these countries lack the 
capacity to respond to these challenges. 
Recommendation 27: The Board calls upon all States to 
regularly provide to the Board and other relevant inter-
national organizations data on drug trafficking and drug 
use prevalence, as well as any information regarding leg-
islation, policies or other efforts on drug use prevention, 
treatment, rehabilitation and social reintegration in 
their territories.
Recommendation 28: Recognizing that national capaci-
ties in many countries in Oceania are inadequate to 
respond to the threat of drug trafficking and that the 
consumption of drugs is on the rise in those countries, 
the Board requests that the international community 
provide support to enhance the capacities of Pacific 
island States to address these new challenges and to safe-
guard their citizens’ health.
811. Despite a decrease in the area used for the cultiva-
tion of opium poppy in Afghanistan, illicit production of 
opium has remained at almost the same level from 2018 
to 2019, possibly owing to higher yields. The low price of 
opium during planting time was one of the main drivers 
of the decline in cultivation. Afghanistan has accounted 
for almost 84 per cent of global opium production over 
the past five years and, to date, there have been no indica-
tions of a reduction in the supply of heroin of Afghan 
origin to consumer markets globally. 
Recommendation 29: The Board notes with concern that 
continued large-scale illicit opium poppy cultivation 
and opium production in Afghanistan, coupled with 
limited eradication efforts, further undermine the 
efforts of Afghanistan and its partners to promote peace, 
security and sustainable development in the country. 
The Board reiterates its call for further technical and 
financial assistance to address the drug control chal-
lenges in the country. 
Psychotropic substances
812. The universal application of the requirement for 
import and export authorizations laid down in the 1971 
Convention is key to preventing the diversion of drugs 
into the illicit market. The 1971 Convention does not 
require import and export authorizations for trade in the 
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psychotropic substances listed in its Schedules III and IV. 
However, in view of the widespread diversion of those 
substances from licit international trade during the 1970s 
and 1980s, the Economic and Social Council, in its resolu-
tions 1985/15, 1987/30 and 1993/38, requested Governments 
to extend the system of import and export authorizations 
to cover those psychotropic substances as well. 
Recommendation 30: The Board urges the Governments 
of the few remaining States in which national legislation 
(Signed)
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and/or regulations do not yet require import and export 
authorizations for all psychotropic substances, regardless 
of whether they are States parties to the 1971 Convention, 
to put into place such legislation or regulations at the 
earliest opportunity. The Board urges Governments to 
extend such controls to all substances listed in Schedules 
III and IV of the 1971 Convention as soon as possible, 
including those recently scheduled and to inform the 
Board in that regard.
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Annex I 
Regional and subregional groupings used in the 
report of the International Narcotics Control 
Board for 2020
The regional and subregional groupings used in the report of INCB for 2020, together with the States in each of those 















Democratic Republic of the Congo Sao Tome and Principe
Djibouti Senegal
Egypt Seychelles








Guinea-Bissau United Republic of Tanzania
Kenya Zambia
Lesotho Zimbabwe
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Central America and the Caribbean






Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America








Ecuador Venezuela (Bolivarian Republic of)




Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand











Georgia State of Palestine











Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina North Macedonia
Bulgaria Romania 
Croatia Serbia
















Italy United Kingdom of Great Britain and Northern Ireland
Latvia
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Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands





Current membership of the International 
Narcotics Control Board
César Tomás Arce Rivas
Born in 1954. National of Paraguay. Retired Director 
General, Office for National and International Cooperation 
and Institutional Strengthening of the National Anti-
Drug Secretariat (2012–2020); Professor of Organic 
Chemistry, Faculty of Exact and Natural Sciences, 
National University of Asunción (since 1993).
Doctorate in Forensic Chemistry, Center for Forensic 
Medicine, Medical University of Vienna (1988–1990); 
Bachelor of Science in Chemistry, Faculty of Exact and 
Natural Sciences, National University of Asunción 
(1971–1975).
Previously held positions as Deputy Executive Secretary, 
National Anti-Drug Secretariat (2008–2012); Laboratory 
Director, National Anti-Drug Secretariat (1987–2007); 
Professor of Organic Chemistry I and II, Catholic 
University, Ciudad del Este, Paraguay (1996–2008); intern, 
laboratories of the Federal Police of Germany (1990). 
Author and co-author of and contributor to numerous 
publications, including “Drug policy, strategy and action 
plan on drugs of Paraguay” (2016) and “Study of the 
interrelation of cannabinoids in marijuana and determi-
nation of the storage and harvest time of a marijuana 
sample, by means of the cannabinoid relation”.
Member of the delegation of Paraguay to the sixtieth ses-
sion of the Commission on Narcotic Drugs (2017); meet-
ing of drug control and drug administration organizations 
for the implementation of prevention and treatment 
courses and the strengthening of health systems, Inter-
American Drug Abuse Control Commission of the 
Organization of American States, held in Cancún, Mexico 
(2017); 12th Specialized Meeting of Drug Enforcement 
Authorities, Southern Common Market (MERCOSUR), 
held in Buenos Aires (2017); preparatory meeting of the 
special session of the General Assembly on the world 
drug problem, held in Vienna (2016); special session of 
the General Assembly on the world drug problem, held 
in New York (2016); biregional high-level meetings of the 
European Union and the Community of Latin and 
Caribbean States on the problem of drugs, held in Buenos 
Aires (2017), The Hague (2016), Montevideo (2015), 
Athens (2014) and Brussels (2012); South American 
Council on the World Drug Problem, Union of South 
American Nations, Asunción (2012) (President pro tem-
pore); Specialized Meetings of Drug Enforcement 
Authorities, MERCOSUR, Asunción (2015 and 2009) 
(President pro tempore); Twenty-fourth Meeting of Heads 
of National Drug Law Enforcement Agencies, Latin 
America and the Caribbean, held in Asunción (2014) 
(Chair); international meeting of executives for the con-
trol of precursors and essential chemical substances, held 
in Santiago (1998); 10th, 15th, 16th and 17th interna-
tional seminars of forensic chemistry, Drug Enforcement 
Administration, Washington, D.C. (1987–1995); Meeting 
of Auditors and Evaluators of the Control of Narcotics and 
Psychotropic Substances in Public Health, Santiago (1992).
Member of INCB (since 2020).1 Member of the Standing 
Committee on Estimates (2020).
1 Elected by the Economic and Social Council on 7 May 2019.
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Sevil Atasoy
Born in 1949. National of Turkey. Professor of Biochemistry 
and Forensic Science, Vice-Rector and Director, Institute 
of Addiction and Forensic Science; Head, Department of 
Forensic Science; Director, Center for Violence and Crime 
Prevention, Uskudar University, Istanbul. Director, 
Institute of Forensic Science, Istanbul University (1988–
2010). Director, Department of Narcotics and Toxicology, 
Ministry of Justice of Turkey (1980–1993). Expert witness 
in civil and criminal courts (since 1980).
Bachelor of Science in Chemistry (1972), Master of 
Science in Biochemistry (1976), Doctor of Philosophy 
(PhD) in Biochemistry (1979), Istanbul University.
Lecturer in biochemistry, criminalistics and crime scene 
investigation (since 1982); supervisor of more than 50 
master’s and doctoral theses in the area of biochemistry 
and forensic science. Author of over 130 scientific papers, 
including papers on drug testing, drug chemistry, drug 
markets, drug-related and drug-induced crime, drug 
abuse prevention, clinical and forensic toxicology, crime 
scene investigation and DNA analysis.
Hubert H. Humphrey Fellow, United States of America 
Information Agency (1995–1996); Guest Scientist at the 
School of Public Health, Department of Forensic Science, 
University of California, Berkeley, and the Drug Abuse 
Research Center, University of California, Los Angeles; 
Department of Genetics, Stanford University; Department 
of Human Genetics, Emory University; California 
Criminalistics Institute; Federal Bureau of Investigation, 
Virginia; Crime Laboratories, Los Angeles Sheriff ’s 
Department, United States; Federal Criminal Police Office 
(BKA), Wiesbaden; Ludwig-Maximilian University, 
Munich Institute for Physical Biochemistry and Institute 
of Legal Medicine; Center of Human Genetics, Bremen 
University; Institute of Legal Medicine, Muenster 
University, Germany; United Nations Drug Laboratory, 
Vienna; Central Bureau of Investigation, New Delhi.
Member, special commission on preventing drug abuse, 
Office of the Prime Minister (since 2014). Founding editor, 
Turkish Journal of Legal Medicine (1982–1993). Member of 
the scientific board of the International Criminal Justice 
Review. Founding President, Turkish Society of Forensic 
Sciences; Honorary Member of the Mediterranean 
Academy of Forensic Sciences. Member of the International 
Society of Forensic Toxicology; the Indo-Pacific Association 
of Law, Medicine and Science; the International Association 
of Forensic Toxicologists; the American Academy of 
Forensic Sciences; the American Society of Crime 
Laboratory Directors; and the American Society of 
Criminology.
Member of INCB (2005–2010 and since 2017). Member 
(2006 and 2018) and Chair (2017 and 2020) of the 
Committee on Finance and Administration. Second Vice-
President and Chair (2006) and Member (2007 and 2020) 
of the Standing Committee on Estimates. Rapporteur 
(2007 and 2019). First Vice-President of the Board (2008). 
President of the Board (2009).
Cornelis P. de Joncheere
Born in 1954. National of the Netherlands. Currently 
Chair of the Netherlands Antibiotics Development 
Platform, Member of the Expert Advisory Group of the 
Medicines Patent Pool in Geneva and a consultant to 
WHO on pharmaceutical policies.
Doctor of Pharmacy (PharmD) and Master of Science 
(MSc) in Pharmacy, University of Groningen and 
University of Amsterdam, the Netherlands (1975–1981); 
Master’s in Business Administration, University of San 
Diego, United States/San José, Costa Rica; Bachelor of 
Science (BSc). Pharmacy, cum laude (honour student), 
University of Groningen, the Netherlands (1972–1975).
Previously held positions as Director, Department of 
Essential Medicines and Health Products at WHO in Geneva 
(2012–2016), which included work on access to controlled 
medicines, and the WHO Expert Committee on Drug 
Dependence; WHO Representative, Kyiv (2011–2012); 
WHO Regional Adviser for Pharmaceuticals and Health 
Technologies, WHO Regional Office for Europe, Copenhagen 
(1996–2010); National Essential Drugs Programme 
Coordinator, Pan American Health Organization (PAHO)/
WHO, Brazil (1994–1996); Pharmacist, Essential Drugs 
Projects Coordinator, PAHO/WHO, Costa Rica (1988–
1993); Pharmaceutical expert, PAHO/WHO, Panama (1986–
1988); pharmaceutical supply expert in Yemen, Ministry of 
Foreign Affairs, Directorate for International Cooperation, 
the Netherlands (1982–1985); hospital and community 
pharmacy in Amsterdam, the Netherlands (1981–1982).
President of the WHO Europe Staff Association (2006–
2010); Member of the WHO Guidelines Review 
Committee (2007–2011); Member of the Royal Dutch 
Pharmaceutical Society; author and co-author of numer-
ous publications in the fields of pharmaceutical and 
health sciences.
Member of INCB (since 2017). Rapporteur (2017). Member 
of the Standing Committee on Estimates (2017–2018). 
Member of the Committee on Finance and Administration 
(2017–2018). President of the Board (2019–2020).
David T. Johnson
Born in 1954. National of the United States. President, 
SwanJohnson LLC; retired diplomat. Bachelor’s degree in 
economics from Emory University; graduate of the 
National Defence College of Canada.
United States Foreign Service officer (1977–2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007–2011). Deputy Chief of 
Mission (2005–2007) and Chargé d’affaires a.i. (2003–2005), 
United States Embassy, London. Afghan Coordinator for 
the United States (2002–2003). United States Ambassador 
to OSCE (1998–2001). Deputy Press Secretary at the 
White House and Spokesman for the National Security 
Council (1995–1997). Deputy Spokesman at the State 
Department (1995) and Director of the State Department 
Press Office (1993–1995). United States Consul General, 
Vancouver (1990–1993). Assistant National Trust 
Examiner, Office of the Comptroller of the Currency, 
United States Treasury (1976–1977).
Member of INCB (since 2012). Member of the Committee 
on Finance and Administration (since 2012). Chair of the 
Committee on Finance and Administration (2014 and 
2018). Second Vice-President and Chair (2019) and mem-
ber (2020) of the Standing Committee on Estimates.
Galina Korchagina
Born in 1953. National of the Russian Federation. 
Professor, Deputy Director of the National Centre for 
Research on Drug Addiction (since 2010).
Graduate of the Leningrad Paediatric Medical Institute, 
Russian Federation (1976); doctor of medicine (2001). 
Thesis based on clinical and epidemiological research 
dealing with new ways of looking at management of drug 
abuse in a time of change. 
Previously held positions as paediatrician at the Central 
District Hospital of Gatchina, Leningrad region, and doc-
tor at a boarding school (1976–1979); Head of the 
Organizational and Policy Division, Leningrad Regional 
Drug Clinic (1981–1989); Lecturer, Leningrad Regional 
Medical Academy (1981–1989); Head Doctor, City Drug 
Clinic, Saint Petersburg (1989–1994); Assistant Lecturer 
(1991–1996) and Professor (2000–2001), Department of 
Social Technologies, State Institute for Services and 
Economics; Assistant Lecturer (1994–2000), Associate 
Professor (2001–2002) and Professor (2002–2008), 
Department for Research on Drug Addiction, Saint 
Petersburg Medical Academy of Postgraduate Studies; 
Chief Professor and Head of the Department for Medical 
Research and Healthy Lifestyles, Herzen State Pedagogical 
University of Russia (2000–2008); Professor, Department 
for Conflict Studies, Faculty of Philosophy, Saint 
Petersburg State University (2004–2008).
Member of many associations and societies, including the 
Association of Psychiatrists and Drug Addiction Specialists 
of the Russian Federation and Saint Petersburg, the Kettil 
Bruun Society for Social and Epidemiological Research 
on Alcohol, the International Council on Alcohol and 
Addictions and the International Society of Addiction 
Medicine. Head of the sociology of science aspects of 
medical and biological research section of the Research 
Council on the Sociology of Science and the Organization 
of Scientific Research, Saint Petersburg Scientific Centre 
of the Russian Academy of Sciences (2002–2008). 
Author of more than 100 publications, including more 
than 70 works published in the Russian Federation, chap-
ters in monographs and several practical guides. Award 
for excellence in health protection from the Ministry of 
Health of the Union of Soviet Socialist Republics (1987). 
Consultant, Global Business Coalition on HIV/AIDS, 
Tuberculosis and Malaria (since 2006).
Expert on the epidemiology of drug addiction, Pompidou 
Group of the Council of Europe (1994–2003); participa-
tion in the WHO cocaine project (1993–1994) as leading 
researcher; WHO Healthy Cities project (1992–1998) as 
leading coordinator in Saint Petersburg; WHO alcohol 
action plan, realization on the basis of the city treatment 
centre, Saint Petersburg (1992–1998). Co-trainer, WHO 
programmes “Helping people change” (since 1992) and 
“Skills for change” (since 1995); and temporary adviser, 
WHO (1992–2008). Participant in meetings of the 
Commission on Narcotic Drugs (2002–2008).
Member of INCB (2010–2015 and since 2017). Vice-
Chair (2011, 2012, 2017 and 2019) and Member (2018) 
of the Standing Committee on Estimates. First 
Vice-President of the Board (2013). Member of the 
Committee on Finance and Administration (2020).
Bernard Leroy 
Born in 1948. National of France. Honorary Deputy 
Prosecutor General and Director of the International 
Institute of Research against Counterfeit Medicines.
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Degrees in Law from the University of Caen, Institute of 
European Studies of Saarbrucken, Germany, and 
University Paris X. Graduate of the French National 
School for the Judiciary (1979).
Previously held positions of Deputy General Prosecutor, 
Versailles Court of Appeal (2010–2013). Senior Legal 
Adviser, UNODC (1990–2010). Adviser in charge of inter-
national, legislative and legal affairs in the French National 
Drug Coordination office (1988–1990). Investigating judge 
specializing in drug cases, Evry High Court (1979–1988). 
Head of the Legal Assistance Programme, UNODC, and 
Coordinator of the de centralized team of legal experts, 
Bogotá, Tashkent and Bangkok (1990–2010). Leader of the 
legal assistance team assisting the Government of 
Afghanistan in the drafting process of the new drug 
control law, 2004. Co-author of the preparatory study for 
the law introducing community service sentencing as an 
alternative to imprisonment in France (1981). Co-founder 
of “Essonne Accueil”, a non-governmental organization 
providing treatment services for drug addicts (1982). 
Member of the French delegation for the final negotiations 
of the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988. 
Chair of the study group on cocaine trafficking in Europe, 
Council of Europe (1989). Author of the report resulting 
in the first European political coordinating committee to 
combat drugs (1989). Chair of the World Bank and 
UNODC joint team (the Stolen Asset Recovery (StAR) 
Initiative) which organized the freezing and subsequent 
recovery in Switzerland of the assets stolen by the former 
dictator Jean-Claude Duvalier in Haiti (2008).
Organizer of the lifelong learning programme on com-
bating drug trafficking and addiction for members of the 
French judiciary, French National School for the Judiciary 
(1984–1994). Lecturer for medical graduates in psychia-
try in the field of forensic expertise and responsibility, 
Faculty of Medicine, Paris-Sud University (1983–1990). 
Lecturer in the field of social work, University of Paris 
13 (1984–1988). Lecturer for second-year Master’s courses 
in Security and Public International Law, Jean Moulin 
Lyon 3 University (2005–2013).
Member of the Executive Board of the international 
section of the National Association of Drug Court 
Professionals (2006). External member of the Management 
Board of the French Monitoring Centre for Drugs and 
Drug Addiction (2013). Member of the committee of the 
Reynaud report (2013). Honours: Chevalier of the Legion 
of Honour.
Selected publications include “Le travail au profit de la com-
munauté, substitut aux courtes peines d’empri sonnement”, 
Revue de science criminelle et de droit comparé, No. 1 (Sirey, 
1983); Drogues et drogués (Association of Studies and 
Research of the French National School for the Judiciary, 
1983); Étude comparative des législations et des pratiques judi-
ciaires européennes face à la drogue (Commission of the 
European Communities, 1991); Ecstasy, Inserm Collective 
Expertise series (Editions Inserm, 1997); The International 
Drug Control System, in cooperation with Cherif Bassiouni 
and J. F. Thony, in International Criminal Law: Sources, 
Subjects and Contents (Martinus Nijhoff Publishers, 2007); 
and Routledge Handbook of Transnational Criminal Law, 
Neil Boister and Robert Curie, eds. (Routledge, 2014).
Member of INCB (since 2015). Rapporteur (2015, 2018 
and 2020). Member of the Standing Committee on 
Estimates (2016). Member of the Committee on Finance 
and Administration (2019).
Viviana Manrique Zuluaga
Born in 1979. National of Colombia. Senior public 
policy consultant.
Master’s degree in interdisciplinary development studies; 
undergraduate studies in law, philosophy and inter-
national relations; specialized university courses in 
government and public policy, administrative law and 
European studies. 
Previously held positions as university professor (2004–
2018), in particular for comparative law (2016–2017) and 
human rights and international humanitarian law (2015–
2017); Adviser to the President on Competitiveness and 
Productivity (2005–2008); Consultant on illicit drugs for 
the Organization of Ibero-American States for Education, 
Science and Culture (2011–2018); Administrative Attorney 
(2014–2017); Director of the Centre for Monitoring 
Weapons and Illicit Drugs, Universidad del Rosario (2010–
2014); Deputy Minister of the Interior (2009–2010); Deputy 
Presidential Commissioner for the Puebla-Panama Plan 
(2007–2008). Honours: award for research on drug traf-
ficking, presented by the Conference of American Armies 
(2015); Bomberos de Colombia (2011); Orden de la Justicia 
(2010); Coronel Bernardo Echeverry Ossa award in the cat-
egory of “special first time”, presented by the National 
Penitentiary and Prison Institute (2010); Recognition by 
the National Narcotics Directorate of contribution to drug 
policy (2010); honour student, Universidad del Rosario 
(2004).
Author and co-author of numerous publications includ-
ing Diagnóstico regional para el posconflicto en Colombia 
(chapter on illicit drugs) (Organization of Ibero-American 
States for Education, Science and Culture, 2018); “Una 
aproximación integral a la problemática de drogas ilícitas 
en Colombia” (2018); “La realidad de las drogas sintéti-
cas” (2015); “Políticas públicas de lucha contra las drogas 
en Colombia: una mirada sistémica” (2015); and La Tenue 
Línea de la Tranquilidad: Estudio Comparado sobre 
Seguridad Ciudadana y Policía (2004). Over 10 years of 
experience as an expert analyst in Colombian written 
media, including www.semana.com, KienyKe online mag-
azine and El Colombiano; television and radio interviews 
for Colombian and international channels and stations 
such as RCN, Caracol, Blue Radio and Cable Noticias; 
and work for international media including CNN en 
Español and the Miami Herald.
Presenter and speaker at over 30 national and interna-
tional conferences on illicit drugs and their relationship 
with citizen security, public policy and national security; 
organizer of the National Conference on Drugs in 
Colombia (2010–2014).
Member of INCB (since 2020).2 Member of the Standing 
Committee on Estimates (2020).
Raúl Martín del Campo Sánchez
Born in 1975. National of Mexico. Director General of 
the National Commission against Addictions (May 2013–
December 2016).
Bachelor’s Degree in Psychology; Honourable Mention, 
Autonomous University of Aguascalientes, 1998. Master’s 
Degree in Health Psychology, Faculty of Psychology, 
National Autonomous University of Mexico, with residency 
in Addictions, 2002. Specialization in Drug Dependence 
and Related Crisis Situations, Drug Dependence Treatment 
Centre, Health Institute of the State of Mexico, 2010. 
Director of Coordination of National Programmes against 
Addictions, Mexican Observatory on Tobacco, Alcohol and 
Drugs, National Commission against Addictions (2012–
2013); Director, Mexican Institute against Addictions 
(IMCA), State of Mexico (2007–2011); Head of the 
Indicator Monitoring Department, National Commission 
against Addictions (2003–2007); Head of the Psychology 
Unit (treatment of drug users), Drug Abuse Treatment 
Centre, Municipality of Aguascalientes (1999–2000); 
residential therapist for drug users and psychiatric patients, 
Addiction Treatment and Rehabilitation Centre (CAPRA) 
and Neuropsychiatric Centre of Aguascalientes (1999–
2000); volunteer providing social services and support to 
the technical team, youth integration centres, Aguascalientes 
(1997–2000). 
2 Elected by the Economic and Social Council on 7 May 2019
Author and co-author of and contributor to numerous 
publications on drug abuse prevention, treatment, surveys 
and related subjects, including: National Survey on Drug 
Use Among Students, 2014 (INPRFM, National Commission 
against Addictions, Ministry of Health of Mexico, 2015); 
“Is the medical use of cannabis supported by science?” 
(National Commission against Addictions, National Centre 
for the Prevention and Control of Addictions, 2014); “The 
treatment model used by the ‘Centros Nueva Vida’ 
addiction treatment centres and its relationship to primary 
health-care services” and “Addiction treatment based on 
models for the State of Mexico: cases in the study of risk 
factors and prevention through the Chimalli model”, 
Actualidades en adicciones 2012, vol. II (National 
Commission against Addictions, 2012); “Is alcohol an 
isolated problem in children and adolescents?”, in 
Actualidades en adicciones 2012, vol. IV (National 
Commission against Addictions, 2012); “Alcohol in primary 
care mental health clinics”, in Alcohol use disorder (World 
Organization of National Colleges, Academies and 
Academic Associations of General Practitioners/Family 
Physicians, 2010); and State of Mexico Survey on Alcohol, 
Tobacco and Drug Use among Students (INPRFM, Mexican 
Institute against Addictions (IMCA), 2009). 
Member of INCB (since 2016). Vice-Chair (2020) and 
Member (2017–2019) of the Standing Committee on 
Estimates. Member of the Committee on Finance and 
Administration (2019).
Richard P. Mattick 
Born in 1955. National of Australia. Honorary Professor 
of Drug and Alcohol Studies at the National Drug and 
Alcohol Research Centre, Faculty of Medicine, University 
of New South Wales; Professor of Brain Sciences, 
University of New South Wales; Principal Research Fellow 
awarded, Australian Government National Health and 
Medical Research Council (2013–2017 and 2019–2023) 
and endorsed and registered clinical psychologist.
Bachelor of Science (Psychology), Honours, Class 1, 
University of New South Wales, 1982; Master of 
Psychology (Clinical), University of New South Wales, 
1989; Doctor of Philosophy, University of New South 
Wales, 1988; and Certificate in Neuroanatomy, Anatomy, 
University of New South Wales, 1992.
Director of Research, Australian National Drug and 
Alcohol Research Centre (1995–2001), and Executive 
Director, Australian National Drug and Alcohol Research 
Centre, Faculty of Medicine, University of New South 
Wales (2001–2009). Member, Australian National Expert 
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Advisory Committee on Illicit Drugs (2002–2004), 
Australian National Expert Advisory Group on Sustained 
Release Naltrexone (2002–2004), Monitoring Committee 
of the Medically Supervised Injecting Centre for the New 
South Wales Government Cabinet Office (2003–2004), 
Australian Ministerial Council on Drug Strategy Working 
Party on Performance and Image Enhancing Drugs (2003–
2005), Australian Government Department of Health and 
Ageing Expert Advisory Committee on Cannabis and 
Health (2005–2006), New South Wales Expert Advisory 
Group on Drugs and Alcohol for the New South Wales 
Minister of Health (2004–2013), Australian National 
Council on Drugs advising the Prime Minister (2004–
2010), WHO/UNODC Technical Guidelines Development 
Group on Pharmacotherapy of Opioid Dependence (2004–
2008), Australian Research Alliance for Children and 
Youth (2005–2015).
Served on the editorial and executive boards of Drug and 
Alcohol Review (1994–2005), and as Deputy Editor (1995–
2000) and Executive Editor (2000–2005). Assistant Editor 
of the international peer-reviewed journal Addiction (1995–
2005). Editor, Cochrane Review Group on Drugs and 
Alcohol (1998–2003). Authored over 300 books, chapters 
in edited volumes on substance abuse, addiction and treat-
ment, and peer-reviewed academic journal articles on 
those subjects. Recent articles include “Buprenorphine 
maintenance versus placebo or methadone maintenance 
for opioid dependence”, “Young adult sequelae of adoles-
cent cannabis use” and “The Pain and Opioids IN Treatment 
study: characteristics of a cohort using opioids to manage 
chronic non-cancer pain”. 
Recipient of academic and research support from the 
Australian Government Department of Health; the New 
South Wales Government Department of Health; the 
Australian National Drug Law Enforcement Research 
Fund; the Alcohol Education and Rehabilitation 
Foundation; UNODC; the National Institute on Drug 
Abuse of the United States; the Australian Research 
Council; and the Australian Government National Health 
and Medical Research Council.
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015–2016).
Luis Alberto Otárola Peñaranda
Born in 1967. National of Peru. Lawyer. Postgraduate 
degree in Public Policy and Public Management from the 
Pontifical Catholic University of Peru.
Executive Director of the National Commission for 
Development and Life without Drugs (2014–2016). 
President of the Inter-American Drug Abuse Control 
Commission of OAS (November 2015–September 2016). 
Minister of Defence (2012), Deputy Minister of the 
Interior (2011), Deputy Minister of Defence (2003), 
Officer of the Peruvian State before the Inter-American 
Court of Human Rights (2001), Professor of Constitutional 
Law and Human Rights.
Author or co-author of the following works: Compendio 
sobre Tráfico Ilícito de Drogas y Desarrollo Alternativo 
(2015); La Constitución Explicada (2011); La Constitución 
de 1993: Estudio y Reforma a Quince Años de su Vigencia 
(2009); Modernización Democrática de las Fuerzas 
Armadas (2002); Parlamento y Ciudadanía (2001); and La 
Constitución de 1993: Análisis Comparado (1999).
Order of Merit for Distinguished Services at the level of Grand 
Cross (decoration awarded by the Constitutional President of 
the Republic). Also received the Order of Ayacucho 
(highest distinction awarded by the Peruvian Army).
Presenter at the workshop entitled “Responding to the 
evolving drug challenge”, Deutsche Gesellschaft für 
Internationale Zusammenarbeit (GIZ), London (2015); 
presenter on alternative development at the Economic 
and Social Council, New York (2015); Head of the 
Peruvian delegation to the seventh meeting of the 
Peruvian-Colombian Joint Committee on Drugs (2014); 
Head of the Peruvian delegation to the Twenty-fourth 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Latin America and the Caribbean (2014); 
speaker at the second Latin American Seminar on 
Democracy and Corruption, Montevideo (2014); Head of 
the Peruvian delegation to the eighth meeting of the 
Peruvian-Brazilian Joint Committee on Drugs (2014); 
speaker at the Latin American Seminar on Youth and 
Democratic Governance, Cartagena de Indias, Colombia 
(2012); speaker at the Latin American Seminar on Youth, 
Violence and Culture of Peace, Antigua, Guatemala (2009).
Member of INCB (since 2017). Member of the Standing 
Committee on Estimates (2017–2019). First Vice-
President of the Board (2020).
Jagjit Pavadia 
Born in 1954. National of India. Graduate in English 
Honours (1974), Dhaka University, LLB from Delhi 
University (1988), Master’s Diploma in Public 
Administration, Indian Institute of Public Administration 
(1996). Completed dissertation “Forfeiture of Property 
under the Narcotics Drugs and Psychotropic Substances 
Act, 1985” towards completion of Master’s Diploma. 
Held several senior positions in the Indian Revenue 
Service for 35 years in the Government of India, including 
Narcotics Commissioner of India, Central Bureau of 
Narcotics (2006–2012); Commissioner, Legal Affairs 
(2001–2005); Chief Vigilance Officer, Power Finance 
Corporation (1996–2001); Customs Training Adviser 
Maldives, deputed by the Commonwealth Secretariat 
(1994–1995); Deputy Director, Narcotics Control Bureau 
(1990–1994); and retired as Chief Commissioner, Customs, 
Central Excise and Service Tax, Nagpur, in 2014.
Recipient of Presidential Appreciation Certificate for 
Specially Distinguished Record of Service on the occasion 
of Republic Day (2005), published in the Gazette of India 
Extraordinary.
Member of the Indian delegation to the Commission on 
Narcotic Drugs, Vienna (2007–2012); introduced 
resolutions 51/15 (2008) and 53/12 (2010), adopted by 
the Commission on Narcotic Drugs, and organized a side 
event on the margins of the Commission’s 2011 session, 
presenting issues involved in the illegal movement of 
opium poppy seeds to producing, importing and exporting 
countries. As representative of the competent national 
authority, attended Project Prism and Project Cohesion 
task force meetings (2006–2012), and coordinated and 
organized the Project Prism and Project Cohesion 
meeting in New Delhi (2008). Participated in the 
Thirtieth Meeting of Heads of National Drug Law 
Enforcement Agencies, Asia and the Pacific, held in 
Bangkok (2006), and organized the Thirty-fifth Meeting 
of Heads of National Drug Law Enforcement Agencies, 
Asia and the Pacific, held in Agra, India (2011). Member 
of the INCB advisory expert group on the scheduling of 
substances (2006), and member of the advisory group 
finalizing the INCB Guidelines for a Voluntary Code of 
Practice for the Chemical Industry (2008). Rapporteur of 
the forty-first session of the Subcommission on Illicit 
Drug Traffic and Related Matters in the Near and Middle 
East, held in Amman (2006); Chair of the forty-second 
session of the Subcommission, held in Accra, India 
(2007); organized the meeting of the Paris Pact Initiative 
Expert Working Group on Precursors, held in New Delhi 
(2011); and participated in the International Drug 
Enforcement Conferences hosted by the United States 
Drug Enforcement Agency, held in Istanbul, Turkey 
(2008) and Cancún, Mexico (2011).
Member of INCB (since 2015). Second Vice-President 
and Chair (2015, 2017 and 2020), Vice-Chair (2018) and 
Member (2019) of the Standing Committee on Estimates. 
Member (2016–2017 and 2020) and Chair (2019) of the 
Committee on Finance and Administration. First Vice-
President of the Board (2016).
Jallal Toufiq 
Born in 1963. National of Morocco. Head of the National 
Centre for Drug Abuse Prevention and Research; Director 
of the Moroccan National Observatory on Drugs and 
Addictions; Director of the Ar-razi University Psychiatric 
Hospital and Professor of Psychiatry at the Rabat Faculty 
of Medicine.
Medical Doctor, Rabat Faculty of Medicine (1989); 
Diploma of Specialization in Psychiatry (1994); and lec-
turer at the Rabat Faculty of Medicine (since 1995). 
Undertook specialized training in Paris at the Sainte-
Anne Psychiatric Hospital and Marmottan Centre (1990–
1991); and at Johns Hopkins University as a National 
Institute on Drug Abuse research fellow and Clinical 
Observer (1994–1995). Conducted research at the 
University of Pittsburgh (1995); and gained Clinical Drug 
Research certificates at the Vienna School of Clinical 
Research (2001 and 2002).
Currently holding positions in Morocco as Head of the 
Harm Reduction Programme, National Centre for Drug 
Abuse Prevention and Research; teaching and residency 
training coordinator, Ar-razi Hospital; Director of the 
National Diploma Programme on Treatment and 
Prevention of Drug Abuse, Rabat Faculty of Medicine; 
Director of the National Diploma Programme on Child 
Psychiatry, Rabat Faculty of Medicine and Member of the 
Ministry of Health Commission on Drug Abuse.
At the international level, Representative of the 
Mediterranean Network (MedNET) for Morocco 
(MedNET/Pompidou Group/Council of Europe); former 
permanent correspondent of the Pompidou Group for 
Morocco (Council of Europe) on drug abuse prevention 
and research and former member of the Reference Group 
to the United Nations on HIV and Injecting Drug Use. 
Founding member and steering committee member, 
Middle East and North Africa Harm Reduction 
Association (MENAHRA); Director of Knowledge Hub 
Ar-razi for North Africa, MENAHRA; Member, Mentor 
International Scientific Advisory Network (drug abuse 
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prevention in youth); former focal point/expert on pre-
vention, United Nations Office on Drug Control and 
Crime Prevention (local network for North Africa); 
founding member, MedNET (advisory group on AIDS 
and drug abuse policies) of the Council of Europe, and 
member of the Reference Group to the United Nations 
on HIV and Injecting Drug Use.
Held consultancy roles with the WHO Regional Office 
for the Eastern Mediterranean, UNODC and other inter-
national institutions, research fellowships and the National 
Institute on Drug Abuse of the United States. Published 
widely in the field of psychiatry, alcohol and drug abuse. 
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015). Member of the 
Committee on Finance and Administration (2016). First 
Vice-President of the Board (2018).
Zukiswa Zingela
Born in 1969. National of South Africa. Head, Department 
of Psychiatry and Behavioural Sciences, Walter Sisulu 
University and Nelson Mandela Academic Hospital, 
Eastern Cape Department of Health (since 2015).
Master of Medicine, Psychiatry (University of Pretoria); 
Fellow of the College of Psychiatrists of South Africa.
Previously held positions as Leader of the Dean’s Advisory 
Committee in charge of the Faculty of Health Sciences, 
Walter Sisulu University (2016–2017); Head of Clinical 
Unit, Dora Nginza Hospital, Eastern Cape Department of 
Health, and Senior Lecturer at Walter Sisulu University 
(2011–2015); Specialist Psychiatrist in private practice 
(2003–2008); Consultant Psychiatrist, Blackpool North 
Community Mental Health Team, National Health 
Service, United Kingdom (2003–2008). Duties in the 
above-mentioned posts included training of undergradu-
ate medical students and postgraduate students in psy-
chiatry with an emphasis on addiction psychiatry and 
substance use, providing substitution treatment for 
patients with opioid use-related disorders, neuropsychia-
try, consultation liaison psychiatry, child and adolescent 
psychiatry, old age psychiatry, psychopharmacology and 
public mental health. Honours: Chairperson of the Board 
of the Ernest Malgas Youth Treatment Centre (Rehabilitation 
for Substance Abuse) (2016–2018); Chairperson of the 
South African Society of Psychiatrists, Eastern Cape 
Subgroup (2016–2018); Chairperson of Walter Sisulu 
University Registrar Training and Implementation 
Committee (2015–2018); Chairperson of Task Team 
appointed by the Head of Department of the Eastern 
Cape Department of Health to investigate allegations of 
patient abuse in Tower Psychiatric Hospital and 
Rehabilitation Centre, with the investigative report 
de livered to Minister of Health in 2018.
Author and co-author of numerous publications includ-
ing “First-episode psychosis and substance use” (authors: 
Thungana and Zingela (supervisor) and van Wyk (co-
supervisor)), South African Journal of Psychiatry, vol. 24 
(2018); and “Personality and personality disorder” (co-
authors M. Nagdee, S. Grobler, Z. Zingela), chapter in 
Oxford Textbook of Psychiatry for Southern Africa 
(J. Burns and L. Roos, eds.), 2nd ed., 2016). 
Member of steering committee for establishment of 
rehabilitation for substance abuse (Ernest Malgas Youth 
Treatment Centre) (2012–2015); consultant, consultation 
committee on the implementation of the Prevention of 
and Treatment of Substance Abuse Act. Advised, on a 
voluntary basis, the Ernest Malgas Youth Treatment 
Centre on implementation of substance abuse act and 
support for stating the rehabilitation programme (2015); 
established a mental health outreach programme for the 
Ernest Malgas Youth Treatment Centre offering assessment 
and interventions (2016 to date); facilitated support from 
the Department of Health to the local drug action 
committee through the allocation of a multidisciplinary 
staff member (clinical psychologist) to serve on the 
committee (2014–2016).
Fifteenth Biannual National Congress of the South 
African Society of Psychiatrists (2018) (presented paper 
on first episode psychosis and substance abuse, by authors 
Thungana, Zingela and van Wyk); substance abuse assess-
ment and intervention: provincial training organized by 
Walter Sisulu University and Eastern Cape Department 
of Health (2017); 7th African Population Conference, 
Johannesburg (South Africa) (2015) (presented paper on 
school-based substance abuse awareness programmes, by 
authors: Zingela, Bronkhorst and Ngwetsheni); Seventh 
African Population Conference, Johannesburg, South 
Africa, 2015 (presented paper on the integration of the 
South African Master Drug Plan Policy and Mental 
Health Policy Framework and Strategic Plan (author: Z. 
Zingela); National Substance Abuse Colloquium (2015) 
(chaired and presented paper on aftercare, outpatient and 
maintenance services for substance abuse); Substance 
Abuse Colloquium, Port Elizabeth (South Africa), in 
preparation for the opening of the Ernest Malgas Youth 
Treatment Centre (2015) (organizer).
Member of INCB (since 2020).3 Member of the Standing 
Committee on Estimates (2020).
3 Elected by the Economic and Social Council on 7 May 2019.
About the International Narcotics 
Control Board 
INCB is an independent and quasi-judicial control organ, 
established by treaty, for monitoring the implementation 
of the international drug control treaties. It had prede-
cessors under the former drug control treaties as far back 
as the time of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their 
personal capacity, not as government representatives. 
Three members with medical, pharmacological or phar-
maceutical experience are elected from a list of persons 
nominated by WHO and 10 members are elected from a 
list of persons nominated by Governments. Members of 
the Board are persons who, by their competence, impar-
tiality and disinterestedness, command general confi-
dence. The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical inde-
pendence of the Board in carrying out its functions. INCB 
has a secretariat that assists it in the exercise of its treaty-
related functions. The INCB secretariat is an administra-
tive entity of UNODC, but it reports solely to the Board 
on matters of substance. INCB closely collaborates with 
UNODC in the framework of arrangements approved by 
the Council in its resolution 1991/48. INCB also cooper-
ates with other international bodies concerned with drug 
control, including not only the Council and its Commission 
on Narcotic Drugs, but also the relevant specialized agen-
cies of the United Nations, particularly WHO. It also 
cooperates with bodies outside the United Nations sys-
tem, especially INTERPOL and WCO.
Functions
The functions of INCB are laid down in the following trea-
ties: Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; Convention on Psychotropic 
Substances of 1971; and United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
of 1988. Broadly speaking, INCB deals with the 
following:
 (a) As regards the licit manufacture of, trade in and 
use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
 (b) As regards the illicit manufacture of, trafficking in 
and use of drugs, INCB identifies weaknesses in national 
and international control systems and contributes to cor-
recting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of 
drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
 (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
 (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
 (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
 (d) Maintains a permanent dialogue with Governments 
to assist them in complying with their obligations under 
the international drug control treaties and, to that end, 
recommends, where appropriate, technical or financial 
assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. If, 
however, INCB notes that the measures necessary to rem-
edy a serious situation have not been taken, it may call 
the matter to the attention of the parties concerned, the 
Commission on Narcotic Drugs and the Economic and 
Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of 
the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in 
national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at 
both the national and the international levels. The annual 
report is based on information provided by Governments 
to INCB, United Nations entities and other organizations. 
It also uses information provided through other inter-
national organizations, such as INTERPOL and WCO, as 
well as regional organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of 
article 12 of the 1988 Convention, INCB reports annu-
ally to the Commission on Narcotic Drugs on the imple-
mentation of that article. That report, which gives an 
account of the results of the monitoring of precursors and 
of the chemicals frequently used in the illicit manufac-
ture of narcotic drugs and psychotropic substances, is also 
published as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the international 
drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of illicit 
drug promotion
1998:  International control of drugs: past, present and 
future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001:  Globalization and new technologies: challenges to 
drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the micro-level impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005:  Alternative development and legitimate 
livelihoods
2006:  Internationally controlled drugs and the unregu-
lated market
2007:  The principle of proportionality and drug-related 
offences
2008:  The international drug control conventions: 
history, achievements and challenges
2009:  Primary prevention of drug abuse
2010: Drugs and corruption
2011:  Social cohesion, social disorganization and illegal 
drugs
2012:  Shared responsibility in international drug control 
2013:  Economic consequences of drug abuse
2014:  Implementation of a comprehensive, integrated 
and balanced approach to addressing the world 
drug problem
2015:  The health and welfare of mankind: challenges 
and opportunities for the international control of 
drugs
2016:  Women and drugs
2017:  Treatment, rehabilitation and social reintegration 
for drug use disorders: essential components of 
drug demand reduction
2018:  Cannabis and cannabinoids for medical, scientific 
and “recreational” use: risks and benefits
2019:  Improving substance use prevention and treat-
ment services for young people
Chapter I of the report of the Board for 2020 is entitled 
“A hidden epidemic: the use of drugs among older persons”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide 
control of all licit activities related to narcotic drugs and 
psycho tropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents global issues and some of the main 
developments in drug use and trafficking and measures 
by Governments to implement the international drug 
control treaties by addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other 
relevant international and regional organizations.

 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODC/INCB secretariata
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a The INCB secretariat reports on substantive matters to INCB only.
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INTERNATIONAL NARCOTICS CONTROL BOARD
The International Narcotics Control Board (INCB) is the independent monitoring body for the 
implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
Based on its activities, INCB publishes an annual report that is submitted to the United Nations 
Economic and Social Council through the Commission on Narcotic Drugs. The report provides a 
comprehensive survey of the drug control situation in various parts of the world. As an impartial 
body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
be taken.
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